

**DUKE UNIVERSITY MEDICAL CENTER  
CURRICULUM VITAE**

**Name:** Robert McKinnon Califf, M.D., M.A.C.C.

**Primary academic appointment:** Vice Chancellor for Clinical and Translational Research

**Present academic rank and title:** Vice Chancellor for Clinical and Translational Research  
Duke University Medical Center  
Director, Duke Translational Medicine Institute  
Professor of Medicine, Division of Cardiology  
Donald F. Fortin Professor, Cardiology

**Medical licensure:** North Carolina License # 26208

**Specialty certification:**

American Board of Internal Medicine	1984
Cardiovascular Diseases	1986
Fellow, American College of Cardiology	1988

<b>Education:</b>	<b><u>Institution</u></b>	<b><u>Year</u></b>	<b><u>Degree</u></b>
<b>College:</b>	Duke University	1973	BS, Psychology
<b>Graduate/</b>	Duke University	1978	MD
<b>Professional School</b>			
<b>Training:</b>	University of California, San Francisco Intern, Medicine	1978 - 1979	
	University of California, San Francisco Assistant Resident, Medicine	1979 - 1980	
	Duke University Medical Center Fellow, Cardiology	1980 - 1983	

**Faculty appointments:**

Associate in Medicine Duke University Medical Center	1982 - 1983
Assistant Professor of Medicine Duke University Medical Center	1983 - 1989
Associate Professor of Medicine Duke University Medical Center	1989 - 1995
Director, Duke Clinical Research Institute Duke University Medical Center	1995 - 2006
Professor of Medicine	1995 - Present
Associate Vice Chancellor for Clinical Research	1995 - 2006
Vice Chancellor for Clinical Research	2006 - 2011
Director, Duke Translational Medicine Institute	2006 - Present
Vice Chancellor for Clinical and Translational Research	2012 - present

**Duke positions held:**

Director, CCU	1982 - 1994
Medical Officer – Life Flight	1984 - 1990
Executive Committee of the Medical Staff, Member	1995 -
Chair, Committee on Health Information Policy & Services	1995 - 2007
Executive Committee, Duke University School of Medicine, Member	1995 -
Strategy Committee, Duke Health System	1995 - 2004
Chair, Clinical Sciences Faculty Council	1996 - 1998
University Patent Policy Committee	2002 - 2008
Academic Council Trustee Nomination Committee	2002 - 2005
Executive Committee for the Development of the Personalized Health Plan	2003 - 2006
Executive Management Committee of the Health System, Duke University School of Medicine, Member	2004 -
Department of Medicine Advisory Board - Senior Advisor	2003 - 2006
University Intellectual Property Board	2003 - 2006
Chancellor’s Academic Cabinet, Member	2005 -
Chair – Quality Metrics Committee – Duke Health Systems	2005 - 2006
Academic Leadership Council	2005 -
Duke School of Medicine Executive Compliance Committee	2007 -
Duke School of Medicine Strategic Funds Committee	2007 -
Y.T. and Alice Chen Pediatric Genetics & Genomics Research Center Scientific Advisory Board	2007 - present
Duke Heart Center Executive Leadership Committee	2008 - 2010
Co-Chair, Durham Health Innovations Oversight Committee	2008 –
David H. Murdock Research Institute, Board Member	2008
Clinical Research Redesign Committee	2009
UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program Steering Committee	2011-2016
Williams Faculty Research Prize Selection Committee	2012
University Patent Policy Committee member	2012

**Professional positions:**

American Board of Medical Specialties	1999 -
American College of Cardiology- Fellow (F.A.C.C)	1988 – 2006
Chair, Merck Fellowship Awards Committee	1990 – 1996
Board of Trustees	2000 - 2005
Task Force on Science and Quality of Care	2000 - 2002
Board of Trustees Working Group on Compensation	2002 - 2004
Annual Self Assessment	2002 - 2003
Quality Strategic Oversight Committee	2002 – 2008
Task Force on Work Force	2003 - 2004
AHA/ Consensus Conference on Ethics	2003 –
Quality Strategic Directions Committee	2005 - 2008
Master (M.A.C.C.)	2006 -
Young Investigators Award Committee	2006 - 2009
Awards Committee	2007 - 2009
American Heart Association Council on Clinical Cardiology	1995 –
Scientific Publishing Committee	2006 -
American Heart Journal – Editor-in-Chief	1996 - 2008
Donald W Reynolds Foundation Cardiovascular Research Advisory	1997 - 2009
Doris Duke-Scientific Advisory Committee	1998 - 2004
FDA Cardio-Renal Advisory Committee	1996 - 2000
FDA Science Board Working Group	2007 - 2008

National Cancer Inst. Implementation Committee on Clinical Trials	1997 - 1998
National Heart, Lung, and Blood Institute Working Group on Clinical Research	1998 - 2000
Coordinating Center for Education and Research on- Therapeutics (CERTs) – PI	1999 – 2007
Center for Education and Research in Therapeutics (CERTs) Vice-Chair of Steering Committee	2007 - 2009
Canadian Heart Research Center Advisory Board	2002 - 2003
Fellow of the European Society of Cardiology	2002 -
Medicare Coverage Advisory Committee	2002 - 2003
Institute of Medicine, Clinical Research Roundtable	2003 - 2005
Institute of Medicine Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy	2003 - 2004
Institute of Medicine Committee on Medication Errors	2004 - 2006
Institute of Medicine Forum, Drug Discovery, Development And Translation	2005 - 2006
Center for Information and Study on Clinical Research Participation Board of Advisors	2004 -
National Heart, Lung, and Blood Working Group on Hypertension Trials	2004 - 2006
National Library of Medicine Board of Scientific Counselors	2005 - 2009
National Heart, Lung, and Blood Institute Cardiovascular Disease Executive Planning Committee	2006 - 2007
National Heart, Lung, and Blood Institute Working Group On Clinical Trial Design, Co-Chair	2006 - 2007
National Heart, Lung, and Blood Institute Board of External Experts	2007-
National Heart, Lung, and Blood Institute Clinical Guidelines Leadership Group for CV Risk Reduction	2007 - 2008
National Heart, Lung and Blood Institute Chairman, Steering committee of the Warfarin Therapy trial	2008 -
National Institute of Health – Board of Scientific Counselors	2008 - 2009
National Institute of Health/National Cancer Institute SPORE In Brain Cancer –Internal Advisory Committee	2008 -
National Cancer Institute/National Institute of Health Operational Efficiency Working Group (OEWG)	2008 -
CTSA Consortium Oversight Steering Committee - Co-Chair	2007 - 2009
Clinical Trials Transformation Initiative (CTTI) - Co-Chair Public-Private Partnership with FDA	2008 -
Institute of Medicine Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease	2009 -
National Institute of Environmental Health Science (NIEHS)/NIH - Member, External Clinical Advisory Council	2009 - 2013
CTSA External Advisory Board Membership	
Columbia University	2008 -
UC Davis	2009 -
University of Colorado	2009 -
University of Chicago	2009
Clinical Research Forum – Chairman	2010 - 2013
NIH-National Advisory Council on Aging	2010 – 2013
American Orthopaedic Association Institute of Medicine Taskforce On Ethics	2010
HHS – Secretary’s Advisory Council on Human Research Protections (SACHRP) – Subcommittee on Harmonization	2010 - 2011
Society for Clinical and Translational Sciences – Board of Directors	2009 – 2013
NC House of Representatives, Office of the Speaker,	

Comparative Effectiveness Study Committee Advisory Board	2010 – 2011
National Heart, Lung, and Blood –	
Value of Information working group	2010
Fellow of the American College of Physicians (ACP)	2010
Institute of Medicine –	
Board on Health Sciences Policy	2011-2013
President’s Council of Advisors on Science and Technology	
PCAST Working Group on Advancing Innovation in	
Drug Development and Evaluation	2011-2012
Clinical Trials Advisory Panel – member	2012-2018
President of David H. Murdock Research Institute (DHMRI)	2012-
IMEDS Steering Committee	2013-

**Journal reviewer:**

**Current**

American Heart Journal  
American Journal of Cardiology  
Annals of Internal Medicine  
Cardiosource Clinical Trials  
Circulation  
European Heart Journal  
Heart Lung and Circulation  
Journal of the American College of Cardiology  
Journal of the American Medical Association  
Journal of Invasive Cardiology  
Lancet  
New England Journal of Medicine  
American Journal of Kidney Disease  
American Journal of Medicine  
Archives of Internal Medicine  
Canadian Journal of Cardiology  
Chest  
Journal of Clinical Epidemiology  
Journal of General Internal Medicine  
Thrombosis and Hemostasis  
Health Affairs

**Editorial boards:**

**Current**

American Heart Journal  
Cardiosource Clinical Trials  
Circulation  
Clinical Trials, The Journal of the Society for Clinical Trials  
European Heart Journal  
Heart Lung and Circulation  
Science Translational Medicine (Advisory Board)  
Therapeutic Innovation & Regulatory Science (2016)

**Past**

American Journal of Cardiology  
Current Treatment Options in Cardiovascular Diseases  
Journal of Interventional Cardiology  
Journal of the American College of Cardiology

**Consultancy:**

Health Services Research & Development Veterans Administration Donald W. Reynolds Foundation Scientific Advisory Panel Cardiovascular Research	1984 - Present   1998
---	--------------------------------

**Honors and awards:**

Phi Beta Kappa Duke University	1973
Alpha Omega Alpha Duke University Medical School	1976
President, Senior Class Duke University Medical School	1978
Lange Book Award Duke University Medical School	1978
Distinguished Resident Teaching Award University of California at San Francisco School of Medicine	1981
Donald F. Fortin Professor, Cardiology	1995
Distinguished Scientist Award for Clinical Research American College of Cardiology	2004
Master of the American College of Cardiology	2006
2006 Clinical Research Award American Heart Association	2006
Duke Distinguished Alumni Faculty Award	2006
American Heart Association; Distinguished Scientist Award	2009
Council on Quality Of Care and Outcomes (QCOR) American Heart Association Outstanding Achievement Award	2011
Duke Research Mentoring Award for clinical research	2012

**Memberships**

**Current**

- American College of Cardiology
- American College of Physicians
- American Medical Association
- American Society of Clinical Investigation
- Argentine Society of Cardiology
- Association of American Physicians
- Drug Information Association
- Society for Clinical Epidemiology and Health Care Research
- American Heart Association
- Association of University Cardiologists
- European Society of Cardiology
- Association of American Physicians

**Selected Recent Invited Lectures:**

- 1998 Dallas, TX, Baylor University Medical Center Visiting Professor, presentation, “Do We Need Academic Cardiologists?”  
Birmingham, AL, University of Alabama School of Medicine Visiting Professor
- 1999 Stanford, CA, Stanford University School of Medicine Visiting Professor
- 2000 St. Louis, MO, Washington University School of Medicine, 16<sup>th</sup> Massie Lecturer, Visiting Professor, presentation, “Evidence, Medical Errors, and Academic Medicine in the United States”
- 2001 Boston, MA, Tufts University, Dr. Joseph Nicholson Lectureship, presentation, “Medical Errors”  
Indianapolis, IN, Krannert Institute of Cardiology Grand Rounds  
Greenville, NC, East Carolina University Grand Rounds, presentations, “Combined Therapy for Acute Myocardial Infarction” and “Redefining the Treatment of Acute Coronary Syndromes”
- 2002 33<sup>rd</sup> Annual Louis F. Bishop, American College of Cardiology, presentation, “Clinical Trials: Moving from Proof of Concept to Basis for Quality”  
Cleveland, OH, The Cleveland Clinic Foundation Visiting Professor, presentation, “The Cycle of Quality in Cardiovascular Disease” and “Lessons for Practice from Clinical Trials”  
San Francisco, CA, UCSF, John J. Sampson Visiting Professor, presentations, “Developments on the Treatment of ST Elevation MI,” “Development in the Treatment of Heart Failure,” and “Developments in the Treatment of Non-ST Elevation MI”
- 2003 Cleveland, OH, The 40<sup>th</sup> Annual Carl J. Wiggers Memorial Lecture, presentation, “Creating the Evidence for Practice in Coronary Disease”  
Rochester, MN, Mayo Clinic, Visiting Professor, presentation, “The Cycle of Medical Quality Applied to Acute Coronary Syndromes”  
Baltimore, MD, Johns Hopkins Visiting Professor, presentation, “An Academic Model of Clinical Research Applied to Heart Failure”  
San Francisco, CA, McClelland Visiting Professorship, presentations, “Heart Failure-Progress in Therapeutics,” “Therapy for Acute Coronary Syndromes,” “The Medical Mistakes you Hear About Are Only the Tip of the Iceberg,” and “Revascularization-Where Are We Headed?”  
Dallas, TX, University of Texas SW Medical Center, Visiting Professor, presentation, “Problems with Allowing Doctors and Patients to Fly Without a Cockpit and Automated Pilot: The Glass Cockpit Project”  
Charleston, SC, John M. Eisenberg Memorial Lectureship on Therapeutic Research, presentation, “A System Goal: Benefit the Patient, Manage the Risk”  
New York, NY, The Edward and Michael Leahy Lecture, presentation, “Societal Imperative for Academic Medical Centers to Develop Efficient Clinical Research Capability: Should we base Clinical Practice on the Hippocampus or the Cortex?”
- 2004 Chicago, IL, Northwestern University Visiting Professor, presentation, “Integrating Evidence and Clinical Quality”  
Springfield, IL, Southern Illinois University Visiting Professor, presentation, “Bridging Quality Care Initiatives with Improved Outcomes”  
Denver, CO, University of Colorado Visiting Professor, presentation, “Post MI Heart Failure—insights and questions” and “Non ST elevation acute coronary syndromes update”  
Chapel Hill, NC UNC Department of Epidemiology Seminar, University of North Carolina School of Public Health, invited speaker  
Omaha, Nebraska, Creighton University Medical Center Visiting Professor, presentation, “Developing a system of quality for acute coronary syndromes” and Medical Errors: The Perspective from a place that was burned”  
Chicago, IL, AAPASCI Meeting, presentation, “Translating from Bedside to Populations”  
Plenary Session  
Washington, DC FDA Science Board, presentation, “Perspective on Chronic Disease Therapies”

Toronto Ontario, Heart & Stroke/Richard Lewar Centre of Excellence, Distinguished Visiting Professor, “The Heart Failure Quartet: 4 Large trials in heart failure populations”  
Columbia, SC, Providence Health Institute Visiting Professor  
Washington, DC AHRQ Translating Research Into Practice (TRIPomics) Advancing Excellence from Discovery to Delivery  
Philadelphia, PA Presbyterian Hospital, Visiting Professor, presentation, “The Cycle of Quality in Acute Coronary Syndromes”  
Tucson, Arizona, University of Arizona Visiting Professor, presentation, “Acute coronary syndromes as a model for developing a system of quality in health care”, Blood Typing for Heart Transplantation and other Medical Errors-A Personal Perspective”, “Megatrends in Medicine: How should you view the future as a doctor?”

- 2005 Houston, TX, The Dennis Distinguished Lectureship, presentation, “Understanding the Quality of Cardiovascular Care”  
Washington, DC, CRT 2005 Course, presentation, “Implications of Critical Path and Devices Approval: Reflections  
Washington, DC, FDA Science Forum, presentation, “ Research Drug & Device Therapeutics”  
Charlottesville, VA, Grollman Lecturer, presentation, “The Cycle of Quality in Clinical Medicine” and Update on Heart Failure Clinical Trials”  
Gainesville, FL, University of Florida, presentation, A risk-based approach to managing patients with CVD: Quality cycle – Acute Coronary Syndromes“  
Chicago, IL, AHA Herrick Lecturer, presentation, “Overcoming the Second Translational Block: Drug Development, Clinical Implementation, and Quality of Care“  
Charleston, SC, International Society of CV Infections, Curing Complex Cardiovascular Infections: Therapeutic drug Development at a Crossroads  
Boston, MA, Harvard BWH Course, presentation, “Defibrillators and Drug-Eluting Stents: Policy Implications”  
Boston, MA, Harvard/Schering Plough Workshop, presentation, “Data: Why, When?”  
Pinehurst, NC, Southwest Lipid Association, presentation, “Implications of Recent Clinical Trials”  
Singapore, International Healthcare Facilities Exhibition, presentation, “Future Trends in Clinical Research”  
Greensboro, NC, NC/SC ACC Meeting, presentation, “Medical Cost in the Next Decade”  
Oxford, UK, 10<sup>th</sup> International Symposium, presentation, “Bureaucracy in Clinical Trials”  
Bethesda, MD, FDA Cardiac Safety Think Tank Meeting, “What is Drug Safety?”  
Bethesda, MD, NIDA NIH Meeting, presentation, “Map of the Road”  
Washington, DC, Conference on Research Education & Training in Otolaryngology, presentation, “Share historical perspective and emerging crisis that supports the need for standardized data elements – for TB, Ischemic Heart Disease, other”.  
Bethesda, MD, ACC Program, “How to become a CV investigator”, presentation, “Careers in Clinical Trials and Epidemiology”
- 2006 Glasgow, London, British Cardiac Society Annual Scientific Conference, “Improving Clinical Outcomes through a Cycle of Quality: Local and Global Perspectives”  
Beaver Creek, Colorado, Fifteenth Annual Cardiovascular conference, “Drug and Device Safety: Have We Gone Too Far?”  
Amelia Island, FL, Heart Failure Management 2006 Meeting, “Assessing the Risk/Benefit Ratio of Observational Treatment Analysis”  
Washington, DC, IOM Drug Forum – Meeting #5, “Simplifying Clinical Trial Monitoring Practices”  
Washington, DC, Improving Long-Term Outcomes in Atherothrombotic Disease: Benefits of Antiplatelet Therapy, “Managing Atherothrombotic Disease Across the Continuum of Care”  
Washington, DC, Challenges and Practical Aspects of Assessing Clinical QT Prolongation/Proarrhythmia Risk and Implications for the Critical Pathway, “Drug Safety: Balancing Safety and Efficacy”  
Lake Buena, FL, 27th Annual Meeting Society for Clinical Trials, “Presenting Annual Founders Lecture”  
Boston, MA, MGH Clinical Research Day, “The Cycle of Quality and the 2nd Translational Block”  
Seattle, WA, Heart Failure Society of America 10th Annual Scientific Meeting, “How to Design a Perfect Global Study in Heart Failure: The Investigator Perspective (North America)”  
Rockville, MD, Effective Risk Communication Think Tank, presentation, Iterative Polling to Identify Common Priorities  
Rockville, MD, Effective Risk Communication Think Tank, presentation, “A Research Agenda for Risk Communication” and The Media

Arlington, VA, Think Tank Meeting, Chronic Advanced Coronary Artery Disease, presentation, Nicorandil: Why Don't Americans Believe IONA

- 2007 Washington, DC, Sensible & Practical Guidelines Workshop, presentation, "Different approaches to ensuring patient safety, including the identification and reporting of adverse events"  
Beaver Creek, CO Annual CV Conference, presentation, "How will quality be valued?"  
Washington, DC, Keynote Address: Roadmap/CTSA  
Washington, DC, Cardiovascular Revascularization Therapy (CRT) 2007, speaker, "Challenges of Pharmacology Trials" and "Synthesis of Adjunctive Therapy" and "Day Synthesis"  
Washington, DC, Drug Forum Workshop on IOM Drug Safety Report, presentation, "Funding large research studies"  
Washington, DC, CERTs PATHs Committee Meeting, presentation, "The future of drug safety and Research Gaps"  
Rockville, MD, DES Thrombosis Think Tank Mtg, presentation, "Safety, DES, and DAP Therapy in Real World Medicine"  
Durham, NC, Health Summit 2007, presentation, "Seamless Continuation from Discovery to Translation to Care Delivery"  
Washington, DC, AHA 8<sup>th</sup> Scientific Forum, presentation, "Modern Quality Systems: How do we measure quality for given clinical trial designs?"  
Amelia Island, FL, Heart Failure Management 2007, presentation, "Assessing the Risk/Benefit Ratio of Observational Treatment Analysis"  
Charleston, SC, MUSC invited lecturer: "One Person's view on how to succeed with the Clinical & Translational Science Award"  
Washington, DC, 11th Annual Scientific Meeting of the Heart Failure Society of America, "Challenges for the Clinical Science Investigator"  
Washington, DC, IOM Committee on Health Research and the Privacy of Health Information: the HIPPA Privacy Rule, "Implications of the Privacy Rule for trialists and academic research"  
Lexington, KY, 10th Annual Gill Heart Institute Cardiovascular Research Day, "Trials and Tribulations of Clinical Trials"  
Williamsburg, VA, The 34<sup>th</sup> Annual Williamsburg Conference on Heart Disease, "Principles learned from recent cardiovascular trials"  
Washington, DC, IOM Genomics Workshop, "Translational of Innovations: A Broad Perspective"  
New York, NY, 40<sup>th</sup> Annual New York Cardiovascular Symposium, Henry I. Russek Lecture, "The Elderly and Cardiovascular Disease: A Challenging Future in what Respect?"  
Washington, DC, IOM Roundtable, "Innovative Approaches to Trials"
- 2008 Louisville KY, Leonard Leight Distinguished Lecturer, "Translating Discoveries into Practice"  
Washington, DC; The National Academies, "Biomedical Engineering Materials and application; Device Innovation and Regulation"  
Philadelphia, PA ISMPP meeting, Keynote address, "The Changing Academic Landscape"  
Bethesda, MD, NIH/NHLBI Outcomes in CV Imaging, "Randomized Trails of diagnostic test"  
San Francisco, CA, Heart Rhythm 2008, "Importance and Feasibility of Large, Multicenter, Randomized Trials"  
Washington, DC, DIA & FDA Clinical Trial Monitoring Forum, "Goals of Monitoring"  
Bethesda, MD CTSA Clinical Management Workshop, "Why is Improved Clinical Research Management Important?"  
Rockville, MD, NIDA, "How the CTSA transforms the Translational Research"  
Buenos Aires, Argentina, World Congress of Cardiology 2008, "When to perform surgical revascularization in patients with stable coronary artery disease?" and Low Molecular heparin is the first choice"  
Philadelphia, PA, ITMAT Symposium, "Adaptive Trials and Community Translation"  
Durham, NC, 10<sup>th</sup> Annual Duke Medicine Spring Cardiovascular Symposium, "The Role of Prevention in Reducing Cardiac Emergencies"  
Washington, DC, National Cancer Policy Forum, Workshop on Multi-Center Phase III Clinical trials and NCI Cooperative Groups, "Organizing Multi-Center Trials: Are Oncopolitics different than other Clinical Research Politics?"



- Silver Spring, MD, FDA Advisory Committee Meeting, Endocrinologic & Metabolic Drugs Advisory Committee Meeting, "Implementation of Pragmatic Clinical Trials in Diabetes"
- Warrenton, VA, OBSSR/NIH Summer Training Institute on Randomized controlled Trials Involving Behavioral Interventions, "Large Simple Trials: Principles and Importance"
- Washington, DC, The National Academies Drug Forum Meeting, "Academic McCarthyism-The intimidation of investigators attempting to collaborate with industry"
- Nashville, TN, 12<sup>th</sup> Annual Fred D. Ownby, MD Visiting Professor, "Lesson from Recent Clinical Trials" and "Can we Create a Common Framework for Personalized Medicine and Public Health"
- Philadelphia, PA, "Society for Medical Decision Making, 30<sup>th</sup> Annual Meeting, Comparative Effectiveness Research: Practice and Policy: Challenges and Opportunities, "Registries and Large Data Bases"
- Burlington, MA, Rose Weiss Visiting Professor, "New Standards for Assessing Cardiovascular Effects of Diabetes Treatment" and "New Findings from Clinical Trials"
- Washington, DC, IOM Drug Forum Workshop, "Practical Implications of pre-and procompetitive data sharing (a critique of the concepts relative to what is being practiced)"
- Bethesda, MD, NHLBI, Biomedical Lectures Series, "Creating a Continuum between Molecular Signatures and Population Health in CV Disease"
- Philadelphia, PA, Society for Medical Decision Making, "Registries and Large Data Bases"
- 2009 Chicago, IL, ASCI/AAP Joint Meeting, "Translational Research: Converting the Valley of Death into the Garden of Eden"
- Washington, DC; Race and Ethnicity in CV Clinical Trials: Historical Disparities, Current Barriers and Future Opportunities, "Lessons from the Durham County Initiatives"
- Milwaukee, WI; Medical College of Wisconsin, Tresch Memorial Lecturer, "A Tiered Approach to Reducing Cardiovascular Death and Disability"
- Washington, DC; IOM Committee on Qualifications of Biomarkers as Surrogate Endpoints of Chronic Disease Risk; presentation, "Reactions from the Workshop, Cancer/Cardiovascular comparison"
- Boston, MA; Harvard School of Public Health; "Money, ethics, culture of practice and genetic variation: unresolved issues in globalization of clinical trials in four dimensions"
- Bethesda, MD; CTSA Workshop on Clinical Research Management; presentation, "Benefits: discussion on Consortium sharing issues the unified Consortium-wide approach"
- RTP, NC; Grand Opening of the NIEHS Clinical Research Unit; presentation, "A Local Partner's Perspective"
- Columbus, OH, The Ohio State Univ Visiting Professor, "The Quality Cycle in CV Medicine" and "Durham Health Innovations: Connecting Personalized Medicine and Public Health"
- Boston, MA; Brigham and Women's Hospital; Annual Laurence H. Green Lecturer, "The Price for Evidence deficits in CV Disease" and "Integrating "Personalized Medicine" and Global Health"
- Columbia Missouri, Univ of Missouri, Health Sciences Research Day, "The Role of the Academic Medical Center in Reconciling Personalized Medicine and Public Health"
- Washington, DC; Professional Society Leader Meeting funded by AHRQ Bridging the Chasm Meeting, "The Importance of Unambiguous Terminology in Research and Patient Care"
- Durham, NC; North Carolina Central University: CISRP Aware for All Clinical Research Education Day, "What Clinical Research Means to You", and "Clinical Research Focus on Cardiovascular Disease"
- Washington, DC; 2009 Industry/Statistics Workshop: Global Harmonization, "Ethical and Scientific Considerations"
- Waterloo, NY; The Lifetime Health Care Companies Advisory Board, "An Introduction to Comparative Effectiveness Research"
- Edmonton Alberta Canada; symposium, "Health Systems to Lower CV Deaths and Disability", and Leaders and Legacies in Clinical Trials, "Evolution of the DCRI"
- San Diego, CA; American Society of Nephrology: Public Policy Forum- Conflicts of Interest in Medicine, Christopher R. Blagg Endowed Lectureship, "Bias in Clinical Trial Reporting"
- Leuven; Atherothrombosis Summit, "Clinical Trial Design in the new era of Comparative Effectiveness"
- Greensboro, GA; GA Chapter ACC, "Emerging Trends in Cardiovascular Medicine"
- 2010 Durham, NC; DCRI Research Conference; "The Future of Clinical and Translational Research at Duke: Planning the Next 6 years of DTMI"
- Washington, DC; 5<sup>th</sup> Workshop in a Series on Pharmacogenomics: Generating & Weighing Evidence in Drug Development and Regulatory Decision Making; "Evidence-based Medicine in the Era of Pharmacogenetics"
- Beaver Creek, Colorado; 19<sup>th</sup> Annual CV Conference, "Comparative Effectiveness Research: What Can We

Expects?”

Atlanta, GA; St. Joseph's Heart and Vascular Institute, Visiting Professor, “Defining Quality in Cardiovascular Care: Merging High Tech and Community Care”

Ann Arbor, MI; The University of Michigan Internal Medicine Grand Rounds, “The Common Platform for Personalized Medicine and Public Health”

Washington, DC; 2010 Clinical and Translational Research and Education Meeting; “Critical Systems for Prospective Comparative Effectiveness Research: the Future of Trial Networks and Registries”

Washington, DC; Clinical Research Forum Annual Meeting; “The Future Vision for the Forum”

Minneapolis, MN; Twelfth Annual Jay N. Cohn Lecture, “Creating a Continuum from Molecular Medicine to Population Health”; “Rationalizing mechanistic and outcomes research: Cohn and Califf really disagree”

Tampa, FL; Academy of Pharmaceutical Physicians and Investigators Meeting, “New Horizon in Clinical Research”

Denver, CO; Heart Rhythm 31st Annual Meeting, “Quality Commentator”

Baltimore, MD; SCT 31<sup>st</sup> Annual Meeting; “Global Harmonization-Ethical and Scientific Considerations”

Indiana, IN; Indiana University Grand Rounds, “Creating a Continuum between Molecular Medicine and Public Health”

New York, NY, New York School of Medicine Cardiology grand rounds; “Linking Molecular Medicine and Community Health”

Orlando, FL; 70<sup>th</sup> American Diabetes Association meeting, “Implications of NAVIGATOR Trial Results for Preventing Cardiovascular Disease in Subjects with Impaired Glucose Tolerance”

Nashville, TN, “11<sup>th</sup> Annual Visiting Scholars Day, “Disrupting Current Patterns of Clinical and Translational Research in the United States”

Denver, CO, University of Colorado Distinguished Visiting Professor, “Creating a Continuum from Molecular Medicine to Population Health-- We are the Impediment”

Washington, DC; Accelerating Therapies for Rare Disease Workshop; “Academic perspective on the development of Orphan Products”

Cleveland, OH; 21<sup>st</sup> Century Treatment of Heart Failure: Synchronizing Surgical and Medical Therapies for Better Outcomes, “Will clinical site research survive in the US and can we afford it?”

Bethesda, MD; DIA-Multi Regional Clinical Trials Conference; “Towards the Definition of Appropriate Globalization in Clinical Trials: The Case for Transparent Cooperation”

Baltimore, MD; Johns Hopkins Mirowski Lecturer; “The Common Basis for Translational Medicine from Laboratory to Practice to Population”

Bethesda, MD; CTTI Steering Committee Meeting; “Improving the Public Interface for Use of Aggregate Data in CT.gov” and “An Academic's Vision of the Future of Clinical Trials”

- 2011 Ft. Wayne, IN; Parkview Research Center Annual Meeting; “The Role of Genomics and Information Technology in the Transformation of the Health Care”
- Columbia, SC; MUSC Visiting Professor; Translational Medicine: Moving from Better Ideas to Better Health”
- Washington, DC; AHA Quality of Care and Outcomes Research in CV Disease and Stroke, 2011 Scientific Sessions; Keynote address, “A report Card on Progress towards a Learning Health System”
- New Haven, CT; Yale School of Medicine Bicentennial Symposium; “Translational Medicine: Moving from Better Ideas to Better Health”
- Bethesda, MD; 2011 NLM/Friends of the National Library of Medicine Conference: Clinical Trials’: New Challenges and Opportunities; “Clinical Trials’ Response to Public Health Needs”
- Gothenburg, Sweden: Karl Swedberg Symposium “CONSENSUS – a breakthrough and its impact on future heart failure research”
- New York, NY; 44<sup>th</sup> Annual New York Cardiovascular Symposium “Need for New Antithrombotic or Combinations? Role of IT and Stakeholders (FDA, NHLBI, Industry)”
- 2012 Menlo Park, CA; Stanford Cardiovascular Grand Rounds; “Learning Health System and CV Disease: a Possibility in the US?”
- Beaver Creek, Colorado; 21st Annual CV Conference; “What can the US do to Reach its potential in clinical research?”
- Washington, DC; NIH Mind the Gap Lecture; “Innovative Approaches to Clinical Trials”
- Atlanta, GA; NIDA Blending Initiative Meeting at ASAM Conference; “Closing the Evidence Gap: Can the Same Principles Apply to Substance Abuse Disorders Research and to other Chronic Conditions?”
- Toronto, Ontario; Annual Cosbie Lecture – NCIC Clinical Trials Group Annual Spring Meeting; “The American Clinical Trials Enterprise: Are we reaching the tipping point for transformation”

Boston, MA; Society of Cardiovascular Anesthesiologist Annual Meeting; Keynote Lecture “Major Trends in Cardiovascular Disease Epidemiology and Treatment”  
Madison, Wisconsin; Department of Medicine Research Day; “The Clinical Trials Enterprise: Getting Reliable Answers More Efficiently”  
Cleveland, OH; Rakita Lecture Series at the Heart & Vascular Center MetroHealth Campus of Case Western Reserve University; “Clinical Trials in Cardiovascular Medicine: The End of an Era?”  
New York, NY; Mt Sinai Medical Center Grand Rounds “Principles of Therapeutics derived from Clinical Trials”.  
Washington, DC; DIA Conference on Rare Diseases and Orphan Products: Shaping the Future Now Keynote address “Future of Clinical Research”  
Baltimore, MD; John Hopkins Visiting Scholar Medicine Grand Rounds “Risk/Benefit Balance for Anticoagulation in a Atrial Fibrillation to Prevent Stroke”.

2013 Chicago, IL; Northwestern University Medicine Grand Rounds “Use of Electronic Health Records for Individual and Population Health in a Learning Health System”

## Table of Contents

1.	Journals.....	10
2.	Non-Peer Reviewed Journals.....	68
3.	Reviews.....	69
4.	Abstract.....	75
5.	Editorial.....	99
6.	Interview.....	103
7.	Book.....	104
8.	Book Chapter.....	106

## Journal

1. Califf RM, Burks JM, Behar VS, Margolis JR, Wagner GS. Relationships among ventricular arrhythmias, coronary artery disease, and angiographic and electrocardiographic indicators of myocardial fibrosis. *Circulation* 1978;57:725-732.
2. Califf RM, Wagner GS, Rosati RA. Prognostic value of ventricular arrhythmias. *Am J Cardiol* 1981;47:397.
3. Califf RM, Lee KL, Harrell FE, Jr., Kimm SY, Grufferman S, Rosati RA. Assessment of the use of the age- and sex-specific United States population as a control group for analysis of survival in coronary artery disease. *Am J Cardiol* 1982;50:1279-1282.
4. Califf RM, McKinnis RA, Burks J, Lee KL, Harrell FE, Jr., Behar VS, Pryor DB, Wagner GS, Rosati RA. Prognostic implications of ventricular arrhythmias during 24 hour ambulatory monitoring in patients undergoing cardiac catheterization for coronary artery disease. *Am J Cardiol* 1982;50:23-31.
5. Harrell FE, Jr., Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. *JAMA* 1982;247:2543-2546.
6. Pryor DB, Stead WW, Hammond WE, Califf RM, Rosati RA. Features of TMR for a successful clinical and research database. *Proceedings of the 6th Annual Symposium on computer Applications in Medical Care* 1982;79-84.
7. Rosati RA, Lee KL, Califf RM, Pryor DB, Harrell FE, Jr. Problems and advantages of an observational data base approach to evaluating the effect of therapy on outcome. *Circulation* 1982;65:27-32.
8. Wagner GS, Califf RM, Pryor D, Rosati RA. Early hospital discharge after uncomplicated acute myocardial infarction. *Del Med J* 1982;54:565-572.
9. Albert DE, Califf RM, LeCocq DA, McKinnis RA, Ideker RE, Wagner GS. Comparative rates of resolution of QRS changes after operative and nonoperative acute myocardial infarcts. *Am J Cardiol* 1983;51:378-381.
10. Califf RM, Tomabechi Y, Lee KL, Phillips H, Pryor DB, Harrell FE, Jr., Harris PJ, Peter RH, Behar VS, Kong Y, Rosati RA. Outcome in one-vessel coronary artery disease. *Circulation* 1983;67:283-290.
11. Califf RM, McKinnis RA, McNeer JF, Harrell FE, Jr., Lee KL, Pryor DB, Waugh RA, Harris PJ, Rosati RA, Wagner GS. Prognostic value of ventricular arrhythmias associated with treadmill exercise testing in patients studied with cardiac catheterization for suspected ischemic heart disease. *J Am Coll Cardiol* 1983;2:1060-1067.
12. Godwin JD, Califf RM, Korobkin M, Moore AV, Breiman RS, Kong Y. Clinical value of coronary bypass graft evaluation with CT. *AJR* 1983;American Journal of:649-655.
13. Hlatky MA, Califf RM, Kong Y, Harrell FE, Jr., Rosati RA. Natural history of patients with single-vessel disease suitable for percutaneous transluminal coronary angioplasty. *Am J Cardiol* 1983;52:225-229.
14. Pryor DB, Harrell FE, Jr., Lee KL, Califf RM, Rosati RA. An improving prognosis over time in medically treated patients with coronary artery disease. *Am J Cardiol* 1983;52:444-448.
15. Pryor DB, Harrell FE, Jr., Lee KL, Califf RM, Rosati RA. Using experience to improve clinical decision making. *Proceedings of the 7th Annual Symposium on Computer Applications in Medical Care* 1983;936-939.
16. Pryor DB, Harrell FE, Jr., Lee KL, Califf RM, Rosati RA. Estimating the likelihood of significant coronary artery disease. *Am J Med* 1983;75:771-780.
17. Roberts KB, Califf RM, Harrell FE, Jr., Lee KL, Pryor DB, Rosati RA. The prognosis for patients with new-onset angina who have undergone cardiac catheterization. *Circulation* 1983;68:970-978.
18. Califf RM, Conley MJ, Behar VS, Harrell FE, Jr., Lee KL, Pryor DB, McKinnis RA, Rosati RA. "Left main equivalent" coronary artery disease: its clinical presentation and prognostic significance with nonsurgical therapy. *Am J Cardiol* 1984;53:1489-1495.

19. Crimm A, Severance HW, Jr., Coffey K, McKinnis R, Wagner GS, Califf RM. Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction. *Am J Med* 1984;76:983-988.
20. Godwin JD, Moore AV, Ideker RE, Califf RM. Prospective demonstration of myocardial infarction by CT. *AJR* 1984;American Journal of:985-986.
21. Harrell FE, Jr., Lee KL, Califf RM, Pryor DB, Rosati RA. Regression modelling strategies for improved prognostic prediction. *Stat Med* 1984;3:143-152.
22. Hassel D, Heinsimer J, Califf RM, Benson A, Rice J, German L. Complete heart block in Reiter's syndrome. *Am J Cardiol* 1984;53:967-968.
23. Hlatky MA, Lee KL, Harrell FE, Jr., Califf RM, Pryor DB, Mark DB, Rosati RA. Tying clinical research to patient care by use of an observational database. *Stat Med* 1984;3:375-387.
24. Hlatky MA, Pryor DB, Harrell FE, Jr., Califf RM, Mark DB, Rosati RA. Factors affecting sensitivity and specificity of exercise electrocardiography. Multivariable analysis. *Am J Med* 1984;77:64-71.
25. Komrad MS, Coffey CE, Coffey KS, McKinnis R, Massey EW, Califf RM. Myocardial infarction and stroke. *Neurology* 1984;34:1403-1409.
26. Mark DB, Califf RM, Morris KG, Harrell FE, Jr., Pryor DB, Hlatky MA, Lee KL, Rosati RA. Clinical characteristics and long-term survival of patients with variant angina. *Circulation* 1984;69:880-888.
27. Pryor DB, Harrell FE, Jr., Lee KL, Rosati RA, Coleman RE, Cobb FR, Califf RM, Jones RH. Prognostic indicators from radionuclide angiography in medically treated patients with coronary artery disease. *Am J Cardiol* 1984;53:18-22.
28. Rankin JS, Newton JR, Jr., Califf RM, Jones RH, Wechsler AS, Oldham HN, Jr., Wolfe WG, Lowe JE. Clinical characteristics and current management of medically refractory unstable angina. *Ann Surg* 1984;200:457-465.
29. Trask N, Califf RM, Conley MJ, Kong Y, Peter R, Lee KL, Hackel DB, Wagner GS. Accuracy and interobserver variability of coronary cineangiography: a comparison with postmortem evaluation. *J Am Coll Cardiol* 1984;3:1145-1154.
30. Williams RS, McKinnis RA, Cobb FR, Higginbotham MB, Wallace AG, Coleman RE, Califf RM. Effects of physical conditioning on left ventricular ejection fraction in patients with coronary artery disease. *Circulation* 1984;70:69-75.
31. Califf RM, Hlatky MA, Mark DB, Lee KL, Harrell FE, Jr., Rosati RA, Pryor DB. Randomized trials of coronary artery bypass surgery: impact on clinical practice at Duke University Medical Center. *Circulation* 1985;72:V136-44.
32. Califf RM, Phillips HR3, Hindman MC, Mark DB, Lee KL, Behar VS, Johnson RA, Pryor DB, Rosati RA, Wagner GS, et al. Prognostic value of a coronary artery jeopardy score. *J Am Coll Cardiol* 1985;5:1055-1063.
33. Hlatky MA, Califf RM, Lee KL, Pryor DB, Wagner GS, Rosati RA. Prognostic significance of precordial ST-segment depression during inferior acute myocardial infarction. *Am J Cardiol* 1985;55:325-329.
34. Morris KG, Palmeri ST, Califf RM, McKinnis RA, Higginbotham MB, Coleman RE, Cobb FR. Value of radionuclide angiography for predicting specific cardiac events after acute myocardial infarction. *Am J Cardiol* 1985;55:318-324.
35. White RD, Grande P, Califf L, Palmeri ST, Califf RM, Wagner GS. Diagnostic and prognostic significance of minimally elevated creatine kinase-MB in suspected acute myocardial infarction. *Am J Cardiol* 1985;55:1478-1484.
36. Graham ML2, Corey R, Califf RM, Phillips H. Isotretinoin and Staphylococcus aureus infection. A possible association. *Arch Dermatol* 1986;122:815-817.
37. Heinsimer JA, Skelton TN, Califf RM. Rate-related left bundle branch block with chest pain and normal coronary arteriograms treated by exercise training. *Am J Med Sci* 1986;292:317-319.

38. Hlatky MA, Haney T, Barefoot JC, Califf RM, Mark DB, Pryor DB. Medical, psychological and social correlates of work disability among men with coronary artery disease. *Am J Cardiol* 1986;58:911-915.
39. Lamas GA, Muller JE, Turi ZG, Stone PH, Rutherford JD, Jaffe AS, Raabe DS, Rude RE, Mark DB, Califf RM, et al. A simplified method to predict occurrence of complete heart block during acute myocardial infarction. *Am J Cardiol* 1986;57:1213-1219.
40. Lee KL, Pryor DB, Harrell FE, Jr., Califf RM, Behar VS, Floyd WL, Morris JJ, Waugh RA, Whalen RE, Rosati RA. Predicting outcome in coronary disease. Statistical models versus expert clinicians. *Am J Med* 1986;80:553-560.
41. Papanicolaou MN, Califf RM, Hlatky MA, McKinnis RA, Harrell FE, Jr., Mark DB, McCants B, Rosati RA, Lee KL, Pryor DB. Prognostic implications of angiographically normal and insignificantly narrowed coronary arteries. *Am J Cardiol* 1986;58:1181-1187.
42. Slater DK, Califf RM. "Left main equivalent" coronary artery disease: prognostic significance of coronary anatomy descriptors. *Primary Cardiology* 1986;12:47-55.
43. Williams RB, Jr., Haney TL, McKinnis RA, Harrell FE, Jr., Lee KL, Pryor DB, Califf RM, Kong YH, Rosati RA, Blumenthal JA. Psychosocial and physical predictors of anginal pain relief with medical management. *Psychosom Med* 1986;48:200-210.
44. Aldrich HR, Hindman NB, Hinohara T, Jones MG, Lee KL, Califf RM, Wagner GS. Identification of the optimal electrocardiographic leads for detecting acute epicardial injury in acute myocardial infarction. *Am J Cardiol* 1987;59:20-23.
45. Boswick JM, Lee KL, Aronson LG, O'Connor CM, Honan MB, Califf RM, Pryor DB. Use of computerized statistical models to educate medical housestaff in estimating clinical outcomes. *Proceedings of the 11th Annual Symposium of computer Applications in Medical Care* 1987;162-165.
46. Chu A, Califf RM, Pryor DB, McKinnis RA, Harrell FE, Jr., Lee KL, Curtis SE, Oldham HN, Jr., Wagner GS. Prognostic effect of bundle branch block related to coronary artery bypass grafting. *Am J Cardiol* 1987;59:798-803.
47. Mark DB, Hlatky MA, Harrell FE, Jr., Lee KL, Califf RM, Pryor DB. Exercise treadmill score for predicting prognosis in coronary artery disease. *Ann Intern Med* 1987;106:793-800.
48. Mark DB, Hlatky MA, Lee KL, Harrell FE, Jr., Califf RM, Pryor DB. Localizing coronary artery obstructions with the exercise treadmill test. *Ann Intern Med* 1987;106:53-55.
49. Mark DB, Hlatky MA, Harrell FE, Jr., Lee KL, Califf RM, Pryor DB. Treadmill score for predicting prognosis in coronary artery disease. *Ann Intern Med* 1987;107:595-596.
50. Pryor DB, Harrell FE, Jr., Rankin JS, Lee KL, Muhlbaier LH, Oldham HN, Hlatky MA, Mark DB, Reves JG, Califf RM. The changing survival benefits of coronary revascularization over time. *Circulation* 1987;76:V13-21.
51. Slater DK, Hlatky MA, Mark DB, Harrell FE, Jr., Pryor DB, Califf RM. Outcome in suspected acute myocardial infarction with normal or minimally abnormal admission electrocardiographic findings. *Am J Cardiol* 1987;60:766-770.
52. Utz JA, Herfkens RJ, Heinsimer JA, Califf RM, Glover G, Pelc N, Shimakawa A. Cine MR determination of left ventricular ejection fraction. *AJR* 1987;American Journal of:839-843.
53. Bellinger RL, Califf RM, Mark DB, Weber RA, Collins P, Stone J, Phillips HR3, German L, Stack RS. Helicopter transport of patients during acute myocardial infarction. *Am J Cardiol* 1988;61:718-722.
54. Bounous EP, Jr., Califf RM, Harrell FE, Jr., Hinohara T, Mark DB, Ideker RE, Selvester RH, Wagner GS. Prognostic value of the simplified Selvester QRS score in patients with coronary artery disease. *J Am Coll Cardiol* 1988;11:35-41.
55. Califf RM, Topol EJ, George BS, Boswick JM, Sigmon KN, Candela R, Masek R, Kereiakes D, O'Neill WW, et al. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. *Am J Med* 1988;85:353-359.

56. Califf RM, Mark DB, Harrell FE, Jr., Hlatky MA, Lee KL, Rosati RA, Pryor DB. Importance of clinical measures of ischemia in the prognosis of patients with documented coronary artery disease. *J Am Coll Cardiol* 1988;11:20-26.
57. Califf RM, O'Neil W, Stack RS, Mark DB, Mantell S, George BS, Candela RJ, Kereiakes DJ, et al. Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. *Ann Intern Med* 1988;108:658-662.
58. Califf RM, Harrell FE, Jr., Lee KL, Rankin JS, Mark DB, Hlatky MA, Muhlbaier LH, Wechsler AS, Jones RH, Oldham HN, Jr., et al. Changing efficacy of coronary revascularization. Implications for patient selection. *Circulation* 1988;78:1185-91.
59. Califf RM, Topol EJ, George BS, Boswick JM, Lee KL, Stump D, Dillon J, Candela RJ, Kereiakes DJ, for the TAMI I Investigators. Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial. *Circulation* 1988;77:1090-1099.
60. Cummings RG, Reimer KA, Califf RM, Hackel D, Lowe JE. Quantitative analysis of right and left ventricular infarction in the presence of postinfarction ventricular septal defect. *Circulation* 1988;77:33-42.
61. Dunham G, Califf RM. Digoxin toxicity in renal insufficiency treated with digoxin immune fab: case summaries of two patients. *Primary Cardiology* 1988;15(1):31-34.
62. Hickey MS, Smith LR, Muhlbaier LH, Harrell FE, Jr., Reves JG, Hinohara T, Califf RM, Pryor DB, Rankin JS. Current prognosis of ischemic mitral regurgitation. Implications for future management. *Circulation* 1988;78:151-9.
63. Hlatky MA, Cotugno H, O'Connor C, Mark DB, Pryor DB, Califf RM. Adoption of thrombolytic therapy in the management of acute myocardial infarction. *Am J Cardiol* 1988;61:510-514.
64. Hlatky MA, Califf RM, Harrell FE, Jr., Lee KL, Mark DB, Pryor DB. Comparison of predictions based on observational data with the results of randomized controlled clinical trials of coronary artery bypass surgery. *J Am Coll Cardiol* 1988;11:237-245.
65. Hlatky MA, Cotugno HE, Mark DB, O'Connor C, Califf RM, Pryor DB. Trends in physician management of uncomplicated acute myocardial infarction, 1970 to 1987. *Am J Cardiol* 1988;61:515-518.
66. Kereiakes DJ, Topol EJ, George BS, Abbottsmith CW, Stack RS, Candela RJ, O'Neill WW, Martin LH, Califf RM. Emergency coronary artery bypass surgery preserves global and regional left ventricular function after intravenous tissue plasminogen activator therapy for acute myocardial infarction. *J Am Coll Cardiol* 1988;11:899-907.
67. Mark DB, Pollock BG, Hlatky MA, Harrell FE, Jr., Lee KL, Rankin JS, Wechsler AS, Pryor DB, Califf RM. Surgical survival benefits for coronary disease patients with left ventricular dysfunction. *Circulation* 1988;78:1151-7.
68. Rankin JS, Feneley MP, Hickey MS, Muhlbaier LH, Wechsler AS, Floyd RD, Reves JG, Skelton TN, Califf RM, Lowe JE, et al. A clinical comparison of mitral valve repair versus valve replacement in ischemic mitral regurgitation. *J Thorac Cardiovasc Surg.* 1988;95:165-177.
69. Simonton CA, Mark DB, Hinohara T, Rendall DS, Phillips H, Peter RH, Behar VS, Kong Y, O'Callaghan WG, O'Connor C, et al. Late restenosis after emergent coronary angioplasty for acute myocardial infarction: comparison with elective coronary angioplasty. *J Am Coll Cardiol* 1988;11:698-705.
70. Stack RS, O'Connor CM, Mark DB, Hinohara T, Phillips H, Lee MM, Ramirez NM, O'Callaghan WG, Simonton CA, Carlson EB, et al. Coronary perfusion during acute myocardial infarction with a combined therapy of coronary angioplasty and high-dose intravenous streptokinase. *Circulation* 1988;77:151-161.
71. Stack RS, Califf RM, Hinohara T, Phillips HR, Pryor DB, Simonton CA, Carlson EB, Morris KG, Behar VS, Kong Y, et al. Survival and cardiac event rates in the first year after emergency coronary angioplasty for acute myocardial infarction. *J Am Coll Cardiol* 1988;11:1141-1149.
72. Topol EJ, Califf RM, George BS, Kereiakes DJ, Rothbaum D, Candela RJ, Abbottsmith CW, Pinkerton CA, Stump DC, Collen D, et al. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. *Circulation* 1988;77:1100-1107.



73. Topol EJ, George BS, Kereiakes DJ, Candela RJ, Abbottsmith CW, Stump DC, Boswick JM, Stack RS, Califf RM. Comparison of two dose regimens of intravenous tissue plasminogen activator for acute myocardial infarction. *Am J Cardiol* 1988;61:723-728.
74. Worley SJ, Mark DB, Smith WM, Wolf P, Califf RM, Strauss HC, Manwaring MG, Ideker RE. Comparison of time domain and frequency domain variables from the signal-averaged electrocardiogram: a multivariable analysis. *J Am Coll Cardiol* 1988;11:1041-1051.
75. Antman EM, Dupont WD, Bonalsky J, Califf RM, Corwin S, Fink L, Hansen DE, Kawanishi DT, Kronenberg MW, McKay CR, for the Phase IV Metoprolol in Myocardial Infarction Study Group. Early treatment with intravenous metoprolol for suspected acute myocardial infarction: a phase IV United States trial. *Int J Cardiol* 1989;23:185-197.
76. Bates ER, Califf RM, Stack RS, George BS, Candela RJ, Kereiakes DJ, Abbottsmith CW, Pitt B, for the TAMI-1 Investigators. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality. *J Am Coll Cardiol* 1989;13:12-18.
77. Califf RM, Harrell FE, Jr., Lee KL, Rankin JS, Hlatky MA, Mark DB, Jones RH, Muhlbaier LH, Oldham HN, Jr., Pryor DB. The evolution of medical and surgical therapy for coronary artery disease. A 15-year perspective. *JAMA* 1989;261:2077-2086.
78. Cummings RG, Califf RM, Jones RN, Reimer KA, Kong YH, Lowe JE. Correlates of survival in patients with postinfarction ventricular septal defect. *Ann Thorac Surg* 1989;47:824-830.
79. Ellis SG, Topol EJ, George BS, Kereiakes DJ, Debowey D, Sigmon KN, Pickel A, Lee KL, Califf RM. Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. *Circulation* 1989;80:1159-1165.
80. Grines CL, Topol EJ, Califf RM, Stack RS, George BS, Kereiakes D, Boswick JM, Kline E, O'Neill WW, for the TAMI Study Groups. Prognostic implications and predictors of enhanced regional wall motion of the noninfarct zone after thrombolysis and angioplasty therapy of acute myocardial infarction. *Circulation* 1989;80:245-253.
81. Hlatky MA, Boineau RE, Higginbotham MB, Lee KL, Mark DB, Califf RM, Cobb FR, Pryor DB. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). *Am J Cardiol* 1989;64:651-654.
82. Hlatky MA, Mark DB, Califf RM, Pryor DB. Angina, myocardial ischemia and coronary disease: gold standards, operational definitions and correlations. *J Clin Epidemiol* 1989;42:381-384.
83. Honan MB, Pryor DB, Rendall DS, Stack RS, Hinohara T, Skelton TN, Califf RM, Hlatky MA, Mark DB. Exercise treadmill testing is a poor predictor of anatomic restenosis after angioplasty for acute myocardial infarction. *Circulation* 1989;80:1585-1594.
84. Kereiakes DJ, Topol EJ, George BS, Abbottsmith CW, Stack RS, Candela RJ, O'Neill WW, Anderson LC, Califf RM, for the TAMI Study Group. Favorable early and long-term prognosis following coronary bypass surgery therapy for myocardial infarction: results of a multicenter trial. *Am Heart J* 1989;118:199-207.
85. Kong DF, Lee KL, Harrell FE, Jr., Boswick JM, Mark DB, Hlatky MA, Califf RM, Pryor DB. Clinical experience and predicting survival in coronary disease. *Arch Intern Med* 1989;149:1177-1181.
86. Mark DB, Hlatky MA, Califf RM, Morris JJ, Jr., Sisson SD, McCants CB, Lee KL, Harrell FE, Jr., Pryor DB. Painless exercise ST deviation on the treadmill: long-term prognosis. *J Am Coll Cardiol* 1989;14:885-892.
87. Quigley PJ, Hlatky MA, Hinohara T, Rendall DS, Perez JA, Phillips HR, Califf RM, Stack RS. Repeat percutaneous transluminal coronary angioplasty and predictors of recurrent restenosis. *Am J Cardiol* 1989;63:409-413.
88. Stump DC, Califf RM, Topol EJ, Sigmon K, Thornton D, Masek R, Collen D, for the TAMI Study Group. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. *Circulation* 1989;80:1222-1230.

89. Topol EJ, George BS, Kereiakes DJ, Stump DC, Candela RJ, Abbottsmith CW, Pickel A, Boswick JM, Lee KL, Ellis SG, Califf RM, the TAMI Study Group. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. *Circulation* 1989;79:281-286.
90. Topol EJ, Ellis SG, Califf RM, George BS, Stump DC, Bates ER, Nabel EG, Walton JA, Candela RJ, Lee KL, for the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. *J Am Coll Cardiol* 1989;14:877-884.
91. Wall TC, Strickland J, Masoud J, Tse A, Pasi D, Zawodniak M, Hoekstra J, Mantell S, Sigmon K, Stack RS, Phillips HR, Califf RM. Thrombolytic therapy on the homefront. Intravenous urokinase in community hospitals. *NC Med J* 1989;50:363-366.
92. Wall TC, Mark DB, Califf RM, Collins G, Burgess R, Skelton TN, Hinohara T, Kong DF, Mantell S, et al. Prediction of early recurrent myocardial ischemia and coronary reocclusion after successful thrombolysis: a qualitative and quantitative angiographic study. *Am J Cardiol* 1989;63:423-428.
93. Abbottsmith CW, Topol EJ, George BS, Stack RS, Kereiakes DJ, Candela RJ, Anderson LC, Harrelson-Woodlief SL, Califf RM. Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty. *J Am Coll Cardiol* 1990;16:770-778.
94. Bates ER, Clemmensen PM, Califf RM, Gorman LE, Aronson LG, George BS, Kereiakes DJ, Topol EJ, for the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Precordial ST segment depression predicts a worse prognosis in inferior infarction despite reperfusion therapy. *J Am Coll Cardiol* 1990;16:1538-1544.
95. Califf RM, Topol EJ, George BS, Kereiakes DJ, Aronson LG, Lee KL, Martin L, Candela R, O'Neill WW, for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. One-year outcome after therapy with tissue plasminogen activator: report from the Thrombolysis and Angioplasty in Myocardial Infarction trial. *Am Heart J* 1990;119:777-785.
96. Hlatky MA, Lipscomb J, Nelson C, Califf RM, Pryor D, Wallace AG, Mark DB. Resource use and cost of initial coronary revascularization. Coronary angioplasty versus coronary bypass surgery. *Circulation* 1990;82:IV208-13.
97. Honan MB, Harrell FE, Jr., Reimer KA, Califf RM, Mark DB, Pryor DB, Hlatky MA. Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. *J Am Coll Cardiol* 1990;16:359-367.
98. Krucoff MW, Croll MA, Pope JE, Granger CB, Pieper KS, Sigmon KN, Lee KL, Califf RM. Heuristic and logistic principles of ST-segment interpretation in the time domain. Evolution in the context of the TAMI 7 trial design. *J Electrocardiol* 1990;23 Suppl:6-10.
99. Lee JC, Lipscomb J, Bashore TM, Mark DB, Califf RM, Pryor DB, Hlatky MA. Feasibility and cost-saving potential of outpatient cardiac catheterization. *J Am Coll Cardiol* 1990;15:378-384.
100. Lee KL, Pryor DB, Pieper KS, Harrell FE, Jr., Califf RM, Mark DB, Hlatky MA, Coleman RE, Cobb FR, Jones RH. Prognostic value of radionuclide angiography in medically treated patients with coronary artery disease. A comparison with clinical and catheterization variables. *Circulation* 1990;82:1705-1717.
101. Mark DB, Honan MB, Rendall DS, Hinohara T, Stack RS, Hlatky MA, Califf RM, Lee KL, Pryor DB. Detection of restenosis after elective percutaneous transluminal coronary angioplasty using the exercise treadmill test. *Am J Cardiol* 1990;65:28-34.
102. Muller DW, Topol EJ, Califf RM, Sigmon KN, Gorman L, George BS, Kereiakes DJ, Lee KL, Ellis SG, for the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. *Am Heart J* 1990;119:224-231.
103. Muller DW, Topol EJ, George BS, Kereiakes DJ, Aronson LG, Lee KL, Abbottsmith CW, Ellis SG, Califf RM, for the Thrombolysis and Angioplasty Study Group. Two-year outcome after angiographically documented myocardial reperfusion for acute coronary occlusion. *Am J Cardiol* 1990;66:796-801.

104. O'Connor CM, Califf RM, Massey EW, Mark DB, Kereiakes DJ, Candela RJ, George B, Stack RS, et al. Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis. *J Am Coll Cardiol* 1990;16:533-540.
105. Ohman EM, Califf RM, Topol EJ, Candela R, Ellis S, Sigmon KN, Kereiakes D, George B, Stack R, for the TAMI Study Group. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. *Circulation* 1990;82:781-791.
106. Wall TC, Califf RM, Harrelson-Woodlief L, Mark DB, Honan M, Abbottsmith CW, Candela R, Phillips HR, Topol EJ, for the TAMI Study Group. Usefulness of a pericardial friction rub after thrombolytic therapy during acute myocardial infarction in predicting amount of myocardial damage. *Am J Cardiol* 1990;66:1418-1421.
107. Wall TC, Phillips HR, Stack RS, Mantell S, Sigmon K, DiMeo M, Chaplin D, Whitcomb D, et al. Results of high dose intravenous urokinase for acute myocardial infarction. *Am J Cardiol* 1990;65:124-131.
108. Williams DO, Topol EJ, Califf RM, Roberts R, Mancini GB, Joelson JM, Ellis SG, Kleiman NS. Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo- controlled, randomized trial. *Circulation* 1990;82:376-383.
109. Belkin RN, Mark DB, Szwed H, Califf RM, Kisslo J. Pericardial effusion after intravenous recombinant tissue-type plasminogen activator for acute myocardial infarction. *Am J Cardiol* 1991;67:496-500.
110. Califf RM, Topol EJ, Stack RS, Ellis SG, George BS, Kereiakes DJ, Samaha JK, Worley SJ, Anderson JL, Harrelson-Woodlief L, for the TAMI Investigators. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. *Circulation* 1991;83:1543-1556.
111. Clemmensen P, Bates ER, Califf RM, Hlatky MA, George BS, Lee KL, Kereiakes DJ, Gacioch G, for the TAMI Investigators. Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. *Am J Cardiol* 1991;67:225-230.
112. Jackman JD, Jr., Navetta FI, Smith JE, Tchong JE, Davidson CJ, Phillips HR, Califf RM, Nelson CL, Gardner LH, Stack RS. Percutaneous transluminal coronary angioplasty in octogenarians as an effective therapy for angina pectoris. *Am J Cardiol* 1991;68:116-119.
113. Kereiakes DJ, Topol EJ, George BS, Stack RS, Abbottsmith CW, Ellis S, Candela RJ, Harrelson L, Martin LH, Califf RM, for the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Myocardial infarction with minimal coronary atherosclerosis in the era of thrombolytic reperfusion. *J Am Coll Cardiol* 1991;17:304-312.
114. Kereiakes DJ, Califf RM, George BS, Ellis S, Samaha J, Stack R, Martin LH, Topol EJ, for the TAMI Study Group. Coronary bypass surgery improves global and regional left ventricular function following thrombolytic therapy for acute myocardial infarction. *Am Heart J* 1991;122:390-399.
115. Mark DB, Shaw L, Harrell FE, Jr., Hlatky MA, Lee KL, McCants CB, Califf RM, Pryor DB. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. *N Engl J Med* 1991;325:849-853.
116. Mark DB, Sigmon K, Topol EJ, Kereiakes DJ, Pryor DB, Candela RJ, Califf RM. Identification of acute myocardial infarction patients suitable for early hospital discharge after aggressive interventional therapy. Results from the Thrombolysis and Angioplasty in Acute Myocardial Infarction Registry. *Circulation* 1991;83:1186-1193.
117. Muller DW, Topol EJ, Ellis SG, Sigmon KN, Lee K, Califf RM, for the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Multivessel coronary artery disease: a key predictor of short- term prognosis after reperfusion therapy for acute myocardial infarction. *Am Heart J* 1991;121:1042-1049.
118. Muller DW, Topol EJ, Ellis SG, Woodlief LH, Sigmon KN, Kereiakes DJ, George BS, Worley SJ, Samaha JK, Phillips H3, et al. Determinants of the need for early acute intervention in patients treated conservatively after thrombolytic therapy for acute myocardial infarction. TAMI-5 Study Group. *J Am Coll Cardiol* 1991;18:1594-1601.

119. Nelson CL, Herndon JE, Mark DB, Pryor DB, Califf RM, Hlatky MA. Relation of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index. *Am J Cardiol* 1991;68:973-975.
120. Ohman EM, Califf RM, George BS, Quigley PJ, Kereiakes DJ, Harrelson-Woodlief L, Candela RJ, Flanagan C, Stack RS, Topol EJ, for the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction. *Am Heart J* 1991;121:895-901.
121. Pryor DB, Shaw L, Harrell FE, Jr., Lee KL, Hlatky MA, Mark DB, Muhlbaier LH, Califf RM. Estimating the likelihood of severe coronary artery disease. *Am J Med* 1991;90:553-562.
122. Sane DC, Stump DC, Topol EJ, Sigmon KN, Kereiakes DJ, George BS, Mantell SJ, Macy E, Collen D, Califf RM. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. *Thromb Haemost.* 1991;65:275-279.
123. Sane DC, Stump DC, Topol EJ, Sigmon KN, Clair WK, Kereiakes DJ, George BS, Stoddard MF, Bates ER, Stack RS, et al. Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group [see comments]. *Circulation* 1991;83:170-175.
124. Smith LR, Harrell FE, Jr., Rankin JS, Califf RM, Pryor DB, Muhlbaier LH, Lee KL, Mark DB, Jones RH, Oldham HN, et al. Determinants of early versus late cardiac death in patients undergoing coronary artery bypass graft surgery. *Circulation* 1991;84:III245-53.
125. Tenaglia AN, Califf RM, Candela RJ, Kereiakes DJ, Young SY, Stack RS, Topol EJ. Thrombolytic therapy in patients requiring cardiopulmonary resuscitation. *Am J Cardiol* 1991;68:1015-1019.
126. Wallis DE, Boden WE, Califf RM, Crawford MH, Hakki AH, Iskandrian AS, Labovitz A, O'Connor C, Sutton R, Scanlon PJ. Failure of adjuvant heparin to reduce myocardial ischemia in the early treatment of patients with unstable angina. *Am Heart J* 1991;122:949-954.
127. Bickell NA, Pieper KS, Lee KL, Mark DB, Glower DD, Pryor DB, Califf RM. Referral patterns for coronary artery disease treatment: gender bias or good clinical judgment? *Ann Intern Med* 1992;116:791-797.
128. Califf RM, Pieper KS, Harlan WR3, Lee KL. Serum cholesterol in patients undergoing cardiac catheterization for suspected coronary artery disease: diagnostic and prognostic implications. *Ann Epidemiol* 1992;2:137-145.
129. Kaplan AJ, Pieper KS, Wildermann NM, Mark DB, Pryor DB, Phillips HR3, Califf RM. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. *J Am Coll Cardiol* 1992;20:1482-1489.
130. Krucoff MW, Croll M, Pope J, Ryan J, Pieper K, Sawchak S, Wagner B, Crater S, Califf RM. Unstable infarct artery. Quantification across angiographic subgroups using continuous digital 12-lead ST-segment recovery analysis. *J Electrocardiol* 1992;24 Suppl:15
131. Mark DB, Lam LC, Lee KL, Clapp-Channing NE, Pryor DB, Califf RM, Hlatky MA. Identification of patients with coronary disease at high risk for loss of employment. A prospective validation study. *Circulation* 1992;86:1485-1494.
132. Muhlbaier LH, Pryor DB, Rankin JS, Smith LR, Mark DB, Jones RH, Glower DD, Harrell FE, Jr., Lee KL, Califf RM, et al. Observational comparison of event-free survival with medical and surgical therapy in patients with coronary artery disease. 20 years of follow-up. *Circulation* 1992;86:III198-204.
133. Ortel TL, Gockerman JP, Califf RM, McCann RL, O'Connor CM, Metzler DM, Greenberg CS. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. *Thromb Haemost.* 1992;67:292-296.
134. Popma JJ, Califf RM, Ellis SG, George BS, Kereiakes DJ, Samaha JK, Worley SJ, Anderson JL, Stump D, et al. Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study. *J Am Coll Cardiol* 1992;20:1305-1312.

- 135.Sane DC, Gresalfi NJ, Enney-O'Mara LA, Califf RM, Greenberg CS, Bovill EG, Oberhardt BJ. Exploration of rapid bedside monitoring of coagulation and fibrinolysis parameters during thrombolytic therapy. *Blood Coagulation & Fibrinolysis* 1992;3:47-54.
- 136.Sketch MH, Jr., Quigley PJ, Perez JA, Davidson CJ, Muhlestein JB, Herndon JE2, Glower DD, Phillips HR, Califf RM, Stack RS. Angiographic follow-up after internal mammary artery graft angioplasty. *Am J Cardiol* 1992;70:401-403.
- 137.Tcheng JE, Jackman JD, Jr., Nelson CL, Gardner LH, Smith LR, Rankin JS, Califf RM, Stack RS. Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarction. *Ann Intern Med* 1992;117:18-24.
- 138.Topol EJ, Califf RM, Vandormael M, Grines CL, George BS, Sanz ML, Wall T, O'Brien M, Schwaiger M, Aguirre FV, for the Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group. A randomized trial of late reperfusion therapy for acute myocardial infarction. *Circulation* 1992;85:2090-2099.
- 139.Topol EJ, Van de Werf F, Kleiman N, Lee K, Morris D, Simoons M, White H, Califf RM. Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee. *J Am Coll Cardiol* 1992;19:1123-1128.
- 140.Veldkamp RF, Sawchak ST, Pope JE, Mertens JR, Mortara DW, Califf RM, Krucoff MW. Evolution of an automated ST-segment analysis program for dynamic real-time, noninvasive detection of coronary occlusion and reperfusion. *J Electrocardiol* 1992;25 Suppl:182-187.
- 141.Wall TC, Califf RM, George BS, Ellis SG, Samaha JK, Kereiakes DJ, Worley SJ, Sigmon K, Topol EJ, for the TAMI-7 Study Group. Accelerated plasminogen activator dose regimens for coronary thrombolysis. *J Am Coll Cardiol* 1992;19:482-489.
- 142.Williams RB, Barefoot JC, Califf RM, Haney TL, Saunders WB, Pryor DB, Hlatky MA, Siegler IC, Mark DB. Prognostic importance of social and economic resources among medically treated patients with angiographically documented coronary artery disease. *JAMA* 1992;267:520-524.
- 143.Bernardi MM, Califf RM, Kleiman N, Ellis SG, Topol EJ, for the TAMI Study Group. Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. *Am J Cardiol* 1993;72:1121-1125.
- 144.Chapman GD, Ohman EM, Topol EJ, Candela RJ, Kereiakes DJ, Samaha J, Pieper KS, Young SY, Califf RM, for the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Minimizing the risk of inappropriately administering thrombolytic therapy. *Am J Cardiol* 1993;71:783-787.
- 145.Dudley RA, Harrell FE, Jr., Smith LR, Mark DB, Califf RM, Pryor DB, Glower D, Lipscomb J, Hlatky M. Comparison of analytic models for estimating the effect of clinical factors on the cost of coronary artery bypass graft surgery. *J Clin Epidemiol* 1993;46:261-271.
- 146.Ellis SG, Tcheng JE, Navetta FI, Muller DW, Weisman HF, Smith C, Anderson KM, Califf RM, Topol EJ. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. *Coron Artery Dis* 1993;4:167-175.
- 147.Granger CB, Califf RM, Candela R, Samaha J, Kereiakes DJ, Topol EJ, for the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. *J Am Coll Cardiol* 1993;21:920-925.
- 148.Harrison JK, Califf RM, Woodlief LH, Kereiakes D, George BS, Stack RS, Ellis SG, Lee KL, O'Neill W, Topol EJ, for the TAMI Study Group. Systolic left ventricular function after reperfusion therapy for acute myocardial infarction. Analysis of determinants of improvement. *Circulation* 1993;87:1531-1541.
- 149.Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. *J Am Coll Cardiol* 1993;22:381-389.

150. Krucoff MW, Croll MA, Pope JE, Granger CB, O'Connor CM, Sigmon KN, Wagner BL, Ryan JA, Lee KL, Kereiakes DJ, Samaha JK, Worley SJ, Califf RM. Continuous 12-lead ST-segment recovery analysis in the TAMI 7 study. *Circulation* 1993;88:437-446.
151. Krucoff MW, Croll MA, Pope JE, Pieper KS, Kanani PM, Granger CB, Veldkamp RF, Wagner BL, Sawchak ST, Califf RM. Continuously updated 12-lead ST-segment recovery analysis for myocardial infarct artery patency assessment and its correlation with multiple simultaneous early angiographic observations. *Am J Cardiol* 1993;71:145-151.
152. Lincoff AM, Califf RM, Ellis SG, Sigmon KN, Lee KL, Leimberger JD, Topol EJ, for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Thrombolytic therapy for women with myocardial infarction: is there a gender gap? *J Am Coll Cardiol* 1993;22:1780-1787.
153. Ohman EM, Christenson RH, Califf RM, George BS, Samaha JK, Kereiakes DJ, Worley SJ, Wall TC, Sigmon KN, for the TAMI 7 Study Group. Noninvasive detection of reperfusion after thrombolysis based on serum creatine kinase MB changes and clinical variables. *Am Heart J* 1993;126:819-826.
154. Ohman EM, Topol EJ, Califf RM, Bates ER, Ellis SG, Kereiakes DJ, George BS, Samaha JK, Kline E, Sigmon KN, for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. An analysis of the cause of early mortality after administration of thrombolytic therapy. *Coron Artery Dis* 1993;4:957-964.
155. Pryor DB, Shaw L, McCants CB, Lee KL, Mark DB, Harrell FE, Jr., Muhlbaier LH, Califf RM. Value of the history and physical in identifying patients at increased risk for coronary artery disease. *Ann Intern Med* 1993;118:81-90.
156. Simoons ML, Maggioni AP, Knatterud G, Leimberger JD, de Jaegere P, van Domburg R, Boersma E, Franzosi MG, Califf RM, Schroder R, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. *Lancet* 1993;342:1523-1528.
157. Stead WW, Bird WP, Califf RM, Elchlepp JG, Hammond WE, Kinney TR. The IAIMS at Duke University Medical Center: transition from model testing to implementation. *MD Computing* 1993;10:225-230.
158. Tenaglia AN, Fortin DF, Frid DJ, Gardner LH, Nelson CL, Tchong JE, Stack RS, Califf RM. Long-term outcome following successful reopening of abrupt closure after coronary angioplasty. *Am J Cardiol* 1993;72:21-25.
159. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators [see comments] [published erratum appears in *N Engl J Med* 1994 Feb 17;330(7):516]. *N Engl J Med* 1993;329:1615-1622.
160. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators [see comments]. *N Engl J Med* 1993;329:673-682.
161. Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, Masden RR, Serruys PW, Leon MB, Williams DO, et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group [see comments]. *N Engl J Med* 1993;329:221-227.
162. Wall TC, Califf RM, Ellis SG, Sigmon K, Kereiakes D, George BS, Samaha J, Sane D, Stump DC, Stack RS, for the TAMI Study Group. Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. *J Am Coll Cardiol* 1993;21:597-603.
163. Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ, for the EPIC Investigators. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. *Am J Cardiol* 1994;74:1166-1170.
164. Brodie BR, Grines CL, Ivanhoe R, Knopf W, Taylor G, O'Keefe J, Weintraub RA, Berdan LG, Tchong JE, Woodlief LH, et al. Six-month clinical and angiographic follow-up after direct angioplasty for acute myocardial infarction. Final results from the Primary Angioplasty Registry. *Circulation* 1994;90:156-162.

165. Ellis SG, Lincoff AM, George BS, Kereiakes DJ, Ohman EM, Krucoff MW, Califf RM, Topol EJ, for the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for the treatment of acute myocardial infarction: a new look at an old study. *Coron Artery Dis* 1994;5:611-615.
166. Faxon DP, Spiro TE, Minor S, Cote G, Douglas J, Gottlieb R, Califf RM, Dorosti K, Topol E, Gordon JB, for the ERA Investigators. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. *Circulation* 1994;90:908-914.
167. FTT Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group [published erratum appears in *Lancet* 1994 Mar 19;343(8899):742] [see comments]. [Review] [58 refs]. *Lancet* 1994;343:311-322.
168. Granger CB, White HD, Bates ER, Ohman EM, Califf RM. A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. *Am J Cardiol* 1994;74:1220-1228.
169. GUSTO IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators [see comments]. *Circulation* 1994;90:1631-1637.
170. Harrington RA, Sane DC, Califf RM, Sigmon KN, Abbottsmith CW, Candela RJ, Lee KL, Topol EJ, for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. *J Am Coll Cardiol* 1994;23:891-898.
171. Hillegass WB, Ohman EM, Leimberger JD, Califf RM. A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty. *Am J Cardiol* 1994;73:835-839.
172. Hillegass WB, Jollis JG, Granger CB, Ohman EM, Califf RM, Mark DB. Intracranial hemorrhage risk and new thrombolytic therapies in acute myocardial infarction. *Am J Cardiol* 1994;73:444-449.
173. Kleiman NS, White HD, Ohman EM, Ross AM, Woodlief LH, Califf RM, Holmes DR, Jr., Pfisterer M, Vahanian A, for the GUSTO Investigators. Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. *Circulation* 1994;90:2658-2665.
174. Krucoff MW, Green CL, Harrell FE, Jr., Wildermann NM, Trollinger KM, Sawchak ST, Pope JE, Shah A, Granger CB, Califf RM, Simoons ML, Lee KL. Reconsidering the statistical analysis of continuous ST-segment data streams with gaps: potential optimization of application specific information content using left, right and interval censoring. *J Electrocardiol* 1994;27:
175. Lee KL, Califf RM, Simes J, Van de Werf F, Topol EJ. Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. *Ann Intern Med* 1994;120:876-81; discussion 882-5.
176. Mark DB, Lam LC, Lee KL, Jones RH, Pryor DB, Stack RS, Clapp-Channing NE, Califf RM, Hlatky MA. Effects of coronary angioplasty, coronary bypass surgery, and medical therapy on employment in patients with coronary artery disease. A prospective comparison study. *Ann Intern Med* 1994;120:111-117.
177. Mark DB, Naylor CD, Hlatky MA, Califf RM, Topol EJ, Granger CB, Knight JD, Nelson CL, Lee KL, Clapp-Channing NE, et al. Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. *N Engl J Med* 1994;331:1130-1135.
178. Mark DB, Nelson CL, Califf RM, Harrell FE, Jr., Lee KL, Jones RH, Fortin DF, Stack RS, Glower DD, Smith LR, et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. *Circulation* 1994;89:2015-2025.
179. Mark DB, Shaw LK, DeLong ER, Califf RM, Pryor DB. Absence of sex bias in the referral of patients for cardiac catheterization. *N Engl J Med* 1994;330:1101-1106.

180. O'Connor CM, Meese R, Carney R, Smith J, Conn E, Burks J, Hartman C, Roark S, Shadoff N, Heard M3, et al. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1. *J Am Coll Cardiol* 1994;23:11-18.
181. O'Neill WW, Brodie BR, Ivanhoe R, Knopf W, Taylor G, O'Keefe J, Grines C, Weintraub R, Sickinger BG, Berdan LG, et al. Primary coronary angioplasty for acute myocardial infarction (the Primary Angioplasty Registry). *Am J Cardiol* 1994;73:627-634.
182. Ohman EM, George BS, White CJ, Kern MJ, Gurbel PA, Freedman RJ, Lundergan C, Hartmann JR, Talley JD, Frey MJ, et al. Use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction. Results of a randomized trial. The Randomized IABP Study Group. *Circulation* 1994;90:792-799.
183. Ohman EM, Marquis JF, Ricci DR, Brown RI, Knudtson ML, Kereiakes DJ, Samaha JK, Margolis JR, Niederman AL, Dean LS, et al. A randomized comparison of the effects of gradual prolonged versus standard primary balloon inflation on early and late outcome. Results of a multicenter clinical trial. Perfusion Balloon Catheter Study Group. *Circulation* 1994;89:1118-1125.
184. Reiner JS, Lundergan CF, van den Brand M, Thompson MA, Machecourt J, Py A, Pilcher GS, Fink CA, Burton JR, et al. Early angiography cannot predict post thrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. *J Am Coll Cardiol* 1994;24:1439-1444.
185. Selker HP, Beshansky JR, Schmid CH, Griffith JL, Longstreth WT, Jr., O'Connor CM, Caplan LR, Massey EW, D'Agostino RB, Laks M, et al. Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage. Thrombolytic Predictive Instrument (TPI) Project results. *Circulation* 1994;90:1657-1661.
186. Shah A, Green CL, Trollinger KM, Wilderman NM, Pope JE, Califf RM, Wagner GS, Krucoff MW. Reassessing the clinical significance of ST-segment depression that occurs concomitantly with the ST-segment elevation during acute myocardial infarction with the use of continuous ST-segment analysis. *J Electrocardiol* 1994;27 Suppl:256-259.
187. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. *Circulation* 1994;90:1757-1764.
188. Tenaglia AN, Fortin DF, Califf RM, Frid DJ, Nelson CL, Gardner L, Miller M, Navetta FI, Smith JE, Tcheng JE, et al. Predicting the risk of abrupt vessel closure after angioplasty in an individual patient. *J Am Coll Cardiol* 1994;24:1004-1011.
189. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation [see comments]. *N Engl J Med* 1994;330:956-961.
190. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK, Tannenbaum MA, et al. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. *Circulation* 1994;89:1557-1566.
191. Topol EJ, Califf RM. Scorecard cardiovascular medicine. Its impact and future directions. *Ann Intern Med* 1994;120:65-70.
192. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Ivanhoe R, George BS, Fintel D, Weston M, for the EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. *Lancet* 1994;343:881-886.
193. Veldkamp RF, Green CL, Wilkins ML, Pope JE, Sawchak ST, Ryan JA, Califf RM, Wagner GS, Krucoff MW, for the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 7 Study Group. Comparison of continuous ST-segment recovery analysis with methods using static electrocardiograms for noninvasive patency assessment during acute myocardial infarction. *Am J Cardiol* 1994;73:1069-1074.



194. Wall TC, Califf RM, Talley JD, Tannenbaum M, Schwaiger M, Gacioch G, Cohen MD, Sanz M, Leimberger JD, for the TAMI 9 Research Group. Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. *Circulation* 1994;90:114-120.
195. Aguirre FV, Topol EJ, Ferguson JJ, Blankenship JC, Heuser R, Sigmon K, Taylor M, Gottlieb R, Hanovich G. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. *Circulation* 1995;91:2882-2890.
196. Barbash GI, Reiner J, White HD, Wilcox RG, Sadowski Z, Morris D, Woodlief LH, Topol EJ. Evaluation of paradoxical beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. *Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol* 1995;26:1222-1229.
197. Boehrer JD, Ellis SG, Pieper K, Holmes DR, Keeler GP, Debowey D, Chapekis AT, Leya F, Mooney MR, Gottlieb RS, et al. Directional atherectomy versus balloon angioplasty for coronary ostial and nonostial left anterior descending coronary artery lesions: results from a randomized multicenter trial. The CAVEAT- I investigators. *Coronary Angioplasty Versus Excisional Atherectomy Trial. J Am Coll Cardiol* 1995;25:1380-1386.
198. Burnett RE, Blumenthal JA, Mark DB, Leimberger JD, Califf RM. Distinguishing between early and late responders to symptoms of acute myocardial infarction. *Am J Cardiol* 1995;75:1019-1022.
199. Christenson RH, Ohman EM, Topol EJ, O'Hanesian MA, Sigmon KN, Duh SH, Kereiakes D, Worley SJ, George BS, Pizzo CK, et al. Creatine kinase MM and MB isoforms in patients receiving thrombolytic therapy and acute angiography. TAMI Study Group. *Clin Chem* 1995;41:844-852.
200. Elliott JM, Berdan LG, Holmes DR, Isner JM, King SB, Keeler GP, Kearney M, Califf RM, Topol EJ. One-year follow-up in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT I). *Circulation* 1995;91:2158-2166.
201. Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, Barbash GI, Van de Werf F, Aylward PE, Topol EJ, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. *Global Use of Strategies to Open Occluded Coronary Arteries [see comments]. Circulation* 1995;92:2811-2818.
202. Granger CB, Topol EJ, Worley SJ, Kereiakes DJ, George BS, Ohman EM, Leimberger JD, Mark DB, Califf RM, for the TAMI Study Group. Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. *Am J Cardiol* 1995;76:1007-1013.
203. Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Krucoff MW, Green C, Harrington RA, Ohman EM, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. *Circulation* 1995;91:1929-1935.
204. Grines CL, Topol EJ, O'Neill WW, George BS, Kereiakes D, Phillips HR, Leimberger JD, Woodlief LH, Califf RM. Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. *Circulation* 1995;91:298-303.
205. Hamel MB, Goldman L, Teno J, Lynn J, Davis RB, Harrell FE, Jr., Connors AF, Jr., Califf RM, Kussin P, for the SUPPORT Investigators. Identification of comatose patients at high risk for death or severe disability. *JAMA* 1995;273:1842-1848.
206. Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff A, Tchong JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. *Am J Cardiol* 1995;76:1222-1227.
207. Harrington RA, Lincoff AM, Califf RM, Holmes DR, Jr., Berdan LG, O'Hanesian MA, Keeler GP, Garratt KN, Ohman EM, Mark DB, for the CAVEAT Investigators. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). *J Am Coll Cardiol* 1995;25:1693-1699.
208. Hlatky MA, Lam LC, Lee KL, Clapp-Channing NE, Pryor DB, Califf RM, Mark DB. Job strain and the prevalence and outcome of coronary artery disease. *Circulation* 1995;92:327-333.

209. Holmes DR, Jr., Topol EJ, Califf RM, Berdan LG, Leya F, Berger PB, Whitlow PL, Safian RD, Adelman AG, Kellett MA, Jr., for the CAVEAT-II Investigators. A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. *Circulation* 1995;91:1966-1974.
210. Holmes DR, Jr., Simpson JB, Berdan LG, Gottlieb RS, Leya F, Keeler GP, Califf RM, Topol EJ. Abrupt closure: the CAVEAT I experience. *Coronary Angioplasty Versus Excisional Atherectomy Trial*. *J Am Coll Cardiol* 1995;26:1494-1500.
211. Holmes DR, Jr., Bates ER, Kleiman NS, Sadowski Z, Horgan JH, Morris DC, Califf RM, Berger PB, Topol EJ, for the GUSTO-I Investigators. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. *J Am Coll Cardiol* 1995;26:668-674.
212. Karnash SL, Granger CB, White HD, Woodlief LH, Topol EJ, Califf RM. Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. *J Am Coll Cardiol* 1995;26:1651-1656.
213. Knaus WA, Harrell FE, Jr., Lynn J, Goldman L, Phillips RS, Connors AF, Jr., Dawson NV, Fulkerson WJ, Jr., Califf RM, Desbiens N, for the SUPPORT Investigators. The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments. *Ann Intern Med* 1995;122:191-203.
214. Krucoff MW, Veldkamp R, Trollinger KM, Bengston JR, Keeler GP, Pieper KS, Sawchak ST, Pope JE, Califf RM, Greenfield JC, Jr. Inter-and-intra-observer variability performing continuously updated ST-segment recovery analysis following thrombolytic therapy for myocardial infarction. *J Electrocardiol* 1995;
215. Langer A, Krucoff MW, Klootwijk P, Veldkamp R, Simoons ML, Granger C, Califf RM, Armstrong PW. Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. *J Am Coll Cardiol* 1995;25:1552-1557.
216. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, Simoons M, Van de Werf F, Califf RM, for the GUSTO-I Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. *Circulation* 1995;91:1659-1668.
217. Lefkowitz J, Holmes DR, Califf RM, Safian RD, Pieper K, Keeler G, Topol EJ. Predictors and sequelae of distal embolization during saphenous vein graft intervention from the CAVEAT-II trial. *Coronary Angioplasty Versus Excisional Atherectomy Trial*. *Circulation* 1995;92:734-740.
218. Lincoff AM, Topol EJ, Califf RM, Sigmon KN, Lee KL, Ohman EM, Rosenschein U, Ellis SG, for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). *Am J Cardiol* 1995;75:871-876.
219. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, White H, Simoons ML, Nelson CL. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. *N Engl J Med* 1995;332:1418-1424.
220. Mark DB, O'Neill WW, Brodie B, Ivanhoe R, Knopf W, Taylor G, O'Keefe J, Grines CL, Davidson-Ray L, Knight JD, et al. Baseline and 6-month costs of primary angioplasty therapy for acute myocardial infarction: results from the primary angioplasty registry. *J Am Coll Cardiol* 1995;26:688-695.
221. Maynard C, Selker HP, Beshansky JR, Griffith JL, Schmid CH, Califf RM, D'Agostino RB, Laks MM, Lee KL, Wagner GS, et al. The exclusion of women from clinical trials of thrombolytic therapy: implications for developing the thrombolytic predictive instrument database. *Med Decis Making* 1995;15:38-43.
222. Moliterno DJ, Harrington RA, Califf RM, Rapold HJ, Topol EJ. Randomized, placebo-controlled study of Lamifiban with thrombolytic therapy for the treatment of acute myocardial infarction: rationale and design for the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction. *J Thromb Thrombolysis*. 1995;2:165-169.

223. Moliterno DJ, Califf RM, Aguirre FV, Sigmon KN, Weisman HF, Topol EJ. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. *Am J Cardiol* 1995;75:559-562.
224. Omoigui NA, Califf RM, Pieper K, Keeler G, O'Hanesian MA, Berdan LG, Mark DB, Talley JD, Topol EJ. Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). *J Am Coll Cardiol* 1995;26:922-930.
225. Pilote L, Califf RM, Sapp S, Miller DP, Mark DB, Weaver WD, Gore JM, Armstrong PW, Ohman EM, Topol EJ, for the GUSTO-I Investigators. Regional variation across the United States in the management of acute myocardial infarction. *N Engl J Med* 1995;333:565-572.
226. Simes RJ, Topol EJ, Holmes DR, Jr., White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf RM, for the GUSTO-I Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. *Circulation* 1995;91:1923-1928.
227. Tchong JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta F, Smith JE, Worley SJ, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. *Circulation* 1995;91:2151-2157.
228. The SUPPORT Principal Investigators. A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators [see comments] [published erratum appears in *JAMA* 1996 Apr 24;275(16):1232]. *JAMA* 1995;274:1591-1598.
229. Van de Werf F, Califf RM, Armstrong PW, Bates ER, Ross AM, Kleiman NS, Topol EJ. Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. *Eur Heart J* 1995;16:1024-1026.
230. Van de Werf F, Topol EJ, Lee KL, Woodlief LH, Granger CB, Armstrong PW, Barbash GI, Hampton JR, Guerci A, Simes RJ, et al. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. *JAMA* 1995;273:1586-1591.
231. Anderson JL, Karagounis LA, Califf RM. Meta analysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. *Am J Cardiol* 1996;78:1-8.
232. Aylward PE, Wilcox RG, Horgan JH, White HD, Granger CB, Califf RM, Topol EJ, for the GUSTO-I Investigators. Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. *Ann Intern Med* 1996;125:891-900.
233. Barefoot JC, Helms MJ, Mark DB, Blumenthal JA, Califf RM, Haney TL, O'Connor CM, Siegler IC. Depression and long-term mortality risk in patients with coronary artery disease. *Am J Cardiol* 1996;78:613-617.
234. Brener SJ, Leya FS, Apperson-Hansen C, Cowley MJ, Califf RM, Topol EJ. A comparison of debulking versus dilatation of bifurcation coronary arterial narrowings (from the CAVEAT I Trial). *Coronary Angioplasty Versus Excisional Atherectomy Trial-I*. *Am J Cardiol* 1996;78:1039-1041.
235. Califf RM, White HD, Van de Werf F, Sadowski Z, Armstrong PW, Vahanian A, Simoons ML, Simes RJ, Lee KL, Topol EJ, for the GUSTO-I Investigators. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. *Circulation* 1996;94:1233-1238.
236. Connors AF, Jr., Speroff T, Dawson NV, Thomas C, Harrell FE, Jr., Wagner D, Desbiens N, Goldman L, Wu AW, Califf RM, Fulkerson WJ, Jr., Vidaillet H, Broste S, Lynn J, Knaus WA, for the SUPPORT Investigators. The effectiveness of right heart catheterization in the initial care of critically ill patients. *JAMA* 1996;276:889-897.

237. Granger CB, Hirsch J, Califf RM, Col J, White HD, Betriu A, Woodlief LH, Lee KL, Bovill EG, Simes RJ, Topol EJ. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. *Circulation* 1996;93:870-878.
238. GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators [see comments]. *N Engl J Med* 1996;335:775-782.
239. Hakim RB, Teno JM, Harrell FE, Jr., Knaus WA, Wenger N, Phillips RS, Layde P, Califf RM, Connors AF, Jr., Lynn J, for the SUPPORT Investigators. Factors associated with do-not-resuscitate orders: patients' preferences, prognosis, and physicians' judgments. *Ann Intern Med* 1996;125:284-293.
240. Holmes DR, Jr., Garratt KN, Isner JM, Kearney M, Berdan LG, Schwartz RS, Califf RM, Topol EJ. Effect of subintimal resection on initial outcome and restenosis for native coronary lesions and saphenous vein graft disease treated by directional coronary atherectomy. A report from the CAVEAT I and II investigators. *J Am Coll Cardiol* 1996;28:645-651.
241. Jollis JG, DeLong ER, Peterson ED, Muhlbaier LH, Fortin DF, Califf RM, Mark DB. Outcome of acute myocardial infarction according to the specialty of the admitting physician. *N Engl J Med* 1996;335:1880-1887.
242. Jones RH, Kesler K, Phillips HR3, Mark DB, Smith PK, Nelson CL, Newman MF, Reves JG, Anderson RW, Califf RM. Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. *J Thorac Cardiovasc Surg.* 1996;111:1013-1025.
243. Kennard MJ, Speroff T, Puopolo AL, Follen MA, Mallatratt L, Phillips R, Desbiens N, Califf RM, Connors AF, Jr. Participation of nurses in decision making for seriously ill adults. *Clin Nurs Res* 1996;5:199-219.
244. Labinaz M, Sketch MH, Jr., Stebbins AL, DeFranco AC, Holmes DR, Jr., Kleiman NS, Betriu A, Rutsch WR, Vahanian A, Topol EJ, Califf RM, for the GUSTO-I Investigators. Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. *Am J Cardiol* 1996;78:1338-1344.
245. Lefkowitz J, Blankenship JC, Anderson KM, Stoner GL, Talley JD, Worley SJ, Weisman HF, Califf RM, Topol EJ. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. *J Am Coll Cardiol* 1996;28:849-855.
246. Lefkowitz J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, Weisman HF, Topol EJ, for the EPIC Investigators. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. *Am J Cardiol* 1996;77:1045-1051.
247. Lesnefsky EJ, Lundergan CF, Hodgson JM, Nair R, Reiner JS, Greenhouse SW, Califf RM, Ross AM. Increased left ventricular dysfunction in elderly patients despite successful thrombolysis: the GUSTO-I angiographic experience. *J Am Coll Cardiol* 1996;28:331-337.
248. Mahaffey KW, Granger CB, Collins R, O'Connor CM, Ohman EM, Bleich SD, Col JJ, Califf RM. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. *Am J Cardiol* 1996;77:551-556.
249. Mark DB, Talley JD, Topol EJ, Bowman L, Lam LC, Anderson KM, Jollis JG, Cleman MW, Lee KL, Aversano T, Untereker WJ, Davidson-Ray L, Califf RM, for the EPIC Investigators. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. *Circulation* 1996;94:629-635.
250. Midgette AS, Griffith JL, Califf RM, Laks MM, Dietz SB, Beshansky JR, Selker HP. Prediction of the infarct-related artery in acute myocardial infarction by a scoring system using summary ST-segment and T-wave changes. *Am J Cardiol* 1996;78:389-395.
251. Narins CR, Hillegeass WB, Jr., Nelson CL, Tchong JE, Harrington RA, Phillips HR, Stack RS, Califf RM. Relation between activated clotting time during angioplasty and abrupt closure. *Circulation* 1996;93:667-671.

252. Newby LK, Rutsch WR, Califf RM, Simoons ML, Aylward PE, Armstrong PW, Woodlief LH, Lee KL, Topol EJ, Van de Werf F, for the GUSTO-I Investigators. Time from symptom onset to treatment and outcomes after thrombolytic therapy. *J Am Coll Cardiol* 1996;27:1646-1655.
253. Newby LK, Califf RM, Guerci A, Weaver WD, Col J, Horgan JH, Mark DB, Stebbins A, Van de Werf F, Gore JM, Topol EJ. Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. *J Am Coll Cardiol* 1996;27:625-632.
254. O'Brien JE, Peterson ED, Keeler GP, Berdan LG, Ohman EM, Faxon DP, Jacobs AK, Topol EJ, Califf RM. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. *J Am Coll Cardiol* 1996;28:1111-1118.
255. O'Connor CM, Meese RB, McNulty S, Lucas KD, Carney RJ, LeBoeuf RM, Maddox W, Bethea CF, Shadoff N, Trahey TF, Heinsimer JA, Burks JM, O'Donnell G, Krucoff MW, Califf RM, for the DUCCS-II Investigators. A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. *Am J Cardiol* 1996;77:791-797.
256. Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O'Hanesian MA, Wagner GS, Kleiman NS, Harrell FE, Jr., Califf RM, Topol EJ, for the GUSTO-IIa Investigators. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. *N Engl J Med* 1996;335:1333-1341.
257. Peterson ED, Hathaway WR, Zabel KM, Pieper KS, Granger CB, Wagner GS, Topol EJ, Bates ER, Simoons ML, Califf RM. Prognostic significance of precordial ST segment depression during inferior myocardial infarction in the thrombolytic era: results in 16,521 patients. *J Am Coll Cardiol* 1996;28:305-312.
258. Phillips RS, Hamel MB, Teno JM, Broste SK, Califf RM, Vidaillet H, Davis RB, Muhlbaier LH, Connors AF, Jr., for the SUPPORT Investigators. Race, resource use, and survival in seriously ill hospitalized adults. *J Gen Intern Med* 1996;11:387-396.
259. Phillips RS, Wenger NS, Teno J, Oye RK, Youngner S, Califf RM, Layde P, Desbiens N, Connors AF, Jr., Lynn J, for the SUPPORT Investigators. Choices of seriously ill patients about cardiopulmonary resuscitation: correlates and outcomes. *Am J Med* 1996;100:128-137.
260. Pilote L, Miller DP, Califf RM, Rao JS, Weaver WD, Topol EJ. Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. *N Engl J Med* 1996;335:1198-1205.
261. Rosenfeld KE, Wenger NS, Phillips RS, Connors AF, Dawson NV, Layde P, Califf RM, Liu H, Lynn J, Oye RK, for the SUPPORT Investigators. Factors associated with change in resuscitation preference of seriously ill patients. *Arch Intern Med* 1996;156:1558-1564.
262. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel BJ, Russell RO, Smith EE, Weaver WD. ACC/AHA Guidelines for the management of patients with acute myocardial infarction. A report of the ACC/AHA Task Force on Practice Guidelines (Committee on Management of Acute MI). *J Am Coll Cardiol* 1996;28:1328-1428.
263. Schulman KA, Buxton M, Glick H, Sculpher M, Guzman G, Kong J, Backhouse M, Mauskopf J, Bell L, Eisenberg JM. Results of the economic evaluation of the FIRST study. A multinational prospective economic evaluation. FIRST Investigators. Flolan International Randomized Survival Trial. *Int J Technol Assess Health Care* 1996;12:698-713.
264. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harrington RA, Lincoff AM, Yakubov SJ, Bray PF, Bahr RD, Wolfe CL, Yock PG, Anderson HV, Nygaard TW, Mason SJ, Effron MB, Fatterpacker A, Raskin S, Smith J, Brashears L, Gerstenblith G, et al. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. *Circulation* 1996;94:2083-2089.
265. Sgarbossa EB, Pinski SL, Underwood DA, Gates KB, Topol EJ, Califf RM, Wagner GS, for the GUSTO-I Investigators. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. *N Engl J Med* 1996;334:481-487.

- 266.Sgarbossa EB, Pinski SL, Underwood DA, Gates KB, Topol EJ, Califf RM, Wagner GS. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators [see comments] [published erratum appears in *N Engl J Med* 1996 Apr 4; 334(14):931]. *N Engl J Med* 1996;334:481-487.
- 267.Shaw LJ, Peterson ED, Kesler K, Hasselblad V, Califf RM. A meta- analysis of predischage risk stratification after acute myocardial infarction with stress electrocardiographic, myocardial perfusion, and ventricular function imaging. *Am J Cardiol* 1996;78:1327-1337.
- 268.The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. *N Engl J Med* 1996;335:217-225.
- 269.Veldkamp RF, Sawchak S, Pope JE, Califf RM, Krucoff MW. Performance of an automated real-time ST-segment analysis program to detect coronary occlusion and reperfusion. *J Electrocardiol* 1996;29:257-263.
- 270.Weaver WD, White HD, Wilcox RG, Aylward PE, Morris D, Guerci A, Ohman EM, Barbash GI, Betriu A, Sadowski Z, Topol EJ, Califf RM, for the GUSTO-I Investigators. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. *JAMA* 1996;275:777-782.
- 271.White HD, Barbash GI, Califf RM, Simes RJ, Granger CB, Weaver WD, Kleiman NS, Aylward PE, Gore JM, Vahanian A, Lee KL, Ross AM, Topol EJ. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. *Circulation* 1996;94:1826-1833.
- 272.Woodfield SL, Lundergan CF, Reiner JS, Greenhouse SW, Thompson MA, Rohrbeck SC, Deychak Y, Simoons ML, Califf RM, Topol EJ, Ross AM. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. *J Am Coll Cardiol* 1996;28:1661-1669.
- 273.Anderson RD, Ohman EM, Holmes DR, Jr., Col I, Stebbins AL, Bates ER, Stomel RJ, Granger CB, Topol EJ, Califf RM. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. *J Am Coll Cardiol* 1997;30:708-715.
- 274.Barbagelata NA, Granger CB, Oqueli E, Suarez LD, Borruel M, Topol EJ, Califf RM. TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. *Am Heart J* 1997;133:273-282.
- 275.Barsness GW, Peterson ED, Ohman EM, Nelson CL, DeLong ER, Reves JG, Smith PK, Anderson RD, Jones RH, Mark DB, Califf RM. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. *Circulation* 1997;96:2551-2556.
- 276.Bart BA, Shaw LK, McCants CB, Jr., Fortin DF, Lee KL, Califf RM, O'Connor CM. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. *J Am Coll Cardiol* 1997;30:1002-1008.
- 277.Berdan LG, Kleiman NS, Woodlief LH, Harrington RA, Granger CB, Califf RM. Physicians' use of heparin following thrombolytic therapy: an international perspective. *J Thromb Thrombolysis* 1997;4:415-423.
- 278.Berger PB, Holmes DR, Jr., Stebbins AL, Bates ER, Califf RM, Topol EJ. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. *Circulation* 1997;96:122-127.
- 279.Berkowitz SD, Granger CB, Pieper KS, Lee KL, Gore JM, Simoons M, Armstrong PW, Topol EJ, Califf RM, for the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. *Circulation* 1997;95:2508-2516.
- 280.Califf RM, McKenna WJ, Gheorghiane M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE, Jr., Wheeler W, Soler-Soler J, Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). *Am Heart J* 1997;134:44-54.

281. Califf RM, Sgarbossa EB, Goodman SG, Stebbins AL, Granger CB, Suarez LD, Borruel M, Gates K, Starr S, Wagner GS, for the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. *J Am Coll Cardiol* 1997;29:770-777.
282. Califf RM, Woodlief LH, Harrell FE, Jr., Lee KL, White HD, Guerci A, Barbash GI, Simes RJ, Weaver WD, Simoons ML, Topol EJ, for the GUSTO-I Investigators. Selection of thrombolytic therapy for individual patients: development of a clinical model. *Am Heart J* 1997;133:630-639.
283. CARS Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators [see comments]. *Lancet* 1997;350:389-396.
284. Chaitman BR, Rosen AD, Williams DO, Bourassa MG, Aguirre FV, Pitt B, Rautaharju PM, Rogers WJ, Sharaf B, Attubato M, Hardison RM, Srivatsa S, Kouchoukos NT, Stocke K, Sopko G, Detre K, Frye R. Myocardial infarction and cardiac mortality in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial [see comments]. *Circulation* 1997;96:2162-2170.
285. Christenson RH, Ohman EM, Topol EJ, Peck S, Newby LK, Duh SH, Kereiakes DJ, Worley SJ, Wall TC, Califf RM, for the TAMI 7 Study Group. Assessment of coronary reperfusion after thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical variables. *Circulation* 1997;96:1776-1782.
286. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F, for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. *N Engl J Med* 1997;337:447-452.
287. Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. *Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol* 1997;30:406-413.
288. Eisenberg MJ, Keeler GP, Pieper KS, Califf RM, Topol EJ. Medical therapy at the time of referral for percutaneous coronary revascularization: results from the CAVEAT trial. *Am J Cardiol* 1997;79:867-872.
289. Eisenberg MJ, Califf RM, Cohen EA, Adelman AG, Mark DB, Topol EJ, for the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators. Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. *Am J Cardiol* 1997;79:867-872.
290. Eisenstein EL, Peterson ED, Jollis JG, Tardiff BE, Califf RM, Knight JD, Mark DB. Assessing the value of newer pharmacologic agents in non-ST elevation patients: a decision support system application. *Proceedings / AMIA Annual Fall Symposium* 1997;273-277.
291. FitzGerald JD, Wenger NS, Califf RM, Phillips RS, Desbiens NA, Liu H, Lynn J, Wu AW, Connors AF, Jr., Oye RK, for the SUPPORT Investigators. Functional status among survivors of in-hospital cardiopulmonary resuscitation. *Arch Intern Med* 1997;157:72-76.
292. GUSTO IIb Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators [published erratum appears in *N Engl J Med* 1997 Jul 24;337(4):287] [see comments]. *N Engl J Med* 1997;336:1621-1628.
293. GUSTO III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators [see comments]. *N Engl J Med* 1997;337:1118-1123.
294. Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks M, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators [see comments]. *N Engl J Med* 1997;336:92-99.

295. Holmes DR, Jr., Califf RM, Van de Werf F, Berger PB, Bates ER, Simoons ML, White HD, Thompson TD, Topol EJ. Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. *Lancet* 1997;349:75-78.
296. Levine GN, Jacobs AK, Keeler GP, Whitlow PL, Berdan LG, Leya F, Topol EJ, Califf RM, for the CAVEAT-I Investigators. Impact of diabetes mellitus on percutaneous revascularization (CAVEAT-I). *Am J Cardiol* 1997;79:748-755.
297. Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ, for the EPIC Investigators. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. *J Am Coll Cardiol* 1997;30:149-156.
298. Lincoff AM, Tchong JE, Califf RM, Popma JJ, Teirstein PS, Kleiman NS, Hattel LJ, Anderson HV, Ferguson JJ, Cabot CF, Anderson KM, Berdan LG, Musco MH, Weisman HF, Topol EJ, for the PROLOG Investigators. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. *Am J Cardiol* 1997;79:286-291.
299. Mahaffey KW, Granger CB, Toth CA, White HD, Stebbins AL, Barbash GI, Vahanian A, Topol EJ, Califf RM. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. *Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol* 1997;30:1606-1610.
300. Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM, Topol EJ, for the GUSTO-I Investigators. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. *J Am Coll Cardiol* 1997;30:171-179.
301. Mak KH, Challapalli R, Eisenberg MJ, Anderson KM, Califf RM, Topol EJ, for the EPIC Investigators. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. *Am J Cardiol* 1997;80:985-988.
302. Mattimore TJ, Wenger NS, Desbiens NA, Teno JM, Hamel MB, Liu H, Califf RM, Connors AF, Jr., Lynn J, Oye RK. Surrogate and physician understanding of patients' preferences for living permanently in a nursing home. *J Am Geriatr Soc* 1997;45:818-824.
303. Migrino RQ, Young JB, Ellis SG, White HD, Lundergan CF, Miller DP, Granger CB, Ross AM, Califf RM, Topol EJ, for the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. *Circulation* 1997;96:116-121.
304. Moen EK, Asher CR, Miller DP, Weaver WD, White HD, Califf RM, Topol EJ. Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. *Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Journal of Womens Health* 1997;6:285-293.
305. O'Connor CM, Hathaway WR, Bates ER, Leimberger JD, Sigmon KN, Kereiakes DJ, George BS, Samaha JK, Abbottsmith CW, Candela RJ, Topol EJ, Califf RM. Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. *Am Heart J* 1997;133:663-673.
306. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, Anderson HV, Ellis SG, Cohen MD, Spriggs D, Miller M, Kereiakes D, Kitt MM, Sigmon KN, Califf RM, Krucoff MW, Topol EJ, for the IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. *Circulation* 1997;95:846-854.
307. Peterson ED, Shaw LK, DeLong ER, Pryor DB, Califf RM, Mark DB. Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter? *N Engl J Med* 1997;336:480-486.



- 308.Puma JA, Sketch MH, Jr., Tchong JE, Gardner LH, Nelson CL, Phillips HR, Stack RS, Califf RM. The natural history of single-vessel chronic coronary occlusion: a 25-year experience. *Am Heart J* 1997;133:393-399.
- 309.Puopolo AL, Kennard MJ, Mallatratt L, Follen MA, Desbiens NA, Conners Jr, Califf RM, Walzer J, Soukup J, Davis RB, Phillips RS. Preferences for cardiopulmonary resuscitation. *Image - the Journal of Nursing Scholarship* 1997;29:229-235.
- 310.Selker HP, Griffith JL, Beshansky JR, Schmid CH, Califf RM, D'Agostino RB, Laks MM, Lee KL, Maynard C, Selvester RH, Wagner GS, Weaver WD. Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. *Ann Intern Med* 1997;127:538-556.
- 311.Shah A, Wagner GS, Green CL, Crater SW, Sawchak ST, Wildermann NM, Mark DB, Waugh RA, Krucoff MW. Electrocardiographic differentiation of the ST-segment depression of acute myocardial injury due to the left circumflex artery occlusion from that of myocardial ischemia of nonocclusive etiologies. *Am J Cardiol* 1997;80:512-513.
- 312.Shah A, Wagner GS, Califf RM, Boineau RE, Green CL, Wildermann NM, Trollinger KM, Pope JE, Krucoff MW. Comparative prognostic significance of simultaneous versus independent resolution of ST segment depression relative to ST segment elevation during acute myocardial infarction. *J Am Coll Cardiol* 1997;30:1478-1483.
- 313.Talley JD, Ohman EM, Mark DB, George BS, Leimberger JD, Berdan LG, Davidson-Ray L, Rawert M, Lam LC, Phillips HR, Califf RM, for the Randomized IABP Study Group. Economic implications of the prophylactic use of intraaortic balloon counterpulsation in the setting of acute myocardial infarction. *Am J Cardiol* 1997;79:590-594.
- 314.Tardiff BE, Califf RM, Morris D, Woodlief LH, Lee KL, Green C, Rutsch W, Betriu A, Aylward PE, Topol EJ, for the GUSTO Investigators. Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. *J Am Coll Cardiol* 1997;29:240-249.
- 315.The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. *Circulation* 1997;96:1761-1769.
- 316.The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators [see comments]. *N Engl J Med* 1997;336:1689-1696.
- 317.The IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatid on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II [see comments]. *Lancet* 1997;349:1422-1428.
- 318.Thel MC, Armstrong AL, McNulty SE, Califf RM, O'Connor CM. Randomised trial of magnesium in in-hospital cardiac arrest. *Duke Internal Medicine Housestaff. Lancet* 1997;350:1272-1276.
- 319.Topol EJ, Ferguson JJ, Weisman HF, Tchong JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. *JAMA* 1997;278:479-484.
- 320.Tsang TS, Califf RM, Stebbins AL, Lee KL, Cho S, Ross AM, Armstrong PW. Incidence and impact on outcome of streptokinase allergy in the GUSTO-I trial. *Global Utilization of Streptokinase and t-PA in Occluded Coronary Arteries. Am J Cardiol* 1997;79:1232-1235.
- 321.Ward SR, Sutton JM, Pieper KS, Schwaiger M, Califf RM, Topol EJ, for the TAMI Investigators. Effects of thrombolytic regimen, early catheterization, and predischage angiographic variables on six-week left ventricular function. *Am J Cardiol* 1997;79:539-544.
- 322.Woodfield SL, Lundergan CF, Reiner JS, Thompson MA, Rohrbeck SC, Deychak Y, Smith JO, Burton JR, McCarthy WF, Califf RM, White HD, Weaver WD, Topol EJ, Ross AM. Gender and acute myocardial infarction: is there a different response to thrombolysis? *J Am Coll Cardiol* 1997;29:35-42.

323. Writing Group for the BARI Investigators. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease. A multicenter randomized trial. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators [see comments]. *JAMA* 1997;277:715-721.
324. Alexander KP, Peterson ED, Granger CB, Casas AC, Van de Werf F, Armstrong PW, Guerci A, Topol EJ, Califf RM. Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. *J Am Coll Cardiol* 1998;32:2023-2030.
325. Anderson RD, Ohman EM, Holmes DR, Jr., Harrington RA, Barsness GW, Wildermann NM, Phillips HR, Topol EJ, Califf RM. Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions. *J Am Coll Cardiol* 1998;32:936-941.
326. Armstrong PW, Fu Y, Chang WC, Topol EJ, Granger CB, Betriu A, Van de Werf F, Lee KL, Califf RM, for the GUSTO-IIb Investigators. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. *Circulation* 1998;98:1860-1868.
327. Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tchong J, Topol EJ, Califf RM, for the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. *J Am Coll Cardiol* 1998;32:311-319.
328. Betriu A, Califf RM, Bosch X, Guerci A, Stebbins AL, Barbagelata NA, Aylward PE, Vahanian A, Van de Werf F, Topol EJ, for the GUSTO-I Investigators. Recurrent ischemia after thrombolysis: importance of associated clinical findings. *J Am Coll Cardiol* 1998;31:94-102.
329. Blankenship JC, Hellkamp AS, Aguirre FV, Demko SL, Topol EJ, Califf RM. Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. *Am J Cardiol* 1998;81:36-40.
330. Brieger DB, Mak KH, White HD, Kleiman NS, Miller DP, Vahanian A, Ross AM, Califf RM, Topol EJ. Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries. *Am J Cardiol* 1998;81:282-287.
331. Christenson RH, Duh SH, Newby LK, Ohman EM, Califf RM, Granger CB, Peck S, Pieper KS, Armstrong PW, Katus HA, Topol EJ, for the GUSTO-IIa Investigators. Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. *Clin Chem* 1998;44:494-501.
332. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. *Am J Cardiol* 1998;82:19L-24L.
333. Ellis SG, Lincoff AM, Miller D, Tchong JE, Kleiman NS, Kereiakes D, Califf RM, Topol EJ, for the EPIC and EPILOG Investigators. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. *J Am Coll Cardiol* 1998;32:1619-1623.
334. Gebel JM, Sila CA, Sloan MA, Granger CB, Mahaffey KW, Weisenberger J, Green CL, White HD, Gore JM, Weaver WD, Califf RM, Topol EJ. Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-I trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. *Stroke* 1998;29:563-569.
335. Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, Miller DP, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. *Am J Cardiol* 1998;82:7-12.

336. Goodman SG, Langer A, Ross AM, Wildermann NM, Sgarbossa EB, Wagner GS, Granger CB, Califf RM, Topol EJ, Simoons ML, Armstrong PW, for the GUSTO-I Angiographic Investigators. Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. *Circulation* 1998;97:444-450.
337. Granger CB, Tracy RP, Califf RM, Topol EJ, Pieper KS, Ross AM, Roth S, Lambrew C, Bovill EG, for the GUSTO-I Hemostasis Substudy Group. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. *J Am Coll Cardiol* 1998;31:497-505.
338. Hathaway WR, Peterson ED, Wagner GS, Granger CB, Zabel KM, Pieper KS, Clark KA, Woodlief LH, Califf RM, for the GUSTO-I Investigators. Prognostic significance of the initial electrocardiogram in patients with acute myocardial infarction. *JAMA* 1998;279:387-391.
339. Hochrein J, Sun F, Pieper KS, Lee KL, Gates KB, Armstrong PW, Weaver WD, Goodman SG, Topol EJ, Califf RM, Granger CB, Wagner GS. Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). *Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries*. *Am J Cardiol* 1998;81:1078-1084.
340. Jaagosild P, Dawson NV, Thomas C, Wenger NS, Tsevat J, Knaus WA, Califf RM, Goldman L, Vidaillet H, Connors AF, Jr., for the SUPPORT Investigators. Outcomes of acute exacerbation of severe congestive heart failure: quality of life, resource use, and survival. *Arch Intern Med* 1998;158:1081-1089.
341. Kereiakes DJ, Lincoff AM, Miller DP, Tchong JE, Cabot CF, Anderson KM, Weisman HF, Califf RM, Topol EJ, for the EPILOG Trial Investigators. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. *Circulation* 1998;97:857-864.
342. Khan MM, Ellis SG, Aguirre FV, Weisman HF, Wildermann NM, Califf RM, Topol EJ, Kleiman NS, for the EPIC Investigators. Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. *J Am Coll Cardiol* 1998;31:31-36.
343. Kleiman NS, Flaker GC, Pieper KS, Ohman EM, Hochman JS, Corbalan R, Karsch KR, Wilcox RG, Goy JJ, Berdan LG, Lincoff AM, Ribeiro VG, Lorenz TJ, Holmes DR, Simoons ML, Boersma E, Topol EJ, Califf RM. The interaction between percutaneous coronary intervention and platelet inhibition with Eptifibatid on death or myocardial infarction in patients with acute coronary syndromes characterized by the absence of ST-segment elevation. *Circulation* 1998;98:1376-1382.
344. Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson KM, Weisman HF, Califf RM, Topol EJ, for the EPILOG Investigators. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. *Circulation* 1998;97:1912-1920.
345. Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, Tchong JE, Lincoff AM, Hasselblad V, Topol EJ. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. *Circulation* 1998;98:2829-2835.
346. Krumholz HM, Phillips RS, Hamel MB, Teno JM, Broste SK, Califf RM, Vidaillet H, Davis RB, Muhlbaier LH, Connors AF, Jr., Lynn J, Goldman L. Resuscitation preferences among patients with severe congestive heart failure: results from the SUPPORT project. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. *Circulation* 1998;98:648-655.
347. Langer A, Krucoff MW, Klootwijk P, Simoons ML, Granger CB, Barr A, Califf RM, Armstrong PW. Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. *J Am Coll Cardiol* 1998;31:783-789.
348. Lundergan CF, Reiner JS, McCarthy WF, Coyne KS, Califf RM, Ross AM. Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. *Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries*. *J Am Coll Cardiol* 1998;32:641-647.

349. Mahaffey KW, Granger CB, Sloan MA, Thompson TD, Gore JM, Weaver WD, White HD, Simoons ML, Barbash GI, Topol EJ, Califf RM. Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I. *Circulation* 1998;97:757-764.
350. Mandak JS, Blankenship JC, Gardner LH, Berkowitz SD, Aguirre FV, Sigmon KN, Timmis GC, Gilchrist IC, McIvor M, Resar J, Weiner BH, George BS, Talley JD, Lincoff AM, Tchong JE, Califf RM, Topol EJ. Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. *J Am Coll Cardiol* 1998;31:1518-1524.
351. Mark DB, Cowper PA, Berkowitz SD, Davidson-Ray L, DeLong ER, Turpie AG, Califf RM, Weatherley B, Cohen M. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]. *Circulation* 1998;97:1702-1707.
352. Metz BK, White HD, Granger CB, Simes RJ, Armstrong PW, Hirsh J, Fuster V, MacAulay CM, Califf RM, Topol EJ, for the Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. *J Am Coll Cardiol* 1998;31:1493-1498.
353. Newby KH, Thompson T, Stebbins A, Topol EJ, Califf RM, Natale A, for the GUSTO Investigators. Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. *Circulation* 1998;98:2567-2573.
354. Newby LK, Christenson RH, Ohman EM, Armstrong PW, Thompson TD, Lee KL, Hamm CW, Katus HA, Cianciolo C, Granger CB, Topol EJ, Califf RM, for the GUSTO-IIa Investigators. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. *Circulation* 1998;98:1853-1859.
355. Omoigui NA, Silver MJ, Rybicki LA, Rosenthal M, Berdan LG, Pieper K, King SV, Califf RM, Topol EJ, for the CAVEAT I and II Investigators. Influence of a randomized clinical trial on practice by participating investigators: lessons from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). *J Am Coll Cardiol* 1998;31:265-272.
356. PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial. *J Am Coll Cardiol* 1998;32:2003-2010.
357. Pfisterer M, Cox JL, Granger CB, Brener SJ, Naylor CD, Califf RM, Van de Werf F, Stebbins AL, Lee KL, Topol EJ, Armstrong PW. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. *J Am Coll Cardiol* 1998;32:634-640.
358. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy [see comments]. *N Engl J Med* 1998;339:436-443.
359. Ross AM, Coyne KS, Moreyra E, Reiner JS, Greenhouse SW, Walker PL, Simoons ML, Draoui YC, Califf RM, Topol EJ, Van de Werf F, Lundergan CF, for the GUSTO-I Angiographic Investigators. Extended mortality benefit of early postinfarction reperfusion. *Circulation* 1998;97:1549-1556.
360. Sgarbossa EB, Pinski SL, Gates KB, Wagner GS. Predictors of in-hospital bundle branch block reversion after presenting with acute myocardial infarction and bundle branch block. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. *Am J Cardiol* 1998;82:373-374.
361. Sgarbossa EB, Pinski SL, Topol EJ, Califf RM, Goodman SG, Gates KB, Granger CB, Miller DP, Underwood DA, Wagner GS, for the GUSTO-I Investigators. Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. *J Am Coll Cardiol* 1998;31:105-110.
362. Sloan MA, Sila CA, Mahaffey KW, Granger CB, Longstreth WT, Jr., Koudstaal P, White HD, Gore JM, Simoons ML, Weaver WD, Green CL, Topol EJ, Califf RM. Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. *Circulation* 1998;98:1376-1382.

363. The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. *Circulation* 1998;97:2386-2395.
364. Topol EJ, Lincoff AM, Califf RM, Tcheng JE, Kleiman NS, Adelman AG, Burton JR, Talley JD, Ivanhoe RJ, Ducas C, Cheung PK, Schick U, Badard D, Kramer J, Leary J, Snyder H, Wilson R, Dearen M, Caramori P, Webber S, Taylor J, Ferrando T, Cohen EA, Balleza L, Rouse C. Randomized placebo controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. *Lancet* 1998;352(9122):87-92.
365. Zabel KM, Granger CB, Becker RC, Bovill EG, Hirsh J, Aylward PE, Topol EJ, Califf RM. Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. *Am Heart J* 1998;136:868-876.
366. Adams KF, Sueta CA, Gheorghide M, O'Connor CM, Schwartz TA, Koch GG, Uretsky BF, Swedberg K, McKenna WJ, Soler-Soler J, Califf RM. Gender differences in survival in advanced heart failure: insights from the FIRST study. *Circulation* 1999;99:1816-1821.
367. Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, Simoons ML, Guerci AD, Hochman JS, Wilcox RG, Kitt MM, Eisenberg PR, Califf RM, Topol EJ, Karsh K, Ruzyllo W, Widimsky P, Boland JB, Armstrong PW. Prior aspirin use predicts worse 30-day outcomes in patients with non-ST-elevation acute coronary syndromes: insights from PURSUIT. *Am J Cardiol* 1999;83(8):1147-1151.
368. Alexander JH, Granger CB, Sadowski Z, Aylward PE, White HD, Thompson TD, Califf RM, Topol EJ. Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. *Am Heart J* 1999;137:799-805.
369. Bart BA, Irtl G, Held P, Kuch J, Maggioni AP, McMurray J, Michelson E, Rouleau J, Stevenson LW, Swedberg K, Young J, Yusuf S, Sellers MA, Granger CB, Califf RM, Pfeffer M. Contemporary management of patients with left ventricular dysfunction: results from the study of patients intolerant of converting enzyme inhibitors (SPICE) registry. *Eur Heart J* 1999;20(16):1182-1190.
370. Batchelor WB, Peterson ED, Mark DB, Knight JD, Granger CB, Armstrong PW, Califf RM. A comparison of U.S. and Canadian Cardiac Catheterization Practices in Detecting Severe Coronary Artery Disease After Myocardial Infarction: Efficiency, Yield, and Long-term Implications. *J Am Coll Cardiol* 1999; 34 (1):
371. Berger PB, Tuttle RH, Holmes DR, Jr., Topol EJ, Califf RM. One year survival among patients with acute myocardial infarction complicated by cardiogenic shock and its relationship to early revascularization: results from the GUSTO I Trial. *Circulation* 1999;99:873-878.
372. Berger PB, Ellis SG, Holmes DR, Jr., Topol EJ, Granger CB, Criger DA, Califf RM. The relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the GUSTO IIb Trial. *Circulation* 1999;100(1):14-20.
373. Bhatt DL, Lincoff AM, Kereiakes DJ, Tcheng JE, Simoons ML, van der WLR, Godfrey N, Califf RM, Topol EJ. Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention. *Am J Cardiol* 1999;82:1105-1106.
374. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes early benefit during medical treatment only, with additional protectin during percutaneous coronary intervention. *Circulation* 1999;2046-2047.
375. Califf RM, Stump DC, Topol EJ, Mark DB. The impact of the cost-effectiveness study of GUSTO-I on decision making with regard to fibrinolytic therapy. *Am Heart J* 1999;137:890-893.
376. Cohen M, Granger CB, Ohman EM, Stebbins AL, Grinfeld LR, Cagide AM, Elizari MV, Betriu A, Kong DF, Topol EJ, Califf RM. Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I and -III trials. *J Am Coll Cardiol* 1999;34:1729-1737.

377. Detre KM, Guo P, Holubkov R, Califf RM, Sopko G, Bach R, Brooks MM, Bourassa MG, Shemin RJ, Rosen AD, Krone RJ, Frye RL, Feit F. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). *Circulation* 1999;99:633-640.
378. Eisenstein EL, Peterson ED, Jollis JG, Tardiff BE, Califf RM, Knight D, Mark DB. Evaluating the potential economic attractiveness of new therapies in Non-ST elevation acute coronary syndrome patients. *Pharmacoeconomics* 1999;Mar. 17(3):263-272.
379. Gilchrist IC, Gardner LH, Muhlestein JB, Arnold A, Lincoff AM, Califf RM, Tchong JE, Topol EJ. The effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience. *Am J Cardiol* 1999;138(5 Pt 1):976-982.
380. Harrington RA, Califf RM, Holmes DR, Jr., Pieper KS, Lincoff AM, Berdan LG, Thompson TD, Topol EJ, for the CAVEAT-I Investigators. Is all unstable angina the same? Insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). *Am Heart J* 1999;137:227-233.
381. Hasdai D, Holmes DR, Jr., Topol EJ, Berger PB, Criger DA, Hochman JS, Bates ER, Vahanian A, Ohman EM, Califf RM. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving Reteplase or Alteplase: results from GUSTO III. *Eur Heart J* 1999;20:128-135.
382. Hasdai D, Lerman A, Charanjit SR, Criger DA, Garratt KN, Betriu A, White HD, Topol EJ, Granger CB, Stephen GE, Califf RM, Holmes DR. Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction. *Am Heart J* 1999;137(4):612-620.
383. Hasdai D, Holmes DR, Jr., Califf RM, Thompson TD, Hochman JS, Pfisterer ME, Topol EJ. Cardiogenic shock complicating acute myocardial infarction: predictors of death. *Am Heart J* 1999;138:21-31.
384. Hochman JS, Tamis JE, Thompson TD, Weaver WD, White HD, Van de Werf F, Aylward PE, Topol EJ, Califf RM. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. GUSTO. *N Engl J Med* 1999;341(4):226-232.
385. Holmes DR, Jr., Berger PB, Hochman JS, Granger CB, Thompson TD, Califf RM, Vahanian A, Bates ER, Topol EJ. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. *Circulation* 1999;100:2067-2073.
386. Holmes DR, Jr., White HD, Pieper KS, Ellis SG, Califf RM, Topol EJ. Effect of age on outcome with primary angioplasty versus thrombolysis. *J Am Coll Cardiol* 1999;33:412-419.
387. Kleiman NS, Granger CB, White HD, Ardissino D, de Werf FV, Zoldeyhi P, Thompson TD, Califf RM, Topol EJ. Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. *Am Heart J* 1999;137:12-23.
388. Kong DF, Topol EJ, Bittl JA, White HD, Theroux P, Hasselblad V, Califf RM. Clinical outcomes of bivalirudin for ischemic heart disease. *Circulation* 1999;100:2049-2053.
389. Langer A, Fisher M, Califf RM, Goodman S, O'Connor C, Harrington RA, Fuster V, CARS Investigators. Higher rates of coronary angiography and revascularization following myocardial infarction may be associated with greater survival in the United States than in Canada. *Canadian Journal of Cardiology* 1999;15, #10:1095-1102.
390. Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of platelet IIb/IIIa inhibition in stenting investigators. *N Engl J Med* 1999;341(5):319-327.
391. Lincoff AM, Tchong JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab - One-year outcome in the EPILOG trial. *Circulation* 1999;99(15):1951-1958.

392. Lincoff AM, Califf RM, Moliterno DJ, Tchong JE, Ellis SG, Ducas J, Kramer JH, Talley JD, Caramori PO, Kleiman NS, Cohen EA, Burton JR, Kelly TA, Booth JE, Sapp SK, Ivane TB, Cabot CF, Topol EJ. Long-term complementary clinical benefit of stenting and platelet glycoprotein IIb/IIIa blockade. *N Engl J Med* 1999;341(5):319-327.
393. Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, Laskowitz DT, Miller JM, Sloan MA, Berdan LG, MacAulay CM, Lincoff AM, Deckers J, Topol EJ, Califf RM. Stroke in patients with acute coronary syndromes: incidence and outcomes in the PURSUIT trial. *Circulation* 1999;99:2371-2377.
394. Mahaffey KW, Puma JA, Barbagelata A, DiCarli MD, Leeser MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial. The AMISTAD Trial. *J Am Coll Cardiol* 1999;34(6):1711-1720.
395. Mahaffey KW, Granger CB, Sloan MA, Green CL, Gore JM, Weaver WD, White HD, Simoons ML, Barbash GI, Topol EJ, Califf RM, GUSTO-I Investigators. Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from GUSTO I Trial. *Am Heart J* 1999;138 (3 Part I):493-499.
396. McClure MW, Berkowitz SD, Sparapani RA, Tuttle RH, Kleiman NS, Berdan LG, Lincoff AM, Deckers JW, Diaz R, Karsch KR, Gretler D, Kitt MM, Simoons ML, Topol EJ, Califf RM, Harrington RA. The clinical significance of thrombocytopenia during a non-ST elevation acute coronary syndrome: the PURSUIT experience. *Circulation* 1999;99(22):2892-2999.
397. Miller JM, Smalling RE, Ohman EM, Bode C, Betriu A, Kleiman NS, Schildcrout JS, Bastos E, Topol EJ, Califf RM. Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO III trial). *Am J Cardiol* 1999;84(7):779-784.
398. Narins CR, Miller DP, Califf RM, Topol EJ. The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. *J Am Coll Cardiol* 1999;33:647-653.
399. O'Connor CM, Gattis WA, Adams KF, McNulty SE, Uretsky BF, Kramer J, Tudor G, Grossman S, McKenna WJ, Swedberg K, Gheorghide M, Califf RM. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan international randomized survival trial (FIRST). *Am Heart J* 1999;138(1):78-86.
400. Puma JA, Sketch MH, Jr., Thompson TD, Simes RJ, Morris DC, White HD, Topol EJ, Califf RM. Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy. *Am J Cardiol* 1999;83:482-487.
401. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel B, Russell RO, Smith EE, Weaver WD, Gibbons RJ, Alpert JS, Eagle KA, Gardner TJ, Garson A, Gregoratos G, Smith SC. Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). *J Am Coll Cardiol* 1999;34:890-909.
402. Savonitto S, Ardissino D, Granger CB, Morando G, Prando MD, Mafrici A, Cavallini C, Melandri G, Thompson TD, Vahanian A, Ohman EM, Califf RM, Van de Werf F, Topol EJ. Prognostic value of the admission electrocardiogram in acute coronary syndromes. *JAMA* 1999;281:707-713.
403. Simoons ML, Kootstra J, van den Brand M, Van der Wieken R, Vahanian A, Rutsch W, Topol EJ, Califf RM. Minimal myocardial damage during coronary intervention is associated with impaired outcome. *Eur Heart J* 1999;20(15):1112-1119.
404. Stone PH, Califf RM, et al. Factors associated with failure of medical therapy in patients with unstable angina and non-Q-wave MI: a TIMI-III database study. *Eur Heart J* 1999;20(15):1084-1093.
405. Tardiff BE, Califf RM, Tchong JE, Lincoff AM, Sigmon K, Harrington RA, Mahaffey KW, Ohman EM, Teirstein PS, Blankenship JC, Kitt MM, Topol EJ. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. *J Am Coll Cardiol* 1999;33:88-96.

406. Thel MC, Califf RM, Tchong JE, Sigmon KN, Lincoff AM, Topol EJ, Ellis SG, for the EPIC Investigators. Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. *Am Heart J* 1999;137:264-273.
407. Tung CY, Granger CB, Sloan MB, Topol EJ, Knight JD, Weaver WD, Mahaffey KW, White H, Clapp-Channing N, Simoons ML, Gore JM, Califf RM, Mark DB. The effects of stroke on medical resource consumption and costs in survivors of acute myocardial infarction. *Circulation* 1999;99(3):370-376.
408. Van de Werf F, Adgey J, Ardissio D, Armstrong PW, Aylward P, Barbash G, Betriu A, Binbrek AS, Califf RM, Diaz R, Fanebust R, Fox KA, Granger CB, Heikkila J, Husted S, Jansky P, Langer A, Lupi E, Maseri A, Meyer J, Mlczoch JMD, Myburgh D, Oto A, Paolasso E. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. *Lancet* 1999;354(9180):716-722.
409. Wali A, Hochman JS, Berkowitz SD, Clark KA, Malhotra S, Califf RM, Granger CB. Failure to achieve optimal anticoagulation with commonly used heparin regimens: a review of GUSTO II. *Am Heart J* 1999;138 (2 Pt 1):313-318.
410. Whitlow PL, Dimas AP, Bashore TM, Califf RM, Bourassa MG, Chaitman BR, Rosen AD, Kip KE, Stadius ML, Alderman EL. Relationship of extent of revascularization with angina at one year in the bypass angioplasty revascularization investigation (BARI). *J Am Coll Cardiol* 1999;34:1750-1759.
411. Akkerhuis KM, Deckers JW, Boersma E, Harrington RA, Stepinska J, Mahaffey KW, Wilcox RG, Lincoff AM, Keltai M, Topol EJ, Califf RM, Simoons ML. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes: results from PURSUIT. *Eur Heart J* 2000;21:371-381.
412. Akkerhuis KM, Maas ACP, Klootwijk P, Krucoff MW, Meij S, Califf RM, Simoons ML. Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. *J Electrocardiol* 2000;33(2):127-136.
413. Alexander JH, Sparapani RA, Mahaffey KW, Deckers JW, Newby LK, Ohman EM, Corbalan R, Simoons ML, Topol EJ, Califf RM, Chierchia SL, Boland JB, Harrington RA. Association between minor elevations of creatine kinase MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. *JAMA* 2000;283 (3):347-353.
414. Anderson KM, Califf RM, Neumann FJ, Miller DP, Ferguson JJ, Willerson JT, Weisman HF, Topol EJ. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. *J Am Coll Cardiol* 2000;
415. Auerbach AD, Hamel MB, Davis RB, Connors AF, Regueiro C, Desbiens N, Goldman L, Califf RM, Dawson NV, Wenger N, Vidaillet H, Phillips RS. Resource use and survival of patients hospitalized with congestive heart failure: differences in care by specialty of the attending physician. *Ann Intern Med* 2000;132(3):191-200.
416. Barbagelata A, Califf RM, Sgarbossa EB, Goodman SG, Knight D, Mark DB, Granger CB, Benasi MD, Agranatti DA, Suarez LD, Armstrong PW, Gates KB, Wagner GS. Use of resources, quality of life, and outcomes in patients with and without Q waves after thrombolysis for acute myocardial infarction: a GUSTO-I substudy. *Am J Cardiol* 2000;86:24-29.
417. Barsness GW, Buller C, Ohman EM, Schechter E, Pucillo A, Taylor MA, Miller MJ, Reiner JS, Churchill D, Chandler AB, Gonzalez M, Smith J, Tommaso C, Berdan LG, Wildermann NM, Hasdai D, Holmes DR, Jr., for the EDGE Study. Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts. *Am Heart J* 2000;139(5):
418. Batchelor WB, Granger CB, Kleiman NS, Phillips HR, Ellis SG, Betriu A, Criger DA, Stebbins AL, Topol EJ, Califf RM, for the GUSTO IIb Investigators. A comparison of ionic versus nonionic contrast medium during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (GUSTO IIb). *Am J Cardiol* 2000;85:692-697.
419. Bhatt DL, Lincoff AM, Califf RM, Simoons ML, Tchong JE, Brener SJ, Wolski KE, Topol EJ. The benefit of abciximab in percutaneous coronary revascularization is not device-specific. *Am J Cardiol* 2000;85(9):1060-1064.
420. Brener SJ, Ellis SG, Sapp SK, Betriu A, Califf RM, Topol EJ, for the GUSTO IIb and RAPPORT Investigators. Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials. *Am Heart J* 2000;139(3):476-481.



421. Brieger DB, Mak KH, Miller DP, Califf RM, Topol EJ, for the GUSTO I Investigators. Hierarchy of risk based on history and location of prior myocardial infarction in the thrombolytic era. *Am Heart J* 2000;140:29-33.
422. Brooks MM, Jones RH, Bach RG, Chaitman BR, Kern MJ, Orszulak TA, Follmann D, Sopko G, Blackstone EH, Califf RM, BARI Investigators. Predictors of mortality and mortality from cardiac causes in the bypass angioplasty revascularization investigation (BARI) randomized trial and registry. *Circulation* 2000;2682-2689.
423. Califf RM, Pieper KS, Lee KL, Van de Werf F, Simes RJ, Armstrong PW, Topol EJ. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the GUSTO-I trial. *Circulation* 2000;101(19):2231-2238.
424. Chang WC, Fu Y, Ohman EM, Gupta M, Morris A, Roth SN, Granger CB, Califf RM, Topol EJ, Mark DB, Armstrong PW. Temporal evolution in the management of acute ST elevation myocardial infarction: The seven-year GUSTO experience from Canada and the United States. *Canadian Journal of Cardiology* 2000;16 no 10 October:1231-1239.
425. Cho L, Topol EJ, Balon C, Foody JM, Booth JE, Cabot C, Kleiman NS, Tchong JE, Califf RM, Lincoff AM. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: pooled analysis from EPIC, EPILOG, and EPISTENT trials. *J Am Coll Cardiol* 2000;36 No.2:381-386.
426. Christenson RH, Vollmer RT, Ohman EM, Peck S, Thompson TD, Duh SH, Ellis SG, Newby LK, Topol EJ, Califf RM, for the TAMI study group. Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. *Am J Cardiol* 2000;85:543-547.
427. Cohen MD, Stinnett SS, Weatherley BD, Gurfinkel EP, Fromell GJ, Goodman SG, Califf RM, Fox KAA, Lee KL, for the ESSENCE Study Group. Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. *Am Heart J* 2000;139(6):962-970.
428. Crenshaw BA, Granger CB, Birnbaum Y, Pieper KS, Morris DC, Kleiman NS, Vahanian A, Califf RM, Topol EJ. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. *Circulation* 2000;101(1):27-32.
429. Cuffe MS, Califf RM, Adams KF, Bourge RC, Colucci W, Massie B, O'Connor CM, Pina I, Quigg R, Silver MJ, Robinson LA, Leimberger JD, Gheorghide M. Rationale and design of the OPTIME CHF Trial: outcomes of a prospective trial on intravenous milrinone for exacerbations of chronic heart failure. *Am Heart J* 2000;139(1):15-32.
430. Fu Y, Chang WC, Mark D, Califf RM, MacKenzie B, Granger CB, Topol EJ, Hlatky M, Armstrong PW. Canadian-American differences in the management of acute coronary syndromes in the gusto IIB trial one year follow-up of patients without ST-segment elevation. *Circulation* 2000;102 No. 12:1375-1381.
431. Goodman SG, Cohen M, Bigonzi F, Gurfinkel EP, Radley DR, Iouer VL, Fromell GJ, Demers C, Turpie AG, Califf RM, Fox KAA, Langer A. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease. *J Am Coll Cardiol* 2000;36 no. 3, 2000:693-698.
432. Granger CB, Ertl GK, Maggioni AP, McMurray JR, Rouleau JL, Stevenson LW, Swedberg K, Young J, Yusuf S, Califf RM, Bart BA, Held P, Michelson EL, Sellers MA, Ohlin G, Sparapani R, Pfeffer MA. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. *Am Heart J* 2000;139(4):609-617.
433. Greenbaum AB, Califf RM, Jones RH, Gardner LH, Sketch MH, Stack RS, Puma JA. Comparison of medicine alone, coronary angioplasty, and left internal mammary artery-coronary artery bypass for one-vessel proximal left anterior descending coronary artery disease. *Am J Cardiol* 2000;2000; Dec 16; 86:1322-1326.
434. Hasdai D, Harrington RA, Hochman JS, Califf RM, Battler A, Box JW, Simoons ML, Deckers J, Topol EJ, Holmes DR, Jr. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. *J Am Coll Cardiol* 2000;36 No. 3:685-692.
435. Hasdai D, Granger CB, Srivatsa SS, Criger DA, Ellis SG, Califf RM, Topol EJ, Holmes DR, Jr. Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO IIB angioplasty substudy. *J Am Coll Cardiol* 2000;35(6):1502-1512.

436. Hasdai D, Holmes DR, Jr., Criger DA, Topol EJ, Califf RM, Wilcox RG, Paolasso E, Simoons ML, Deckers J, Harrington RA, the PURSUIT Trial Investigators. Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. *Am Heart J* 2000;139(3):454-460.
437. Hasdai D, Topol EJ, Califf RM, Berger PB, Holmes DR. Cardiogenic shock complicating acute coronary syndromes. *Lancet* 2000;356:749-756.
438. Hasdai D, Holmes DR, Jr., Criger DA, Topol EJ, Califf RM, Harrington RA, for the PURSUIT trial Investigators. Age and outcome after acute coronary syndromes without persistent ST-segment elevation. *Am Heart J* 2000;139(5):858-866.
439. Hasdai D, Califf RM, Thompson TD, Hochman JS, Ohman EM, Pfisterer M, Bates ER, Vahanian A, Armstrong PW, Criger DA, Topol EJ, Holmes DR, Jr. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. *J Am Coll Cardiol* 2000;35:136-143.
440. Kereiakes DJ, Berkowitz SD, Lincoff AM, Tchong JE, Wolski K, Achenbach R, Melsheimer R, Anderson KM, Califf RM, Topol EJ. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. *Am Heart J* 2000;140(1):74-79.
441. Kleiman NS, Lincoff AM, Flaker GC, Pieper KS, Wilcox RG, Berdan LG, Lorenz TJ, Cokkinos DV, Simoons ML, Boersma E, Topol EJ, Califf RM, Harrington RA. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. *Circulation* 2000;101(7):751-757.
442. Kleiman NS, Tracy RP, Talley D, Sigmon K, Joseph D, Topol EJ, Califf RM, Kitt M, Ohman EM. Inhibition of platelet aggregation with a glycoprotein IIb/IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction. *J Thromb Thrombolysis*. 2000;9(1):5-12.
443. Lincoff AM, Mark DB, Tchong JE, Califf RM, Bala MV, Anderson KM, Davidson-Ray L, Knight JD, Cabot CF, Topol EJ, for the EPILOG Investigators. Economic assessment of platelet glycoprotein IB/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization. *Circulation* 2000;102, No24:2923-2929
444. Lincoff AM, Harrington RA, Califf RM, Hochman JS, Guerci AD, Ohman EM, Pepine CJ, Kopecky SL, Kleiman NS, Pacchiana CM, Berdan LG, Kitt MM, Simoons ML, Topol EJ. Management of patients with acute coronary syndromes in the united states by platelet glycoprotein IIb/IIIa inhibition. *Circulation* 2000;102 No. 10:1093-1100.
445. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. *J Am Coll Cardiol* 2000;35:1103-1115.
446. Lincoff AM, LeNarz LA, Despotis GJ, Smith PK, Booth JE, Raymond RE, Sapp SK, Cabot CF, Tchen JE, Califf RM, Efron MB, Topol EJ. Abciximab and Bleeding During Coronary Surgery: Results from the EPILOG and EPISTENT Trials. *Ann Intern Med* 2000;70:516-26:
447. Mark DB, Harrington RA, Lincoff AM, Califf RM, Nelson CL, Tsiatis AA, Buell H, Mahaffey KW, Davidson-Ray L, Topol EJ. Cost effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST elevation acute coronary syndromes. *Circulation* 2000;101(4):366-371.
448. Marso SP, Bhatt DL, Roe MT, Houghtaling P, Labinaz M, Kleiman NS, Dyke C, Simoons ML, Califf RM, Harrington RA, Topol EJ, for the PURSUIT Investigators. Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in hospital coronary artery bypass grafting. *Circulation* 2000;102, No 24:2952-2958.
449. McGuire DK, Emanuelsson H, Granger CB, Ohman EM, Moliterno DJ, White HD, Ardissino D, Box JW, Califf RM, Topol EJ, for the GUSTO-IIb Investigators. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes: findings from the GUSTO-IIb. *Eur Heart J* 2000;21 Number 21:1750-1758.

450. Menon V, Hochman JS, Stebbins A, Pfisterer M, Col J, Anderson RD, Hasdai D, Holmes DR, Bates ER, Topol EJ, Califf RM, Ohman EM, for the GUSTO Investigators. Lack of progress in cardiogenic shock: lessons from the GUSTO trials. *Eur Heart J* 2000;19:28-1936.
451. Moliterno DJ, for the PARAGON B International Steering Committee. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B Study. *Am Heart J* 2000;139(4):563-566.
452. Newby LK, Kaplan AL, Granger BB, Sedor F, Califf RM, Ohman EM. Comparison of cardiac troponin T versus creatine kinase-MB for risk stratification in a chest pain evaluation unit. *Am J Cardiol* 2000;85:801-805.
453. Newby LK, Eisenstein EL, Califf RM, Thompson TD, Nelson CL, Peterson ED, Armstrong PW, Van de Werf F, White HD, Topol EJ, Mark DB. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. *N Engl J Med* 2000;342(11):749-755.
454. O'Connor CM, Gattis WA, Shaw L, Cuffe MS, Califf RM. Clinical characteristics and long term outcomes of patients with heart failure and preserved systolic function. *Am J Cardiol* 2000;86 no. 8:863-867.
455. Ohman EM, Armstrong PW, White HD, Granger CB, Wilcox RG, Weaver WD, Gibler WB, Stebbins AL, Cianciolo C, Califf RM, Topol EJ. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. *Am J Cardiol* 2000;84:1281-1286.
456. Pfeffer MA, Gallo P, Califf RM, Henis M, Leizorovicz A, Maggioni A, McMurray J, Neuhart E, Rouleau JL, Van de Werf F, Velazquez EJ, Edwards S, Sellers MA. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. *Am Heart J* 2000;
457. Phillips RS, Hamel MB, Teno JM, Soukup J, Lynn J, Califf RM, Vidaillet H, Davis RB, Goldman L. Patient race and decisions to withhold life-sustaining treatments for seriously ill hospitalized adults. *Am J Med* 2000;108(1):14-19.
458. Puchalski CM, Zhong ZS, Jacobs MM, Fox E, Lynn J, Harrold J, Galanos A, Phillips RS, Califf RM, Teno JM. Patients who want their family and physician to make resuscitation decisions for them: observations from SUPPORT and HELP. *J Am Geriatr Soc* 2000;48(5 Suppl S):S84-S90
459. Roe MT, Harrington RA, Prosper DM, Pieper KS, Bhatt DL, Lincoff AM, Simoons ML, Akkerhuis M, Ohman EM, Kitt MM, Vahanian A, Ruzyllo W, Karsh K, Califf RM, Topol EJ. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease. *Circulation* 2000;102 No. 10:1101-1106.
460. Roe MT, Ohman EM, Maas ACP, Christenson RH, Mahaffey KW, Granger CB, Harrington RA, Califf RM, Krucoff MW. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. *J Am Coll Cardiol* 2000;37 no 1:9-18.
461. Sane DC, Damaraju LV, Topol EJ, Cabot CF, Mascelli MA, Harrington RA, Simoons ML, Califf RM. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. *J Am Coll Cardiol* 2000;June:75-83.
462. Shah A, Wagner GS, Granger CB, O'Connor CM, Green CL, Trollinger KM, Califf RM, Krucoff MW. Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis: reexamining the "gold standard" for myocardial reperfusion assessment. *J Am Coll Cardiol* 2000;35(3):666-672.
463. Shah MR, Granger CB, Bart BA, MacMurray JJV, Petrie MC, Michelson EL, Tudor GE, Swedberg K, Stevenson LW, Califf RM, Pfeffer MA. Sex-related differences in the use and effects of angiotensin-converting enzyme inhibitors in heart failure: the SPICE (Study of Patients Intolerant of converting Enzyme Inhibitors) Registry. *Am J Med* 2000;109 (6):489-492.
464. Strategies for patency enhancement in the emergency department (SPEED) group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. *Circulation* 2000;2788-2794.
465. The BARI Investigators. Seven-year outcome in the bypass angioplasty revascularization investigation (BARI) by treatment and diabetic status. *J Am Coll Cardiol* 2000;35(5):1122-1129.
466. The SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. *The Lancet* 2000;355:337-345.

467. Thel MC, Califf RM, Tardiff BE, Gardner LH, Sigmon KN, Lincoff AM, Topol EJ, Kitt MM, Blankenship JC, Tcheng JE, for the IMPACT II Investigators. Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). *Am J Cardiol* 2000;85(4):427-434.
468. Topol EJ, Easton D, Amarenco P, Califf RM, Harrington RA, Graffagnino C, Davis S, Diener HC, Ferguson J, Fitzgerald D, Shuaib A, Koudstaal PJ, Theroux P, Van de Werf F, Willerson JT, Chan R, Samuels R, Ilson B, Granett J. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) Trial. *Am Heart J* 2000;139(6):927-933.
469. Topol EJ, Ohman EM, Armstrong PW, Wilcox R, Skene AM, Aylward P, Simes J, Dalby A, Betriu A, Bode C, White HD, Hochman JD, Emanuelsson H, Vahanian A, Sapp S, Stebbins A, Moliterno DJ, Califf RM. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction. The results from the global utilization of streptokinase and t-PA for occluded coronary arteries (GUSTO) III trial. *Circulation* 2000;102:1761-1765.
470. Topol EJ, Mark DB, Lincoff AM, Cohen EA, Burton JR, Kleiman NS, Talley JD, Sapp S, Booth JE, Cabot CF, Anderson KM, Califf RM, for the EPISTENT Investigators. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. *The Lancet* 2000;354:2019-2024.
471. Wenger NS, Phillips HR3, Teno JM, Oye RK, Dawson NV, Liu HH, Califf RM, Layde P, Hakim RB, Lynn J. Physician understanding of patient resuscitation preferences: insights and clinical implications. *J Am Geriatr Soc* 2000;48(5 Suppl S):S44-S51
472. Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. *Am Heart J* 2000;Dec 140 ( 6):878-885.
473. Akkerhuis KM, Decker JW, Lincoff AM, Tcheng JE, Boersma E, Anderson K, Balog C, Califf RM, Topol EJ, Simoons ML. Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. *JAMA* 2001;78:82
474. Al-Khatib SM, Califf RM, Hasselblad V, Alexander JH, McCrory DC, Sugarman J. Medicine: Placebo controls in short term clinical trials of hypertension. *Science Magazine* 2001;292:2013-2015.
475. Al-Khatib SM, Pieper KS, Lee KL, Mahaffey KW, Hochman JS, Pepine CJ, Kopecky SL, Akkerhuis M, Stepinska J, Simoons ML, Topol EJ, Califf RM, Harrington RA. Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial. *Am J Cardiol* 2001;88:76-79.
476. Alexander KP, Newby KL, Hellkamp AS, Harrington RA, Peterson ED, Kopecky S, Langer A, O'Gara P, O'Conner CM, Daly RN, Califf RM, Khan S, Fuster V. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. *J Am Coll Cardiol* 2001;38 no 1:1-7.
477. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Califf RM, Ohman EM, Kleiman NS, Keltai M, Wilcox RG, Vahanian A, Armstrong PW, Lauer MS. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. *Lancet* 2001;357 (9262):1063-1068.
478. Bahit MC, Topol EJ, Califf RM, Armstrong PW, Criger DA, Hasselblad V, Betriu A, Hirsh J, Ardissino D, Granger CB. Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. *J Am Coll Cardiol* 2001;37 no. 4:1001-1007.
479. Barbash GI, Birnbaum Y, Bogearts K, Hudson M, Lesaffe E, Fu Y, Goodman S, Houdbracken K, Munsters K, Granger C, Pieper K, Califf RM, Topol E, de Werf FV. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction. *Circulation* 2001;103 No 7:954-966.
480. Berger PB, velianou JL, Vlachos HA, Feit F, Jacobs AK, Faxon DP, Attubato M, Keller N, Stadius ML, Weiner BH, williams DO, Detre K, BARI Investigators. Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. *JAMA* 2001;38:1140-1149.

481. Birnbaum Y, Goodman S, Barr A, Gates KB, Barbash GI, Battler A, Barbagelata A, Clemmensen P, Sgarbossa EB, Granger CB, Califf RM, Wagner GS. Comparison of primary coronary angioplasty versus thrombolysis in patients with ST segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. *Am J Cardiol* 2001;88:842-847.
482. Blazing MA, De Lemos JA, Dyke CK, Califf RM, Bilheimer D, Braunwald E. The A-to-Z trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. *Am Heart J* 2001;211-217.
483. Califf RM, Ellenberg SS. Statistical approaches and policies for the operations of data and safety monitoring committees. *Am Heart J* 2001;141 no. 2:301-306.
484. Califf RM, Lee KL. Data safety and monitoring committees: Philosophy and practice, Introduction. *Am Heart J* 2001;141:154-155.
485. Califf RM, Gibler WB, Gibson CM, Granger CB, Hoekstra JW, Ornato JP, Ross AM, Tiefenbrunn AJ, Van de Werf F, Zalenski RJ. Myocardial reperfusion: new strategies for the new century. *Clinician* 2001;18 no 6:1-25.
486. Cantor WJ, Hellkamp AS, Peterson ED, Zidar JP, Cowper PA, Sketch MH, Tchong JE, Califf RM, Ohman EM. Achieving optimal results with standard balloon angioplasty: Can baseline and angiographic variables predict stent-like outcomes? *J Am Coll Cardiol* 2001;37:1883-1890.
487. Cohen MG, Pacchiana CM, Corbalan R, Perez JA, Ponte CI, Oropeza ES, Diaz R, Paolasso E, Izasa D, Rodas MA, Urrutia CE, Harrington RA, Topol EJ, Califf RM. Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: Results from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. *Am Heart J* 2001;141:391-401.
488. DeLong ER, Nelson CL, Wong JB, Pryor DB, Peterson ED, Lee KL, Mark DB, Califf RM. Using observational data to estimate prognosis: an example using a coronary artery disease registry. *Stat Med* 2001;20 (16) 2505:2505-2532.
489. Dolor RJ, Witsel DL, Hellkamp AS, Williams JW, Califf RM, Simel DL. Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis: The CAFFs trial, a randomized controlled trial. *JAMA* 2001;286:3097-3105.
490. Donohue M, Fuster V, Califf RM. Introduction: Cardiologists should target obesity (Report). *Am Heart J* 2001;142 (6):1088-1090.
491. Greenbaum AB, Harrington RA, Hudson MP, MacAulay CM, Wilcox RG, Simoons ML, Berdan LG, Guerci A, Cokkinos DV, Kitt MM, Lincoff AM, Topol EJ, Califf RM, Ohman EM, for the PURSUIT Investigators. Therapeutic value of eptifibatid at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. *J Am Coll Cardiol* 2001;37 no. 2, 2001:492-498.
492. Harrington RA, Armstrong PW, Graffagnino C, Van de Werf F, Kereiakes DJ, Sigmon KN, Card T, Joseph DM, Samuels R, Granett J, Chan R, Califf RM, Topol EJ, for the APPLAUD Study Investigators. Dose finding safety and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. *Circulation* 2001;102:728-735.
493. Hudson MP, Granger CB, Topol EJ, Pieper KS, Armstrong PW, Barbash GI, Guerci AD, Vahanian A, Califf RM, Ohman EM. Early reinfarction after fibrinolysis. Experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. *Circulation* 2001;104:1229-1235.
494. Jaing W, Cuffe MS, Christopher E, Kuchibhatla M, Gaulden LG, Cuffe MS, Blazing MA, Davenport C, Califf RM, Krishnan KR, O'Connor CM. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. *Arch Intern Med* 2001;161 no 15:1849-1856.
495. Kandzari DE, Lam LC, Eisenstein EL, Clapp-Channing N, Fine JT, Califf RM, Mark DB, Jollis JG. Advanced coronary artery disease: Appropriate end points for trials of novel therapies. *Am Heart J* 2001;142 (5):843-851.

- 496.Kaul P, Fu Y, Chang WC, Harrington RA, Wagner GS, Goodman SG, Granger CB, Moliterno DJ, Van de Werf F, Califf RM, Topol EJ, Armstrong PW. Prognostic value of ST segment depression in acute coronary syndromes: Insights from PARAGON-A applied to GUSTO-IIb. *J Am Coll Cardiol* 2001;38 no 1:64-71.
- 497.Labinaz D, Sketch MH, Ellis SG, Abramowitz BM, Stebbins AL, Pieper KS, Holmes DR, Califf RM, Topol EJ. Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy. *Am Heart J* 2001;141 (3):469-477.
- 498.Lundergan CF, Ross AM, McCarthy WF, Reiner JS, Boyle D, Fink CA, Califf RM, Topol EJ, Simoons ML, van den Brand M, Van de Werf F, Coyne KS. Predictors of left ventricular function after acute myocardial infarction: Effects of time to treatment, patency, and body mass index: the GUSTO-I angiographic experience. *Am Heart J* 2001;142:43-50.
- 499.Mast ST, Gersing KR, Anstron KJ, Krishnan KR, Califf RM, Jollis JG. Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. *Am J Cardiol* 2001;87 no. 8:989-993.
- 500.Morse MA, Califf RM, Sugarman J. Monitoring and ensuring safety during clinical research. *JAMA* 2001;285 no. 9:1201-1205.
- 501.Newby KL, Ohman EM, Christenson RH, Moliterno DJ, Harrington RA, White HD, Armstrong PW, de Werf FV, Pfisterer M, Hasselblad V, Califf RM, Topol EJ. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status. The PARAGON-B troponin T substudy. *Circulation* 2001;102 no. 24:2891-2896.
- 502.O'Connor CM, Gattis WA, Hellkamp AS, Langer A, Larssen RL, Harrington RA, Berkowitz SD, O'Gara PT, Kopecky S, Gheorghiade M, Daly RN, Fuster V. Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). *Am J Cardiol* 2001;88 (5):541-546.
- 503.O'Shea JC, Califf RM. International differences in treatment effects in cardiovascular clinical trials. *Am Heart J* 2001;875-880.
- 504.O'Shea JC, Califf RM. International differences in cardiovascular clinical trial. *Am Heart J* 2001;866-874.
- 505.Peterson JG, Topol EJ, Roe MT, Sapp SK, Lincoff AM, Decker JW, Blackstone EH, Harrington RA, Califf RM, Lauer MS. Prognostic importance of concomitant heparin with eptifibatid in acute coronary syndromes. *Am J Cardiol* 2001;87 no 5:532-536.
- 506.Pilote L, Miller DP, Califf RM, Topol EJ. Recurrent ischemia after thrombolysis for acute myocardial infarction. *Am Heart J* 2001;141 no 4:559-565.
- 507.Roe MT, Guigliano RP, Harrington RA, Gibson CM, Strony J, Kitt MM, Braunwald E. Combination reperfusion therapy with eptifibatid and tenecteplase for acute myocardial infarction. *HeartDrug* 2001;1 no 1:5-13.
- 508.Roe MT, Granger CB, Puma JA, Hellkamp AS, Hochman JS, Ohman EM, White HD, Van de Werf F, Armstrong PW, Ellis SG, Califf RM, Topol EJ. Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. *Am J Cardiol* 2001;88:1403-1406.
- 509.Roffi M, Chew DP, Mukherjee M, Bhatt DL, White JA, Heeschen C, Moliterno DJ, Califf RM, White HD, Kleiman NS, Theroux P, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndromes. *Circulation* 2001;104:2767-2771.
- 510.Shah MR, Hasselblad V, Stinnett SS, Gheorghiade M, Swedberg K, Califf RM, O'Connor CM. Hemodynamic profiles of advanced heart failure: association with clinical characteristics and long-term outcomes. *J Card Failure* 2001;7 (2):105-113.
- 511.Shah MR, O'Conner CM, Sopko G, Hasselblad V, Califf RM, Stevenson LW. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness (ESCAPE): Design and rationale. *Am Heart J* 2001;141, no. 4:528-535.
512. Shah MR, Hasselblad V, Gheorghiade M, Adams KF, Swedberg K, Califf RM, O'Connor CM. Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. *Am J Cardiol* 2001;88 (9):987-993.

513. Shah MR, Stinnett SS, McNulty SE, Gheorghide M, Zannad F, Uretsky BF, Adams KF, Califf RM, O'Connor CM. Hemodynamics as surrogate endpoints for survival in advanced heart failure: an analysis from FIRST. *Am Heart J* 2001;141(6):908-914.
514. Szczech LA, Reddan DN, Owen WF, Califf RM, Racz M, Jones RH, Hannan EL. Differential survival following coronary revascularization among patients with renal insufficiency. *Kidney International* 2001;60(1):292-299.
515. Tchen JE, Talley JD, O'Shea JC, Gilchrist IC, Kleiman NS, Grines CL, Davidson CJ, Lincoff AM, Califf RM, Jennings LK, Kitt MM, Lorenz TJ. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). *Am J Cardiol* 2001;88:1097-1102.
516. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. *The Lancet* 2001;357 no. 9272:1915-1924.
517. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. *The Lancet* 2001;357 no. 9272:1905-1914.
518. The HERO-2 Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. *Lancet* 2001;358:1855-1863.
519. Whellan DJ, Shaw LJ, Bart BA, Kraus WE, Califf RM, O'Connor CM. Cardiac rehabilitation and survival in patients with left ventricular systolic dysfunction. *Am Heart J* 2001;142:160-166.
520. Al-Khatib SM, Granger CB, Huang Y, Lee KL, Califf RM, Simoons ML, Armstrong PW, Van de Werf F, White HD, Simes RJ, Moliterno DJ, Topol EJ, Harrington RA. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation incidence, predictors, and outcomes. *Circulation* 2002;106:309-312.
521. Allen-LaPointe NM, Kramer JM, DeLong ER, Ostbye T, Hammill BG, Muhlbaier LH, McCants B, Chen A, Califf RM. Patient-reported frequency of taking aspirin in a population with coronary artery disease. *Am J Cardiol* 2002;89:1042-1046.
522. Anderson ME, Al-Khatib SM, Roden DM, Califf RM. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. *Am Heart J* 2002;144:769-781.
523. Anderson RD, White HD, Ohman EM, Wagner GS, Krucoff MW, Armstrong PW, Weaver DW, Gibler WB, Stebbins A, Califf RM, Topol EJ. Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: A substudy of the GUSTO III trial. *Am Heart J* 2002;144:81-88.
524. Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, Ohman EM, Mahaffey KW, Newby LK, Califf RM, Simoons ML, Topol EJ, Lauer MS. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. *N Engl J Med* 2002;346:2047-2052.
525. Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell M, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste P, Tchen JE, Califf RM, Harrington RA. Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes. The COMPARE trial. *Circulation* 2002;106:1470-1482.
526. Blankenship JC, Balog C, Sapp SK, Califf RM, Lincoff AM, Tcheng JE, Topol EJ. Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials. *Catheter Cardiovasc. Interv.* 2002;57:476-483.
527. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van der Werf F, de Torbal A, Armstrong PW, Wallentin L, Wilcox RG, Simes J, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. *The Lancet* 2002;359:189-198.
528. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE, III, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC, Jr. ACC/AHA guideline update for the management of patients with

unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). *Circulation* 2002;106:1893-1900.

529. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JD, Jones RH, Kereiakes DJ, Kuppersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EEI, Steward DE, Theroux P. ACC/AHA Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002. *Circulation* 2002;106:1893-1900.
530. Breeman A, Mercado N, Lenzen M, van den Brand M, Harrington RA, Califf RM, Topol EJ, Simoons ML, Boersma E, for the PURSUIT Investigators. Characteristics, Treatment and Outcome of Patients with Non-ST-Elevation Acute Coronary Syndromes and Multivessel Coronary Artery Disease: Observations from PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy). *Cardiology* 2002;98:195-201.
531. Califf RM, Demets DL. Principles from clinical trials relevant to clinical practice: Part I. *Circulation* 2002;106:1015-1021.
532. Califf RM. Evaluating the cost and effectiveness of cardiovascular therapies; Who cares about economics analyses? *Stat Med* 2002;21:2889-2897.
533. Califf RM. Introduction: Redefining acute coronary syndrome care in the era of aggressive revascularization. *Clin Cardiol* 2002;25, (Suppl. 1):I
534. Califf RM, DeLong ER, Ostbye T, Muhlbaier LH, Chen A, Lapointe N, Hammill BG, McCants B, Kramer J. Underuse of aspirin in a referral population with documented coronary artery disease. *Am J Cardiol* 2002;89:653-661.
535. Califf RM. The need for a national infrastructure to improve the rational use of therapeutics. *Pharmacoepidemiol Drug Saf.* 2002;11:319-327.
536. Califf RM, Peterson ED, Gibbons RJ, Garson A, Jr., Brindis RG, Beller GA, Smith SC, Jr. Integrating quality into the cycle of therapeutic development. *J. Am. Coll. Cardiol.* 2002;40:1895-1901.
537. Califf RM. Matching resources to treatment decisions for patients with acute coronary syndromes. *Clin Cardiol* 2002;25 (Suppl.1):I-2-I-8
538. Califf RM, Demets DL. Principles from clinical trials relevant to clinical practice: Part II. *Circulation* 2002;106:1172-1175.
539. Cantor WJ, Newby KL, Christenson RH, Tuttle RH. Prognostic significance of elevated troponin I after percutaneous coronary intervention. *J Am Coll Cardiol* 2002;39:1738-1744.
540. Chang WC, Harrington RA, Simoons ML, Califf RM, Lincoff AM, Armstrong PW. Does eptifibatid confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? *Eur Heart J* 2002;23:1104-1111.
541. Cuffe MS, Califf RM, Adams KF, Jr., Benza R, Bourge RC, Colucci WS, Massie B, O'Connor CM, Pina I, Quigg R, Silver MJ, Gheorghide M, The OPTIME Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial. *JAMA* 2002;287:1541-1547.
542. Demets DL, Califf RM. Lessons learned from recent cardiovascular clinical trials: Part II. *Circulation* 2002;106:880-885.
543. Demets DL, Califf RM. Lessons learned from recent cardiovascular clinical trials: Part I. *Circulation* 2002;106:746-751.
544. Dolor RJ, Williams JW Jr, Simel DL, Califf RM. Efficacy of intranasal corticosteroids for acute sinusitis. *JAMA* 2002;287:1261-1262.
545. Gibler WB, Armstrong PW, Ohman EM, Weaver DW, Stebbins A, Gore JM, Newby KL, Califf RM, Topol EJ, GUSTO Investigators. Persistence of delays in presentation and treatment for patients with acute myocardial infarction: the GUSTO-I and GUSTO-III experience. *Ann Emerg Med* 2002;39:123-130.
546. Gilchrist IC, Berkowitz SD, Thompson TD, Califf RM, Granger CB. Heparin dosing and outcome in acute coronary syndromes: The GUSTO-IIb experience. *Am Heart J* 2002;144:73-80.



547. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Bigger JT, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM. Sertraline treatment of major depression in patients with acute MI or unstable angina. *JAMA* 2002;288:701-709.
548. Hillegass WB, Brott BC, Chapman GD, Phillips HR, Stack RS, Tchong JE, Califf RM. Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications. *Am Heart J*. 2002;144:501-507.
549. Islam MA, Blankenship JC, Balog C, Iliadis EA, Lincoff AM, Tchong JE, Califf RM, Topol EJ. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). *Am J Cardiol*. 2002;90:916-921.
550. James S, Armstrong PA, Califf RM, Husted S, Kontny F, Niemminen M, Pfisterer M, Simoons ML, Wallentin L. Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. *Eur Heart J* 2002;23:1538-1545.
551. Kereiakes DJ, Lincoff AM, Anderson KM, Achenbach R, Kamlesh P, Barnathan ES, Califf RM, Topol EJ. Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. *Am J Cardiol* 2002;90:628-630.
552. Kip KE, Alderman EL, Bourassa MG, Brooks MM, Schwartz L, Holmes DR, Jr., Califf RM, Whitlow PL, Bernard R, Detre KM. Differential influence of diabetes mellitus on increased jeopardized myocardium after initial angioplasty or bypass surgery: Bypass angioplasty revascularization investigation report. *Circulation* 2002;105:1914-1920.
553. Kong DF, Hasselblad V, Kandzari DE, Newby LK, Califf RM. Seeking the optimal aspirin dose in acute coronary syndromes. *Am J Cardiol* 2002;90:622-625.
554. Kottke-Marchant K, Bahit MC, Granger CB, Zoldeyhi P, Ardissino D, Brooks MM, Griffin JH, Potthoff RF, Van de Werf F, Califf RM, Topol EJ. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes. *Eur Heart J* 2002;23:1202-1212.
555. Kramer JM, Bosco LA, Califf RM. Centers for education and research on therapeutics (CERTs). *Drug information journal* 2002;36:717-723.
556. Labinaz M, Kilaru R, Pieper K, Marso SP, Kitt MM, Simoons ML, Califf RM, Topol EJ, Armstrong PA, Harrington RA. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting. *Circulation* 2002;322-327.
557. Labinaz M, Madan M, O'Shea JC, Kilaru R, Chin W, Pieper K, McGuire DK, Saucedo JF, Talley D, Lui D, Kitt MM, Califf RM, Tchong JE. Comparison of one year outcomes following coronary artery stenting in diabetic versus non diabetic patients (From the enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy (ESPIRIT) Trial). *Am J Cardiol* 2002;90:585-590.
558. Lapointe N, Kramer JM, Weinfurt KP, Califf RM. Practitioner acceptance of the dofetilide risk management program. *Pharmacotherapy* 2002;22:1041-1046.
559. Lee MS, Wali AU, Menon V, Berkowitz SD, Thompson TD, Califf RM, Topol EJ, Granger CB, Hochman JS. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. *J Thromb Thrombolysis*. 2002;14:91-101.
560. Lincoff AM, Califf RM, Van de Werf F, Willerson JT, White HD, Armstrong PW, Guetta V, Gibler WB, Hochman JS, Bode C, Vahanian A, Steg PG, Ardissino D, Savonitto S, Bar F, Sadowski Z, Betriu A, Booth JE, Wolski K, Waller M, Topol EJ. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction. *JAMA* 2002;288:2130-2135.
561. Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman N, Connolly P, Berdan LG, Sparapani R, Lee KL, Armstrong PW, Topol EJ, Califf RM, Harrington RA, PARAGON Investigators. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. *Am Heart J* 2002;143:242-248.

562. Mehta RH, Criger DA, Granger CB, Pieper KK, Califf RM, Topol EJ, Bates ER. Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability. *J Am Coll Cardiol*. 2002;40:1034-1040.
563. Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan L, Lauer MS, Manttari M, White HD, Califf RM, Topol EJ. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). *Am Heart J*. 2002;144:995-1002.
564. Newby KH, Kristinsson A, Bhapkar M, Aylward P, Dimas AP, Klein WW, McGuire DK, Moliterno DJ, Verheugt FWA, Weaver DW, Califf RM, For the SYMPHONY Investigators. Early statin initiation and outcomes in patients with acute coronary syndromes. *JAMA* 2002;287:3087-3095.
565. Newby LK, Harrington RA, Bhapkar MV, Van de WF, Hochman JS, Granger CB, Simes RJ, Davis CG, Topol EJ, Califf RM, Moliterno DJ. An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. *J Thromb Thrombolysis*. 2002;14:33-42.
566. Newby LK, Alpert JS, Ohman EM, Thygesen K, Califf RM. Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. *Am Heart J*. 2002;144:957-980.
567. O'Connor CM, Velasquez EJ, Gardner LH, Smith PK, Newman MF, Landolfo KP, Lee KL, Califf RM, Jones RH. Comparison of coronary artery bypass grafting versus medical therapy on long term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Database). *Am J Cardiol* 2002;90:101-107.
568. O'Shea JC, Wilcox RG, Skene AM, Stebbins AL, Granger CB, Armstrong PW, Bode C, Ardissino D, Emanuelsson H, Aylward PE, White HD, Sadowski Z, Topol EJ, Califf RM, Ohman EM. Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone. *Am J Cardiol*. 2002;90:1374-1377.
569. O'Shea JC, Buller CE, Cantor WJ, Chandler AB, Cohen EA, Cohen DJ, Gichrist IC, Kleiman NS, Labinaz M, Madan M, Hafley GE, Califf RM, Kitt MM, Strony J, Tchong JE, The ESPRIT investigators. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatid in coronary stent intervention. *JAMA* 2002;287:618-621.
570. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure. *Circulation* 2002;106:920-926.
571. Ronner E, Boersma E, Laarman G, Somsen GA, Harrington RA, Deckers JW, Topol EJ, Califf RM, Simoons ML. Early angioplasty in acute coronary syndromes without persistent ST segment elevation improves outcome but increases the need for six month repeat revascularization. *J Am Coll Cardiol* 2002;39:1924-1929.
572. Ronner E, Boersma E, Akkerhuis KM, Harrington RA, Lincoff AM, Deckers JW, Karsh K, Kleiman NS, Vahanian A, Topol EJ, Califf RM, Simoons ML. Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most for early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. *Eur Heart J* 2002;23:239-246.
573. Savonitto S, Granger CB, Ardissino D, Gardner L, Cavallini C, Galvani M, Ottani F, White HD, Armstrong PW, Ohman EM, Pieper KS, Califf RM, Topol EJ, The GUSTO-IIb Investigators. The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. *J Am Coll Cardiol* 2002;39:22-29.
574. Schulman KA, Seils DM, Timbre JW, Sugarman J, Dame LA, Weinfurt KP, Mark DB, Califf RM. A national survey of provisions in clinical trial agreements between medical schools and industry sponsors. *N Engl J Med* 2002;347:1335-1341.
575. Selker HP, Raitt MH, Schmid CH, Laks MM, Beshansky JR, Griffith JL, Califf RM, Selvester RH, Maynard C, D'Agostino RB, Weaver DW. Time dependent predictors of primary cardiac arrest in patients with acute myocardial infarction. *Am J Cardiol* 2002;91:286.
576. Suwaidi JA, Reddan DN, Williams K, Pieper K, Harrington RA, Califf RM, Granger CB, Ohman EM, Holmes DR, Jr. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. *Circulation* 2002;106:974-980.

577. Szczech LA, Best PJ, Crowley E, Brooks MM, Berger PB, Bittner V, Gersh BJ, Jones RH, Califf RM, Ting HH, Whitlow PJ, Detre KM, Holmes DR. Outcomes of patients with chronic renal insufficiency in the Bypass Angioplasty Revascularization Investigation (BARI). *Circulation* 2002;105 (19):2253-2258.
578. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in moderately hypercholesterolemic hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *JAMA* 2002;288:2998-3007.
579. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002;288:2981-2997.
580. Topol EJ, Lincoff AM, Kereiakes DJ, Kleiman N, Ferguson JJ, Tcheng JE, Anderson KM, Barnathan ES, Califf RM. Multi-year follow-up of abciximab therapy in three randomized, controlled trials of percutaneous coronary revascularization. *Am J Med* 2002;113:1-6.
581. Whellan DJ, Cohen EJ, Matchar DB, Califf RM. Disease management in the healthcare organizations: Results of in-depth interviews with disease management decision makers. *Am J Manag Care* 2002;8:633-641.
582. Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM. Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. *Heart* 2002;88:357-362.
583. Al-Khatib SM, Allen-LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. *JAMA* 2003;289:2120-2127.
584. Al-Khatib SM, Stebbins A, Califf RM, Lee K, Granger CB, White H, Armstrong PW, Topol EJ, Ohman EM. Ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. *Am Heart J* 2003;145:515-521.
585. Al Khatib SM, Stebbins AL, Califf RM, Lee KL, Granger CB, White HD, Armstrong PW, Topol EJ, Ohman EM. Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. *Am Heart J*. 2003;145:515-521.
586. Alexander JH, Harrington RA, Bhapkar M, Mahaffey KW, Lincoff AM, Ohman EM, Klotzwijk P, Pahlm O, Henden B, Deckers JW, Simoons ML, Califf RM, Wagner GS. Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes. *Am J Med*. 2003;115:613-619.
587. Allen-LaPointe NM, Chen A, Hammill B, DeLong E, Kramer JM, Califf RM. Evaluation of the dofetilide risk-management program. *Am Heart J* 2003;146:901
588. Batchelor WB, Mark D, Knight JD, Granger CB, Armstrong PW, Califf RM, Peterson ED. Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: Potential impact on cardiac catheterization use in the United States and Canada. *Am Heart J* 2003;145:349-355.
589. Califf RM, Muhlbaier LH. Health Insurance Portability and Accountability Act (HIPAA). Must there be a trade off between privacy and quality of health care, or can we advance both? *Circulation* 2003;108:915-918.
590. Califf RM. Issues facing clinical trials of the future. *J Intern Med* 2003;254:433
591. Califf RM, Morse MA, Wittes J, Goodman SN, Nelson DK, Demets DL, Iafrate P, Sugarman J. Toward protecting the safety of participants in clinical trials. *Control Clin Trials* 2003;24:256-271.
592. Califf RM. Supplement on acute coronary syndromes: introduction. *Circulation* 2003;108 (16 supplement 1):5
593. Campbell WH, Califf RM. Improving communications of drug risks to prevent patient injury: proceedings of a workshop. *Pharmacoepidemiol Drug Saf*. 2003;12:183-194.

594. Cho L, Bhatt DL, Marso SP, Brennan D, Holmes DR, Jr., Califf RM, Topol EJ. An invasive strategy is associated with decreased mortality in patients with unstable angina and non-ST-elevation myocardial infarction: GUSTO IIB trial. *Am.J.Med.* 2003;114:106-111.
595. Curtis LH, Ostbye T, Sendersky V, Hutchison S, Allen-LaPointe NM, Al-Khatib SM, Yasuda S, Dans P, Wright A, Califf RM, Woosley RA, Schulman KA. Prescription of QT-prolonging drugs in a large, national outpatient population. *Am J Med* 2003;114:135-141.
596. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, Gheorghide M, O'Connor CM. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. *J.Am.Coll.Cardiol.* 2003;41:997-1003.
597. Fu Y, Goodman S, Chang WC, Van de Werf F, Granger CB, Armstrong PW. Time to treatment influences the impact of ST-segment resolution on one-year prognosis. Insight from the assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) Trial. *Circulation* 2003;104:2659
598. Guigliano RP, Roe MT, Harrington RA, Gibson CM, Zeymer U, Van de Werf F, Baran KW, Hobbach HP, Woodlief LH, Hannan KL, Greenberg S, Miller J, Kitt MM, Strony J, McCabe CH, Braunwald E, Califf RM, Oparil S, On behalf of the INTEGRITI investigators. Combination reperfusion therapy with eptifibatid and reduced-dose tenecteplase for acute myocardial infarction. *J Am Coll Cardiol* 2003;41:1251-1260.
599. Hersi A, Fu Y, Wong B, Mahaffey KW, Harrington RA, Califf RM, Van de WF, Armstrong PW. Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission? *Eur.Heart J.* 2003;24:522-531.
600. James S, Lindahl B, Siegbahn A, Armstrong PW, Venge P, Armstrong PW, Barnathan ES, Califf RM, Topol EJ, Simoons ML, Wallentin L. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. *Circulation* 2003;108:275-281.
601. James S, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, Lindahl B. Troponin T levels and risk of 30-day outcomes in patients with acute coronary syndromes: Prospective verification in the GUSTO IV Trial. *Am J Med* 2003;115:178-184.
602. Kaul P, Newby LK, Fu Y, Mark DB, Califf RM, Topol EJ, Aylward P, Granger CB, Van de Werf F, Armstrong PW, For the VIGOUR Group. International differences in the evolution of early discharge following acute myocardial infarction. *Lancet* 2003;363:511-517.
603. Kaul P, Newby LK, Fu Y, Hasselblad V, Mahaffey KW, Christenson RH, Harrington RA, Ohman EM, Topol EJ, Califf RM, Van de WF, Armstrong PW. Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. *J.Am.Coll.Cardiol.* 2003;41:371-380.
604. Khadour FH, Fu Y, Chang WC, Mark D, Granger CB, Topol EJ, Califf RM, Armstrong PW. Impact of on-site cardiac intervention facilities on management and outcome of patients with acute coronary syndromes. *Canadian Journal of Cardiology* 2003;3:257-263.
605. Kong DF, Hasselblad V, Harrington RA, White HD, Tchong JE, Kandzari DE, Topol EJ, Califf RM. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. *Am J Cardiol* 2003;92:651-655.
606. Kong DF, Hasselblad V, Harrington RA, White HD, Tchong JE, Kandzari DE, Topol EJ, Califf RM. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. *Am.J.Cardiol.* 2003;92:651-655.
607. Kramer JM, Newby LK, Chang WC, Simes RJ, Van de Werf F, Granger CB, White HD, Piegas LS, Topol EJ, Califf RM, Armstrong PW. International variation in the use of evidence-based medicines for acute coronary syndromes. *Eur Heart J* 2003;23:2141

608. LaPointe NM, Al Khatib SM, Kramer JM, Califf RM. Knowledge deficits related to the QT interval could affect patient safety. *Ann. Noninvasive. Electrocardiol.* 2003;8:157-160.
609. Mahaffey KW, Lewis BE, Wilderman NM, Berkowitz SD, Oliverio RM, Turco MA, Shalev Y, Ver Lee P, Traverse JH, Rodriguez AR, Ohman EM, Harrington RA, Califf RM, For the ATBAT Investigators. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. *J Invasive Cardiol.* 2003;611-616.
610. Mukherjee M, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan LG, Lauer MS, Manttari M, White HD, Califf RM, Topol EJ. Promise of combined low molecular weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). *Am Heart J* 2003;144:995-1002.
611. Newby KL, Alpert JS, Ohman ME, Thygesen K, Califf RM. Changing the diagnosis of acute myocardial infarction: Implications for practice and clinical investigations. *Am Heart J* 2003;144:957-978.
612. Newby LK, Hasselblad V, Armstrong PW, Van de WF, Mark DB, White HD, Topol EJ, Califf RM. Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making. *Eur. Heart J.* 2003;24:182-189.
613. Newby LK, Bhapkar MV, White HD, Topol EJ, Dougherty FC, Harrington RA, Smith MC, Asarch LF, Califf RM. Predictors of 90-day outcome in patients stabilized after acute coronary syndromes. *Eur. Heart J.* 2003;24:172-181.
614. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 2003;399:1893-1906.
615. Reddan DN, Szczech LA, Tuttle RH, Shaw LK, Jones RH, Schwab SJ, Smith MS, Califf RM, Mark DB, Owen WF, Jr. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. *J Am Soc Nephrol* 2003;2373-2380.
616. Reddan DN, Szczech LA, O'Shea S, Califf RM. Anticoagulation in acute cardiac care in patients with chronic kidney disease. *Am Heart J* 2003;145:586-594.
617. Roe MT, Ohman EM, Pollack CV, Peterson ED, Brindis RG, Harrington RA, Christenson RH, Smith SC Jr, Califf RM, Gibler WB. Changing the model of care for patients with acute coronary syndromes. *Am Heart J* 2003;146:612
618. Savonitto S, Armstrong PW, Lincoff AM, Jia G, Sila CA, Booth J, Terrosu P, Cavallini C, White HD, Ardissino D, Califf RM, Topol EJ. Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. *Eur Heart J.* 2003;24:1807-1814.
619. Selker HP, Raitt MH, Schmid CH, Laks MM, Beshansky JR, Griffith JL, Califf RM, Selvester RH, Maynard C, D'Agostino RB, Weaver WD. Time-dependent predictors of primary cardiac arrest in patients with acute myocardial infarction. *Am. J. Cardiol.* 2003;91:280-286.
620. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, van Zyl LT, Finkel MS, Krishnan KR, Gaffney M, Harrison WM, Califf RM, O'Connor CM, For the SADHART Study Group. Platelet/ Endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events. The sertraline antidepressant heart attack randomized trial (SADHART) platelet substudy. *Circulation* 2003;108:939-944.
621. Stamler JS, Taber B, Califf RM. Translation of academic discovery into societal benefit: proposal for a balanced approach part I. *Am J Med* 2003;115:599
622. Stamler JS, Taber RL, Califf RM. Translation of academic discovery into societal benefit: proposal for a balanced approach-part 2. *Am. J. Med.* 2003;115:683-688.

623. Tcheng JE, Madan M, O'Shea JC, Cohen EA, Buller C, Lincoff AM, Popma JJ, Teirstein PS, Kitt MM, Lorenz TJ, Greenberg S, Fost N, Califf RM. Ethics and equipoise: Rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention. *J Invas Cardiol* 2003;16:97-104.
624. Tolleson TR, Newby KL, Harrington RA, Bhapkar MV, Verheugt FWA, Berger PB, Moliterno DJ, White HD, Van de Werf F, Topol EJ, Califf RM. Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). *Am J Cardiol* 2003;92:330-333.
625. Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, Davis S, Diener HC, Ferguson J, Fitzgerald D, Granett J, Shuaib A, Koudstaal PJ, Theroux P, Van de Werf F, Sigmon K, Pieper KS, Vallee M, Willerson JT, BRAVO trial investigators. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. *Circulation* 2003;108:399-406.
626. Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, Davis S, Diener HC, Ferguson J, Fitzgerald D, Granett J, Shuaib A, Koudstaal P, Theroux P, Van de Werf F, Sigmon K, Pieper K, Vallee M, Willerson JT, on behalf of the Blockade of BRAVO investigators. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. *Circulation* 2003;108:399-406.
627. Velazquez EJ, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau JL, Van de Werf F, Kober L, White HD, Swedberg K, Leimberger JD, Gallo P, Sellers MA, Edwards S, Henis M, Califf RM, For the VALIANT investigators. Valsartan in acute myocardial infarction (VALIANT) trial: baseline characteristics in context. *European Journal of Heart Failure* 2003;5:537-544.
628. Williams RT, Damaraju LV, Mascelli MA, Barnathan ES, Califf RM, Simoons ML, Deliargyris EN, Sane DC. Anti-platelet factor 4/heparin antibodies. An independent predictor of a 30-day myocardial infarction after acute coronary ischemic syndromes. *Circulation* 2003;107:2307-2312.
629. Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM. Significance of atrial fibrillation during acute myocardial infarction, and its current management: Insights from the GUSTO-3 trial. *Card Electrophysiol Rev* 2003;7:201-207.
630. Berger PB, Sketch MH, Califf RM. Choosing between percutaneous coronary intervention and coronary artery bypass grafting for patients with multivessel disease: what can we learn from the Arterial Revascularization Therapy Study (ARTS)? *Circulation* 2004;109:1079-1081.
631. Bittl JA, Chew DP, Topol EJ, Kong DF, Califf RM. Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty. *J. Am. Coll. Cardiol.* 2004;43:936-942.
632. Blazing MA, De Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste P, Palmisano J, Bilheimer D, Snapinn S, Ramsey KS, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM, The A to Z Investigators. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non ST segment elevation acute coronary syndromes who receive tirofiban and aspirin. *JAMA* 2004;292:55-64.
633. Califf RM. Benefit the patient, manage the risk: a system goal. *Pharmacoepidemiol. Drug Saf* 2004;13:269-276.
634. Califf RM. Defining the balance of risk and benefit in the era of genomics and proteomics. *Health Affairs* 2004;23:77-87.
635. Califf RM, Fowler VJr, Cabell CH, Corey R. Novel approaches to clinical trials: Device related infections. *Am Heart J* 2004;147:599-604.
636. Chang WC, Boersma E, Granger CB, Harrington RA, Califf RM, Simoons ML, Kleiman NS, Armstrong PW, For the GUSTO-IIb and PURSUIT Investigators. Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT. *Am Heart J* 2004;148:62-71.
637. Cowper PA, DeLong ER, Whellan DJ, Allen LaPointe NM, Califf RM. Economic effects of beta-blocker therapy in patients with heart failure. *Am. J. Med.* 2004;116:104-111.

638. Demets DL, Califf RM, Dixon D, Ellenberg SS, Fleming T, Held P, Julian D, Kaplan R, Levine R, Neaton J, Packer M, Pocock S, Rockhold F, Seto B, Siegel J, Snapinn S, Stump D, Temple R, Whitley R. Issues in regulatory guidelines for data monitoring committees. *Clinical Trials* 2004;1:162-169.
639. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington RA, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H, SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. *JAMA* 2004;292:45-54.
640. Gibson CM, Murphy KJ, De Lemos JA, Morrow DA, Guigliano RP, Roe MT, Harrington RA, Antman EM, Califf RM, Braunwald E, Timi Study Group. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. *J Am Coll Cardiol* 2004;43:1170-1176.
641. James SK, Siegbahn A, Armstrong PW, Barnathan E, Califf RM, Simoons ML, Wallentin L. Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. *Am Heart J* 2004;147:267-274.
642. Kandzari DE, Granger CB, Simoons ML, White HD, Simes J, Mahaffey KW, Gore J, Weaver DW, Longstreth WT, Jr., Stebbins A, Lee KL, Califf RM, Topol EJ. Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO). *Am J Cardiol* 2004;93:458-461.
643. Kandzari DE, Chu A, Brodie BR, Stuckey TA, Hermiller JB, Vetrovec GW, Hannan KL, Krucoff MW, Christenson RH, Gibbons RJ, Sigmon KN, Garg J, Hasselblad V, Collins K, Harrington RA, Berger PB, Chronos NA, Hochman JS, Califf RM. Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study). *Am J Cardiol* 2004;93:636-638.
644. Kandzari DE, Hasselblad V, Tcheng JE, Stone GW, Califf RM, Kastrati A, Neumann FJ, Brener SJ, Montalescot G, Kong DF, Harrington RA. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: A systematic overview of randomized clinical trials. *Am Heart J* 2004;147:457-467.
645. Kong DF, Eisenstein EL, Sketch MH Jr, Zidar JP, Ryan TJ, Harrington RA, Newman MF, Smith PK, Mark DB, Califf RM. Economic impact of drug eluting stents on hospital systems: a disease state model. *Am Heart J* 2004;147:449-456.
646. Maas ACP, Wyatt CM, Green CL, Wagner GS, Trollinger KM, Pope JE, Langer A, Armstrong PW, Califf RM, Simoons ML, Krucoff MW. Combining baseline clinical descriptors and realtime response to therapy: The incremental prognostic value of continuous ST-segment monitoring in acute myocardial infarction. *Am Heart J* 2004;147:698-704.
647. March JS, Silva SG, Compton S, Anthony G, DeVaugh-Geiss J, Califf RM, Krishnan R. The Child and Adolescent Psychiatry Trials Network (CAPTN). *J Am Acad Child Adolesc Psychiatry* 2004;43:515-518.
648. McGuire DK, Newby KL, Bhapkar MV, Montague EA, Hochman JS, Klein WW, Weaver WD, Pfisterer M, Corbalan R, Dellborg M, Granger CB, Van de Werf F, Topol EJ, SYMPHONY and 2nd SYMPHONY investigators. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. *Am Heart J* 2004;147:246-252.
649. Nabel EG, Selker HP, Califf RM, Canto JG, Cao JJ, Desvigne-Nikkens P, Goldberg RJ, Finnegan JR, Jr., Vaccarino V, Virmani R. Women's Ischemic Syndrome Evaluation: Current Status and Future Research Directions: Report of the National Heart, Lung and Blood Institute Workshop: October 2-4, 2002: Section 3: Diagnosis and Treatment of Acute Cardiac Ischemia: Gender Issues. *Circulation* 2004;109:e50-e52.
650. Newby LK, Bhapkar M, White HD, Moliterno DJ, LaPointe NM, Kandzari DE, Verheugt FW, Kramer JM, Armstrong PW, Califf RM, For the SYMPHONY Investigators. Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. *J Thromb Thrombolysis* 2004;16:119-128.
651. O'Shea JC, Kramer JM, Califf RM, Peterson ED. Part I: Identifying holes in the safety net. *Am Heart J* 2004;147:977-984.

652. Peterson ED, Hirshfeld JW Jr, Ferguson TB, Kramer JM, Califf RM, Kessler LG. Part II: Sealing holes in the safety net. *Am Heart J* 2004;147:985-990.
653. Pieper KS, Tsatis AA, Davidian M, Hasselblad V, Kleiman NS, Boersma E, Chang WC, Griffin J, Armstrong PW, Califf RM, Harrington RA. Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods. *Circulation* 2004;109:641-646.
654. Quinn MJ, Aronow HD, Califf RM, Bhatt DL, Sapp S, Kleiman N, Harrington RA, Kong DF, Kandzari DE, Topol EJ. Aspirin dose and six-month outcome after acute coronary syndrome. *J Am Coll Cardiol* 2004;43:972-978.
655. Rebeiz AG, Roe MT, Alexander JH, Mahaffey KW, Granger CB, Peterson ED, Califf RM, Harrington RA. Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. *Am.J.Med.* 2004;116:119-129.
656. Reed SD, Friedman JY, Velasquez EJ, Gnanasakthy A, Califf RM, Schulman KA. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). *Am Heart J* 2004;148:122-128.
657. Roe MT, Mahaffey KW, Alexander JH, Akkerhuis KM, Simoons ML, Harrington RA, Tardiff BE, Granger CB, Ohman EM, Moliterno D, Lincoff AM, Armstrong PW, Van de Werf F, Califf RM, Topol EJ. Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. *Eur Heart J* 2004;25:313-321.
658. Waters RE, Singh KP, Roe MT, Lotfi M, Sketch MH, Mahaffey KW, Newby LK, Alexander JH, Harrington RA, Califf RM, Granger CB. Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2004;43:2153-2159.
659. Rebeiz AG, Johanson P, Green C, Crater S, Roe MT, Langer A, Giugliano RP, Lincoff AM, Newby LK, Harrington RA, Topol E, Califf RM, Wagner GS, and Krucoff MW. Comparison of ST-Segment Resolution With Combined Fibrinolytic and Glycoprotein IIb/IIIa Inhibitor Therapy Versus Fibrinolytic Alone (Data from Four Clinical Trials). *Journal of Cardiology* 2005; 95:611-614.
660. Meine TJ, Al-Khatib SM, Alexander JH, Granger CB, White HD, Kilaru R, Williams K, Ohman EM, Topol E, and Califf RM. Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. *Am Heart J* 2005; 149 (4):670-674.
661. Kupersmith J, Sung N, Genel M, Slavkin H, Califf RM, Bonow R, Sherwood L, Reame N, Catanese V, Baase C, Feussner JR, Dobs A, Tilson H, and Reece EA. Creating a New Structure for Research on Health Care Effectiveness. *Journal of Investigative Medicine* 2005; 53 (2):67-72.
662. Borges-Netro S, Shaw LK, Tuttle RH, Alexander JH, Smith WT, Chambless M, Coleman RE, Harrington RA, and Califf RM. Incremental prognostic power of single-photon emission computed tomographic myocardial perfusion imaging in patients with known or suspected coronary artery disease. *Am J Cardiol* 2005 95 (2):182-188.
663. Labinaz M, Mathias J, Pieper K, Granger CB, Lincoff AM, Moliterno DJ, Van de Werf F, Simes J, White HD, Simoons ML, Califf RM, Topol E, Armstrong PW, and Harrington RA. Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. *Eur Heart J* 2005; 26 (2):128-136.
664. Miranda PJ, DeFronzo RA, Califf RM, and Guyton JR. Metabolic syndrome: evaluation of pathological and therapeutic outcomes. Part I. *Am Heart J* 149 2005; (1):20-32.
665. Miranda PJ, DeFronzo RA, Califf RM, and Guyton JR. Metabolic syndrome: definition, pathophysiology, and mechanisms. Part II. *Am Heart J* 149 2005; (1):33-45.
666. Mehta RH, Alexander JH, Van de Werf F, Armstrong PW, Pieper KS, Garg J, Califf RM, and Granger CB. Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. *JAMA* 2005; 293 (14):1746-1750.



667. Cohen MG, Kelly RV, Kong DF, Menon V, Shah M, Ferreira JS, Pieper KS, Criger DA, Poggio R, Ohman EM, Gore J, Califf RM, and Granger CB. Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials. *Am J Med* 2005; 118 (5):482-488.
668. Eisenstein EL, Lemons PW II, Tardiff BE, Schulman KA, Jones MG, and Califf RM. Reducing the costs of phase III cardiovascular clinical trials. *Am Heart J* 2005; 149 (3):482-488.
669. Califf RM and Griffith TF. Results of expert meetings. Uncontrolled systolic hypertension Washington, DC, April 25-27, 2002. *Am Heart J* 2005; 149 (5):768.
670. Klein I, O'Conner CM, Leimberger JD, Gattis WA, Pina I, Felker GM, Adams KF, Califf RM, Gheorghide M, Oqueli E, and OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. *Circulation* 2005; 111 (19):2454-2460.
671. Drew BJ, Califf RM, Funk M, Kaufman ES, Krucoff MW, Laks MM, Macfarlane PW, Sommargren C, Swiryn S, and Van Hare GF. AHA scientific statement: practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association Scientific Statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized electrocardiology and the American Association of Critical-Care Nurses. *J Cardiovasc Nurs* 2005; 20 (2):76-106.
672. Al-Khatib SM, Anstron KJ, Eisenstein EL, Peterson ED, Jollis JG, Mark DB, Li Y, O'Connor CM, Shaw LK, and Califf RM. Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. *Ann Intern Med* 2005; 142 (8):139.
673. Reed SD, Anstron KJ, Bakhai A, Briggs AH, Califf RM, Cohen DJ, Drummond MF, Glick H, Gnanasakthy A, Hlatky M, O'Brien BJ, Torti Jr FM, Tsiatis AA, Willan AR, Mark DB, and Schulman KA. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. *Am Heart J* 2005; 149 (3):434-443.
674. Muni NI, Califf RM, Foy JR, Boam AB, Zuckerman BD, and Kuntz RE. Coronary drug-eluting stent development: issues in trial design. *Am Heart J* 2005; 149 (3):415-433.
675. Al-Khatib SM, Sanders GD, Mark DB, Lee KL, Bardy GH, Bigger JT, Buxton AE, Connolly S, Kadish A, Moss A, Feldman AM, Ellenbogen KA, Singh S, and Califf RM. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: Randomized trial evidence through 2004. *Am Heart J* 2005; 149 (6):1020-1034
676. Alexander JH, Ferguson TB, Joseph D, Mack MJ, Wolf RK, Gibson CM, Gennevois D, Lorenz TJ, Harrington RA, Peterson ED, Lee KL, Califf RM, and Kouchoukos NT. The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: Study rationale, design, and baseline patient characteristics. *Am Heart J* 2005; 150 (4):643-649
677. Barbagelata A, Di Carli MF, Califf RM, Garg J, Birnbaum Y, Grinfeld L, Gibbons RJ, Granger CB, Goodman SG, Wagner GS, and Mahaffey KW. Electrocardiographic infarct size assessment after thrombolysis: Insights from the Acute Myocardial Infarction Study Adenosine (AMISTAD) trial. *Am Heart J* 2005; 150 (4):659-665
678. Binanay C, Califf RM, Hasselblad V, O'Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW, and ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. *JAMA* 2005; 294 (13):1693-1694
679. Califf RM. Major Clinical Trials of Hypertension. What Should Be Done Next? *Hypertension* 2005; 46:1-6
680. Califf RM, Petersen JL, Hasselblad V, Mahaffey KW, and Ferguson JJ. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. *Am Heart J* 2005; 149 (4 Suppl):S91-S99
681. Eisenstein EL, McGuire DK, Bhapkar MV, Kristinsson A, Hochman JS, Kong DF, Califf RM, Van de Werf F, Yancy WS, Jr., and Newby LK. Elevated body mass index and intermediate-term clinical outcomes after acute coronary syndromes. *Am J Med* 2005; 118 (9):981-990

682. Giugliano RP, Newby LK, Harrington RA, Gibson CM, Van de Werf F, Armstrong P, Montalescot G, Gilbert J, Strony JT, Califf RM, and Braunwald E. The Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome (Early ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatid in the treatment of patients with non-ST-segment elevation acute coronary syndrome-Study design and rationale. *Am Heart J* 2005; 150 (1):994-1002.
683. Hernandez AF, Velazquez EJ, Solomon SD, Kilaru R, Diaz R, O'Connor CM, Ertl GK, Maggioni AP, Rouleau JL, Gilst W, Pfeffer MA, and Califf RM. Left Ventricular Assessment in Myocardial Infarction. *Arch Intern Med* 2005; 165 (18):2162-2169.
684. Jiang W, Glassman A, Krishnan R, O'Connor CM, and Califf RM. Depression and ischemic heart disease: What have we learned so far and what must we do in the future? *Am Heart J* 2005; 150 (1):54-78.
685. McMahon TJ, Ahearn GS, Moya MP, Gow AJ, Huang Y, Luchsinger BP, Nudelman R, Yan Y, Krichman AD, Bashore TM, Califf RM, Singel DJ, Piantadosi CA, Tapson VF, and Stamler JS. A nitric oxide processing defect of red blood cells created by hypoxia: Deficiency of S-nitrosohemoglobin in pulmonary hypertension. *Proc Nat'l Acad Sci* 2005; 102 (41):14801-14806.
686. Ohman EM, Van de Werf F, Antman EM, Califf RM, De Lemos JA, Gibson CM, Oliverio RL, Harrelson L, McCabe C, DiBattiste P, and Braunwald E. Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: Results of a randomized trial. *Am Heart J* 2005; 150 (1):79-88.
687. Reddan DN, Szczech LA, Bhapkar MV, Moliterno DJ, Califf RM, Ohman EM, Berger PB, Hochman JS, Van de Werf F, Harrington RA, and Newby LK. Renal function, concomitant medication use and outcomes following acute coronary syndromes. *Nephrol Dial Transplant* 2005; 20 (10):2105-2112.
688. Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, and Schulman KA. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). *Am Heart J* 2005; 150 (2):323-329.
689. Savonitto S, Cohen MG, Politi A, Hudson MP, Kong DF, Huang Y, Pieper KS, Mauri F, Wagner GS, Califf RM, Topol EJ, and Granger CB. Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes. *Eur Heart J* 2005; 26 (20):2106-2113.
690. Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, Velazquez EJ, Ertl GK, Harsanyi A, Rouleau JL, Maggioni A, Kober L, White H, Van de Werf F, Pieper K, Califf RM, and Pfeffer MA. Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. *N Engl J Med* 2005; 352 (25):2581-2588.
691. Szummer KE, Solomon SD, Velazquez EJ, Kilaru R, McMurray JJ, Rouleau JL, Mahaffey KW, Maggioni AP, Califf L, Pfeffer MA, and White HD. Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. *Eur Heart J* 2005; 26 (20):2114-2119.
692. Wong CK, French JK, Aylward PE, Stewart RA, Gao W, Armstrong PW, Van der Werf F, Simes RJ, Raffel OC, Granger CB, Califf RM, White HD, and HERO-2 Trial Investigators. Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes. *J Am Coll Cardiol* 2005; 46 (1):39-41.
693. White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, van Gilst WH, Zannad F, McMurray JJ, Califf RM, Pfeffer MA, VALIANT Investigators. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). *Circulation* 2005; 112:3391-3399.
694. Mahaffey KW, Cohen M, Garg J, Antman E, Kleiman NS, Goodman SG, Berdan LG, Reist CJ, Langer A, White HD, Aylward PE, Col JJ, Ferguson JJ3, Califf RM, SYNERGY Trial Investigators. High-risk Patients with Acute Coronary

Syndromes Treated with Low-molecular-weight or Unfractionated Heparin: Outcomes at 6 months and 1 year in the SYNERGY Trial. *JAMA* 2005;294:2594-2600.

695. March JS, Silva SG, Compton S, Shapiro M, Califf RM, Krishnan R. The Case for Practical Clinical Trials in Psychiatry. *Am J Psychiatry* 2005;162:836-846.
696. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, Mahaffey KW, Califf RM, Harrington RA. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. *Am J Cardiol* 2005;96:1200-1206.
697. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TBJ, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT, PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. *JAMA* 2005;294:2446-2454.
698. Shah MR, Claise KA, Bowers MT, Bhapkar M, Little J, Nohria A, Gaulden LH, McKee VK, Cozart KL, Mancinelli KL, Daniels H, Kinard T, Stevenson LW, Mancini DM, O'Connor CM, Califf RM. Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain Natriuretic Peptide Versus the Clinical Congestion Score (STARBRITE) trial. *Am Heart J* 2005;150:893-898.
699. Califf RM, Petersen JL, Hasselblad V, Mahaffey KW, Ferguson JJ. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. *Am Heart J* 2005;149:S91-S99  
Califf RM, Mark DB. Plagiarism notice. *Am Heart J* 2005;149:743
700. Reddan DN, Szczech LA, Hasselblad V, Lowrie EG, Lindsay RM, Himmelfarb J, Toto RD, Stivelman J, Winchester JF, Zillman LA, Califf RM, Owen WF, Jr. Intradialytic Blood Volume Monitoring in Ambulatory Hemodialysis Patients: A Randomized Trial. *J Am Soc Nephrol* 2005;16:2162-2169.
701. Al-Khatib SM, Allen-LaPointe NM, Kramer JM, Chen AY, Hammill BG, DeLong L, Califf RM. A Survey of Health Care Practitioner Knowledge of the QT Interval. *J Gen Intern Med* 2005;20:392-396.
702. Solomon SD, Skali H, Anavekar NS, Bourgon M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velasquez EJ, Califf RM, McMurray JV, Pfeffer MA. Changes in Ventricular Size and Function in Patients Treated with Valsartan, Captopril or both after Myocardial Infarction. *Circulation* 2005;111:3411-3419.
703. Shah MR, Hasselblad V, Stevenson LW, Binanay C, O'Conner CM, Sopko G, Califf RM. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. *JAMA* 2005;294:1693-1694.
704. Califf RM. Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics. *Pharmacoepidemiol Drug Saf.* 2006;
705. Patel MR, Donohue M, Wilson PW, Califf RM. Clinical trial issues in weight-loss therapy. *Am Heart J* 2006;151:633-642.
706. Rao SV, O'Grady K, Pieper K, Granger CB, Newby LK, Mahaffey KW, Moliterno DJ, Lincoff AM, Armstrong PW, Van de Werf F, Califf RM, Harrington RA. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. *J Am Coll Cardiol* 2006;47:809-816.
707. Kaul P, Chang WC, Lincoff AM, Aylward P, Betriu A, Bode C, Califf RM, Ohman EM, Guetta V, Steg PG, Van de Werf F, Armstrong PW. Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from GUSTO-V trial. *Eur Heart J* 2006;27:1198-1206.
708. Kober L, Swedberg K, McMurray JJ, Pfeffer MA, Velasquez EJ, Diaz R, Maggioni AP, Mareev V, Opolski G, Van de Werf F, Zannad F, Ertl G, Solomon SD, Zelenkofske S, Rouleau JL, Leimberger JD, Califf RM. Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. *Eur.J.Heart Fail.* 2006;

709. Patel MR, Meine TJ, Lindblad L, Griffin J, Granger CB, Becker RC, Van de Werf F, White H, Califf RM, Harrington RA. Cardiac tamponade in the fibrinolytic era: analysis of > 100,000 patients with ST-segment elevation myocardial infarction. *Am Heart J* 2006;151:316-322.
710. Kauf TL, Velasquez EJ, Crosslin DR, Weaver WD, Diaz R, Granger CB, McMurray JJ, Rouleau JL, Aylward PE, White HD, Califf RM, Schulman KA. The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. *Am Heart J* 2006;151:206-212.
711. Galla JM, Mahaffey KW, Snapp SK, Alexander JH, Roe MT, Ohman EM, Granger CB, Armstrong PW, Harrington RA, White HD, Simoons ML, Newby LK, Califf RM, Topol EJ. Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. *Am Heart J* 2006;151:16-24.
712. McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez EJ, White H, Howlett J, Swedberg K, Maggioni A, Kober L, Van de Werf F, Califf RM, Pfeffer M. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). *J Am Coll Cardiol* 2006;47:726-733.
713. Mehta RH, Marks D, Califf RM, Sohn S, Pieper KS, Van de Werf F, Peterson ED, Ohman EM, White HD, Topol EJ, Granger CB. Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction. *Am J Med* 2006;119:e1-e8
714. Orlandini A, Diaz R, Wojdyla D, Pieper K, Van de Werf F, Granger CB, Harrington RA, Boersma E, Califf RM, Armstrong P, White H, Simes J, Paolasso E. Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. *Eur Heart J* 2006;27:527-533.
715. Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. *Circulation* 2006;113:203-212.
716. O'Shea JC, Califf RM. 24-hour ambulatory blood pressure monitoring. *Am Heart J* 2006;151:962-968.
717. Whellan DJ, Tuttle RH, Velasquez EJ, Shaw LK, Jollis JG, Ellis W, O'Conner CM, Califf RM, Borges-Neto S. Predicting significant coronary artery disease in patients with left ventricular dysfunction. *Am Heart J* 2006;152:340-347.
718. Goodman SG, Fu Y, Langer A, Barr A, Tan M, Wagner GS, Bargabelata A, Sgarbossa EB, Birnbaum Y, Granger CB, Califf RM, Van de Werf F, Topol EJ, Armstrong PW. The prognostic value of the admission and predischARGE electrocardiogram in acute coronary syndromes: The GUSTO-II B ECG Core Laboratory experience. *Am Heart J* 2006;152:277-284.
719. Morrow DA, De Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, Rifai N, Califf RM, Braunwald E. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. *Circulation* 2006;114:281-288.
720. Janardhanan R, Kenchaiah S, Velasquez EJ, Park Y, McMurray JJ, Weaver WD, Finn PV, White HD, Marin-Neto JA, O'Connor C, Pfeffer MA, Califf RM, Solomon SD. Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *Am Heart J* 2006;152:183-189.
721. Califf RM. Translating clinical trials into practice. *Tex Heart Inst J* 2006;33:192-196.
722. Menon S, Berezny KY, Kilaru R, Benjamin DKJ, Kay JD, Hazan L, Portman R, Hogg R, Deitchman D, Califf RM, Li JS. Racial differences are seen in blood pressure response to fosinopril in hypertensive children. *Am Heart J* 2006;152:394-399.
723. Califf RM. Evaluation of diagnostic imaging technologies and therapeutics devices: better information for better decisions: proceedings of a multidisciplinary workshop. *Am Heart J* 2006;152:50-58.
724. Heitner J, Lotfi M, Harrison JK, Cabell C, Klem I, Banko L, Kim RJ, Califf RM. Where's the flap? *J Cardiovasc Magn Reson* 2006;8:549-550.

725. Bushnell CD, Griffin J, Newby LK, Goldstein LB, Mahaffey KW, Graffagnino CA, Harrington RA, White HD, Simes RJ, Califf RM, Topol EJ, Easton JD. Statin use and sex-specific stroke outcomes in patients with vascular disease. *Stroke* 2006;37:1427-1431.
726. LaPointe NM, DeLong ER, Chen A, Hammill BG, Muhlbaier LH, Califf RM, Kramer JM. Multifaceted intervention to promote beta-blocker use in heart failure. *Am Heart J* 2006;151:992-998.
727. Mehta RH, Honeycutt E, Peterson ED, Granger CB, Halabi AR, Shaw LK, Smith PK, Califf RM, Harrington RA, Sketch MH. Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft. *Circulation* 2006;114:I396-I401
728. Roe MT, Peterson ED, Newby LK, Chen AY, Pollack CVJ, Brindis RG, Harrington RA, Christenson RH, Smith SC Jr, Califf RM, Braunwald E, Gibler WB, Ohman EM. The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. *Am Heart J* 2006;151:1205-1213.
729. Alexander KP, Newby LK, Bhapkar MV, White HD, Hochman JS, Pfisterer ME, Moliterno DJ, Peterson ED, Van de Werf F, Armstrong PW, Califf RM. International variation in invasive care of the elderly with acute coronary syndromes. *Eur Heart J* 2006;27:1558-1564.
730. Cohen M, Mahaffey KW, Pieper K, Pollack CV, Jr., Antman EM, Hoekstra J, Goodman SG, Langer A, Col JJ, White HD, Califf RM, Ferguson JJ, SYNERGY Trial Investigators. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. *J Am Coll Cardiol* 2006;48:1346-1354.
731. Davidson KW, Kupfer DJ, Bigger JT, Califf RM, Carney RM, Coyne JC, Czajkowski SM, Frank E, Frasure-Smith N, Freedland KE, Froelicher ES, Glassman AH, Katon WJ, Kaufmann PG, Kessler RC, Kraemer HC, Krishnan KR, Lesperance F, Rieckmann N, Sheps DS, Suls JM, National Heart LaBIWG. Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. *Psychosom Med* 2006;68:645-50.
732. White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ, Califf RM. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. *Am Heart J* 2006;152:1042-1050.
733. De Lemos JA, Wiviott SD, Murphy SA, Blazing MA, Lewis EF, Califf RM, Pfeffer MA, Braunwald E. Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial. *Am J Cardiol* 2006;98:739-742.
734. Reed SD, McMurray JJ, Velasquez EJ, Schulman KA, Califf RM, Kober L, Maggioni AP, Van de Werf F, White HD, Diaz R, Mareev V, Murin J, VALIANT Committees and Investigators. Geographic variation in the treatment of acute myocardial infarction in the Valsartan (VALIANT) trial. *Am Heart J* 2006;152:500-508.
735. Reed SD, Califf RM, Schulman KA. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation. *Health Aff.(Millwood.)* 2006;25:1309-1317.
736. Benjamin DK, Jr., Smith PB, Murphy MD, Roberts R, Mathis L, Avant D, Califf RM, Li JS. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. *JAMA* 2006;296:1266-1273.
737. Westerhout CM, Hernandez AV, Steyerberg EW, Bueno H, White H, Theroux P, Moliterno DJ, Armstrong PW, Califf RM, Wallentin LC, Simoons ML, Boersma E. Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes. *Eur Heart J* 2006;27:2956-2961.
738. Echols MR, Felker GM, Thomas KL, Pieper KS, Garg J, Cuffe MS, Gheorghide M, Califf RM, O'Conner CM. Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial. *J Card Failure* 2006;12:684-688.

- 739.Mehta RH, Roe MT, Chen AY, Lytle BL, Pollack CV, Jr., Brindis RG, Smith SC, Jr., Harrington RA, Fintel D, Fraulo ES, Califf RM, Gibler WB, Ohman EM, Peterson ED. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. *Arch Intern Med* 2006;166:2027-2034.
- 740.Grandis JR, Battey JF, Califf RM, Chole RA, Gantz BJ, Gates GA, Gorelic L, Hannley MT, Hardwick KS, Harris JP, Kapoor WN, Lai SY, Lalwani AK, Minor LB, Nadol JP, Post JC, Roland PS, Schechter AM, Schuller DE, Sklare DA, Wackym PA, Weber RS, Weymuller EAJ, Wolf GT, Woodson GE. Research education and training in otolaryngology: meeting summary and research opportunities. *Otolaryngol Head Neck Surg.* 2006;135:361-367.
- 741.Smith PK, Califf RM, Tuttle RH, Shaw LK, Lee KL, DeLong ER, Lilly RE, Sketch MH, Jr., Peterson ED, Jones RH. Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. *Ann Thorac Surg* 2006;82:1420-1428.
- 742.Westerhout CM, Fu Y, Lauer MS, James S, Armstrong PW, Al-Hattab E, Califf RM, Simoons ML, Wallentin L, Boersma E, GUSTO-IV ACS Trial Investigators. Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers. *J Am Coll Cardiol* 2006;48:939-947.
- 743.James SK, Lindback J, Tilly J, Siegbahn A, Venge P, Armstrong P, Califf RM, Simoons ML, Wallentin L, Lindahl B. Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. *J Am Coll Cardiol* 2006;48:1146-1154.
- 744.Califf RM. Clinical trials bureaucracy: unintended consequences of well-intentioned policy. *Clinical Trials* 2006;3:496-502.
- 745.Barbagelata A, Perna ER, Clemmensen P, Uretsky BF, Canella JP, Califf RM, Granger CB, Adams GL, Merla R, Birnbaum Y. Time to reperfusion in acute myocardial infarction. It is time to reduce it! *J.Electrocardiol.* 2007;40:257-264.
- 746.Bethel MA, Califf RM. Role of lifestyle and oral anti-diabetic agents to prevent type 2 diabetes mellitus and cardiovascular disease. *Am.J.Cardiol.* 2007;99:726-731.
- 747.Califf RM. Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics. *Pharmacoepidemiol.Drug Saf* 2007;16:5-16.
- 748.Califf RM, Harrington RA, Madre LK, Peterson ED, Roth D, Schulman KA. Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics. *Health Aff.(Millwood.)* 2007;26:62-74.
- 749.Cantor WJ, Mahaffey KW, Huang Z, Das P, Gulba DC, Glezer S, Gallo R, Ducas J, Cohen M, Antman EM, Langer A, Kleiman NS, White HD, Chisholm RJ, Harrington RA, Ferguson JJ, Califf RM, Goodman SG. Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. *Catheter.Cardiovasc.Interv.* 2007;69:73-83.
- 750.Echols MR, Mahaffey KW, Banerjee A, Pieper KS, Stebbins A, Lansky A, Cohen MG, Velazquez E, Santos R, Newby LK, Gurfinkel EP, Biasucci L, Ferguson JJ, Califf RM. Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial). *Am.J.Cardiol.* 2007;99:315-321.
- 751.Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. *JAMA* 2007;297:159-168.
- 752.Goyal A, Alexander JH, Hafley GE, Graham SH, Mehta RH, Mack MJ, Wolf RK, Cohn LH, Kouchoukos NT, Harrington RA, Gennevois D, Gibson CM, Califf RM, Ferguson TB, Jr., Peterson ED. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. *Ann.Thorac.Surg.* 2007;83:993-1001.
- 753.Hernandez AV, Westerhout CM, Steyerberg EW, Ioannidis JP, Bueno H, White H, Theroux P, Moliterno DJ, Armstrong PW, Califf RM, Wallentin LC, Simoons ML, Boersma E. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups. *Heart* 2007;93:450-455.
- 754.Li JS, Eisenstein EL, Grabowski HG, Reid ED, Mangum B, Schulman KA, Goldsmith JV, Murphy MD, Califf RM, Benjamin DK, Jr. Economic return of clinical trials performed under the pediatric exclusivity program. *JAMA* 2007;297:480-488.

755. Mahaffey KW, Roe MT, Kilaru R, Alexander JH, Van de WF, Califf RM, Simoons ML, Topol EJ, Harrington RA. Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials. *Eur.Heart J.* 2007;28:425-432.
756. Mehta RH, Califf RM, Yang Q, Pieper KS, White HD, Ohman EM, Harrington RA, Granger CB. Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock. *Am.J.Cardiol.* 2007;99:793-796.
757. Mehta RH, Peterson ED, Califf RM. Performance measures have a major effect on cardiovascular outcomes: a review. *Am.J.Med.* 2007;120:398-402.
758. Mehta RH, Califf RM, Garg J, White HD, Van de WF, Armstrong PW, Pieper KS, Topol EJ, Granger CB. The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction. *Eur.Heart J.* 2007;28:415-424.
759. Miller CD, Banerjee A, Mahaffey KW, Kontos MC, Fermann G, Pollack CV, Jr., Antman E, Aylward P, Goodman SG, Santos R, Ferguson JJ, Califf RM, Hoekstra JW. Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial. *Eur.Heart J.* 2007;28:1079-1084.
760. Rankin JS, Tuttle RH, Wechsler AS, Teichmann TL, Glower DD, Califf RM. Techniques and benefits of multiple internal mammary artery bypass at 20 years of follow-up. *Ann.Thorac.Surg.* 2007;83:1008-1014.
761. Rao SV, Eikelboom JA, Granger CB, Harrington RA, Califf RM, Bassand JP. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. *Eur.Heart J.* 2007;
762. Stephenson K, Skali H, McMurray JJ, Velazquez EJ, Aylward PG, Kober L, Van de WF, White HD, Pieper KS, Califf RM, Solomon SD, Pfeffer MA. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience. *Heart Rhythm.* 2007;4:308-313.
763. Turer AT, Mahaffey KW, Compton KL, Califf RM, Schulman KA. Publication or presentation of results from multicenter clinical trials: evidence from an academic medical center. *Am.Heart J.* 2007;153:674-680.
764. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B, Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf RM, Drexler H, Wallentin L. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. *Circulation* 2007;115:962-971.
765. Califf RM, Mehta RH, Peterson ED. Clinical quality in non-ST-elevation acute coronary syndromes. *Am J Med* 2007;120:930-935.
766. Singh M, White J, Hasdai D, Hodgson PK, Berger PB, Topol EJ, Califf RM, Holmes DR, Jr. Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. *J Am Coll Cardiol* 2007;50:1752-1758.
767. Shah MR, Hasselblad V, Tasissa G, Christenson RH, Binanay C, O'Connor CM, Ohman EM, Stevenson LW, Califf RM. Rapid Assay Brain Natriuretic Peptide and Troponin I in Patients Hospitalized With Decompensated Heart Failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). *Am J Cardiol* 2007;100:1427-1433.
768. Mark DB, Van de Werf FJ, Simes RJ, White HD, Wallentin LC, Califf RM, Armstrong PW. Cardiovascular disease on a global scale: defining the path forward for research and practice. *Eur Heart J* 2007;28:2678-2684.
769. nett-Guerrero E, Veldman TH, Doctor A, Telen MJ, Ortel TL, Reid TS, Mulherin MA, Zhu H, Buck RD, Califf RM, McMahon TJ. Evolution of adverse changes in stored RBCs. *Proc.Natl.Acad.Sci.U.S.A* 2007;104:17063-17068.
770. Murphy SA, Cannon CP, Wiviott SD, de Lemos JA, Blazing MA, McCabe CH, Califf RM, Braunwald E. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). *Am J Cardiol* 2007;100:1047-1051.

771. Al-Khatib SM, Shaw LK, O'Connor C, Kong M, Califf RM. Incidence and Predictors of Sudden Cardiac Death in Patients with Diastolic Heart Failure. *J Cardiovasc. Electrophysiol.* 2007;
772. Mehta RH, Greenbaum AB, Lokhnygina Y, Newby LK, Van De WF, Armstrong PW, Pieper KS, Califf RM, Granger CB, Harrington RA. Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials. *J Interv. Cardiol* 2007;20:299-306.
773. Hasselblad V, Gattis SW, Shah MR, Lokhnygina Y, O'Connor CM, Califf RM, Adams KF, Jr. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. *Eur J Heart Fail.* 2007;9:1064-1069.
774. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr., Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jr., Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. *J Am Coll Cardiol* 2007;50:e1-e157
775. Wong CK, Newby LK, Bhapker MV, Aylward PE, Pfisterer M, Alexander KP, Armstrong PW, Hochman JS, Van De WF, Califf RM, White HD. Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrifiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. *Am Heart J* 2007;154:313-321.
776. Westerhout CM, Gnarpe J, Chang WC, FitzPatrick S, Barnathan ES, Boersma E, Califf RM, Wallentin L, Simoons ML, Armstrong PW. No prognostic significance of chronic infection with Chlamydia pneumoniae in acute coronary syndromes: insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trial. *Am Heart J* 2007;154:306-312.
777. Tilson HH, Madre LK, Califf RM. Role of the centers for education and research on therapeutics (CERTs) in pharmacovigilance and proper use of therapeutics. *Clin. Pharmacol. Ther.* 2007;82:118-121.
778. Li JS, Yow E, Berezny KY, Rhodes JF, Bokesch PM, Charpie JR, Forbus GA, Mahony L, Boshkov L, Lambert V, Bonnet D, Michel-Behnke I, Graham TP, Takahashi M, Jagers J, Califf RM, Rakhit A, Fontecave S, Sanders SP. Clinical outcomes of palliative surgery including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease: does aspirin make a difference? *Circulation* 2007;116:293-297.
779. Jiang W, Kuchibhatla M, Clary GL, Cuffe MS, Christopher EJ, Alexander JD, Califf RM, Krishnan RR, O'Connor CM. Relationship between depressive symptoms and long-term mortality in patients with heart failure. *Am Heart J* 2007;154:102-108.
780. Sanders GD, Al-Khatib SM, Berliner E, Bigger JT, Buxton AE, Califf RM, Carlson M, Curtis AB, Curtis JP, Domanski M, Fain E, Gersh BJ, Gold MR, Goldberger J, Haghighi-Mood A, Hammill SC, Harder J, Healey J, Hlatky MA, Hohnloser SH, Lee KL, Mark DB, Mitchell B, Phurrough S, Prystowsky E, Smith JM, Stockbridge N, Temple R. Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy. *Am Heart J* 2007;153:951-959.
781. Al-Khatib SM, Sanders GD, Bigger JT, Buxton AE, Califf RM, Carlson M, Curtis A, Curtis J, Fain E, Gersh BJ, Gold MR, Haghighi-Mood A, Hammill SC, Healey J, Hlatky M, Hohnloser S, Kim RJ, Lee K, Mark D, Mianulli M, Mitchell B, Prystowsky EN, Smith J, Steinhaus D, Zareba W. Preventing tomorrow's sudden cardiac death today: part I: Current data on risk stratification for sudden cardiac death. *Am Heart J* 2007;153:941-950.
782. Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA. Cardiorenal interactions: insights from the ESCAPE trial. *J Am Coll Cardiol.* 2008;51(13):1268-74.



783. Shah MR, Whellan DJ, Peterson ED, Nohria A, Hasselblad V, Xue Z, Bowers MT, O'Connor CM, Califf RM, Stevenson LW. Delivering heart failure disease management in 3 tertiary care centers: key clinical components and venues of care. *Am Heart J.* 2008;155(4):764.e1-5.
784. Mielniczuk LM, Pfeffer MA, Lewis EF, Blazing MA, de Lemos JA, Shui A, Mohanavelu S, Califf RM, Braunwald E. Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome. *Am Heart J.* 2008;155(4):725-31.
785. Anderson RE, Pfeffer MA, Thune JJ, McMurray JJ, Califf RM, Velazquez E, White HD, Rouleau JL, Skali H, Maggioni A, Solomon SD. High-risk myocardial infarction in the young: the VALsartan in Acute myocardial infarction (VALIANT) trial. *Am Heart J.* 2008;155(4):706-11.
786. Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, Califf RM, Topol EJ; CREDO Investigators. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. *Am Heart J.* 2008;155(4):687-93.
787. Michener JL, Yaggy S, Lyn M, Warburton S, Champagne M, Black M, Cuffe M, Califf R, Gilliss C, Williams RS, Dzau VJ. Improving the health of the community: Duke's experience with community engagement. *Acad Med.* 2008;83(4):408-413.
788. Anavekar NS, Solomon SD, McMurray JJ, Maggioni A, Rouleau JL, Califf R, White H, Kober L, Velazquez E, Pfeffer MA. Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. *Am J Cardiol.* 2008;101(7):925-9.
789. Mehta RH, Rao SV, Ohman EM, Bates ER, Marcucci G, Zhang M, Pieper KS, Armstrong PW, White HD, Van de Werf F, Califf RM, Granger CB. Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb. *Eur Heart J.* 2008;29(7):880-7.
790. Benjamin DK Jr, Smith PB, Jadhav P, Gobburu JV, Murphy MD, Hasselblad V, Baker-Smith C, Califf RM, Li JS. Pediatric antihypertensive trial failures: analysis of end points and dose range. *Hypertension.* 2008;51(4):834-40.
791. Lewis EF, Velazquez EJ, Solomon SD, Hellkamp AS, McMurray JJ, Mathias J, Rouleau JL, Maggioni AP, Swedberg K, Kober L, White H, Dalby AJ, Francis GS, Zannad F, Califf RM, Pfeffer MA. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. *Eur Heart J.* 2008;29(6):748-56.
792. Anavekar NS, Skali H, Bourgoun M, Ghali JK, Kober L, Maggioni AP, McMurray JJ, Velazquez E, Califf R, Pfeffer MA, Solomon SD. Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). *Am J Cardiol.* 2008;101(5):607-12.
793. Jolicoeur EM, Ohman EM, Temple R, Stockbridge N, Smith S, Mark D, Califf RM, Henry TD, Chaitman BR, Granger CB; Working Group Members. Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues. *Am Heart J.* 2008;155(3):435-44.
794. Smith PB, Li JS, Murphy MD, Califf RM, Benjamin DK Jr. Safety of placebo controls in pediatric hypertension trials. *Hypertension.* 2008;51(4):829-33.
795. Eisenstein EL, Collins R, Cracknell BS, Podesta O, Reid ED, Sandercock P, Shakhov Y, Terrin ML, Sellers MA, Califf RM, Granger CB, Diaz R. Sensible approaches for reducing clinical trial costs. *Clin Trials.* 2008;5(1):75-84.
796. Yusuf S, Bosch J, Devereaux PJ, Collins R, Baigent C, Granger C, Califf R, Temple R. Sensible guidelines for the conduct of large randomized trials. *Clin Trials.* 2008;5(1):38-9.
797. Olenchock SA Jr, Karpalotis D, Gibson WJ, Murphy SA, Southard MC, Ciaglo L, Buros J, Mack MJ, Alexander JH, Harrington RA, Califf RM, Kouchoukos NT, Ferguson TB Jr, Gibson CM. Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters. *Ann Thorac Surg.* 2008;85(2):520-4.

798. Magee MJ, Alexander JH, Hafley G, Ferguson TB Jr, Gibson CM, Harrington RA, Peterson ED, Califf RM, Kouchoukos NT, Herbert MA, Mack MJ; PREVENT IV Investigators. Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV. *Ann Thorac Surg.* 2008 Feb;85(2):494-9.
799. Rao SV, Kaul PR, Liao L, Armstrong PW, Ohman EM, Granger CB, Califf RM, Harrington RA, Eisenstein EL, Mark DB. Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. *Am Heart J.* 2008;155(2):369-74.
800. Chew DP, Huang Z, Pieper KS, White H, Mahaffey KW, Ferguson JJ, Califf RM, Aylward PE. Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy. *Am Heart J.* 2008;155(2):239-44.
801. Mahaffey KW, Yang Q, Pieper KS, Antman EM, White HD, Goodman SG, Cohen M, Kleiman NS, Langer A, Aylward PE, Col JJ, Reist C, Ferguson JJ, Califf RM; SYNERGY Trial Investigators. Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial. *J Gen Intern Med.* 2008;23(3):310-6.
802. Berger JS, Stebbins A, Granger CB, Ohman EM, Armstrong PW, Van de Werf F, White HD, Simes RJ, Harrington RA, Califf RM, Peterson ED. Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. *Circulation.* 2008;117(2):192-9.
803. Rao SV, Chiswell K, Sun JL, Granger CB, Newby LK, Van de Werf F, White HD, Armstrong PW, Califf RM, Harrington RA. International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes. *Am J Cardiol.* 2008;101(1):25-9.
804. Thomas KL, Al-Khatib SM, Lokhnygina Y, Solomon SD, Kober L, McMurray JJ, Califf RM, Velazquez EJ. Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. *Am Heart J.* 2008;155(1):87-93.
805. Thune JJ, Signorovitch J, Kober L, Velazquez EJ, McMurray JJ, Califf RM, Maggioni AP, Rouleau JL, Howlett J, Zelenkofske S, Pfeffer MA, Solomon SD. Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. *Hypertension.* 2008;51(1):48-54.
806. Prisant M, Thomas KL, Lewis EF, Huang Z, Francis GS, Weaver WD, Pfeffer MA, McMurray JJ, Califf RM, Velazquez EJ. Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with Valsartan, Captopril, or both. *J Am Coll Cardiol* 2008;13;51(19):1865-71.
807. Konstance RP, Eisenstein EL, Anstrom KJ, Shaw LK, Califf RM, Harrington RA, Matchar DB, Schulman KA, Kong DF. Outcomes of second revascularization procedures after stent implantation. *J Med Syst.* 2008 Apr;32(2):177-86.
808. Weinfurt KP, Seils DM, Tzeng JP, Lin L, Schulman KA, Califf RM. Consistency of financial interest disclosures in the biomedical literature: the case of coronary stents. *PLoS ONE.* 2008 May 7;3(5):e2128
809. Chew DP, Mahaffey KW, White HD, Huang Z, Hoekstra JW, Ferguson JJ, Califf RM, Aylward PE. Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict. *Am Heart J.* 2008 May;155(5):841-7.
810. Jackson K, Gersh BJ, Stockbridge N, Fleming TR, Temple R, Califf RM, Connolly SJ, Wallentin L, Granger CB; Duke Clinical Research Institute/ American Heart Journal Expert Meeting on Antithrombotic Drug Development for Atrial Fibrillation. Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. *Am Heart J.* 2008 May;155(5):829-40.
811. Leung S, Gallup D, Mahaffey KW, Cohen M, Antman EM, Goodman SG, Harrington RA, Langer A, Aylward P, Ferguson JJ, Califf RM; SYNERGY Trial Investigators. Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome. *Am Heart J.* 2008 Jul;156(1):177-84
812. Piccini JP, Patel MR, Mahaffey KW, et al. Rivaroxaban, an oral direct factor Xa inhibitor. *Expert Opin Investig Drugs* 2008;17:925-37.

- 813.Szczzech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. *Kidney Int.* 2008;74:791-8.
- 814.Novak JE, Inrig JK Patel UD, Califf RM, Szczzech LA. Negative trials in nephrology: what can we learn? *Kidney Int.* 2008;74:1121-7.
- 815.Roe MT, Chen AY, DeLong ER, Boden WE, Calvin JE Jr, Cairns CB, Smith SC Jr., Pollack CV Jr., Brindis RG, Califf RM, Gibler WB, Ohman EM, Peterson ED. Patterns of transfer for patients with non-ST-segment elevation acute coronary syndrome from community to tertiary care hospitals. *Am Heart J.* 2008 Jul;156(1):185-92
- 816.Lopes RD, Alexander KP, Marcucci G, White HD, Splinler S, Col J, Aylward PE, Califf RM, Mahaffey KW. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. *Eur Heart J.* 2008 Aug;29 (15):1827-33
- 817.Anstrom KJ, Kong DF, Shaw LK, Califf RM, Kramer JM, Peterson ED, Rao SV, Matchar DB, Mark DB, Harrington RA, Eisenstein EL. Long-term clinical outcomes following coronary stenting. *Arch Intern Med.*2008 Aug 11;168(15):1647-55.
- 818.Rao SV, Califf RM, Kramer JM, Peterson ED, Gross TP, Pepine CJ, Williams DO, Donohoe D, Waksman R, Mehran R, Krucoff MW. Postmarket evaluation of breakthrough technologies. *Am Heart J.* 2008 Aug;156(2):201-8.
- 819.Smith PB, Benjamin DK Jr., Murphy MD, Johann-Laing R, Iyasu S, Gould B, Califf RM, Li JS, Rodriguez W. Safety monitoring of drugs receiving pediatric marketing exclusivity. *Pediatrics* 2008 Sep; 122(3):e628-33
- 820.Califf RM, Boolell M, Haffner SM, Bethel AM, McMurray J, Duggal A, Holman R. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (Navigator) Trial. *Am Heart J.* 2008 Oct; 156(4):623-32
- 821.Bethel MA, Holman R, Haffner SM, Califf RM, Huntsman-Labed A, Hua TA, McMurray J. Determining the most appropriate components for a composite clinical trial outcome. *Am Heart J.* 2008 Oct; 156 (4) : 633-40
- 822.Baker-Smith CM, Benjamin DK Jr, Grabowski HG, Reid ED, Mangum B, Goldsmith JV, Murphy MD, Edwards R, Eisenstein EL, Sun J, Califf RM, Li JS. The economic returns of pediatric clinical trials of antihypertensive drugs. *Am Heart J* 2008 Oct;156(4): 682-8
- 823.Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, Califf RM. Analyses of cancer data from three ezetimibe trials. *N Engl J Med.* 2008 Sep 25;359(13):1357-66
- 824.Brilakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, Banerjee S, Blazing MA, Califf RM, Braunwald E. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [IMPROVE IT –TIMI 22] and the Aggrastat to Zocor [AtoZ] trials). *Am J Cardiol.* 2008 Sep 1;102 (5):552-8.
- 825.Yau JM, Alexander JH, Hafley G, Mahaffey KW, Mack MJ, Kouchoukos N, Goyal A, Peterson ED, Gibson CM, Califf RM, Harrington RA, Ferguson TB PREVENT IV Investigators. Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PProject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV). *Am J Cardiol.* 2008 Sep 1;102 (5):546-51
- 826.Li JS, Baker-Smith CM, Smith PB, Hasselblad V, Murphy MD, Califf RM, Bengamin DK Jr. Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis. *Clin Pharmacol Ther.* 2008 Sep;84(3):315-9.
- 827.O'Connor CM, Jiang W, Kuchibhatla M, Mehta RH, Clary GL, Cuffe MS, Christopher EJ, Alexander JD, Califf RM, Krishnan RR. Antidepressant use, depression, and survival in patients with heart failure. *Arch Intern Med* 2008;168:2232-7.
- 828.Aronow HD, Califf RM, Harrington RA, Vallee M, Graffagnino C, Shuaib A, Fitzgerald DJ, Easton JD, Van de Werf F, Diener HC, Ferguson J, Koudstaal PJ, Amarenco P, Theroux P, Davis S, Topol EJ. Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). *Am J Cardiol* 2008;102:1285-90.

829. Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR; NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. *Am Heart J* 2008;156:623-32.
830. Allen LA, Rogers JG, Warnica JW, Disalvo TG, Tasissa G, Binanay C, O'Connor CM, Califf RM, Leier CV, Shah MR, Stevenson LW; Escape Investigators and Coordinators. High mortality without ESCAPE: the registry of heart failure patients receiving pulmonary artery catheters without randomization. *J Card Fail* 2008;14:661-9.
831. Reed SD, Anstrom KJ, Seils DM, Califf RM, Schulman KA. Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs. *Health Aff (Millwood)* 2008;27:w360-w370.
832. Califf RM, Ginsburg GS. Organizational Improvements to Enhance Modern Clinical Epidemiology. *JAMA* 2008;300(19):2300-2.
833. Piccini JP, Hranitzky PM, Kilaru R, Rouleau J, White HD, Aylward PE, Van de Werf F, Solomon SD, Califf RM, Velazquez EJ. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction ( from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry) *Am J Cardiol* 2008;102(11):1427-32.
834. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, McCrary Sisk C, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM for the IMPROVE-IT Investigators. Rationale and design of IMPROVE-IT ( IMPROved Reduction of Outcomes: Vitorin Efficacy International Trial): Comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. *Am Heart J* 2008;156 (5):826-32.
835. Califf RM, Rasiel EB, Schulman KA. Considerations of net present value in policy making regarding diagnostic and therapeutic technologies. *Am Heart J* 2008;156:879-85.
836. Mehta RH, Hafley GE, Gibson CM, Harrington RA, Peterson ED, Mack MJ, Kouchoukos NT, Califf RM, Ferguson TB Jr, Alexander JH; Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT)-IV Investigators. Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery. *J Thorac Cardiovasc Surg* 2008;136:1149-55.
837. Stevenson LW, Hellkamp AS, Leier CV, Sopko G, Koelling T, Warnica JW, Abraham WT, Kasper EK, Rogers JG, Califf RM, Schramm EE, O'Connor CM. Changing preferences for survival after hospitalization with advanced heart failure. *J Am Coll Cardiol* 2008;52:1702-8.
838. Baker-Smith CM, Benjamin DK Jr, Grabowski HG, Reid ED, Mangum B, Goldsmith JV, Murphy MD, Edwards R, Eisenstein EL, Sun J, Califf RM, Li JS. The economic returns of pediatric clinical trials of antihypertensive drugs. *Am Heart J* 2008;156:682-8.
839. Chan MY, Mahaffey KW, Sun LJ, Pieper KS, White HD, Aylward PE, Ferguson JJ, Califf RM, Roe Mt. Prevalence, predictors, and impact of conservative medical management for patients with non-SST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. *JACC Cardiovasc Interv* 2008; 1:369-78.
840. Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M, Velazquez EJ, McMurray JJ, Kober L, Pfeffer MA, Califf RM, Solomon SD. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (Valsartan in acute myocardial infarction) Echocardiographic Study. *JACC Cardiovasc Imaging* 2008; 1: 582-91.
841. Payne KA, Caro JJ, Daley WL, Khan ZM, Ishak KJ, Stark K, Purkayastha D, Flack J, Velazquez E, Nesbitt S, Morisky D Califf R.; BPSZ-BLISS Study Steering Committee. The design of an observational study of hypertension management, adherence and pressure control in blood pressure success zone program participants. *Int J Clin Prac* 2008; 62: 1313-21.
842. Klein L, Masie BM, Leimberg JD, O'Connor CM, Pina IL, Adams KF Jr, Califf RM, Gheorghide M, OPTIME-CHF Investigators. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF). *Circ Heart Fail* 2008; 1: 25-33.

843. Mehta RH, Rogers JG, Hasselblad V, Binanay C, Califf RM, O'Connor CM, on behalf of the ESCAPE trial investigators. Association of weight change with subsequent outcomes in patients hospitalized with acute decompensated heart failure. *Am J Cardiol* 2009;103:76-81.
844. Hernandez AF, O'Connor CM, Starling RC, Reist CJ, Armstrong PW, Dickstein K, Todd JL, Gibler WB, Hasselblad V, Komajda M, Massie B, McMurray JV, Nieminen M, Rouleau JL, Swedberg K, Califf RM. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF) *Am Heart J* 2009;157(2):271-77.
845. Califf RM. A virtuous cycle to improve hypertension outcomes at a national level: linking public health and individualized medicine. *Hypertension* 2009;53:105-7.
846. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC. Scientific evidence underlying the ACC/AHA clinical practice guidelines. *JAMA* 2009;301:831-41.
847. Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, Schulman, KA. Ethical and scientific implications of the globalization of clinical research. *N Engl J Med* 2009;360:816-23.
848. Ezekowitz JA, Hernandez AF, Starling RC, Yancy CW, Massie B, Hill JA, Krum H, Ponikowski P, Metra M, Howlett JG, Gennevois D, O'Connor CM, Califf RM, Fonarow GC. Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). *Am Heart J* 2009;157:219-28.
849. Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van T Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK; the EARLY ACS Investigators. Early versus Delayed, Provisional Eptifibatid in Acute Coronary Syndromes. *N Engl J Med* 2009;360:2176-90.
850. Berry C, Pieper KS, White HD, Solomon SD, Van de Werf F, Velazquez EJ, Maggioni AP, Califf RM, Pfeffer MA, McMurray JJ. Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial infarction trial (VALIANT). *Eur Heart J*. 2009;30:1450-6.
851. Turer AT, Mahaffey KW, Honeycutt E, Tuttle RH, Shaw LK, Sketch MH Jr., Smith PK, Califf RM, Alexander JH. Influence of body mass index on the efficacy of revascularization in patients with coronary artery disease. *J Thorac Cardiovasc Surg* 2009;137:1468-74.
852. Spinler SA, Mahaffey KW, Gallup D, Levine GN, Ferguson JJ III, Rao SV, Gallo R, Ducas J, Goodman SG, Antman E, White HD, Biasucci L, Becker RC, Col JJ, Cohen M, Harrington RA, Califf RM, for the SYNERGY Trial Investigators. Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: Results from SYNERGY. *Int J Cardiol* 2009.
853. Harrington RA, Califf RM, Hodgson PK, Peterson ED, Roe MT, Mark DB. Careers for clinician investigators. *Circulation* 2009;119:2945-50.
854. Chan MY, Sun JL, Newby LK, Shaw LK, Lin M, Peterson ED, Califf RM, Kong DF, Roe MT. Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction. *Circulation* 2009;119:3110-7.
855. Lopes RD, Hafley GE, Allen KB, Ferguson TB, Peterson ED, Harrington RA, Mehta RH, Gibson CM, Mack MJ, Kouchoukos, NT, Califf RM, Alexander JH. Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. *N Engl J Med* 2009;361:235-44.
856. Moukarbel GV, Signorovitch JE, Pfeffer MA, McMurray JJ, White HD, Maggioni AP, Velazquez EJ, Califf RM, Scheiman JM, Solomon SD. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. *Eur Heart J* 2009; 30:2226-32.
857. Berger JS, Elliott L, Gallup D, Roe M, Granger CB, Armstrong PW, Simes RJ, White HD, Van de Werf F, Topol EJ, Hochman JS, Newby LK, Harrington RA, Califf RM, Becker RC, Douglas PS. Sex differences in mortality following acute coronary syndromes. *JAMA* 2009;302:874-82.

858. Califf RM. Clinical research sites--the underappreciated component of the clinical research system. *JAMA* 2009;302:2025-7.
859. Linefsky JP, Lin M, Pieper KS, Reist CJ, Berdan LG, Antman EM, Goodman SG, French JK, Guneri S, Roe MT, Newby LK, Harrington RA, Ferguson JJ, Califf RM, Mahaffey KW. Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY). *Am J Cardiol* 2009;104:1330-5.
860. Al-Khatib SM, Hafley G, Harrington RA, Mack MJ, Ferguson TB, Peterson ED, Califf RM, Kouchoukos NT, Alexander JH. Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PROject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial. *Am Heart J* 2009;158:792-8.
861. Mielniczuk LM, Pfeffer MA, Lewis EF, Blazing MA, Lemos JA, Mohanavelu S, Rouleau J, Fox K, Pedersen TR, Califf RM. Acute Decline in Renal Function, Inflammation, and Cardiovascular Risk after an Acute Coronary Syndrome. *Clin J Am Soc Nephrol* 2009; 11:1811-7.
862. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. *J Am Coll Cardiol* 2009;54:1089-95.
863. Bonaca MP, Steg PG, Feldman LJ, Canales JF, Ferguson JJ, Wallentin L, Califf RM, Harrington RA, Giugliano RP. Antithrombotics in acute coronary syndromes. *J Am Coll Cardiol* 2009;54:969-84.
864. Kumar A, Fonarow GC, Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Boden WE, Steg PG, Shao M, Bhatt DL, Cannon CP; REACH Investigators. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry. *Crit Pathw Cardiol* 2009;8:104-11.
865. Califf RM. Key issues for global cardiovascular medicine. *Lancet* 2009;374:508-10.
866. Califf RM. Angiographic profiles in courage. *Circ Cardiovasc Qual Outcomes* 2009; 2: 292-3.
867. Califf RM, Harrington RA, Blazing MA. Premature release of data from clinical trials of ezetimibe. *N Engl J Med* 2009;361:712-7.
868. Collier BS, Califf RM. Traversing the valley of death: a guide to assessing prospects for translational success. *Sci Transl Med* 2009; 1 (10):10cm9.
869. Bethel MA, Deedwania P, Levitt NS, Schmitz O, Huntsman-Labed A, Califf RM, Haffner SM, Diem P; NAVIGATOR Study Group. Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population. *Diabet Med* 2009; 26:1204-11.
870. Benjamin DK Jr, Smith PB, Sun MJ, Murphy MD, Avant D, Mathis L, Rodriguez W, Califf RM, Li JS. Safety and transparency of pediatric drug trials. *Arch Pediatr Adolesc Med* 2009; 163: 1080-6.
871. Atwater BD, Thompson VP, Vest RN 3<sup>rd</sup>, Shaw LK, Mazzei WR Jr, Al-Khatib SM, Hranitzky PM, Bahnson TD, Velazquez EJ, Califf RM, Lee KL, Roe MT. Usefulness of the duke sudden cardiac death risk score for predicting sudden cardiac death in patients with angiographic (<75% narrowing) coronary artery disease. *Am J Cardiol* 2009; 104:1624-30.
872. Meadows TA, Bhatt DL, Hirsch AT, Creager MA, Califf RM, OHman EM, Cannon CP, Eagle KA, Alberts Mj, Goto S, Smith SC Jr, Wilson PW, Watson KE, STeg PG; REACH Registry Investigators. Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry. *Am Heart J* 2009; 158: 1038-45.
873. Goldschmidt-Clermont PJ, Dong C, Rhodes NM, McNeill DB, Adams MB, Gilliss CL, Cuffe MS, Califf RM, Peterson ED, Lubarsky DA. Perspective: Autonomic care systems for hospitalized patients. *Acad Med* 2009; 84: 1727-31.
874. Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Steg PG, Cannon CP, Brennan DM, Bhatt DL; REACH Registry Investigators. Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the United States: Insights from the REACH Registry. *Crit Pathw Cardiol* 2009; 8:91-7.

- 875.Katz JN, Shah BR, Volz EM, Horton JR, Shaw LK, Newby LK, Granger CB, Mark DB, Califf RM, Becker RC. Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomes. *Cri Care Med* 2010; 38: 375-81.
- 876.Dzau VJ, Ackerly DC, Sutton-Wallace P, Merson MH, Williams RS, Krishnan KR, Taber RC, Califf RM. The role of academic health science systems in the transformation of medicine. *Lancet* 2010; 9718:949-53.
- 877.Piccini JP, Zhang M, Pieper K, Solomon SD, Al-Khatib SM, Van de Werf F, Pfeffer MA, McMurray JJ, Califf RM, Velazquez EJ. Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. *Eur Heart J* 2010;2:211-21.
- 878.Szczzech LA, Barnhart HX, Sapp S, Felker GM, Hernandez A, Reddan D, Califf RM, Inrig JK, Patel UD, Singh AK. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. *Kidney Int* 2010; 77:239-46..
- 879.Mahaffey KW, Tonev ST, Spinler SA, Levine GN, Gallo R, Ducas J, Goodman SG, Antman EM, Becker RC, Langer A, White HD, Aylward PE, Col JJ, Ferguson JJ, Califf RM; on behalf of the SYNERGY Trial Investigators. Obesity in patients with non-ST-segment elevation acute coronary syndromes: Results from the SYNERGY trial. *Int J Cardiol* 2010;139:123-33.
- 880.Peterson JL, Barron JJ, Hammill BG, Cziraky MJ, Anstrom KJ, Wahl PM, Eisenstein EL, Krucoff MW, Califf RM, Schulman KA, Curtis LH. Clopidogrel use and clinical events after drug-eluting stent implementation: findings from the HealthCore Integrated Research Database. *Am Heart J* 2010; 159:462-470.
- 881.O'Connor CM, Hasselblad V, Mehta RH, Tasissa G, Califf RM, Fiuzat M, Rogers JG, Leier CV, Stevenson LW. Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catherization Effectiveness) risk model and discharge score. *J Am Coll Cardiol* 2010; 55:872-8.
- 882.Krum H, McMurray JJ, Horton E, Gerlock T, Holzhauer B, Zuurman L, Haffner SM, Bethel MA, Holman RR, Califf RM. Baseline characteristics of the nateglinide and valsartan impaired glucose tolerance outcomes research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. *Cardiovasc Ther* 2010; 28:124-32.
- 883.Reis SE, Berglund L, Bernard GR, Califf RM, Fitzgerald GA, Johnson PC; National Council and Translational Science Awards Consortium. Reengineering the national clinical and translational research enterprise: the strategic plan of the National Clinical and Translational Science Awards Consortium. *Acad Med* 2010; 85:463-9.
- 884.Califf RM, Berglund L; Principal Investigators of National Institutes of Health Clinical and Translational Science Awards. Linking scientific discovery and better health for the nation: the first three year of the NIH's Clinical and Translational Science Awards. *Acad Med* 2010; 85: 457-62.
- 885.Shin SH, Hung CL, Uno H, Hassanein AH, Verma A, Bourgoun M, Kober L, Ghali JK, Velazquez EJ, Califf RM, Pfeffer MA, Solomon SD; Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both. *Circulation* 2010; 121: 1096-103.
- 886.Cannon CP, Rhee KE, Califf RM, Boden WE, Hirsch AT, Albert MJ, Cable G, Shao M, Ohman EM, Steg PG, Eagle KA, Bhatt DL: REACH Registry Investigators. Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the Reduction of Atherothrombosis for Continued health [REACH] Registry). *Am J Cardiol* 2010; 105:445-52.
- 887.Baker-Smith, CM, Benjamin DK Jr, Califf RM, Murphy MD, Li JS, Smith PB. Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials. *Clin Pharmacol Therp* 2010 Feb 3. [Epub ahead of print]
- 888.Nilsson KR Jr, Al-Khatib SM, Zhou Y, Pieper K, White HD, Maggioni AP, Kober L, Granger CB, Lewis EF, McMurray JJ, Califf RM, Velazquez EJ. Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. *Heart* 2010; April 20. [Epub ahead of print].

- 889.NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamas G, Tognoni G, Tuomilehto J, Villamil AS, Vozar J, Califf RM. Effect of valsartan on the incidence of diabetes and cardiovascular events. *N Engl J Med* 2010; 362: 1477-90.
- 890.NAVIGATOR Study Group, Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Busse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gagiong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R., Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, STender S, Tamas G, Tognoni G, Tuomilehto J, Villamil AS, Vozar J, Califf RM. Effect of nateglinide on the incidence of diabetes and cardiovascular events. *N Engl J Med* 2010; 362:1463-76.
- 891.Califf Rm, Armstrong PW, Granger CB, Harrington RA, Lee K, Simes RJ, Van de Werf F, Wallentin L, White HD: Virtual coordinating centre for global collaborative cardiovascular research organization. Towards a new order in cardiovascular medicine: re-engineering through global collaboration. *Eur Heart J* 2010; 31:911-7.
- 892.Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, James SK. ST2 and mortality in non-ST-segment evaluation acute coronary syndrome. *Am Heart J* 2010; 159:788-94.
- 893.Cohen M, Levine GN, Pieper KS, Lan L, Antman EM, Aylward PE, White HD, Kleiman NS, Califf RM, Mahaffey KW; SYNERGY Trial Investigators. Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTEMI ACS: a subgroup analysis from the SYNERGY trial. *Catheter Cardiovasc Interv* 2010; 75: 928-35.
- 894.Harrington RA, Califf RM. There is a role for industry-sponsored education in cardiology. *Cardiology* 2010; 121:2221-7.
- 895.Simes RJ, O'Connell RL, Aylward PE, Varshavsky S, Diaz R, Wilcox RG, Armstrong PW, Granger CB, French JK, Van de Werf F, Marschner IC, Califf RM, White HD; HERO-2 Investigators. Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. *Am Heart J* 2010; 159:988-97.
- 896.Shamshad F, Kenchaiah S, Finn PV, Soler-Soler J, McMurray JJ, Velazquez EJ, MAggioni AP, Califf RM, Swedberg K, Kober L, Belenkov Y, Varshavsky S, Pfeffer MA, Solomon SD; VALsartan InAcute myocardial infarcTion (VALIANT) Trial Investigators. *Am Heart J* 2010; 160:145-51.
- 897.Kong MH, Shaw LK, O'Connor C, Califf RM, Blazing MA, Al-Khatib SM. Is Rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure? *Ann Noninvasive Electrocardiol* 2010; 15:209-17.
- 898.Pouleur AC, Barkoudah E, Uno H, Skali H, Finn PV, Zelenkofske SL, Belenkov YN, Mareev V, Velazquez EJ, Rouleau JL, Maggioni AP, Kober L, Califf RM, McMurray JJ, Pfeffer MA, Solomon SD, VALIANT Investigators. *Circulation* 2010; 122:597-602.
- 899.West RL, Hernandez AF, O'Connor CM, Starling RC, Califf RM. A review of dyspnea in acute heart failure syndromes. *Am Heart J* 2010; 160:209-14.
- 900.Taekman JM, Stafford-Smith M, Velazquez EJ, Wright MC, Phillips-Bute BG, Pfeffer MA, Sellers MA, Pieper KS, Newman MF, Van de Werf F, Diaz R, Leimberger J, Califf RM. Departures from the protocol during conduct of a clinical trial: a pattern from the data record consistent with a learning curve. *Qual Saf Health Care* 2010; 19: 405-10.
- 901.Boden WE, Cherr GS, Eagle KA, Cannon CP, Califf RM, Hirsch AT, Alberts MJ, Criqui M, Creager MA, Massaro JM, D'Agostino RB Sr, Steg PG, Bhatt DL; REACH Registry Investigators. Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis. *Crit Pathw Cardiol* 2010; 9:116-25.



902. Goyal A, Bhatt DL, Stegg PG, Gersh BJ, Alberts MJ, Ohman EM, Corbalan R, Eagle KA, Gaxiola E, Gao R, Goto S, D'Agostino RB, Califf RM, Smith SC Jr, Wilson PW; Reduction of Atherothrombosis for continued health (REACH) Registry Investigators. Attained educational level and incident atherothrombotic events in low-and middle-income compared with high-income countries. *Circulation*; 2010; 112:1167-75.
903. Shah SH, Granger CB, Hauser ER, Kraus WE, Sun JL, Pieper K, Nelson CL, DeLong ER, Califf RM, Newby LK; MURDOCK Horizon 1 Cardiovascular Disease Investigators. Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of a rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease Study. *Am Heart J* 2010; 160:371-79.e2.
904. Tackett AH, Bailey AL, Foody JM, Miller JM, Apperson-Hansen C, Ohman EM, Hochman JS, Karnash SL, Califf RM, Topol EJ, Moliterno DJ. Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: insights from the GUSTO-III trial. *Am Heart J* 2010; 160:678-84.
905. Piccini JP, Schulte PJ, Pieper KS, Mehta RH, White HD, Van de Werf F, Ardissino D, Califf RM, Granger CB, Ohman EM, Alexander JH. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. *Crit Care Med* 2010 Oct 14 (epub ahead of print)
906. Shah AM, Uno H, Kober L, Velazquez EJ, Maggioni AP, MacDonald MR, Petrie MC, McMurray JJ, Califf RM, Pfeffer MA, Solomon SD. The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. *Eur J Heart Fail* 2010;12:1229-37.
907. Thune JJ, Signorovitch JE, Kober L, McMurray JJ, Swedberg K, Rouleau J, Maggioni A, Velazquez E, Califf RM, Pfeffer MA, Solomon SD. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. *Eur J Heart Fail* 2010 Oct 29 (epub ahead of print)
908. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database – update and key issues. *N Engl J Med* 2011; 364: 852-60.
909. Mehta RH, Ferguson TB, Lopes RD, Hafley GE, Mack MJ, Kouchoukos NT, Gibson CM, Harrington RA, Califf RM, Peterson ED, Alexander JH on behalf of the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Investigators. Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial. *Circulation* 2011 July 19; 124 (3):280-88.
910. Mahaffey KW, Pieper KS, Lokhnygina Y, Califf RM, Antman EM, Kleiman NS, Goodman SG, White HD, Rao SV, Hochman JS, Cohen M, Col JJ, Roe MT, Ferguson JJ, SYNERGY Investigators. The impact of postrandomization crossover of therapy in acute coronary syndromes care. *Circ Cardiovasc Qual Outcomes* 2011 Mar 1;4(2): 211-9.
911. Patel K, Lucas JE, Thompson JW, Dubois LG, Tillman HL, Thompson AJ, Uzarski D, Califf RM, Moseley MA, Ginsberg GH, MCHutchison JG, McCarthy JJ; MURDOCK Horizon I Study Team. High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients. *Hepatology* 2011 Jun; 53(6):1809-18.
912. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2<sup>nd</sup>, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr; 2011 Writing group members: ACCF/AHA Task Force Members. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2011 May 10; 123 (18):e-426-579.
913. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP, Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2<sup>nd</sup>, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. *J Am Coll Cardiol* 2011 May 10;57(19) 1920-59.

914. Armstrong PW, Westerhout CM, Van de Werf F, Califf RM, Welsh RC, Wilcox RG, Bakal JA. Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. *Am Heart J* 2011 May; 161(5): 848-54.
915. Verma A, Pfeffer MA, Skali H, Rouleau J, Maggioni A, McMurray JJ, Califf RM, Velazquez EJ, Solomon SD. Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. *Am Heart J* 2011 Jun; 161(6): 1156-62.
916. Tricoci P, Newby LK, Hasselblad V, Kong DF, Giugliano RP, White HD, Theroux P, Stone GW, Moliterno DJ, Van de Werf F, Armstrong PW, Prabhakaran D, Rasoul S, Bolognese L, Durand E, Braunwald E, Califf RM, Harrington RA. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. *Circ Cardiovasc Qual Outcomes* 2011 Jul 1;4(4): 448-58.
917. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. *N Engl J Med* 2011 Jul 7;365(1): 32-43.
918. Shah MR, Califf RM, Nohria A, Bhapkar M, Bowers M, Mancini DM, Fiuzat M, Stevenson LW, O'Connor CM. The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. *J Card Fail* 2011 Aug; 17(8): 613-21.
919. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 2011 Sep 8;365(10): 883-91.
920. Fiuzat M, Califf RM. Conduct of clinical trials in acute heart failure: regional differences in heart failure clinical trials. *Heart Fail Clin* 2011 Oct; 7(4): 539-44.
921. Mehta RH, Honeycutt E, Patel UD, Lopes RD, Williams JB, Shaw LK, O'Brien SM, Califf RM, Hughes GC, Sketch MH Jr. Relationship of the time interval between cardiac catheterization and elective coronary artery bypass surgery with postprocedural acute kidney injury. *Circulation* 2011 Sept 13; 124 (11 Suppl): S149-55.
922. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. *Eur Heart J* 2011 Oct; 32(19): 2387-94.
923. Melloni C, James SK, White JA, Giugliano RP, Harrington RA, Huber K, Tricoci P, Armstrong PW, Van de Werf F, Montalescot G, Califf RM, Newby LK. Safety and efficacy of adjusted-dose eptifibatid in patients with acute coronary syndromes and reduced renal function. *Am heart J* 2011 Nov; 162(5): 884-892.e1.
924. Lopes RD, Mehta RH, Hafley GE, Williams JB, Mack MJ, Peterson ED, Allen KB, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB Jr, Alexander JH. Relationship Between Vein Graft Failure and Subsequent Clinical Outcomes Following Coronary Artery Bypass Surgery. *Circulation* 2012 Jan 11 [epub ahead of print]
925. Mehta RH, Stebbins AS, Lopes RD, Califf RM, Pieper KS, Armstrong PW, Van de Werf F, Hochman JS, White HD, Topol EJ, Alexander JH, Granger CB. Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis. *Am J Cardiol* 2012 Feb 1; 109(3): 320-6.
926. Adams J, Kuchibhatla M, Christopher EJ, Alexander JD, Clary GL, Cuffe MS, Califf RM, Krishnan RR, O'Connor CM, Jiang W. Association of Depression and Survival in Patients with Chronic Heart Failure over 12 Years. *Psychosomatics* 2012 Jan 24 [epub ahead of print].
927. Kramer JM, Smith PB, Califf RM. Impediments to clinical research in the United States. *Clin Pharmacol Ther* 2012 Mar;91(3): 535-41.

928. Thomas MP, Mahaffey KW, Chiswell K, Cohen M, Kontos MC, Antman EM, Ferguson JJ, Califf RM, Goodman SG, Becker RC. Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin. *J Thromb Thrombolysis* 2012 Jul; 34(1): 114-9.
929. Granger BB, Prvu-Bettger J, Aucoin J, Fuchs MA, Mitchell PH, Holditch-Davis D, Roth D, Califf RM, Gilliss CL. An academic-health service partnership in nursing: lessons from the field. *J Nurs Scholarsh* 2012 Mar; 44(1):71-9.
930. Chan MY, Sun JL, Newby LK, Lokhnygina Y, White HD, Moliterno DJ, Theroux P, Ohman EM, Simoons ML, Mahaffey KW, Pieper KS, Giugliano RP, Armstrong PW, Califf RM, Van de Werf F, Harrington RA. *Int J Cardiol* 2012 Feb 16 [Epub ahead of print].
931. Roe MT, White JA, Kaul P, Tricoci P, Lokhnygina Y, Miller CD, van't Hof AW, Montalescot G, James SK, Saucedo J, Ohman EM, Pollack CV Jr, Hochman JS, Armstrong PW, Giugliano RP, Harrington RA, Van de Werf F, Califf RM, Newby LK. Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndrome: insights from the EARLY ACS Trial. *Circ Cardiovasc Qual Outcomes* 2012 Mar 1;5(2): 205-213.
932. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Max JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke w; ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. *Lancet Neurol* 2012 Apr;11(4):315-22.
933. Califf RM, Kornbluth S. Establishing a framework for improving the quality of clinical and translational research. *J Clin Oncol* 2012 May10;30(14): 1725-6.
934. Ezekowitz JA, Hernandez AF, O'Connor CM, Starling RC, Proulx G, Weiss MH, Bakal JA, Califf RM, McMurray JJ, Armstrong PW. Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. *J Am Coll Cardiol* 2012 Apr 17;59(16):1441-8.
935. Inrig JK, Barnhart HX, Reddan D, Patel UD, Sapp S, Califf Rm, Singh AK, Szczech LA. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of hemoglobin and outcomes in renal insufficiency) trial. *Am J Kidney Dis* 2012 Sep;60(3):390-401. doi:10.1053/j.ajkd.2012.03.009.
936. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. *JAMA* 2012 May 2;307(17):1838-47.
937. Califf RM. A new look at an old therapy. *JAMA* 2012 May 9;307(18) 1972-3.
938. Inrig JK, Sapp S, Barnhart H, Patel UD, Reddan D, Singh A, Califf RM, Szczech L. Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR. *Nephrol Dial Transplant* 2012 Sep; 27(9):3606-14. Doi:10.1093/ndt/gfs123.
939. Shah SH, Sun JL, Stevens RD, Bain JR, Muehlbauer MJ, Pieper KS, Haynes C, Hauser ER, Kraus WE, Granger CB, Newgard CB, Califf RM, Newby LK. Baseline metabolomics profiles predict cardiovascular events in patients at risk for coronary artery disease. *Am Heart J* 2012 May;163(5):844-850.
940. Piccini JP, White JA, Mehta RH, Lokhnygina Y, Al-Khatib SM, Tricoci P, Pollack CV Jr, Montalescot G, Van de Werf F, Gibson Cm, Giugliano RP, Califf RM, Harrington RA, Newby LK. Sustained ventricular tachycardia and ventricular fibrillation complicating Non-ST-Segment elevation acute coronary syndromes. *Circulation* 2012 Jul3;126(1):41-9. doi:10.1161/CIRCULATIONAHA.111.071860.
941. Duval S, Massaro JM, Jaff MR, Boden WE, Alberts MJ, Califf RM, Eagle KA, D'Agostino RB, Pedley A, Fonarow GC, Murabito JM, Steg PG, Bhatt DL, Hirsch AT. An evidence-based score to detect prevalent peripheral artery disease (PAD). *Vasc Med* 2012 Oct;17(5):342-51. doi:10.1177/1358863X12445102.
942. Felker GM, Hasselblad V, Tang WH, Hernandez AF, Armstrong PW, Fonarow GC, Voors AA, Metra M, McMurray JJ, Butler J, Heizer GM, Dickstein K, Massie BM, Atar D, Troughton RW, Anker SD, Califf RM, Starling RC, O'Connor CM.

Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. *Eur J Heart Fail.* 2012 Nov; 14(11):1257-64. Doi:10.1093/eurjhf/hfs110.

- 943.Lopes RD, White JA, Tricoci P, White HD, Armstrong PW, Braunwald E, Giugliano RP, Harrington RA, Lewis BS, Brogan GX Jr, Gibson CM, Califf RM, Newby LK. Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS trial. *Int J Cardiol* 2012 Jul [Epub ahead of print].
- 944.Califf RM. The grouble with ischemia. *Am Heart J* 2012 Aug; 164(2) 133-4. Doi: 10.1016/j.ahj.2012.06.007.
- 945.Califf RM. In search of the efficient way to medical decisions: the case of acute heart failure syndrome. *Am Heart J.* 2012 Aug; 164(2):135-7. Doi: 10.1016/j.ahj.2012.05.006.
- 946.Tenenbaum JD, Christian V, Cornish MA, Dolor RJ, Dunham AA, Ginsburg GS, Kraus VB, McHutchison JG, Nahm ML, Newby LK, Svetkey LP, Udayakumar K, Califf. The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records. *Am J Transl Res.* 2012; 4(3):291-301. [Epub 2012 July 23].
- 947.Lopes, RD, Williams JB, Mehta RH, Reyes EM, Hafley GE, Allen KB, Mack MJ, Peterson ED, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB, Lorenz TJ, Alexander JH. Edifoligide and long-term outcomes after coronary artery bypass grafting: PProject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. *Am Heart J.* 2012 Sep;164(3): 379-396. el. Doi: 10.1016/j.ahj.2012.05.019.
- 948.Pride YB, Mahonavelu S, Zorkun C, Kunadian V, Giugliano RP, Newby LK, Braunwald E, Califf RM, Harrington RA, Gibson CM; EARLY ACS Investigators. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic study. *JACC Cardiovasc Interv* 2012 Sept;5(9):927-35. Doi: 10.1016/j.jcin.2012.05.007.
- 949.Fuster V, Bhatt DL, Califf RM, Michelson AD, Sabatine MS, Angiolillo DJ, Bates ER, Cohen DJ, Collier BS, Furie B, Hulot JS, Mann KG, Mega JL, Musunuru K, O'Donnell CJ, Price CJ, Schneider DJ, Simon DI, Weitz JI, Williams MS, Hoots WK, Rosenberg YD, Hasan AA. Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. *Circulation* 2012 Sep 25;126(13): 1645-62.
- 950.McMurray JJ, Califf RM, Bethel AM, Haffner SM, Holman RR. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study. *J Clin Hypertens (Greenwich)* 2012 Oct; 14(10):731. Doi: 10.1111/j.1751-7176.2012.
- 951.McMurray JJ, Haffner SM, Califf RM, Holman RR. Prediabetes and the risk of diabetes. *Lancet* 2012 Oct 6:380(9849): 1225-6; author reply 1226. Doi: 10.1016/S0140-6736(12)61706-1.
- 952.Einstein EL, Wojdyla D, Anstrom KJ, Brennan JM, Califf RM, Peterson ED, Douglas PS. Evaluating the impact of public health notification: duke clopidogrel experience. *Circ Cardiovasc Qual Outcomes.* 2012 Nov;5(6):767-74. Doi: 10.1161/CIRCOUTCOMES.111.963330.
- 953.Califf RM, Sanderson I, Miranda ML. The future of cardiovascular clinical research: informatics, clinical investigators, and community engagement. *JAMA* 2012 Nov 7;308(17):1747-8. Doi: 10.1001/jama.2012.28745.
- 954.Leonardi S, Thomas L, Neely ML, Tricoci P, Lopes RD, White HD, Armstrong PW, Giugliano RP, Antman EM, Califf RM, Newby LK, Mahaffey KW. Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction. *J Am Coll Cardiol.* 2012 Dec 4;60(22):2296-304. Doi:10.1016/j.jacc.2012.09.005.
- 955.Bhattacharya S, Dunham AA, Cornish MA, Christian VA, Ginsburg GS, Tenenbaum JD, Nahm ML, Miranda ML, Califf RM, Dolor RJ, Newby LK. The measurement to understand reclassification of disease of Cabarrus/Kannapolis (MURDOCK) Study Community Registry and Biorepository. *Am J Transl Res.* 2012;4(4):458-70. [Epub 2012 Oct 10].
- 956.Mentz RJ, Hernandez AF, Stebbins A, Ezekowitz JA, Felker GM, heizer GM, Atar D, Teerlink JR, Califf RM, Massie BM, Hasselblad V, Starling RC, O'Connor CM, Ponikowski P. Predictors of early dyspnea relief in acute heart failure and the association of 30-day outcomes: findings from ASCEND-HF. *Eur J Heart Fail.* 2012 Nov 15 [Epub ahead of print].

957. Preiss D, Thomas LE, Sun JL, Haffner SM, Holman RR, Standl E, Leiter LA, Mazzone T, Rutten GE, Tognoni G, Martinez FA, Chiang FT, Califf RM, McMurray JJ. Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. *BMJ Open*. 2012 Nov 30;2(6). Doi:pii:e001925.10.1136/bmjopen-2012-001925.
958. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, Califf RM; for the ROCKET AF Steering Committee and Investigators. Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoatulation and Risk factors In Atrial fibrillation) Study Cohorts. *Circulation*. 2013 Jan 15;127(2):224-232.
959. Califf RM. Biomarkers, putative surrogates, surrogates and decision making. *Circ Cardiovasc Imaging*. 2013 Jan 1;6(1):6-7. Doi:10.1161/CIRCIMAGING.112.982538.

#### NR Journal

1. Krucoff, M. W., Croll, M. A., Pendley, L. P., Burdette, D. L., Pope, J. E., Hutchinson, D. D., Stone, J. S., Weber, R. A., and Califf, R. M. Continuous computer-assisted electrocardiographic monitoring in patients with acute myocardial infarction: early experience. *Computers in Cardiology* . 1989.
2. O'Connor, C. M., Mark, D.B., Hinohara, T., Stack, R. S., Rendall, D. S., Hlatky, M. A., Pryor, D. B., Phillips, H. R. 3rd., and Califf, R. M. Rescue coronary angioplasty after failure of intravenous streptokinase in acute myocardial infarction: in-hospital and long-term outcomes. *Journal of Invasive Cardiology* 1, 85-95. 1989.
3. George, B. S., Candela, R. J., Topol, E. J., Stack, R. S., Kereiakes, D. J., Abbottsmith, C. W., Masek, R., Pickel, A., Dillon, J., Harrelson, L., Califf, R. M., and TAMI Study Group. The brachial approach to emergency cardiac catheterization during thrombolytic therapy for acute myocardial infarction. *Catheterization and Cardiovascular Diagnosis* 20, 221-226. 1990.
4. Sane, D. C., Califf, R. M., Sigmon, K. N., Topol, E. J., and Stump, D. C. Effect of heparin administration on fibrinogenolysis during thrombolytic therapy with tissue plasminogen activator for acute myocardial infarction. *Fibrinolysis* 7, 103-107. 1993.
5. Aguirre, F. V., Anderson, K. M., Weisman, H. F., Topol, E. J., and Califf, R. M. Clinical benefit within patient subgroups receiving C7E3 Fab (abciximab) during percutaneous coronary revascularization: subgroup analysis from the EPIC Trial. *Journal of Invasive Cardiology* 8, 21B-29B. 1996.
6. Ohman, E. M., Williams, P. A., Hodgson, P. K., Weldon, P. M., and Califf, R. M. Using the Internet to enhance clinical trials performance. *Cardio-Vascular Clinical Trials* 1, 27-29. 1997.
8. Simons, G. R., Sgarbossa, E. B., Wagner, G. S., Califf, R. M., and Natale, A. Atrioventricular and intraventricular conduction disorders in acute myocardial infarction: a reappraisal in the thrombolytic era. *Pacing Clinical Electrophysiol* 21, 2651-2663. 1998.

9. Califf, R. M. How can we identify patients at high risk of coronary heart disease events. *Dialogues in cardiovascular medicine* 4, 139-145. 1999.
10. Ohman, E. M., Williams, P. A., Armstrong, P. W., Katus, H. A., Hamm, C. W., Califf, R. M., and Topol, E. J. An early troponin T level predicts mortality after acute coronary ischemia. *Medical Updates on Therapy, Diagnosis, and Prevention* 2, 42-43. 1999.
11. Veldkamp, R. F., Pope, J. E., Wilderman, N. M., Trollinger, K. M., Sawchak, S. T., Califf, R. M., Wagner, G. S., and Krucoff, M. W. ST-segment deviatie op het 12-afleidingen electrocardiogram tijdens het acute myocardinfarct: optimale afleidingen voor continue ST-segmentbewaking. *Intensive Care Capita Selecta 2000 - Venti-Care, Uitgeverij Venti-Care 2000, Utrecht . 2000.*
12. Schneider, S.M., Turner, B.S., Califf, R.M., Burks, W., McHutchinson, J.G., Gilliss, C.L. Academic research units: Opportunities and challenges for nursing practice. *Research Practitioner* 9, 175-185. 2008
13. Califf RM. Translations of innovation: A broad perspective. In: *Diffusion and Use of Genomic Innovations in Health and Medicine: Workshop Summary*. Hernandez L, ed. Washington DC: National Academies Press; 2008.

#### **Review**

1. Williams RS, Wallace AG, Hindman MC, Califf RM, Blumenthal JA, Koisch FP, Morey MC, Wagner ED, Mau HS, Williams JS, Rhoads MK, Erickson P, Leckie DJ, James JM. Duke University's preventive approach to cardiology. *Journal of Cardiac Rehabilitation* 1982;2(6):509-514.
2. Blumenthal JA, Califf RM, Williams RS, Hindman MC. Cardiac rehabilitation: a new frontier for behavioral medicine. *Journal of Cardiac Rehabilitation* 1983;3:637-656.
3. Califf RM, Pryor DB, Harrell FE, Jr. Ventricular arrhythmias: prognostic importance in CAD. *Primary Cardiology* 1983;9(11):146-160.
4. Pryor DB, Hindman MC, Wagner GS, Califf RM, Rhoads MK, Rosati RA. Early discharge after acute myocardial infarction. *Ann Intern Med* 1983;99:528-538.
5. Pryor DB, Califf RM, Harrell FE, Jr., Hlatky MA, Lee KL, Mark DB, Rosati RA. Clinical data bases. Accomplishments and unrealized potential. *Med Care* 1985;23:623-647.
6. Califf RM, Pryor DB, Greenfield JC, Jr. Beyond randomized clinical trials: applying clinical experience in the treatment of patients with coronary artery disease. *Circulation* 1986;74:1191-1194.
7. Mark DB, Califf RM. Variant angina: prognosis and therapy. *Primary Cardiology* 1986;12:25-38.
8. Blackshear JL, O'Callaghan WG, Califf RM. Medical approaches to prevention of restenosis after coronary angioplasty. *J Am Coll Cardiol* 1987;9:834-848.
9. Califf RM, Papanicolaou MN, McCants CB, Hlatky MA, Pryor DB. Prognosis in angiographically normal or near-normal coronary arteries. *Cardiology Board Review* 1987;4(7):21-25.
10. Topol EJ, Califf RM, Kereiakes DJ, George BS. Thrombolysis and angioplasty in myocardial infarction (TAMI) Trial. *J Am Coll Cardiol* 1987;10:65B-74B.
11. Califf RM, Mantell S, Westawski C, Honan MB, Bellinger RL, Wall TC. Experience with the use of tPA in the treatment of acute myocardial infarction. *Ann Emerg Med* 1988;17:1176-1189.

12. Mark DB, Hlatky MA, O'Connor CM, Pryor DB, Wall TC, Honan MB, Phillips HR3, Califf RM. Administration of thrombolytic therapy in the community hospital: established principles and unresolved issues. *J Am Coll Cardiol* 1988;12:32A-43A.
13. Munster M, Califf RM. Heart attack. *NC Med J* 1988;49:441-444.
14. Stack RS, Califf RM, Phillips HR, Pryor DB, Quigley PJ, Bauman RP, Tchong JE, Greenfield JC, Jr. Interventional cardiac catheterization at Duke Medical Center. *Am J Cardiol* 1988;62:3F-24F.
15. Topol EJ, Califf RM, George BS, Kereiakes DJ, Lee KL. Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials. *J Am Coll Cardiol* 1988;12:24A-31A.
16. Califf RM, Topol EJ, Gersh BJ. From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy. *J Am Coll Cardiol* 1989;14:1382-1388.
17. Gersh BJ, Califf RM, Loop FD, Akins CW, Pryor DB, Takaro TC. Coronary bypass surgery in chronic stable angina. *Circulation* 1989;79:I46-59.
18. Rankin JS, Hickey MS, Smith LR, Debruijn NP, Clements FM, Muhlbaier LH, Lowe JE, Wechsler AS, Califf RM, Reves JG, et al. Current management of mitral valve incompetence associated with coronary artery disease. *J Cardiac Surg* 1989;4:25-42.
19. Rankin JS, Livesey SA, Smith LR, Sheikh KH, Van Trigt P, de Bruijn NP, Califf RM, Glower DD, Kisslo JA, Wolfe WG, et al. Trends in the surgical treatment of ischemic mitral regurgitation: effects of mitral valve repair on hospital mortality. *Seminars in Thoracic & Cardiovascular Surgery* 1989;1:149-163.
20. Sane DC, Califf RM, Topol EJ, Stump DC, Mark DB, Greenberg CS. Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. *Ann Intern Med* 1989;111:1010-1022.
21. Califf RM, Harrelson-Woodlief L, Topol EJ. Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. *Circulation* 1990;82:1847-1853.
22. Califf RM, Granger CB. Monoclonal IIB/IIIa antibody. *Interventional Cardiology* 1990;4(2):8
23. Fortin DF, Califf RM. Long-term survival from acute myocardial infarction: salutary effect of an open coronary vessel. *Am J Med* 1990;88:9N-15N.
24. Hlatky MA, Califf RM, Harrell FE, Jr., Lee KL, Mark DB, Muhlbaier LH, Pryor DB. Clinical judgment and therapeutic decision making. *J Am Coll Cardiol* 1990;15:1-14.
25. Ohman EM, Califf RM. Thrombolytic therapy: overview of clinical trials. *Coron Artery Dis* 1990;1:23-33.
26. Califf RM, Fortin DF, Frid DJ, Harlan WR, Bengston JR, Nelson CL, Tchong JE, Mark DB, Stack RS. Restenosis after coronary angioplasty: an overview. *J Am Coll Cardiol* 1991;17:2B-13b.
27. Jackman JD, Tchong JE, Califf RM, Stack RS. Current concepts in the management of ischemic mitral regurgitation. *Cardiology* 1991;76-83.
28. Kirklin JW, Akins CW, Blackstone EH, Booth DC, Califf RM, Cohen LS, Hall RJ, Harrell FE, Jr., Kouchoukos NT, McCallister BD, Naftel DC, Parker JO, Shelden WC, Smith HC, Wechsler AS, Williams JF, Jr. Guidelines and indications for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee on coronary artery bypass graft surgery). *J Am Coll Cardiol* 1991;17:543-589.
29. Califf RM. Why are large-scale trials needed? *Coron Artery Dis* 1992;3:92-95.
30. Califf RM, Fortin DF, Tenaglia AN, Sane DC. Clinical risks of thrombolytic therapy. *Am J Cardiol* 1992;69:12A-20A.

31. Califf RM, Ohman EM. The diagnosis of acute myocardial infarction. *Chest* 1992;101:106S-115S.
32. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction. A review. *Drugs* 1992;44:293-325.
33. Levine MN, Goldhaber SZ, Califf RM, Gore JM, Hirsh J. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. *Chest* 1992;102:364S-373S.
34. O'Connor CM, Califf RM. Aggressive therapy of myocardial infarction in the elderly. *Hospital Practice* 1992;27:59-76.
35. Tcheng JE, Ohman EM, Stack RS, Califf RM. Restenosis after PTCA. *Choices in Cardiology* 1992;6:50-52.
36. Topol EJ, Califf RM. Answers to complex questions cannot be derived from "simple" trials. *Br Heart J* 1992;68:348-351.
37. Leung L, Charo IF, Califf RM. Newer approaches to anti-thrombolytic therapy. *American Society of Hematology* 1993;95-102.
38. Ohman EM, O'Connor CM, Califf RM. Role of thrombolytic therapy in the treatment of acute myocardial infarction. *Cardiology in the Elderly* 1993;1:54-61.
39. Scheidt S, Adgey AAJ, Califf RM, Neuhaus KL, Ross AM, Topol EJ, Wilcox RG. Waiting for GUSTO: current status of thrombolytic therapy. (Medical panel discussion). *Cardiovascular Reviews & Reports* 1993;14:26-57.
40. Tcheng JE, Jackman JD, Nelson CL, Gardner LH, Smith LR, Rankin JS, Califf RM, Stack RS. Does reperfusion improve prognosis when mitral regurgitation complicates infarction? *Cardiology Board Review* 1993;10:17-33.
41. Tcheng JE, Jackman JD, Califf RM, Stack RS. Managing myocardial infarction complicated by mitral regurgitation. *Primary Cardiology* 1993;19:40-48.
42. Califf RM, Granger CB. Trials of new antithrombin agents. *Journal of Myocardial Ischemia* 1994;6(6):10-14.
43. Califf RM. Cardiogenic shock. *N Engl J Med* 1994;330:1724-1730.
44. Califf RM, Mark DB. Percutaneous intervention, surgery, and medical therapy: a perspective from the Duke Databank for Cardiovascular Diseases. *Seminars in Thoracic & Cardiovascular Surgery* 1994;6:120-128.
45. Harrington RA, Califf RM. The role of angioplasty after failed thrombolysis for acute myocardial infarction. *Coron Artery Dis* 1994;5:392-398.
46. Holmes DR, Jr., Topol EJ, Adelman AG, Cohen EA, Califf RM. Randomized trials of directional coronary atherectomy: implications for clinical practice and future investigation. *J Am Coll Cardiol* 1994;24:431-439.
47. National Heart Attack Alert Program Coordinating Committee 60 Minutes to Treatment Working Group. Emergency Department: Rapid identification and treatment of patients with acute myocardial infarction. *Ann Emerg Med* 1994;23:311-329.
48. Scheidt S, Adgey AAJ, Braunwald E, Califf RM, Neuhaus KL, Ross AM, Topol EJ, Weaver WD. Thrombolytic therapy after GUSTO. Medical roundtable discussion. *Cardiovascular Reviews & Reports* 1994;15:13-46.
49. Brodie BR, Grines CL, Ivanhoe RJ, Knopf WD, Taylor GJ, O'Keefe JH, Weintraub RA, Berdan LG, Tcheng JE, Woodlief LH, Califf RM, O'Neill WW. Six month follow-up after direct angioplasty for acute myocardial infarction. *Cardiology Board Review* 1995;
50. Califf RM. How should clinicians interpret clinical trials? *Cardiol Clin* 1995;13:459-468.
51. Califf RM. Acute ischemic syndromes. *Med Clin North Am* 1995;79:999-1024.
52. Califf RM. Restenosis: the cost to society. *Am Heart J* 1995;130:680-684.



53. Califf RM, Lincoff AM, Tcheng JE, Topol EJ. An overview of the results of the EPIC trial. *Eur Heart J* 1995;16 Suppl L:43-49.
54. Harrington RA, Califf RM. PTCA in acute myocardial infarction. *Journal of Myocardial Ischemia* 1995;7:23-28.
55. Holmes DR, Jr., Califf RM, Topol EJ. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. *J Am Coll Cardiol* 1995;25:10S-17S.
56. Levine MN, Goldhaber SZ, Gore JM, Hirsh J, Califf RM. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. *Chest* 1995;108:291S-301S.
57. Mahaffey KW, Granger CB, Califf RM. Thrombolytic therapy. *Interventional Cardiology Newsletter* 1995;3(4):25-32.
58. Puma JA, Sketch MH, Jr., Tcheng JE, Harrington RA, Phillips HR, Stack RS, Califf RM. Percutaneous revascularization of chronic coronary occlusions: an overview. *J Am Coll Cardiol* 1995;26:1-11.
59. Topol EJ, Califf RM, Sigmon KM, Lee KL. Thrombolytic therapy for women with acute myocardial infarction: is there a gender gap? *Cardiovascular Reviews & Reports* 1995;16:22-27.
60. Weitz JI, Califf RM, Ginsberg JS, Hirsh J, Theroux P. New antithrombotics. *Chest* 1995;108:471S-485S.
61. Barsness GW, Ohman EM, Califf RM, Kereiakes DJ, George BS, Topol EJ. The thrombolysis and angioplasty in myocardial infarction (TAMI) Trials: a decade of reperfusion strategies. *J Interv Cardiol* 1996;9:89-115.
62. Califf RM, Armstrong PW, Carver JR, D'Agostino RB, Strauss WE. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. *J Am Coll Cardiol* 1996;27:1007-1019.
63. Califf RM, Newby LK. How much do we gain by reducing time to reperfusion therapy? *Am J Cardiol* 1996;78:8-15.
64. Califf RM, Tardiff BE, Pieper KS, Hillegass WB. Use of calcium channel antagonists in myocardial revascularization procedures. *Am J Cardiol* 1996;77:26D-31D.
65. Califf RM. The rationale for thrombolytic therapy. *Eur Heart J* 1996;17:2-8.
66. Committee on Management of Acute Myocardial Infarction, Ryan TJ, Anderson JF, Antman EM, Braniff BA, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel BJ, Russell RO, Smith EEI, Weaver WD. ACC/AHA Guidelines for the management of patients with acute myocardial infarction: executive summary. A report of the ACC/AHA Task Force on practice guidelines. *Circulation* 1996;94(9):2341-2350.
67. Crenshaw BS, Harrington RA, Califf RM. Preventing restenosis after percutaneous coronary intervention. *Contemporary Internal Medicine* 1996;8(11):49-60.
68. Fetters JK, Peterson ED, Shaw LJ, Newby LK, Califf RM. Sex-specific differences in coronary artery disease risk factors, evaluation, and treatment: have they been adequately evaluated? *Am Heart J* 1996;131:796-813.
69. Jelesoff NE, Feinglos M, Granger CB, Califf RM. Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trials. *Coron Artery Dis* 1996;7:732-743.
70. Newby KH, Califf RM. Identifying patient risk: the basis for rational discharge planning after acute myocardial infarction. *J Thromb Thrombolysis*. 1996;3:107-115.
71. Puma JA, Califf RM, Sketch MH, Jr. The natural history of single vessel chronic total occlusions. *J Am Coll Cardiol* 1996;5(2):73-76.
72. Veldkamp RF, Pope JE, Sawchak ST, Wagner GS, Califf RM, Krucoff MW. ST-segment recovery endpoints in clinical trials: past, present, future. *J Electrocardiol* 1996;26:256-261.

73. Califf RM, Woodlief LH. Pragmatic and mechanistic trials. *Eur Heart J* 1997;18:367-370.
74. Califf RM, Karnash SL, Woodlief LH. Developing systems for cost-effective auditing of clinical trials. *Control Clin Trials* 1997;18:651-60; discussion 661-6.
75. Califf RM, Lee KL, Granger CB, Ohman EM. Predictors of outcome of reperfusion therapy. *Eur Heart J* 1997;18:728-735.
76. Califf RM, Mark DB. Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease. *Am Heart J* 1997;134:S88-96.
77. Califf RM. The GUSTO trial and the open artery theory. *Eur Heart J* 1997;18 Suppl F:F2-10.
78. Jelesoff NE, Feinglos M, Granger CB, Califf RM. Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trials. *J Cardiovasc Risk* 1997;4:100-111.
79. Peterson ED, Shaw LJ, Califf RM. Risk stratification after myocardial infarction. *Ann Intern Med* 1997;126:561-582.
80. Peterson ED, Shaw LJ, Califf RM. Clinical Guidelines: Part II. Risk stratification after myocardial infarction. *Ann Intern Med* 1997;126(7):561-582.
81. Peterson ED, Shaw LJ, Califf RM, Thibault GE, Feussner JR, Audet AMJ, Friesinger GC, Kent DL, Marton KI, Palda VA, Whyte JJ, Winter PL. ACP Position Papers: Clinical Guidelines Part I. Guidelines for risk stratification after myocardial infarction. *Ann Intern Med* 1997;126:556-560.
82. Topol EJ, Califf RM, Van de Werf F, Simoons M, Hampton J, Lee KL, White H, Simes J, Armstrong PW. Perspectives on large-scale cardiovascular clinical trials for the new millennium. The Virtual Coordinating Center for Global Collaborative Cardiovascular Research (VIGOUR) Group. *Circulation* 1997;95:1072-1082.
83. Van de Werf F, Vahanian A, Gulba DC, Muller JE, Arnold AER, Bar F, Vermeer F, Verheugt FWA, Boersma H, Vanes GA, Deckers JW, Lenderrink T, Simoons ML, Steyerberg E, Van Der Zwaan C, De Boer JM, Zijlstra F, Wilcox RD, Sleight P, Selker HP, Califf RM, Granger CB, Lee KL, Ohman EM, Weaver DW, Love T. Selection of reperfusion therapy for individual patients with evolving myocardial infarction. *Eur Heart J* 1997;18:1371-1381.
84. Williams PA, Califf RM, Topol EJ. Tissue-type plasminogen activator's 10% one-year edge. *Cardiology Reviews* 1997;14:41-46.
85. Braunwald E, Maseri A, Armstrong PW, Califf RM, Gibler WB, Hamm CW, Simoons ML, Van de Werf F. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. *Am Heart J* 1998;135(4):S56-66.
86. Califf RM. Role and significance of coagulation markers in understanding and treating acute coronary syndromes. Introduction. *Am Heart J* 1998;136:S1-6.
87. Califf RM. Robert McKinnon Califf, MD: a conversation with the editor. 1998;82:639-658.
88. Califf RM. A perspective on the regulation of the evaluation of new antithrombotic drugs. *Am J Cardiol* 1998;82:25P-35P.
89. Califf RM, Vidaillet H, Goldman L. Advanced congestive heart failure: What do patients want? *Am Heart J* 1998;135:S320-6.
90. Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, Cohen EA, Kleiman NS, Mahaffey KW, Topol EJ, Pepine CJ, Lipicky RJ, Granger CB, Harrington RA, Tardiff BE, Crenshaw BS, Bauman RP, Zuckerman BD, Chaitman BR, Bittl JA, Ohman EM. Myonecrosis after revascularization procedures. *J Am Coll Cardiol* 1998;31:241-251.
91. Schulman KA, Mark DB, Califf RM. Outcomes and costs within a disease management program for advanced congestive heart failure. *Am Heart J* 1998;135:S285-92.
92. Straznicky IT, French JK, White HD, Califf RM. Fibrinolysis for acute myocardial infarction in the elderly patient: is it effective, or too dangerous? *American Journal of Geriatric Cardiology* 1998;7(1):22-27.

93. Califf RM. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics. *Am Heart J* 1999;137(5):S35-S37
94. Califf RM. Introduction: evaluating the economic implications of cardiovascular therapeutics. *Am Heart J* 1999;137(5):535-537.
95. Califf RM, Holmes DR. Should the emergence of new agents change the management of patients with acute coronary syndromes without ST-segment elevation? *Am Heart J* 1999;138(6 Pt 2):S586-S594
96. GUSTO. The GUSTO Trials. *J Interv Cardiol* 1999;12(1):13-31.
97. Kong DF, Califf RM. Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation. *Drugs* 1999;58(4):609-620.
98. McGuire DK, Califf RM. Proceedings of a symposium - Diabetes and cardiovascular diseases current opinions and future directions - Introduction. *Am Heart J* 1999;138(5 Part 1):S327-S329
99. Auerbach AD, Hamel MB, Califf RM, Davis RB, Wenger NS, Desbiens N, Goldman L, Vidaillet H, Connors AF, Lynn J, Dawson NV, Phillips RS, for the SUPPORT Investigators. Patient characteristics associated with care by a cardiologist among adults hospitalized with severe congestive heart failure. *American College of Cardiology Current Journal Reviews* 2000;Vol 36:2119-2125.
100. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Decker JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML, for the PURSUIT Investigators. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from the international trial of 9,461 patients. *American College of Cardiology Current Journal Reviews* 2000;9 no. 6:47
101. Braunwald E, Califf RM, Cannon CP, Fox KAA, Fuster V, Gibler WB, Harrington RA, King SB, Kleiman NS, Theroux P, Topol EJ, Van de Werf F, White HD, Willerson JT. Redefining medical treatment in the management of unstable angina. *Am J Med* 2000;108(1):41-53.
102. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes DJ, Kuppersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO, Smith SC. ACC/AHA Guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. *Circulation* 2000;102:1193-1209:1193-1209.
103. Califf RM, Eisenstein EL. Critical concepts in cost-effectiveness for cardiovascular specialists. *Am Heart J* 2000;Dec 140 (supplement 6):S143-S147
104. Califf RM, Cohn JN. Cardiac protection: evolving role of angiotensin receptor blockers. *Am Heart J* 2000;139(1)#2:S15-S22
105. Califf RM. Combining strategies to improve patient outcomes in acute myocardial infarction. *Clinical Courier* 2000;18. No. 10:1-8.
106. Califf RM. Introduction: Evidence to practice in acute coronary syndromes. *Am J Cardiol* 2000;December 28, 2000 vol 86 (12b):1m-9m.
107. Califf RM. Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIa/IIIb inhibition. *Am Heart J* 2000;139(2) Part 2:
108. Gent M, Califf RM. Chronic ischemic heart disease. *Am Heart J* 2000;139, Number 4:S182-S188
109. Kleiman NS, Califf RM. Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000. *J Am Coll Cardiol* 2000;36(1):310-325.
110. Califf RM. Review: PCI has lower risk for procedural stroke but higher risks for angina and repeated revascularization than CABG. *ACP J Club* 2008;148:44.

111. Lopes RD, Becker RC, Alexander JH, Armstrong PW, Califf RM, Chan MY, Crowther M, Granger CB, Harrington RA, Hylek EM, James SK, Jolicœur EM, Mahaffey KW, Newby LK, Peterson ED, Pieper KS, Van de Werf F, Wallentin L, White HD, Carvalho AC, Giraldez RR, Guimaraes HP, Nader HB, Kalil RA, Bizzachi JM, Lopes AC, Garcia DA. Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA) Oct 14-16, 2010, Sao Paulo, Brazil. *J Thromb Thrombolysis* 2011 Aug; 32(2): 242-66.

### Abstracts

1. Califf RM, Burks JM, Behar VS, Wagner GS. Ventricular arrhythmias in patients with coronary artery disease. *Circulation* 1977;Supplement III-177:684
2. Califf RM, McNeer JF, Lee KL, Rosati RA. Prognostic implications of ventricular arrhythmias in treadmill exercise testing. *Circulation* 1978;Supplement II-198:57-58.
3. Califf RM, Ornstein S, Kimm SY, Grufferman S, Lee KL, Rosati RA. Use of the age and sex specific population for analysis of survival in coronary disease. *Circulation* 1981;Supplement II-329:64
4. Conley MJ, Behar VS, Harrell FE, Jr., Califf RM, Rosati RA. Prognostic significance of left main equivalent stenosis. *Am J Cardiol* 1981;47:408
5. Wagner GS, Califf RM, Harrell FE, Jr., Selvester RH. QRS score as a prognosticator in coronary artery disease. *Circulation* 1981;64
6. Morris KG, Califf RM, Palmeri ST, McKinnis RA, Coleman RE, Cobb FD. Prognostic significance of serial rest and exercise radionuclide angiography after acute myocardial infarction. *Am J Cardiol* 1982;49:901
7. Phillips HR, Hindman MC, Califf RM, Lee KL, Harrell FE, Jr., Behar VS, Wagner GS, Johnson RA, Rosati RA. Prognostic value of a coronary artery jeopardy score. *Circulation* 1982;66:
8. Califf RM, Harrell FE, Jr., Pryor DB, Lee KL, Rosati RA. Prognostic stratification using ejection fraction. *Circulation* 1983;68:
9. Califf RM, Harrell FE, Jr., Pryor DB, Lee KL, Rosati RA. Clinical signs and symptoms of ischemia and prognostic information to cardiac catheterization. *Circulation* 1983;68:
10. Coffey CE, Komrad MS, Massey EW, Coffey KS, McKinnis RA, Califf RM. The natural history of stroke complicating myocardial infarction. *Neurology* 1983;33:92
11. Mark DB, Califf RM, Morris KG, Harrell FE, Jr., Pryor DB, Lee KL, Rosati RA. Long term prognosis in medically treated variant angina. *Circulation* 1983;68:
12. Morris KG, Califf RM, Palmeri ST, McKinnis RA, Coleman RE, Cobb FR. Independent prognostic value of rest and exercise radionuclide angiography 3 and 8 weeks after infarction. *Circulation* 1983;68:

13. Williams RS, McKinnis RA, Cobb FR, Califf RM. Enhanced left ventricular ejection fraction during exercise in subjects with coronary artery disease following physical conditioning. *Circulation* 1983;68:
14. Corsa AT, Hindman NB, Califf RM, McKinnis RA, Wagner GS. The ability of initial quantitative epicardial injury to predict infarction size estimated by QRS score. *J Am Coll Cardiol* 1984;3:597.
15. Rocha MM, Williams RS, McKinnis RA, Califf RM. Survival during cardiac rehabilitation: importance of early functional improvement. *Circulation* 1984;70:
16. Heinsimer JA, Califf RM, Duke University Preventive Approach to Cardiology Staff. "Cure" of the rate-dependent left bundle branch block-chest pain syndrome by exercise training. *Clin Res* 1985;33:
17. Papanicolaou MN, Califf RM, Pryor DB, Harrell FE, Paulson EK, Hlatky MA, Rosati RA. Normal coronaries: normal prognosis? *J Am Coll Cardiol* 1985;5:519
18. Bellinger RL, O'Callaghan WG, Simonton CA, Phillips HR, Califf RM, Ramirez N, Hoffman P, Weber R, Stack RS. Safety and efficacy of emergency air transport in the management of patients with acute myocardial infarction. *Circulation* 1986;74:
19. Califf RM, Kereiakes DJ, George BS, O'Neill WW, Abbottsmith CW, Candela RJ, Stack RS, Topol EJ. Failure to reperfuse with tissue plasminogen activator predicts high reocclusion rate after angioplasty. *Circulation* 1986;74:
20. Collins GJ, Califf RM, Phillips HR, Peter RH, Kong Y, Behar VS, Stack RS. Quantitative angiographic changes occurring within 24 hours and one week following treatment with tissue plasminogen activator in patients randomized to immediate and late angioplasty. *Circulation* 1986;74:
21. Kereiakes DJ, Topol EJ, George BS, Abbottsmith CW, O'Neill WW, Candela RJ, Califf RM. Emergent coronary bypass following intravenous recombinant tissue plasminogen activator therapy for acute myocardial infarction: results from a multicenter randomized trial. *Circulation* 1986;74:368
22. Lamas G, Muller J, Turi Z, Mark D, Califf RM, Jaffe A, Raabe D, Rude R, Stone P, Rutherford J, Gold H, Passamani E, Braunwald E, MILIS Study Group. Validation of a simplified method to predict the occurrence of complete heart block in patients with acute myocardial infarction. *Pace* 1986;9:291.
23. Mark DB, Pryor DB, Lee KL, Hlatky MA, Harrell FE, Jr., Califf RM. Catheterization does not add to clinical and treadmill data for predicting prognosis in low-risk patients. *J Am Coll Cardiol* 1986;7:224A
24. Mark DB, Pryor DB, Harrell FE, Jr., Lee KL, Hlatky MA, Califf RM. Treadmill ST deviation predicts survival. *J Am Coll Cardiol* 1986;7:164A
25. Mark DB, Pryor DB, Hlatky MA, Lee KL, Harrell FE, Jr., Califf RM. Exercise ST elevation: a reliable guide to coronary anatomy. *J Am Coll Cardiol* 1986;7:163A
26. Martin JC, Califf RM, Harrell FE, Jr., Mark DB, Hlatky MA, Lee KL, Pryor DB. Post-infarction angina: a high risk presentation of unstable angina. *J Am Coll Cardiol* 1986;7:211A
27. Muhlbaier LH, Rankin JS, Califf RM, Pryor DB, Lee KL, Harrell FE, Jr., Sabiston DC, Jr. Influence of operative therapy on long-term prognosis in patients with three-vessel coronary artery disease. *J Am Coll Cardiol* 1986;7:217A
28. Pryor DB, Harrell FE, Jr., Rankin JS, Lee KL, Muhlbaier LH, Oldham HN, Mark DB, Hlatky MA, Califf RM. Changing survival benefits of coronary revascularization over time. *Circulation* 1986;74:
29. Bellinger RL, Califf RM, Collins P, Boeshart J, Collins G, Weber R, Stack R. Complications during air transport of patients with acute myocardial infarction. *J Am Coll Cardiol* 1987;9(2):22A
30. Califf RM, Abbottsmith CW, George BS, TAMI Study Group. Failure of clinical findings to predict infarct artery patency after tissue plasminogen activator (t-PA) therapy for acute myocardial infarction. *Circulation* 1987;76:98A

31. Califf RM, Stump DC, Thornton D, Kereiakes DJ, George BS, Abbottsmith CW, Candella RJ, Boswick JM, Topol EJ, TAMI Study Group. Hemorrhagic complications after tissue plasminogen activator (t-PA) therapy for acute myocardial infarction. *Circulation* 1987;76:1A
32. Califf RM, Topol EJ, Kereiakes DJ, George BS, Abbottsmith CW, Candella RJ, Aronson LG, Pitt B, Lee KL, TAMI Study Group. Long-term outcome in the thrombolysis and angioplasty in myocardial infarction trial. *Circulation* 1987;76:260A
33. Kereiakes DJ, Topol EJ, George BS, Candela RJ, Abbottsmith CW, Stack RS, O'Neill WW, Califf RM. Emergent coronary bypass preserves left ventricular function following intravenous tissue plasminogen activator therapy for acute myocardial infarction. *J Am Coll Cardiol* 1987;9(2):191A
34. Lee KL, Boswick JM, Harrell FE, Jr., Rosati RA, Califf RM, Mark DB, Hlatky MA, Pryor DB. The impact on coronary disease mortality of an intervening nonfatal myocardial infarction during patient follow-up. *J Am Coll Cardiol* 1987;9(2):77A
35. Mark DB, Califf RM, Harrell FE, Jr., Hlatky MA, Lee KL, Pryor DB. A simple clinical angina score stratifies prognosis in patients with documented coronary disease. *J Am Coll Cardiol* 1987;9(2):175A
36. O'Neill WW, Kereiakes DJ, Stack RS, George BS, Califf RM, Candela RJ, Abbottsmith CW, Topol EJ. Cardiothoracic surgical support is required during interventional therapy of myocardial infarction: results from the TAMI Study Group. *J Am Coll Cardiol* 1987;9(2):124A
37. O'Neill WW, Topol EJ, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, Boswick JM, Califf RM. Improvement in left ventricular function after thrombolytic therapy and angioplasty: results of the TAMI Study. *Circulation* 1987;76:259A
38. Ramirez NR, Califf RM, O'Callaghan WG, Hinohara T, Mark DB, Morris KG, Peter RH, Behar VS, Kong Y, Phillips HR, Stack RS. Does clinical indication for coronary angioplasty affect outcome? *J Am Coll Cardiol* 1987;9(2):182A
39. Stack RS, Mark DB, Hinohara T, Phillips HR, O'Connor CM, Simonton CA, Ramirez NM, Califf RM. Coronary reperfusion during acute myocardial infarction using combined coronary angioplasty and high dose intravenous streptokinase. *Clin Res* 1987;35:328A
40. Stack RS, Hinohara T, Phillips HR, Morris KG, Behar VS, Kong Y, Peter RH, Carlson EB, Simonton CA, Ramirez N, O'Callaghan WG, Hoffman P, Califf RM. Treatment of acute myocardial infarction with emergency coronary angioplasty. *J Am Coll Cardiol* 1987;9(2):232A
41. Stack RS, Topol EJ, O'Neill WW, George BS, Candela RJ, Kereiakes DJ, Abbottsmith CW, Califf RM, TAMI Study Group. Abrupt recurrent thrombosis after intravenous tissue plasminogen activator and emergency coronary angioplasty in acute myocardial infarction. *J Am Coll Cardiol* 1987;9(2):232A
42. Topol EJ, Califf RM, O'Neill WW, George BS, Kereiakes DJ, Pinkerton CA, Candela RJ, Abbottsmith CW, Rothbaum D, Stack RS, TAMI Study Group. Synergism of tissue-type and urokinase plasminogen activators for acute myocardial infarction: results of the multicenter TAMI-2 Trial. *Circulation* 1987;76:307A
43. Belkin RN, Mark DB, Szwed H, Califf RM, Aronson LG, Kisslo JA. Prevalence of pericardial effusion and ventricular thrombus formation among acute MI patients receiving tissue plasminogen activator. *J Am Coll Cardiol* 1988;11(2):104A
44. Califf RM, Topol EJ, George BS, Kereiakes DJ, Pinkerton CA, Boswick JM, Rothbaum DA, Candela RJ, Abbottsmith CW, Stack RS, TAMI Study Group. Combination thrombolytic therapy: improved pre-discharge vessel patency without increased hemorrhage. *J Am Coll Cardiol* 1988;11(2):231A
45. Califf RM, Topol EJ, Kereiakes DJ, Abbottsmith CW, George BS, Candela RJ, Aronson LG, Bauman RP, Ellis SG. Cardiac resuscitation should not be a contraindication to thrombolytic therapy for myocardial infarction. *Circulation* 1988;78:127
46. Califf RM, Wall TC, Tchong JE, Parsons WJ, Bauman RP, Phillips HR, Mantell SJ, Aronson LG. High-dose urokinase for acute myocardial infarction results in high rate of sustained infarct artery patency. *Circulation* 1988;78:304

47. Califf RM, Parsons WJ, Tcheng JE, Hinohara T, Boswick JM, Honan MB, Wall TC. Baseline function, not time to treatment, is most closely associated with LV function improvement during the first week after thrombolytic therapy. *Circulation* 1988;78:213
48. Califf RM, Topol EJ, George BS, Kereiakes DJ, Candela RJ, Abbottsmith CW, Stack RS, TAMI Study Group. Are adjunctive therapies needed when t-PA is used? *J Am Coll Cardiol* 1988;11(2):186A
49. Ellis SG, Topol EJ, Debowey D, Stack RS, O'Neill WW, Boswick JM, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, Califf RM, TAMI Study Group. Recurrent ischemia without warning: inability to predict ischemic events from residual stenosis after successful coronary thrombolysis. *J Am Coll Cardiol* 1988;11(2):105A
50. Honan MB, Rendall DS, Pryor DB, Hinohara T, Stack RS, Califf RM, Hlatky MA, Mark DB. Exercise tests cannot identify patients with angiographic restenosis after angioplasty for myocardial infarction. *Circulation* 1988;78:112
51. Irwin JM, Smith PM, Stack RS, Califf RM, Prystowsky EN. Successful reperfusion of infarcting myocardium is associated with reversal of electrical predictors of sudden cardiac death. *J Am Coll Cardiol* 1988;11(2):183A
52. Kereiakes DJ, Topol EJ, George BS, Abbottsmith CW, Candela RJ, O'Neill WW, Stack RS, Califf RM, Flege JB, Jr., TAMI Study Group. Favorable long term outcome of coronary bypass surgery before hospital discharge following intravenous t-PA therapy for myocardial infarction. *J Am Coll Cardiol* 1988;11(2):107A
53. Mark DB, Hlatky MA, Lee KL, Harrell FE, Jr., Califf RM, Pryor DB. The exercise treadmill test is a poor predictor of the risk of nonfatal myocardial infarction. *J Am Coll Cardiol* 1988;11(2):212A
54. O'Connor CM, Califf RM, Topol EJ, Kereiakes DJ, Candela RJ, Abbottsmith CW, George BS, Aronson LG, Mantell SJ. Stroke and acute myocardial infarction: new trends and unpredictability in the thrombolytic era. *Circulation* 1988;78:112
55. Rankin JS, Smith LR, Muhlbaier LH, Califf RM, Jones RH, Wolfe WG, Oldham HN, Trigot PV, Reves JG, Sabiston DC, Jr. The importance of acute clinical presentation to survival prognosis after coronary artery bypass. *Circulation* 1988;78:477
56. Sanz ML, Topol EJ, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, Stack RS, O'Neill WW, Califf RM, TAMI Study Group. Lack of evidence for enhanced thrombolysis with combined urokinase plus tissue plasminogen activator compared with tissue plasminogen activator alone using quantitative angiography. *J Am Coll Cardiol* 1988;11(2):231A
57. Simonton CA, Hinohara T, Skilton T, Bashore TM, Sane DC, Bellinger RL, Phillips HR, Califf RM. Early and long-term patency rate of the infarct artery after tissue plasminogen activator (t-PA) and coronary angioplasty for acute myocardial infarction. *J Am Coll Cardiol* 1988;11(2):192A
58. Stack RS, O'Neill WW, Hinohara T, Boswick JM, Topol EJ, George BS, Califf RM, TAMI Study Group. TAMI I vs TAMI II: does choice of initial thrombolytic therapy influence outcome of salvage angioplasty? *J Am Coll Cardiol* 1988;11(2):193A
59. Stump DC, Topol EJ, Sigmon KN, Stoddard MF, Califf RM. Pronounced sensitivity of Blacks to tissue-type plasminogen activator (T-PA) for acute myocardial infarction. *Circulation* 1988;78:275
60. Topol EJ, George BS, Kereiakes DJ, Candela RJ, Abbottsmith CW, Aronson LG, O'Neill WW, Stack RS, Califf RM, TAMI Study Group. A multicenter, randomized, controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. *J Am Coll Cardiol* 1988;11(2):232A
61. Topol EJ, Ellis SG, George BS, Bates ER, Nabel EG, Walton JA, Kline EM, Pitt B, Califf RM, TAMI Study Group. Combined prostacyclin and tissue plasminogen activator therapy for acute myocardial infarction: evidence for a new drug-drug interaction. *Circulation* 1988;78:303
62. Bengtson JR, Lee J, Lipscomb J, Bashore TM, Mark DB, Califf RM, Pryor DB, Hlatky MA. Can in-patient cardiac catheterization be eliminated by out-patient procedures? *J Am Coll Cardiol* 1989;13, No 2:

63. Califf RM, Topol EJ, George BS, Kereiakes DJ, Samaha JK, Worley SJ, Anderson JL, Sasahara A, Lee KL, Stack RS. TAMI 5: a randomized trial of combination thrombolytic therapy and immediate cardiac catheterization. *Circulation* 1989;80:418
64. Califf RM, Stump DC, Topol EJ, Wall TC, Kline EM, Kereiakes DJ, George BS, Mantell SJ, Sigmon KN, Stack RS. Overview of bleeding risk from the TAMI trials: two agents are better than one. *J Am Coll Cardiol* 1989;13(2):198A
65. Califf RM, George BS, Candela RJ, Wall TC, Sigmon K. Immediate and deferred angioplasty after acute myocardial infarction: long-term angiographic follow-up. *Circulation* 1989;80:478
66. Clemmensen PM, Bates ER, Califf RM, Hlatky MA, George BS, Kereiakes DJ, Aronson LG, Topol EJ. Is complete heart block in inferior myocardial infarction a benign phenomenon following reperfusion therapy? *J Am Coll Cardiol* 1989;13(2):26A
67. Hlatky MA, Lipscomb J, Nelson CL, Califf RM, Pryor DB, Mark DB. What is the difference in cost between coronary angioplasty and coronary bypass surgery? *Circulation* 1989;80:628
68. Kereiakes DJ, Topol EJ, George BS, Abbottsmith CW, Candela RJ, Anderson LC, Aronson LG, Califf RM. Myocardial infarction with minimal coronary atherosclerosis: a syndrome of young women with guarded long term prognosis. *J Am Coll Cardiol* 1989;13(2):27A
69. Krucoff MW, Jackson YR, Burdette DL, Croll MA, Pendley LP, Aronson LG, Pope JE, Califf RM. Digital real-time 12-lead ST segment trends: a bedside noninvasive monitor of infarct vessel patency. *Circulation* 1989;80:354
70. Lee KL, Pryor DB, Pieper KS, Harrell FE, Jr., Califf RM, Mark DB, Hlatky MA, Coleman RE, Cobb FR, Jones RH. Exercise radionuclide angiography yields prognostic information equivalent to cardiac catheterization. *J Am Coll Cardiol* 1989;13(2):126A
71. Lee KL, Pieper KS, Harrell FE, Jr., Califf RM, Mark DB, Hlatky MA, Coleman RE, Cobb FR, Pryor DB, Jones RH. The role of radionuclide angiography in selecting patients for coronary bypass surgery. *J Am Coll Cardiol* 1989;13(2):213A
72. Muller DW, Ellis SG, Kline EM, Ohman EM, Sigmon KN, Califf RM, Topol EJ. Silent vs clinically overt reocclusion following successful thrombolysis for evolving myocardial infarction. *Eur Heart J* 1989;10:276
73. Tchong JE, Califf RM, Nelson CL, Mark DB, Pryor DB, Stack RS. Poor outcome with acute mitral regurgitation despite interventional therapy. *Circulation* 1989;80:348
74. Topol EJ, Califf RM, George BS, Kereiakes DJ, Candela RJ, Sigmon KN, Ellis SG, TAMI Study Group. Overriding heightened risk, prior angina denotes a favorable response to myocardial reperfusion. *J Am Coll Cardiol* 1989;13(2):95A
75. Topol EJ, Califf RM, George BS, Kereiakes DJ, Samaha JK, Worley SJ, Wall TC, Harrelson L, Lee KL, TAMI Study Group. Can emergency coronary angiography and rescue angioplasty improve infarct vessel patency after thrombolysis? The TAMI-5 trial preliminary results. *Circulation* 1989;80:418
76. Topol EJ, Ellis SG, George BS, Kereiakes DJ, Candela RJ, Stack RS, Abbottsmith CW, Sigmon KN, Lee KL, Pitt B, Califf RM, TAMI Study Group. The pivotal role of multi-vessel coronary artery disease and the remote zone in the reperfusion era. *J Am Coll Cardiol* 1989;13(2):92A
77. Topol EJ, Kleiman NS, Joelson JM, Ellis SG, Wahl T, Califf RM, O'Brien M, Hopkins A, Roberts R, Williams DO. Tissue plasminogen activator for unstable angina pectoris: a multicenter, randomized, double-blind, placebo-controlled trial. *J Am Coll Cardiol* 1989;19:1A
78. Wall TC, Topol EJ, Harrelson L, Honan MB, Abbottsmith CW, Kereiakes DJ, Mantell SJ, Phillips HR, Califf RM. Pericarditis in the face of thrombolytic intervention denotes severe myocardial damage. *J Am Coll Cardiol* 1989;13(2):236A
79. Califf RM, Topol EJ, Harrelson L, George BS, Kereiakes DJ, Phillips HR, Samaha JK, Worley SJ, Anderson JL, Stack RS, TAMI Study Group. In-hospital clinical outcomes in the TAMI 5 Study. *J Am Coll Cardiol* 1990;15(2):76A



80. Harlan WR3, Fortin DF, Frid DJ, Ramos RF, Lee KL, Rendall DS, Califf RM. Are serum lipoprotein levels important in predicting restenosis after coronary angioplasty? *Circulation* 1990;427
81. Kaplan AJ, Aronson LG, Frid DJ, Phillips HR, Quigley PJ, Califf RM. Reperfusion improves survival in patients with cardiogenic shock after acute myocardial infarction. *J Am Coll Cardiol* 1990;15(2):155A
82. Krucoff MW, Croll MA, Granger CB, O'Connor CM, Sigmon DN, Pope JE, Waugh RA, Kereiakes DJ, George BS, Samaha JK, Califf RM. Prospective blinded non-invasive detection of failed thrombolysis using digital trending from continuous 12-lead ST segment monitoring. *Circulation* 1990;1008:254
83. Muller DW, Topol EJ, Harrelson L, Ellis SG, George BS, Kereiakes DJ, Samaha JK, Worley SJ, Califf RM. Failure of conservative management post-thrombolysis: profile of the TAMI-5 crossover population. *J Am Coll Cardiol* 1990;15(2):63A
84. Nelson CL, Tchong JE, Frid DJ, Fortin EF, Ohman EM, Califf RM, Stack RS. Incomplete angiographic follow-up results in significant underestimation of true restenosis rates after PTCA. *Circulation* 1990;1237:312
85. O'Connor CM, Aldrich HR, Massey EW, Uglietta J, Mark DB, Califf RM. Intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: clinical characteristics and in-hospital outcome. *J Am Coll Cardiol* 1990;15(2):213A
86. Ohman EM, Christenson RH, Sigmon KN, Flanagan CH, Frid DJ, Califf RM, TAMI Study Group. Non-invasive detection of reperfusion after thrombolysis using rapid CK-MB analysis. *Circulation* 1990;1115:281
87. Ohman EM, Califf RM, Lee KL, Fortin DF, Frid DJ. Restenosis after angioplasty: overview of clinical trials using aspirin and Omega-3 fatty acids. *J Am Coll Cardiol* 1990;15(2):88A
88. Topol EJ, Ellis SG, Wall TC, George BS, Vandormael M, Grines CL, Sanz ML, O'Brien M, Califf RM, TAMI Study Group. A randomized, controlled trial of late (6-24 hour) reperfusion for acute myocardial infarction. *Circulation* 1990;2139:539
89. Wall TC, Topol EJ, George BS, Ellis SG, Samaha JK, Kereiakes DJ, Worley SJ, Sigmon KN, Califf RM. The TAMI-7 trial of accelerated plasminogen activator dose regimens for coronary thrombolysis. *Circulation* 1990;2136:538
90. Barefoot JC, Califf RM, Haney TL, Saunders WB, Pryor DB, Hlatky MA, Siegler IC, Mark DB. Income and social support are independent predictors of survival in angiographically-documented coronary disease. *Circulation* 1991;882:222
91. Frid DJ, Fortin DF, Gardner LH, Nelson CL, Smith JE, Navetta FI, Rendall DS, Ramos R, Harlan WR, III, Tchong JE, O'Connor CM, Wall TC, Stack RS, Califf RM. The effect of diabetes on restenosis. *J Am Coll Cardiol* 1991;17(2):268A
92. Granger CB, Kalbfleisch J, Califf RM, Woodlief LH, Karnish S, Topol EJ, GUSTO Coordinating Center. The global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO) pilot study: combined streptokinase and t-PA. *Circulation* 1991;2277:573
93. Kaplan AF, Pieper KS, Pryor DB, Califf RM. Long-term survival in patients with cardiogenic shock after acute myocardial infarction. *J Am Coll Cardiol* 1991;17(2):167A
94. Kereiakes DJ, Califf RM, George BS, Samaha JK, Young SY, Anderson LC, Topol EJ. Comparison of immediate and long term outcome of patients having emergent or deferred coronary bypass surgery following intravenous thrombolytic therapy for acute myocardial infarction. *J Am Coll Cardiol* 1991;17(2):246A
95. Mark DB, Lam LC, Hlatky MA, Melton JR, Davidson-Ray L, Woodlief LH, Lipscomb J, Sassahara A, Califf RM. Effects of three thrombolytic regimens and two interventional strategies on acute myocardial infarction costs: results from a prospective randomized trial. *Circulation* 1991;878:221
96. Ohman EM, George BS, Kereiakes DJ, Samaha JK, Topol EJ, Berrios ED, Sigmon KN, Califf RM. Event-free hospitalization after early and sustained patency using combination thrombolytic therapy in acute myocardial infarction. *J Am Coll Cardiol* 1991;17(2):187A

97. Sane DC, Califf RM, Sigmon KN, Topol EJ, Stump DC. Early heparin administration reduces fibrinogenolysis during thrombolytic therapy with tissue plasminogen activator. *Thrombosis* 1991;210A
98. Tcheng JE, Blunden PB, Ross CC, Harrington JS, Stack RS, Hammond WE, Pryor DB. The Duke Data Bank interventional cardiology database. *J Am Coll Cardiol* 1991;17(2):5A
99. Tcheng JE, Frid DJ, Fortin DF, Nelson CL, Stack RK, Peter RH, Stack RS, Califf RM. Anatomic propensity for restenosis following coronary angioplasty. *J Am Coll Cardiol* 1991;17(2):345A
100. Tenaglia AN, Fortin DF, Frid DJ, Gardner LH, Nelson CL, Tcheng JE, Califf RM. Restenosis and long-term outcome following successful treatment of abrupt closure during and after angioplasty. *Circulation* 1991;523:131
101. Tenaglia AN, Fortin DF, Nelson CL, Gardner LH, Frid DJ, Miller M, Tcheng JE, Califf RM. Predicting the risk of angioplasty abrupt closure using lesion morphology. *Circulation* 1991;2058:517
102. Topol EJ, Ellis SG, Wall TC, George BS, Vandormael M, Grines CL, Sanz ML, O'Brien M, Califf RM. Does late reperfusion therapy for myocardial infarction improve left ventricular function? Preliminary results of the TAMI-6 randomized, controlled trial. *J Am Coll Cardiol* 1991;17(2):45A
103. Wiseman A, Sorrention RA, Califf RM, Pressley JC, Wharton JM. When complete heart block complicates streptokinase-treated acute myocardial infarction, is urgent catheterization warranted? *J Am Coll Cardiol* 1991;17(2):46A
104. Califf RM, Topol EJ, Ohman EM, Kereiakes DJ, George BS, Leimberger JD, Mark DB, Klinker KA, TAMI Study Group. Isolated recurrent ischemia after thrombolytic therapy is a frequent, important and expensive adverse clinical outcome. *J Am Coll Cardiol* 1992;19(3):301A
105. Califf RM, Nelson CL, Mark DB, Jones RH, Harrell FE, Jr. The effects of revascularization on survival in patients with single vessel coronary disease: a 20 year experience. *Circulation* 1992;86:717
106. Christenson RH, Ohman EM, Wall TC, Sigmon KN, Martin LH, Chapekis AT, Topol EJ, Califf RM, TAMI Study Group. Relationship between infarct related coronary artery flow after thrombolytic therapy and release of tissue specific isoforms of creatine kinase. *J Am Coll Cardiol* 1992;19(3):303A
107. Faxon DP, Spiro TE, Minor S, Douglas J, Cote G, Dorosti K, Gottlieb R, Califf RM, Topol EJ, Gordon JB. Enoxaparin, a low molecular weight heparin, in the prevention of restenosis after angioplasty: results of a double blind randomized trial. *J Am Coll Cardiol* 1992;19(3):258A
108. Fortin DF, Frid DJ, Nelson CL, Gardner LH, Miller M, Puma JA, Perez JA, Tcheng JE, Califf RM, Stack RS. Failure of increasing lesion complexity alone to predict restenosis after angioplasty. *J Am Coll Cardiol* 1992;19(3):170A
109. Fortin DF, Frid DJ, Nelson CL, Miller M, Tcheng JE, Califf RM, Stack RS. Restenosis rates after dissection during angioplasty: a case of withdrawal bias? *J Am Coll Cardiol* 1992;19(3):168A
110. Granger CB, Califf RM, Hirsh J, Woodlief LH, Topol EJ, GUSTO Investigators. APTT's after thrombolysis and standard intravenous heparin are often low and correlate with body weight, age, and sex: experience from the GUSTO Trial. *Circulation* 1992;86:258
111. Grines CL, Califf RM, Brodie BR, Ivanhoe RJ, Knopf W, Taylor G, O'Keefe JH, Woodlief LH, Strzelicki M, O'Neill WW. Bleeding complications associated with direct angioplasty for acute myocardial infarction: report of primary angioplasty research (PAR) group. *J Am Coll Cardiol* 1992;19(3):137A
112. Hathaway WR, Califf RM, Goldman L, Vidaillet A, Winchell MT, SUPPORT Investigators. Prognosis, preferences and communication in severe congestive heart failure. *Circulation* 1992;86:101
113. Ivanhoe RJ, Sicklinger BG, Brokie BR, Grines CL, Knopf WD, O'Keefe JH, Taylor GJ, Samuel A, Berdan LG, Woodlief LH, Tcheng JE, Califf RM. Effects of collateral circulation in patients treated with primary angioplasty during acute myocardial infarction. *J Am Coll Cardiol* 1992;19(3):59A

114. Kline EM, Smith DD, Martin JS, Dracup K, Woodlief LH, Granger CB, Califf RM. In-hospital treatment delays in patients treated with thrombolytic therapy: a report of the GUSTO time to treatment study. *Circulation* 1992;86:702
115. Lee KL, Sigmon KN, Califf RM, Topol EJ, TAMI Study Group. How much prognostic information does catheterization after thrombolytic therapy add to noninvasive clinical factors? *J Am Coll Cardiol* 1992;19(3):80A
116. Lee KL, Sigmon KN, Topol EJ, Califf RM, TAMI Study Group. The utility of easily-obtained noninvasive clinical data for predicting survival following thrombolytic therapy. *J Am Coll Cardiol* 1992;19(3):42A
117. Mark DB, Nelson CL, Harrell FE, Jr., Pryor DB, Jones RH, Stack RS, Glower DD, Phillips HR3, Lee KL, Califf RM. Medical, surgical and angioplasty survival outcomes in 7655 coronary disease patients. *J Am Coll Cardiol* 1992;19(3):209A
118. Mark DB, Nelson CL, Harrell FE, Jr., Fortin DF, Pryor DB, Jones RH, Stack RS, Califf RM. Improved survival benefits with coronary angioplasty and coronary bypass surgery: assessment using a new coronary prognostic index. *Circulation* 1992;86:536
119. O'Connor CM, Meese RB, MacKrell J, Conn E, Burks JM, Shadoff N, Hartman C, Roark S, Heard ME, Mittler B, Hanger K, Collins GJ, Lucas KD, Roberts G, Califf RM. Reduced hemorrhagic complications following APSAC therapy in acute myocardial infarction by withholding heparin. *J Am Coll Cardiol* 1992;19(3):91A
120. Ohman EM, Califf RM, Topol EJ, Leimberger JD, George BS, Berrios ED, Anderson LC, Kereiakes DJ, Stack RS, TAMI Study Group. Aortic counterpulsation with thrombolysis for myocardial infarction: salutary effect on reocclusion of the infarct related artery. *J Am Coll Cardiol* 1992;19(3):381A
121. Ohman EM, Marquis JF, Ricci DR, Brown RI, Knudtson ML, Kereiakes DJ, Samaha JK, Margolis JR, Niederman AL, Dean LJ, Gurbel PA, Sketch MH, Jr., Wildermann NM, Lee KL, Califf RM. Effect of gradual prolonged inflation during angioplasty on in-hospital and long-term outcome: results of a multi-center randomized trial. *J Am Coll Cardiol* 1992;19(3):33A
122. Ohman EM, Christenson RH, Califf RM, Sigmon KN, Lee KL, Topol EJ, TAMI Study Group. Non-invasive detection of reperfusion after thrombolysis based on clinical assessment and rapid CK-MB analysis. XIVth Congress of the European Society of Cardiology, Barcelona 1992;
123. Selker HP, Griffith JL, Beshansky JR, Schmid CH, Califf RM, D'Agostino RB, Laks MM, Lee KL, Maynard C, Wagner GS, Weaver WD. A thrombolytic predictive instrument for acute myocardial infarction. *Circulation* 1992;86:41
124. Sutton JM, Califf RM, Woodlief LH, Higby NA, Karnash SL, Schwaiger M, Topol EJ. Thrombolytic therapy and immediate catheterization for triage to rescue angioplasty: is improved infarct zone wall motion after rescue PTCA sustained at six weeks? *J Am Coll Cardiol* 1992;19(3):360A
125. Tchong JE, Fortin DF, Hanemann JD, Blunden PB, Spero LA, Bashore TM, Stack RS, Mark DB, Pryor DB, Califf RM. Development of a client-server, relational patient and cardiac catheterization database management system. *J Am Coll Cardiol* 1992;19(3):6A
126. Tenaglia AN, Fortin DF, Frid DJ, Nelson CL, Gardner LH, Miller M, Tchong JE, Califf RM, Stack RS. A simple scoring system to predict PTCA abrupt closure. *J Am Coll Cardiol* 1992;19(3):139A
127. Wall TC, Topol EJ, Califf RM, Blankenship JC, Talley JD, Tannenbaum MA, Gacioch G, Cohen MD, Sanz ML, Leimberger JD, TAMI Study Group. TAMI 9: Preliminary report of a prospective randomized trial of intravenous fluosol in acute myocardial. *Circulation* 1992;86:642
128. Aguirre FV, Ferguson JJ, Califf RM. Clinical predictors of bleeding complications in high risk angioplasty patients: results from the EPIC Study Group. *Circulation* 1993;88:I-252
129. Berdan LG, Califf RM. Restenosis: does the six month angiogram tell the story? CAVEAT one year follow-up. *Circulation* 1993;88:595

130. Fortin DF, Nelson CL, Gardner LH, Harrell FE, Jr., Frid DI, Tcheng JE, Phillips HR3, Califf RM, Mark DB, Stack RS. Pre-Angioplasty lesion morphology: a case of diminishing effect on survival? *J Am Coll Cardiol* 1993;21:35A
131. Granger CB, Simes RJ, Califf RM, Woodlief LH, Lee KL. Simultaneous patient enrollment in multiple randomized trials: experience in GUSTO. *Control Clin Trials* 1993;14:461
132. Harrington RA, Leimberger JD, Berdan LG, Topol EJ, Califf RM. The ACT Index: a method for stratifying likelihood of success and risk of acute complications in coronary intervention. *Circulation* 1993;88:I-208
133. Isner JM, Kearney M, Berdan LG, Keeler GP, Califf RM, Topol EJ. Core pathology lab findings in 425 patients undergoing directional atherectomy for a primary coronary artery stenosis and relationship to subsequent outcome: the CAVEAT Study. *J Am Coll Cardiol* 1993;21:380A
134. Karnash SL, Lee JC, Woodlief LH, Granger CB, Califf RM. Source verification in large clinical trials: is 10% enough? Presented at the 14th Annual Meeting of the Society for Clinical Trials, Orlando, Florida, May 24-26, 1993 Poster #P80. *Control Clin Trials* 1993;14:461
135. Krucoff MW, Trollinger KM, Veldkamp RF, Green CL, Wilderman NM, Ryan JA, Sawchak ST, Pope JE, Califf RM. Cyclic changes in coronary flow: underlying disease, result of therapy, or both? *J Am Coll Cardiol* 1993;21:349A
136. Mark DB, Naylor CD, Califf RM, Hlatky MA, Granger CB, Clapp-Channing N, Knight JD, Sutherland W, Pilote L, Armstrong PW. Less catheterization and revascularization following myocardial infarction in Canada is associated with more angina: initial results from the Canadian-U.S. GUSTO substudy. *Circulation* 1993;88:479
137. Mark DB, Brodie BR, Ivanhoe RJ, Taylor GJ, O'Keefe JH, Davidson-Ray L. Follow-up cost and other economic outcomes in patients treated with direct angioplasty for acute myocardial infarction. *J Am Coll Cardiol* 1993;21:176A
138. Mark DB, Nelson CL, DeLong ER, Fortin DF, Pryor DB, Stack RS, Jones RH, Califf RM, Phillips HR3, Hlatky MA. Comparison of quality of life outcomes following coronary angioplasty coronary bypass surgery and medicine. *J Am Coll Cardiol* 1993;21:216A
139. Mark DB, Nelson CL, DeLong ER, Hlatky MA, Fortin DF, Glower DD, Jollis JG, Califf RM, Pryor DB. Quality of life measures predict long-term mortality in coronary disease independently of disease severity. *J Am Coll Cardiol* 1993;21:33A
140. Nathan PE, Sketch MHJr, Fortin DF, Puma JA, Gardner LH, Nelson CL, Stack RS, Califf RM. Acute myocardial infarction in patients with previous coronary bypass surgery: association of complex anatomy and lower reperfusion rates with poor long-term survival. *J Am Coll Cardiol* 1993;21:349A
141. Ohman EM, George BS, White CJ, Kern MJ, Gurbel PA, Freedman RJ, Lundergan CF, Hartmann JR, Talley JD, Taylor GJ, Knopf WD, Leimberger JD, Cortright CA, Stack RS, Califf RM. The use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction: results of a randomized trial. *J Am Coll Cardiol* 1993;21:397A
142. Ohman EM, Christenson RH, Califf RM, Krucoff MW, Sigmon KN, Quintero K, George BS, Ellis SG, Topol EJ, TAMI Study Group. Clinical outcome based on a probability index for non-invasive detection of reperfusion. *J Am Coll Cardiol* 1993;21:197A
143. Ohman EM, George BS, White CJ, Kern MJ, Gurbel PA, Freedman RJ, Lundergan CF, Hartmann JR, Talley JD, Taylor GJ, Leimberger JD, Owens P, Stack R, Califf RM. The use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction: results of a randomized trial. *Eur Heart J* 1993;14:119
144. Ohman EM, Kelsey SF, Wisniewski SR, Lee KL, Alderman EL, Califf RM, BARI Study Group. Consistency of assessment of eligibility for multivessel revascularization by physicians enrolling in the bypass angioplasty revascularization investigation. *J Am Coll Cardiol* 1993;21:339A

145. Schulman SP, Goldschmidt-Clermont PJ, Navetta FI, Chandra NC, Guerci AD, Califf RM, Ferguson JJ, Willerson JT, Wolfe CL, Bahr RD, Yakubov SJ, Nyggard TW, Mason SJ, Brashears L, Charo I, du Mee C, Kitt MM, Gerstenblith GG. Integrelin in unstable angina: a double-blind randomized trial. *Circulation* 1993;88:608
146. Selker HP, Griffith JL, Beshansky JR, Schmid CH, Califf RM, D'Agostino RB, Laks MM, Lee KL, Maynard C, Wagner GS, Weaver WD. A thrombolytic predictive instrument for emergency AMI treatment. *J Am Coll Cardiol* 1993;21:348A
147. Simes RJ, Califf RM, Mark DB. Tradeoffs between stroke and mortality after acute myocardial infarction: net clinical benefit of accelerated tissue plasminogen activator compared with streptokinase. *Circulation* 1993;88:I-291
148. Tcheng JE, Ellis SG, Kleiman NS, Harrington RA, Mick MJ, Navetta FI, Worley SJ, Smith JE, Kereiakes DJ, Kitt MM, Miller JA, Sigmon KN, Califf RM, Topol EJ. Outcome of patients treated with the GPIIb/IIIa inhibitor integrilin during coronary angioplasty: results of the IMPACT Study. *Circulation* 1993;88:595
149. Tcheng JE, Topol EJ, Kleiman NS, Ellis SG, Navetta FI, Fintel DJ, Weisman HF, Wang AL, Miller JA, Sigmon KN, Califf RM, EPIC Investigators. Improvement in clinical outcomes of coronary angioplasty by treatment with the GPIIb/IIIa inhibitor chimeric 7E3: multivariable analysis of the EPIC Study. *Circulation* 1993;8:506
150. Berdan LG, Holmes DR, Jr., Keeler GP, Califf RM, Topol EJ. High event rate in patients with saphenous vein grafts undergoing percutaneous coronary interventions: CAVEAT II one year follow-up. *Circulation* 1994;90:63
151. Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ. Profound platelet inhibition does not increase emergency bypass surgery complications: the EPIC experience. *J Am Coll Cardiol* 1994;23:105A
152. Califf RM, Simoons ML, Lee KL, Harrell FE, Jr., Topol EJ. Advantages of patient predictions over subgroup analysis in defining differential treatment effects of t-PA and streptokinase from the GUSTO trial. *J Am Coll Cardiol* 1994;23:27A
153. Califf RM. The use of coronary artery bypass grafting in the GUSTO trial. *Circulation* 1994;90:434
154. Elliott JM, Califf RM, Berdan LG, Keeler GP, Kearney M, Topol EJ. Late deaths in the CAVEAT study: statistical of clinical significance? *J Am Coll Cardiol* 1994;23:300A
155. Granger CB, Sadowski Z, Pfisterer M, Lee KL, Califf RM. Prophylactic lidocaine was commonly used in the GUSTO trial. *J Am Coll Cardiol* 1994;23:315A
156. Harrington RA, Marchant K, Kleiman NS, Leimberger JD, Tcheng JE, Sigmon KN, Smith DD, Kitt MM, Topol EJ, Califf RM. Bleeding associated with use of a platelet glycoprotein IIb/IIIa inhibitor during routine coronary angioplasty: is too much heparin the culprit? *J Am Coll Cardiol* 1994;23:106A
157. Harrington RA, Marchant K, Kleiman NS, Sigmon KN, Joseph D, Parker J, Rios G, Tcheng JE, Kitt MM, Califf RM, Topol EJ. Immediate, reversible platelet aggregation inhibition in patients undergoing coronary angioplasty. *J Am Coll Cardiol* 1994;23:106A
158. Harrington RA, Holmes DR, Berdan LG, Keeler GP, Califf RM, Topol EJ. Clinical characteristics and outcomes of patients with unstable angina undergoing percutaneous coronary intervention in CAVEAT. *J Am Coll Cardiol* 1994;288A
159. Hillegass WB, Narins CR, Brott BC, Haura EB, Phillips HR, Stack RS, Califf RM. Activated clotting time predicts bleeding complications from angioplasty. *J Am Coll Cardiol* 1994;23:184A
160. Hillegass WB, Brott BC, Narins CR, Haura EB, Phillips HR3, Stack RS, Califf RM. Predictors of blood loss and bleeding complications after angioplasty. *J Am Coll Cardiol* 1994;23:69A
161. Karnash SL, Granger CB, Kline-Rogers E, Smith DD, Topol EJ, Califf RM. Menstruating women may be safely and effectively treated with thrombolytic therapy: experience from the GUSTO trial. *J Am Coll Cardiol* 1994;23:315A
162. Krucoff MW, Crater SW, Sawchak ST, Veldkamp RF, Green CL, Wildermann NM, Pope JE, Granger CB, Califf RM. Gender differences in speed and stability of coronary reperfusion following thrombolytic therapy for acute myocardial infarction. *J Am Coll Cardiol* 1994;23:316A

163. Krucoff MW, Jones RH, O'Connor CM, Crater SW, Green CL, Higginbotham MB, Zidar JP, Tcheng JE, Stack RS, Califf RM. The high risk myocardial ischemia trial (HIRMT) randomized pilot & registry: 6 day, 6 week, 6 month & 1 year mortality. *Circulation* 1994;90:334
164. Labinaz M, Ohman EM, Sketch MH, Jr., Marquis JF, Fortin DF, Labinaz D, Owens P, Dowell H, Wildermann NM, Califf RM. Directional coronary atherectomy versus perfusion balloon angioplasty in the proximal left anterior descending artery. *J Am Coll Cardiol* 1994;23:386A
165. Lee KL, Woodlief LH, Granger CB, Topol EJ, Califf RM. The risk of mortality following thrombolytic therapy is chiefly influenced by baseline clinical factors: results from the GUSTO trial. *J Am Coll Cardiol* 1994;23:29A
166. Lincoff AM, Califf RM, Anderson KM, Weisman HF, Topol EJ. Striking clinical benefit with platelet GP IIb/IIIa inhibition c7E3 among patients with unstable angina: outcome in the EPIC Trial. *Circulation* 1994;90:21
167. Mark DB, Talley JD, Lam LC, Berdan LG, Davidson-Ray L, Califf RM, Topol EJ. Economic outcomes following coronary angioplasty versus coronary atherectomy: results from the CAVEAT randomized trial. *J Am Coll Cardiol* 1994;23:284A
168. Mark DB, Naylor CD, Hlatky MA, Topol EJ, Knight JD, Clapp-Channing NE, Nelson CL, Califf RM, Granger CB, Armstrong PA. Patient satisfaction with health care is insensitive to variations in care received and quality of life: U.S.-Canada GUSTO Substudy results. *J Am Coll Cardiol* 1994;23:166A
169. McKenna WJ, Swedberg K, Zannad F, Darius H, Soler-Soler J, Handberg E, Harrell FE, Jr., Uretsky BF, Gheorghide M, Califf RM. Experience of chronic intravenous epoprostenol infusion in end-stage cardiac failure: results of FIRST. *Eur Heart J* 1994;15:36
170. Moliterno DJ, Califf RM, Sigmon KN, Aguirre FV, Weisman HF, Topol EJ, EPIC Study Investigators. Activated clotting time is increased during coronary interventions with platelet IIb/IIIa antagonism: results from the EPIC trial. *J Am Coll Cardiol* 1994;23:106A
171. Narins CR, Hillegass WB, Jr., Nelson CL, Harrington RA, Phillips HR3, Stack RS, Califf RM. Activated clotting time predicts abrupt closure risk during angioplasty. *J Am Coll Cardiol* 1994;23:470A
172. Newby LK, Califf RM. Redefining uncomplicated myocardial infarction in the thrombolytic era. *Circulation* 1994;90:110
173. Ohman EM, White HD, Granger CB, Califf RM, GUSTO Investigators. Rescue thrombolysis for suspected reinfarction following thrombolytic therapy: experience from the GUSTO trial. *J Am Coll Cardiol* 1994;23:29A
174. Omoigui NA, Califf RM, Keeler GP, Berdan LG, Pieper KS, Topol EJ. Can patients at risk of developing in-hospital peripheral vascular complications after percutaneous coronary intervention be identified from baseline characteristics and treatment assignment? *J Am Coll Cardiol* 1994;23:355A
175. Puma JA, Sketch MH, Jr., Tcheng JE, Gardner LH, Nelson CL, Phillips HR3, Stack RS, Califf RM. Chronic total coronary occlusion of an isolated vessel in 891 patients over 24 years: is medical management an adequate approach? *J Am Coll Cardiol* 1994;23:390A
176. Sgarbossa EB, Califf RM, Woodlief LH, Gates KB, Granger CB, Starr S, Wagner GS. Non-Q wave infarction following thrombolytic therapy: prognosis after hospital discharge in GUSTO patients with first myocardial infarction. *Circulation* 1994;90:664
177. Shadoff N, Califf RM. Impact of clinical site on ischemic events and bleeding complications: results from the EPIC trial. *J Am Coll Cardiol* 1994;23:404A
178. Shah A, Green CL, Trollinger KM, Wilderman NM, Califf RM, Pope JE, Krucoff MW. Differentiation of "benign mirror image" from high risk reciprocal ST depression using continuous 12-lead ST-segment recovery analysis. *J Am Coll Cardiol* 1994;23:195A
179. Topol EJ, Califf RM, Weisman HF, Wang AL, Willerson JT. Six-month follow-up after acute phase platelet IIb/IIIa integrilin blockade in the EPIC trial: reduction in need for revascularization procedures. *J Am Coll Cardiol* 1994;23:60A

180. Zabel KM, Granger CB, Becker RC, Woodlief LH, Chesebro JH, Califf RM. Bedside aPTT monitoring is associated with less bleeding among GUSTO patients receiving the IV heparin following thrombolytic administration. *Circulation* 1994;90:553
181. Aguirre FV, Topol EJ, Donohue TJ, Kern MJ, Leimberger JD, Califf RM, EPIC Investigators. Impact of ionic and non-ionic contrast media on post-PTCA ischemic complications: results from the EPIC Trial. *J Am Coll Cardiol* 1995;25:8A
182. Berkowitz SD, Granger CB, Pieper KS, Califf RM. Hemorrhagic non-CNS complications associated with four thrombolytic strategies for acute myocardial infarction. *Circulation* 1995;92:2196
183. Brener SJ, Cox JL, Pfisterer ME, Armstrong PW, Califf RM, Topol EJ, GUSTO Investigators. The potential for unexpected hazard of intravenous beta-blockade for acute myocardial infarction: results from the GUSTO Trial. *J Am Coll Cardiol* 1995;25:5A
184. Christenson RH, Ohman ME, Sigmon KN, O'Hanesian MA, Alonsozana GL, Newby LK, Duh SH, Krucoff MW, Califf RM. Combining myoglobin and clinical variables for assessing coronary reperfusion after thrombolytic therapy. *J Am Coll Cardiol* 1995;25:148A
185. Crenshaw BS, Becker RC, Granger CB, Tracy RP, Lambrew CT, Ross AM, Califf RM, Topol EJ, Bovill EG, GUSTO Investigators. Thrombin activity, but not generation, is inhibited by intravenous heparin following thrombolysis: results from the GUSTO hemostasis substudy. *J Am Coll Cardiol* 1995;25:309A
186. Dawson NV, Arkes H, Connors AF, Jr., Speroff T, Thomas C, Harrell FE, Jr., Alzola C, Phillips RS, Goldman L, Fulkerson WJ, Jr. Physician-patient discussion does not increase agreement about prognosis in severely ill patients. *J Gen Intern Med* 1995;11:
187. Drazner MH, McNulty SE, Califf RM, O'Connor CM. The sick-euthyroid syndrome in acute myocardial infarction. *J Am Coll Cardiol* 1995;25:105A
188. Eisenberg MJ, Pilote L, Keeler GP, Califf RM, Topol EJ, CAVEAT Investigators. Inadequate pre-hospital medical therapy in patients undergoing percutaneous coronary revascularization: results from the CAVEAT Trial. *J Am Coll Cardiol* 1995;25:313A
189. Granger CB, Van de Werf F, Horrigan MCG, Califf RM, Woodlief LH, Topol EJ. Hemorrhagic stroke associated with high APTTs following thrombolytic therapy and heparin or hirudin. *J Am Coll Cardiol* 1995;310A
190. Granger CB, Melton JR, Bandy S, Karnash SL, Califf RM. Objective classification of clinical events in large clinical trials: is it worth the cost? *Control Clin Trials* 1995;16:119S
191. Granger CB, White HD, Simoons ML, Weaver WD, Gore JM, Aylward PE, Barbash GI, Lee KL, Califf RM, GUSTO Investigators. Risk factors for stroke following thrombolytic therapy: case-control study from the GUSTO Trial. *J Am Coll Cardiol* 1995;25:232A
192. Hathaway WR, McNulty SE, Pieper KS, Harrell FE, Jr., Mark DB, Jones RH, Bashore TM, Califf RM, O'Connor CM. Prognostic value of right heart catheterization hemodynamic data in surgically treated patients with coronary artery disease. *J Am Coll Cardiol* 1995;25:25A
193. Hathaway WR, Zabel KM, Peterson ED, Simoons ML, Wagner GS, Woodlief LH, Lee KL, Califf RM, Granger CB, GUSTO Investigators. Incremental prognostic value of electrocardiographic findings when added to baseline clinical variables in patients with acute myocardial infarction. *J Am Coll Cardiol* 1995;25:60A
194. Hillegass WB, Brott BC, Haura EB, Harrington RA, Phillips HR, Stack RS, Califf RM. Patient-specific heparin dosing during angioplasty. *J Am Coll Cardiol* 1995;25:391A
195. Hillegass WB, Ohman EM, O'Hanesian MA, Harrington RA, Faxon DP, Fortin DF, Ellis SG, Stack RS, Holmes DR, Jr., Califf RM. The effect of preprocedural intracoronary thrombus on patient outcome after percutaneous coronary intervention. *J Am Coll Cardiol* 1995;25:94A

196. Holmes DR, Jr., Berger PB, Bates ER, Woodlief LH, Topol EJ, Califf RM, GUSTO Investigators. Predictors of mortality in cardiogenic shock: the GUSTO Experience. *J Am Coll Cardiol* 1995;25:86A
197. Horrigan MCG, Eccleston DS, Wildermann NM, Sigmon KA, Califf RM, Topol EJ, EPIC Investigators. Heparin pretreatment may confer additional benefit in patients treated with 7E3 and PTCA for unstable coronary syndromes. *J Am Coll Cardiol* 1995;25:420A
198. Karnash SL, Granger CB, White HD, Woodlief LH, Topol EJ, Califf RM. Thrombolytic therapy in menstruating women. *Eur Heart J* 1995;10:127
199. Krucoff MW, Croll MA, Pope JE, Ryan JA, Pieper KS, Sawchak ST, Wagner BL, Califf RM. Quantification of ST segment recovery suggesting unstable reperfusion: heterogenous behavior across angiographically homogenous groups. XIIIth Congress of the European Society of Cardiology, Amsterdam 1995;
200. Labinaz M, Sketch MH, Jr., Stebbins AL, Vahanian A, Topol EJ, Califf RM, GUSTO Investigators. Improved outcome in patient with prior percutaneous transluminal coronary angioplasty and an evolving myocardial infarction. *J Am Coll Cardiol* 1995;25:131A
201. Lincoff AM, Tchong JE, Bass TA, Popma JJ, Teirstein PS, Kleiman NS, Weisman HF, Musco MH, Cabot CF, Berdan LG, Califf RM, Topol EJ, PROLOG Investigators. A multicenter, randomized, double-blind pilot trial of standard versus low dose weight-adjusted heparin in patients treated with the platelet GP IIb/IIIa receptor antibody c7E3 during percutaneous coronary revascularization. *J Am Coll Cardiol* 1995;25:80A
202. Lincoff AM, Topol EJ, Califf RM, Weisman HF, Wildermann NM, Ellis SG. Influence of platelet GP IIb/IIIa receptor inhibition with c7E3 on the sequelae of dissection during percutaneous coronary revascularization. *J Am Coll Cardiol* 1995;25:390A
203. Lincoff AM, Califf RM, Rutsch WR, Stebbins AL, Topol EJ, GUSTO Investigators. Thrombolytic therapy during the "golden first hour" in GUSTO. *J Am Coll Cardiol* 1995;25:87A
204. Moliterno DJ, Granger CB, Califf RM, Elliott JM, Stebbins AL, Topol EJ, GUSTO Investigators. Improved prognosis for heavy weight patients receiving thrombolysis in acute myocardial infarction - bigger is better: results from GUSTO. *J Am Coll Cardiol* 1995;25:232A
205. Moliterno DJ, Califf RM, Anderson KM, Weisman HF, Topol EJ, EPIC Study Investigators. Special considerations for diabetics receiving platelet IIb/IIIa antagonists during coronary interventions: results from the EPIC Trial. *J Am Coll Cardiol* 1995;25:155A
206. Ohman EM, Califf RM, O'Hanesian MA, Hamm CW, Katus HA, Granger CB, Christenson RH, Cianciolo C, Topol EJ, GUSTO-IIa Investigators. Risk stratification in acute ischemic syndromes using serum troponin T. *J Am Coll Cardiol* 1995;25:148A
207. Ohman EM, Talley JD, George BS, Kern MJ, White CJ, Lundergan CF, Gurbel PA, Berdan LG, Califf RM, Mark DB. Cost implications of aortic counterpulsation in acute myocardial infarction: results from a randomized clinical trial. *Eur Heart J* 1995;102:648
208. Ohman EM, Califf RM, O'Hanesian MA, Hamm CW, Katus HA, Granger CB, Christenson RH, Cianciolo C, Topol EJ. Risk stratification in acute ischemic syndromes using serum troponin T. *Eur Heart J* 1995;179:1019
209. Omoigui NA, Silver MJ, Rybicki LA, Rosenthal M, Califf RM, Topol EJ, CAVEAT Investigators. Influence of randomized trials on clinical practice: a comparison of directional atherectomy and new device use before and after the CAVEAT Trial at CAVEAT sites. *J Am Coll Cardiol* 1995;25:393A
210. Peterson ED, Shaw LJ, Kesler K, Califf RM. Is exercise treadmill testing useful for post-infarction risk stratification in the thrombolytic era? A meta-analysis of the literature. *Circulation* 1995;92:1294



211. Pilote L, Stebbins AL, Mark DB, Califf RM, Topol EJ, GUSTO Investigators. Regional variations in the use of cardiac procedures after thrombolytic thrombolysis: New England is an outlier in the GUSTO Trial. *J Am Coll Cardiol* 1995;25:343A
212. Puma JA, O'Connor CM, Gardner LH, Sketch MH, Jr., Phillips HR3, Jones RH, Califf RM. Expanding the paradigm of treatment in ischemic heart failure: a comparison of long-term survival following medical therapy, angioplasty, and bypass surgery. *Circulation* 1995;92:3196
213. Puma JA, Sketch MH, Jr., Tchong JE, Gardner LH, Nelson CL, Fortin DF, Phillips HR3, Stack RS, Califf RM. Long-term survival with a chronic total coronary occlusion: a comparison of medical therapy versus angioplasty in patients with single vessel disease. *J Am Coll Cardiol* 1995;25:149A
214. Puma JA, Sketch MH, Jr., Gardner LH, Nelson CL, Phillips HR3, Stack RS, Califf RM. The evolution of therapy for single vessel disease: a treatment comparison of medicine, angioplasty and left internal mammary artery graft for proximal left anterior descending disease. *J Am Coll Cardiol* 1995;25:149A
215. Puma JA, Sketch MH, Jr., Simes RJ, Morris DC, Topol EJ, Califf RM, GUSTO Investigators. Long-term impact of a patent infarct-related artery: 1-year survival in the GUSTO Trial. *J Am Coll Cardiol* 1995;25:130A
216. Ross AM, Cho S, Lundergan CF, Reiner JS, Simoons ML, Van de Werf F, Coyne KS, Califf RM, Topol EJ, GUSTO Investigators. The survival advantage of early grade 3 patency after thrombolysis for infarction increases over time. *J Am Coll Cardiol* 1995;25:6A
217. Shaw LJ, Califf RM. Should women be treated differently than men? A meta-analysis of randomized trials of acute and secondary prevention of myocardial infarction. *Circulation* 1995;92:3234
218. Swedberg K, Califf RM, Gheorghide M, Harrel FB, McKenna WJ, Schulman KA, Soler-Soler J, Uretsky BF, Zannad F, FIRST Investigators. Six minute walk test gives prognostic information in severe heart failure. *J Am Coll Cardiol* 1995;25:339A
219. Talley JD, Ohman EM, George BS, Kern MJ, White CJ, Lundergan CF, Hartmann JR, Gurbel PA, Phillips HR, Berdan LG, Lam LC, Califf RM, Mark DB. Cost implications of aortic counterpulsation in acute myocardial infarction: results from a randomized clinical trial. *J Am Coll Cardiol* 1995;25:87A
220. Tardiff BE, Granger CB, Woodlief LH, Mahaffey KW, Harrington RA, Califf RM. Prognostic significance of post-intervention isozyme elevation. *Circulation* 1995;92:544
221. Tchong JE, Lincoff AM, Sigmon KN, Kitt MM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa inhibition with integrilin during percutaneous coronary intervention: the IMPACT II Trial. *Circulation* 1995;92:2595
222. Woodlief LH, Lee KL, Califf RM. Validation of a mortality model in 1384 patients with acute myocardial infarction. *Circulation* 1995;92:3733
223. Zabel KM, Hathaway WR, Peterson ED, Granger CB, Armstrong PW, Morris DC, Wagner GS, Califf RM, GUSTO Investigators. Baseline electrocardiogram predicts 30-day mortality among 32,812 patients with acute myocardial infarction treated with thrombolysis. *J Am Coll Cardiol* 1995;25:342A
224. Aguirre FV, Ferguson JJ, Blankenship JC, Pieper KS, Taylor M, Harrington RA, Rund M, Caracciolo EA, Donohue TJ, Califf RM, Lincoff AM, Tchong JE, Topol EJ. Association of pre-intervention activated clotting times (ACT) and clinical outcomes following percutaneous coronary revascularization: results from the IMPACT-II Trial. *J Am Coll Cardiol* 1996;27:83A
225. Armstrong PW, Califf RM, Granger CB, Woodlief LH, Topol EJ. Recurrent ischemia in the GUSTO Trial. *Circulation* 1996;94(8):I 381-382.
226. Armstrong PW, Califf RM, Granger CB, Woodlief LH, Topol EJ. Recurrent ischemia in the GUSTO-IIb Trial. *Can J Cardiol* 1996;12:96E

227. Beatt KJ, Van de Werf F, Simoons ML, Vahanian A, Califf RM, Topol EJ. The use of cardiac catheterization and coronary angioplasty post myocardial infarction in Europe: observations from the GUSTO I Trial. *Eur Heart J* 1996;17:298
228. Bergelson BA, Davidson CJ, Hafley G, Ivanhoe RJ, Ferguson JJ, Tardiff BE, Mahaffey KW, Lincoff AM, Tchong JE, Califf RM, Topol EJ. Predictors of abrupt closure and consequences of emergency endpoints in the IMPACT II Trial. *J Am Coll Cardiol* 1996;27:83A
229. Berkowitz SD, Sane DC, Shavender JH, Sigmon KN, Topol EJ, Califf RM. Analysis of the occurrence and clinical significance of thrombocytopenia with (Abcixmab) in the EPIC Trial. *J Am Coll Cardiol* 1996;27:82A
230. Bito S, Wenger NS, Connors AF, Jr., Phillips RS, Desbiens NA, Califf RM, Lynn J, Liu HH, Oye RK. Influences on seriously ill patients' medical decisions. *Society of General Internal Medicine* 1996;
231. Brener SJ, Leya FS, Ellis SG, Califf RM, Apperson-Hansen C, Debowey D, Topol EJ. Contradictory evidence for the empiric observation favoring debulking instead of balloon angioplasty for bifurcation lesions. *J Am Coll Cardiol* 1996;8(1):32A
232. Califf RM, Armstrong PW, Darius H, Gheorghide M, Handberg E, Harrell FE, Jr., McKenna WJ, McNulty SE, Schulman KA, Soler-Soler J, Swedberg K, Uretsky BF, Wheeler WS, Zannad F. Flolan international randomized survival trial (FIRST): final results. *J Am Coll Cardiol* 1996;27:141A
233. Califf RM. Academic medical centers and clinical trials. 1996 APM Fall Symposium 1996;September 7-8, 1996:67
234. Eisenstein EL, Newby LK, Knight D, Shaw LJ, Califf RM, Topol EJ, Mark DB. Regional variation in treatment costs and resources utilization for uncomplicated acute myocardial infarction (UMI). *J Am Coll Cardiol* 1996;27:330A
235. Federici RE, Puma JA, Baker WA, Hearne SE, Fortin DF, Shaw LK, Sketch MH, Jr., Stack RS, Califf RM, Peters KG. Serum levels of vascular endothelial growth factor (VEGF) are increased in patients with acute coronary ischemia. *J Am Coll Cardiol* 1996;27:271A
236. Granger CB, Califf RM, Armstrong PW, Hafley G, Mark DB, Topol EJ. Non-invasive testing is done only in low risk patients with unstable angina and non-Q-wave myocardial infarction (MI): Results from GUSTO-IIa. *J Am Coll Cardiol* 1996;181A
237. Horrigan MCG, Miller DP, Granger CB, Califf RM, Topol EJ. Acute myocardial infarction in young patients: the significance of smoking. Results from the GUSTO I Trial. *J Am Coll Cardiol* 1996;27:68A
238. Horrigan MCG, Tchong JE, Califf RM, Kitt MM, Lorenz TJ, Sigmon KA, Lincoff AM, Topol EJ. Maximal benefit of integrin platelet IIb/IIIa blockade 6-24 hours after therapy: results of the IMPACT II Trial. *J Am Coll Cardiol* 1996;27:55A
239. Mahaffey KW, Granger CB, White HD, Gore JM, Weaver WD, Sloan MA, Topol EJ, Califf RM. Risk factors for ischemic stroke in patients with acute myocardial infarction treated with thrombolytic therapy. *J Am Coll Cardiol* 1996;27:81A
240. Mahaffey KW, Tardiff BE, Granger CB, Woodlief LH, Clapp-Channing NE, Karnash SL, Lee KL, Califf RM. Patient self-addressed postcard follow-up is inadequate. (Contributed Paper Session III). 17th Annual Meeting of the Society for Clinical Trials, Pittsburgh 1996;
241. Mahaffey KW, Granger CB, Woodlief LH, Tardiff BE, Bandy S, Califf RM. Centralized systematic adjudication of clinical endpoints in multicenter trials of acute coronary syndromes identifies patients at high risk for adverse clinical outcomes. *J Am Coll Cardiol* 1996;27:250A
242. Mahaffey KW, Tardiff BE, Granger CB, Karnash SL, Woodlief LH, Lee KL, Califf RM. Comparison of investigator and central events review of myocardial infarction rates as a means to improve events classification: results from GUSTO-IIa. *Control Clinical Trials* 1996;17:64S-65S.
243. Moliterno DJ, Sgarbossa EB, Armstrong PW, Granger CB, Van de Werf F, Califf RM, Topol EJ. A major dichotomy in unstable angina outcome: ST depression versus T-wave inversion: GUSTO II results. *J Am Coll Cardiol* 1996;27:182A

244. Muller DW, Mak KH, Leimberger JD, Califf RM, Topol EJ. The paradox of cigarette smoking and long-term benefit after coronary interventions with platelet IIb/IIIa receptor blockade. *J Am Coll Cardiol* 1996;27:181A
245. O'Connor CM, Puma JA, Gardner LH, Califf RM, Jones RH. A 25-year experience in patients (PTS) with coronary artery disease (CAD) and chronic heart failure (CHF): outcomes with medical therapy and bypass surgery (CABG). *J Am Coll Cardiol* 1996;27:142A
246. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Talley JD, Navetta FI, Anderson HV, Sprigg D, Miller M, Cohen MD, Kereiakes DJ, George BS, Sigmon KN, Krucoff MW, Califf RM, Topol EJ. Simultaneous platelet glycoprotein IIb/IIIa integrin blockade and front-loaded tissue plasminogen activator in acute myocardial infarction: results from a randomized trial. *J Am Coll Cardiol* 1996;167A:
247. Pilote L, Ohman EM, Miller DP, Califf RM, Topol EJ. Ischemia after thrombolysis is frequent, somewhat predictable, and pre-empted by early angiography. *J Am Coll Cardiol* 1996;27:249A
248. Pilote L, Miller DP, Califf RM, Topol EJ. Classification and regression trees (CART) models to delineate use of angiography and revascularization after thrombolysis for acute myocardial infarction. *J Am Coll Cardiol* 1996;27:245A
249. Shaw LJ, Kesler KL, Peterson ED, DeLong ER, Borges-Netro S, Califf RM. Long-term prognostic implications of abnormal stress electrocardiographic or myocardial perfusion scintigraphic measures in patients with angiographically-insignificant coronary artery disease. *J Am Coll Cardiol* 1996;27:78A
250. Shaw LJ, Peterson ED, Kesler KL, Califf RM. Are stress imaging modalities of value in post-myocardial infarction pre-discharge risk stratification? A meta-analysis of stress perfusion and ventricular function imaging studies. *J Am Coll Cardiol* 1996;27:329A
251. Simes RJ, Granger CB, Antman EM, Califf RM, Braunwald E, Topol EJ. Impact of Hirudin versus Heparin on mortality and (re)infarction in patients with acute coronary syndroms: a prospective meta-analysis of the GUSTO-IIb and TIMI 9b trials. *Circulation* 1996;94(8):I-430
252. Sketch MH, Jr., DeFranco AC, Puma JA, Stinnett SS, Ohman EM, Topol EJ, Califf RM. Impact of percutaneous revascularization on clinical outcome following acute myocardial infarction-an analysis of 40,745 patients. *J Am Coll Cardiol* 1996;27(2):220A
253. Tardiff BE, Davidson-Ray L, Mahaffey KW, Sigmon KN, Mark DB, Karnash SL, Granger CB, Califf RM. Reliability of economic and quality of life data for collection of follow-up clinical outcome information. *Control Clinical Trials* 1996;17:110S
254. Tardiff BE, Mahaffey KW, Karnash SL, Granger CB, Califf RM. An iterative process for defining nonfatal endpoints in the context of clinical trials. *Control Clinical Trials* 1996;17:136S
255. Tardiff BE, Mahaffey KW, Tcheng JE, Granger CB, Califf RM, Lee KS. Impact of the clinical events committee process on data safety monitoring. *Control Clin Trials* 1996;17:135S
256. Tardiff BE, Mahaffey KW, Sigmond KN, Tcheng JE, Karnash SL, Granger CB, Califf RM. Prognostic significance of clinically silent infarctions detected through systematic screening in clinical trials. *Control Clinical Trials* 1996;17:108-109S.
257. Tardiff BE, Califf RM, Tcheng JE, Lincoff AM, Sigmon KN, Harrington RA, Mahaffey KW, Teirstein PS, Heinsimer JA, Topol EJ. Post-intervention cardiac enzyme elevations: prognostic significance in IMPACT II. *J Am Coll Cardiol* 1996;27:83A
258. Tardiff BE, Mahaffey KW, Sigmon K, Tcheng JE, Karnash SL, Granger CB, Califf RM. Differences in endpoint identification by investigators versus independent review. *Control Clinical Trials* 1996;17:65S-66S.
259. Teirstein PS, Yakubov SJ, Thel MC, Wildermann NM, Kereiakes DJ, Popma JJ, Lincoff MA, Tcheng JE, Califf RM, Topol EJ. Platelet IIb/IIIa blockade with integrilin: atherectomy patients. *J Am Coll Cardiol* 1996;27:334A

260. Vorchheimer DA, Baruch L, Kukin ML, Pieper KS, Granger CB, Topol EJ, Califf RM. Does the presence or absence of chest pain at initiation of thrombolysis in acute myocardial infarction affect outcome? *J Am Coll Cardiol* 1996;27:389A
261. Wenger NS, Oye RK, Phillips RS, Teno JM, Califf RM, Desbiens NA, Bellamy PE, Connors AF, Dawson NV, Liu HH, Lynn J, Knaus WA. A quantifiable adverse outcome of aggressive medical care. *Society of General Internal Medicine* 1996;
262. Aguirre FV, Topol EJ, Leimberger JD, Kleiman NS, Lincoff AM, Donohue TJ, Califf RM. Incidence and clinical outcome of abrupt vessel closure among patients receiving abciximab during high-risk percutaneous coronary intervention: EPIC Trial results. *J Am Coll Cardiol* 1997;29(2):394A
263. Alexander JH, Newby LK, Moliterno DJ, Bhapkar M, Van de Werf F, White HD, Harrington RA, Topol EJ, Califf RM. Relationship of outcomes to treatment with lamifiban in patients undergoing PTCA: analysis of PARAGON A. *J Am Coll Cardiol* 1997;29(2):409A
264. Alexander KP, Peterson ED, Hellkamp AS, Granger CB, Topol EJ, Califf RM. Early catheterization is standard strategy in unstable angina/NQWMI. *J Am Coll Cardiol* 1997;29(2):450A
265. Alexander KP, Peterson ED, Mahaffey KW, Casas AC, Granger CB, Van de Werf F, Armstrong PW, Mark DB, Topol EJ, Califf RM. Medical interventions in unstable angina: does international clinical practice match evidenced-based guidelines? *J Am Coll Cardiol* 1997;29(2):50A
266. Amsterdam PB, Hafley GE, Harrington RA, Granger CB, Topol EJ, Califf RM. Is the ECG adequate to identify patients with left circumflex occlusions in acute coronary syndromes? *J Am Coll Cardiol* 1997;29(2):492A
267. Ardissino D, Morando G, Savonitto S, Melandri G, Galvani M, Rosi A, Politi A, Bertocchi F, Granger CB, Thompson TD, Califf RM, Topol EJ. Differential clinical benefit of hirudin versus heparin according to electrocardiogram at presentation in acute coronary syndromes. *Eur Heart J* 1997;18:130
268. Barnes GW, Ohman EM, Thompson TD, Sketch MH, Jr., Holmes DR, Jr., Califf RM. Early hazard of "rescue" angioplasty after thrombolysis is reduced by improved long-term outcome. *J Am Coll Cardiol* 1997;29(2):71A
269. Berger PB, Holmes DR, Jr., Califf RM, Criger DA. Hospital delay in achieving reperfusion with direct PTCA in GUSTO-IIb: relationship to 30-day mortality. *Circulation* 1997;96(8):I-531
270. Boineau RE, Green CL, Trollinger KM, Pope JE, Topol EJ, Califf RM, Krucoff MW. Is continuous ST monitoring a better predictor outcome than enrolling electrocardiogram in acute myocardial infarction? *J Am Coll Cardiol* 1997;29(2):431A
271. Cohen MD, Fox KA, Turpie AG, Demers C, Gurfinkel EP, Langer A, Califf RM, Fromell GJ, Bigonzi F. Patient populations and clinical practices: inter-region differences observed in the international ESSENCE Trial. *Eur Heart J* 1997;18:166
272. Deckers JW, Califf RM, Topol EM, Lincoff AM, Tchong JE, Simoons ML. Use of abciximab (ReoPro) is not associated with an increase in the risk of stroke: overview of three randomized trials. *J Am Coll Cardiol* 1997;29(2):241A
273. Eisenstein EL, Peterson ED, Jollis JG, Tardiff BE, Califf RM, Knight JD, Cowper PA, Granger CB, Topol EJ, Mark DB. Can newer therapies be cost-neutral or cost-saving in myocardial infarction patients? *International Society of Technology Assessment Health Care, Barcelona* 1997;75
274. Eisenstein EL, Newby LK, Knight JD, Shaw LJ, Califf RM, Topol EJ, Mark DB. Cost avoidance through early discharge of the uncomplicated acute myocardial infarction patient. *J Am Coll Cardiol* 1997;27(2):244A
275. Ellis SG, Lincoff AM, Tchong JE, Miller DP, Booth JE, Califf RM, Topol EJ. Is there a differential benefit of ReoPro during PTCA for patients with certain lesions types? *J Am Coll Cardiol* 1997;29(2):395A
276. Granger CB, Phillips HR3, Betriu A, Ellis SG, Weaver WD, Aylward PE, Stebbins AL, Lee KL, Califf RM, Topol EJ. Direct angioplasty may be less advantageous in patients presenting early after symptom onset: results from GUSTO IIb. *J Am Coll Cardiol* 1997;29(2):366A

277. Granger CB, Betriu A, Phillips HR3, Stebbins AL, Califf RM. Nearly half of early benefit of direct angioplasty lost in longer-term follow-up: 6-month results from the GUSTO-IIb direct angioplasty substudy. *Circulation* 1997;96:1-205
278. Harrington RA, Moliterno DJ, Van de Werf F, Keech A, Kleiman NS, Bhapkar M, Rames A, Peek M, Topol EJ, Califf RM, Armstrong PW. Delaying and preventing ischemic events in patients with acute coronary syndromes using the platelet glycoprotein IIb/IIIa inhibitor lamifiban. *J Am Coll Cardiol* 1997;29(2):409A
279. Harrington RA, Moliterno DJ, Newby LK, Armstrong PW, Van de Werf F, Simes RJ, Rames A, Bhapkar M, Califf RM, Keech A, Topol EJ. Amplification of clinical benefit at six months with the glycoprotein IIb/IIIa inhibitor Lamifiban in patients with non-ST segment elevation acute coronary syndromes. *Circulation* 1997;96:1-473
280. Harrington RA, Berkowitz SD, McDougal M, O'Connor CM, Langer A, O'Gara PT, Kopecky SL, Sutton JM, Hainer J, Lee R, Feyzi JM, Jett L, Califf RM, Fuster V. Level of anticoagulation achieved in myocardial infarction patients following chronic administration of fixed, low-dose warfarin therapy: results from the Coumadin Aspirin Reinfarction Study (CARS). *J Am Coll Cardiol* 1997;29(2):376A
281. Harrington RA, Newby LK, Moliterno DJ, Bhapkar M, Armstrong PW, Simes RJ, White HD, Van de Werf F, Rames A, Topol EJ, Califf RM, PARAGON Investigators. Combining IIb/IIIa inhibition and heparin for acute coronary syndromes: evidence of a gradient for bleeding hazard from the PARAGON randomized factorially designed trial. *J Am Coll Cardiol* 1997;29(2):410A
282. Kereiakes DJ, Cabot K, Melsheimer RM, Lincoff AM, Califf RM, Topol EJ. Abciximab reduces emergency bypass surgery following bailout coronary stent deployment: EPILOG trial results. *Am J Cardiol* 1997;80:TCT 29
283. Kereiakes DJ, Cabot K, Melsheimer RM, Lincoff AM, Califf RM, Topol EJ. Abciximab-mediated GPIIb/IIIa blockade improves outcomes following multiple interventional technologies: results of the EPILOG Trial. *Am J Cardiol* 1997;80:TCT-29
284. Kleiman NS, Lincoff AM, Miller DP, Aguirre FV, Weisman HF, Cabot CF, Califf RM, Topol EJ. Abciximab (c7E3) reduces death and myocardial infarction but not target vessel revascularization in diabetics undergoing percutaneous transluminal coronary angioplasty: the EPILOG experience. *Eur Heart J* 1997;18:13
285. Krucoff MW, Green CL, Trollinger KM, Pope JE, Harrington RA, Granger CB, Ohman EM, Neuhaus KL, Topol EJ, Califf RM. Temporal distribution of important ECG information in patients with MI: when should you take the next ECG after lytics? *J Am Coll Cardiol* 1997;29(2):131A
286. Krucoff MW, Landis DI, Green CL, Loeffler AK, Eisenstein EL, Moore AV, Tchong JE, Califf RM, Mark DB, Morris KG, Sketch MH, Jr. Upright posture with a flexible femoral sheath: safety and cost results from 900 patients in the "Heads Up" trial. *J Am Coll Cardiol* 1997;29(2):278A
287. Krucoff MW, Harrington RA, Moliterno DJ, Green CL, Trollinger KM, Krisinsson A, Morgan CD, Burks JM, Nygaard TW, Pope JE, Topol EJ, Califf RM. The paradigm for anti-platelet effect on continuous 12-lead ST-segment recovery in acute MI. *J Am Coll Cardiol* 1997;29(2):185A
288. Krucoff MW, Green CL, Trollinger KM, Pope JE, Granger CB, Ohman EM, Califf RM. ST-segment recovery parameters predictive of outcome in AMI: variability with infarct artery location and implications for therapeutic targets. *J Am Coll Cardiol* 1997;29(2):409A
289. Langer A, Califf RM, Goodman SG, Fisher MR, Fuster V, Daly B. Does higher intervention rate post MI result in better outcome in US vs. Canada? *Canadian Journal of Cardiology* 1997;13:109C
290. Lincoff AM, Mark DB, Califf RM, Tchong JE, Ellis SG, Davidson-Ray L, Anderson KM, Stoner GL, Topol EJ. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade during coronary intervention in the EPILOG Trial. *J Am Coll Cardiol* 1997;29(2):241A

291. Lincoff AM, Tcheng JE, Califf RM, Cabot CF, Miller DP, Booth JE, Montague EA, Anderson KM, Topol EJ. Abciximab (c7E3 Fab, ReoPro) with reduced heparin dosing during coronary intervention: final results of the EPILOG Trial. *J Am Coll Cardiol* 1997;29(2):187A
292. Mahaffey KW, Puma JA, Barbagelata NA, Casas CA, Lambe L, Orlandi C, Gibbons RJ, Califf RM, Granger CB. Does adenosine in conjunction with thrombolysis reduce infarct size? Results from the controlled, randomized AMISTAD Trial. *Circulation* 1997;96:I-206
293. Mahaffey KW, Granger CB, Tardiff BE, Woodlief LH, Lee KL, Weaver WD, Topol EJ, Califf RM. Endpoint adjudication by a Clinical Events committee can impact the statistical outcome of a clinical trial: results from GUSTO-IIb. *J Am Coll Cardiol* 1997;29(2):410A
294. Mahaffey KW, Granger CB, Sloan MA, Sila CA, Green CL, White HD, Gore JM, Weaver WD, Topol EJ, Califf RM. Mortality prediction model for patients with intracranial haemorrhage after thrombolysis. *Eur Heart J* 1997;18:281
295. Moliterno DJ, Asher CA, Califf RM, Clark KA, Guerci AD, Topol EJ. Less myocardial but more cerebral ischemic events in African Americans than Caucasians with acute coronary syndromes: results from the GUSTO-II Trial. *J Am Coll Cardiol* 1997;29(2):131A
296. Newby LK, Ohman EM, Granger CB, Sawyer T, Sedor F, Holleman CM, Califf RM. Use of diagnostic tools in a chest pain evaluation unit: value of troponin T testing. *J Am Coll Cardiol* 1997;29(2):211A
297. Ohman EM, Sigmon KN, Samaha JK, Stack RS, George BS, Pickel A, Kereiakes DJ, Lee KL, Califf RM. Prediction of reocclusion after successful reperfusion during acute myocardial infarction. *J Am Coll Cardiol* 1997;17:187A
298. Savonitto S, Ardissino D, Ottani F, Prando MD, Mafriqi A, Merlini PA, Vahanian A, Van de Werf F, Granger CB, Thompson TD, Califf RM, Topol EJ. Prognostic value of the admission electrocardiogram in acute coronary syndromes. *Eur Heart J* 1997;18:124
299. Simoons ML, Harrington RA, Lincoff AM, Anderson KM, Deckers JW, Zelinger D, Hoynck van Papendrecht M, Califf RM, Topol EJ. Impaired prognosis after small, non-Q myocardial infarction during PTCA. *Eur Heart J* 1997;18:132
300. Tardiff BE, Mabe B, Wildermann NM, Sketch MH, Jr., Holmes DR, Jr., Ohman EM, Califf RM. Predictors of myocardial infarction (MI) with percutaneous revascularization in a large multicenter population. *J Am Coll Cardiol* 1997;29(2):277A
301. Tardiff BE, Anderson KM, Tcheng JE, Cabot CF, Lincoff AM, Deckers JW, Simoons JL, Califf RM, Topol EJ. Reduced need for coronary bypass surgery after percutaneous intervention in patients treated with abciximab. *Eur Heart J* 1997;18:55
302. Tardiff BE, Sketch MH, Jr., Peterson ED, Thompson TD, Pilote L, Lee KL, Mark DB, Califf RM, GUSTO-I Investigators. Revascularization after acute myocardial infarction (AMI): impact of treatment selection on mortality. *J Am Coll Cardiol* 1997;29(2):135A
303. Tardiff BE, Tcheng JE, Peck A, Lincoff AM, Harrington RA, Califf RM, Topol EJ, IMPACT II Investigators. Bleeding with coronary artery bypass surgery (CABG) in patients treated with a platelet glycoprotein IIb/IIIa inhibitor. *J Am Coll Cardiol* 1997;29(2):141A
304. Tardiff BE, Granger CB, Pieper KS, Newman MF, Califf RM. Stroke with coronary bypass surgery (CABG) in acute coronary syndromes. *Anesthesiology* 1997;84:
305. Tcheng JE, Anderson KM, Tardiff BE, Cabot CF, Lincoff AM, Califf RM, Topol EJ. Reducing the risk of percutaneous intervention after coronary bypass surgery; beneficial effects of abciximab treatment. *J Am Coll Cardiol* 1997;29(2):187A
306. Tcheng JE, Lincoff AM, Miller DP, Booth JE, Rund MM, Cabot CF, Califf RM, Topol EJ. Benefits of abciximab accrue in the full spectrum of coronary interventional patients: insights from the EPILOG Trials. *J Am Coll Cardiol* 1997;29(2):276A

307. Thel MC, Davidson CJ, Aguirre FV, Peck, Tchong JE, Lincoff AM, Topol EJ, Califf RM. What predicts contrast nephropathy after coronary intervention: insights from the IMPACT II trial. *J Am Coll Cardiol* 1997;29(2):500A
308. Thel MD, McNulty SE, Armstrong PW, Califf RM, O'Connor CM. A randomized trial of magnesium in cardiac arrest. *J Am Coll Cardiol* 1997;29(2):147A
309. Vahanian A, Granger CB, Califf RM, Topol EJ. Outcomes in GUSTO IIb in patients with ST-segment depression versus those with T-wave inversion. *J Am Coll Cardiol* 1997;29(2):216A
310. Vorchheimer DA, Saffra N, Feyzi JM, Halperin J, DePenafta E, Guzman IC, Califf RM, Fuster V. Temporal trends in medical therapy after acute myocardial infarction: US and Canadian experience in the Coumadin aspirin reinfarction Study (CARS). *Cardiovascular Drugs & Therapy* 1997;11:400
311. Vorchheimer DA, Baruch L, DePeralta ET, Guzman IC, Hayes RM, Hellkamp AS, Granger CB, Topol EJ, Califf RM. Weight adjusted antithrombotic regimes eliminate the nitroglycerin-antithrombotic interaction. *J Am Coll Cardiol* 1997;29(2):412A
312. White AD, Anderson RD, Weaver WD, Armstrong PW, Iparraguirre HP, Wagner GS, Schildcrout J, Gates K, Califf RM. Resolution of ST-segment elevation with Reteplase vs. Alteplase: results from the GUSTO-III ECG Substudy. *Circulation* 1997;96:1-331
313. Alderman EL, Bourassa MG, Whitlow PL, Califf RM, Schwartz L, Kip KE. Clinical results and revascularization status five years following randomization to PTCA or CABG in bypass angioplast revascularization investigation (BARI). *J Am Coll Cardiol* 1998;31:214A
314. Alexander JH, Harrington RA, Guerci AD, Weatherley BD, Karsch KR, Califf RM, Topol EJ, Lincoff AM, Armstrong PW, for the PURSUIT Investigators. Prior aspirin use potentiates the effect of GP IIb/IIIa inhibition in patients with non-ST elevation acute coronary syndromes. *J Am Coll Cardiol* 1998;31:93A
315. Anderson RD, White HD, Ohman EM, Wagner GS, Krucoff MW, Armstrong PW, Iparraguirre HP, Weaver WW, Gibler WB, Califf RM. Resolution of ST-segment elevation 90 minutes after thrombolysis for acute myocardial infarction predicts outcome: a GUSTO-III substudy. *J Am Coll Cardiol* 1998;31:371A
316. Armstrong PW, Fu Y, Chang WC, MacKenzie B, Mark DB, Granger CB, Califf RM, for the GUSTO II Investigators. Canadian-American differences in management and outcome of non-ST elevation acute coronary syndromes: 6 month follow-up from the GUSTO IIb Study. *Circulation* 1998;98:1-479
317. Califf RM. Towards 2000: new strategies for acute coronary syndromes (II). *Journal of Thrombolysis and Therapeutics* 1998;
318. Deckers JW, Harrington RA, Lincoff AM, Topol EJ, Califf RM, Berdan LG, Weatherly BD, Wilcox RG, Armstrong PW, Kitt MM, Simoons ML, for the PURSUIT Investigators. Regional variation in outcomes as determined by investigators and clinical events committee in an international trial of Eptifibatide in non-ST segment elevation acute coronary syndromes. *J Am Coll Cardiol* 1998;31:309A
319. Fu Y, Chang WC, Ohman EM, Gupta M, Morris A, Roth A, Granger CB, Califf RM, Mark DB, Armstrong PW. Impact of temporal trends in management on outcomes of acute myocardial infarction in Canada vs. US. *Circulation* 1998;98:1-479
320. Granger CB, Van de Werf F, Armstrong PW, Simes RJ, White HD, MacAulay CM, Califf RM. Hirudin reduces death and myocardial re-infarction at 6-months: follow-up results of the GUSTO-IIb Trial. *J Am Coll Cardiol* 1998;31:79A
321. Greenbaum AB, Harrington RA, Hudson MP, Miller GP, MacAulay CM, Berdan LG, Guerci AD, Kitt MM, Califf RM, Ohman EM. Enhanced benefit of eptifibatide in patients with acute coronary syndromes using a seamless transition from community hospitals to tertiary care centers. *Circulation* 1998;98:1-561 #2952
322. Harrington RA, Lincoff AM, Berdan LG, MacAulay CM, Kint PP, Mahaffey KW, Kitt MM, Simoons ML, Califf RM, PURSUIT Investigators. Maintenance of clinical benefit at six months in patients treated with the platelet glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event. *Circulation* 1998;98:1-359 \*1886

323. Harrington RA, Graffagnino C, Armstrong PW, Joseph D, Card TL, Sigmon KN, Granett JR, Chan R, Califf RM, Topol EJ, APLAUD Investigators. Dose-finding and tolerability of a new oral platelet glycoprotein IIb/IIIa inhibitor, SB 214857, in patients with coronary artery and cerebrovascular disease: the APLAUD results. *Circulation* 1998;98:I-250 #1303
324. Kereiakes DJ, Lincoff AM, Simoons ML, De Boer JM, Tcheng JE, Vahanian A, Anderson KM, Weisman HF, Califf RM, Topol EJ. Complementarity of stenting and abciximab for percutaneous coronary intervention. *J Am Coll Cardiol* 1998;31:54A
325. Kereiakes DJ, Berkowitz SD, Anderson KM, Simoons ML, Vahanian A, Lincoff AM, Tcheng JE, Weisman HF, Califf RM, Topol EJ. Abciximab associated thrombocytopenia: evidence for a complex interaction with heparin. *J Am Coll Cardiol* 1998;31:55A
326. Krucoff MW, Green CL, Trollinger KM, Granger CB, Ohman EM, O'Connor CM, Harrington RA, Armstrong PW, Simoons ML, Topol EJ, Califf RM. A comparison of static serial vs continuous ST-segment recovery to predict outcome after lytics for MI. *J Am Coll Cardiol* 1998;31:228A
327. Lincoff AM, Harrington RA, Califf RM, Berdan LG, Kitt MM, Weatherly BD, Kleiman NS, Topol EJ, for the PURSUIT Investigators. Clinical efficacy of integrilin in unstable angina is accompanied by a modest increase in hemorrhagic risk: The PURSUIT Trial. *J Am Coll Cardiol* 1998;31:185A
328. Lincoff AM, Tcheng JE, Califf RM, Cabot CF, Booth JE, Godfrey NK, Topol EJ. The EPISTENT Trial at 6 months: relative and combined effects of abciximab and stenting on reduction of acute ischemic events and late revascularization. *Circulation* 1998;98:I-767 #4021
329. Mahaffey KW, Tardiff BE, Granger CB, Lee KL, Harrington RA, Topol EJ, Califf RM. Disagreement between site investigators and clinical event committees is common and can affect trial results. *J Am Coll Cardiol* 1998;31:184A
330. Mahaffey KW, Harrington RA, Graffagnino C, Sloan MA, Miller JM, Granger CB, Simoons ML, Topol EJ, Califf RM. Comparison of stroke rate in patients with acute coronary syndromes and patients with acute myocardial infarction. *J Am Coll Cardiol* 1998;31:406A
331. McClure M, Kleiman NS, Berdan LG, Sparapani RA, Topol EJ, Diaz R, Califf RM, Gretier D, Karsch KR, Harrington RA. Thrombocytopenia in a large, international trial of the GO IIb/IIIa inhibitor Eptifibatide in patients with acute coronary syndromes. *J Am Coll Cardiol* 1998;31:93A
332. Miller JM, Ohman EM, Schildcrout JS, Smalling RW, Betriu A, Califf RM, Topol EJ. Survival benefit of Abciximab administration during early rescue angioplasty: analysis of 387 patients from the GUSTO-III Trial. *J Am Coll Cardiol* 1998;31:191A
333. Miller JM, Ohman EM, Schildcrout JS, Moliterno DJ, Hochman JS, Karnash SL, Califf RM. Hormone replacement therapy among post menopausal women with acute myocardial infarction: insights from GUSTO III. *Circulation* 1998;98:I-8
334. Miller JM, Ohman EM, Hasselblad V, Granger CB, Sketch MH, Jr., Kong DF, Califf RM. Can TIMI 3 flow at 60 minutes after thrombolysis substitute as a new angiographic standard? *Circulation* 1998;98:I-784 #4108
335. Moliterno DJ, Harrington RA, Newby KL, Armstrong PW, Van de Werf F, White HD, Califf RM, Topol EJ, for the PARAGON Study Investigators. Late diverging event curves for survival following IIb/IIIa antagonism in patients with unstable angina: PARAGON Study: 1 year follow-up. *J Am Coll Cardiol* 1998;31:208A
336. Narins CR, Miller DP, Califf RM, Topol EJ. Does preprocedural MI during PTCA reduce subsequent clinical restenosis? *J Am Coll Cardiol* 1998;31:417A
337. Natale A, Thompson T, Sgarbossa EB, Wagner GS, Barbagelata NA, Topol EJ, Califf RM. Different outcome of patients with sustained monomorphic ventricular tachycardia requiring cardioversion during acute myocardial infarction: analysis in the GUSTO-I study. *J Am Coll Cardiol* 1998;31:96A
338. Newby LK, Eisenstein EL, Califf RM, Thompson TD, Nelson CL, Peterson ED, Mark DB. Hospital stays past 72 hours in uncomplicated acute myocardial infarction patients are not cost effective. *Circulation* 1998;98:I-753 #3952



339. Peterson JG, Lauer MS, Young JB, Sapp S, Califf RM, Topol EJ. Evidence for an adverse interaction between ACE inhibitors and aspirin following myocardial infarction: the GUSTO-I Trial. *J Am Coll Cardiol* 1998;31:96A
340. Akkerhuis M, Boersma E, Harrington RA, Decker JW, Califf RM, Simoons ML. Eptifibatide protects against adverse cardiac complications both before and during percutaneous intervention in patients with acute coronary syndromes without ST-elevation. *J Am Coll Cardiol* 1999;33:40A
341. Alexander JH, Sparapani RA, Mahaffey KW, Boersma E, Lincoff AM, Wilcox RG, Kitt MM, Simoons ML, Topol EJ, Califf RM, Harrington RA. Eptifibatide reduces the size and incidence of myocardial infarction in patients with non-ST-elevation acute coronary syndromes. *J Am Coll Cardiol* 1999;33:331A
342. Birnbaum Y, Wagner GS, Thompson TD, Gates KB, Barbash GI, Granger CB, Crenshaw BS, Califf RM. Ventricular septal defect in anterior acute myocardial infarction in the thrombolytic era: electrocardiographic and clinical variables associated with increased risk. *J Am Coll Cardiol* 1999;33:328A
343. Blankenship JC, Godfrey NK, Demko SL, Califf RM, Lincoff AM, Tcheng JE, Topol EJ. Elimination of excess vascular access site bleeding during coronary intervention with abciximab. *J Am Coll Cardiol* 1999;33:73A
344. Blankenship JC, Godfrey NK, Balog C, Demko SL, Califf RM, Lincoff AM, Tcheng JE, Topol EJ. CKMB enzyme rise after in-lab adverse events during coronary intervention in EPISTENT. *J Am Coll Cardiol* 1999;33:26A
345. Boersma E, Pieper KS, Wilcox RG, Steyerberg E, Lee KL, Akkerhuis M, Harrington RA, Califf RM, Simoons ML. The risk of adverse outcome in patients with acute coronary syndromes without ST-elevation is mainly determined by baseline clinical factors. *J Am Coll Cardiol* 1999;33:359A-360A.
346. Califf RM. Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials. *Am Heart J* 1999;138(1 Pt 2):S12-5.
347. Cohen MD, Granger CB, Gore JM, Ferreira JS, Criger DA, Ohman EM, Topol EJ, Califf RM. Mortality is not increased with pulmonary artery catheterization in acute coronary syndromes: the GUSTO Trial. *J Am Coll Cardiol* 1999;33:395A
348. Hudson MP, Granger CB, Pieper KS, Armstrong PW, Guerci AD, Vahanian A, Califf RM, Ohman EM. Reinfarction after thrombolytic therapy: experience from the GUSTO-I & II Trials. *J Am Coll Cardiol* 1999;33:325A
349. Lincoff AM, Tcheng JE, Cabot CF, Califf RM, Booth JE, Sapp S, Topol EJ. Marked benefit in diabetic patients treated with stent and abciximab combination: 6 month outcome of the EPISTENT Trial. *J Am Coll Cardiol* 1999;33:34A
350. Mahaffey KW, Miller JM, MacAulay CM, Laskowitz DL, Alberts MJ, Sloan MA, Granger CB, Simoons ML, Topol EJ, Califf RM, Harrington RA. Substantial number of patients with acute coronary syndromes at risk for stroke each year: results from the PURSUIT trial. *J Am Coll Cardiol* 1999;33:366A
351. Roe MT, Lauer MS, Houghtaling P, Granger CB, Harrington RA, Califf RM, Topol EJ. An ischemia-guided strategy of cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes may be associated with improved outcomes. *J Am Coll Cardiol* 1999;33:391A
352. Shah MR, Granger CB, Bart BA, McMurray JJ, Petrie MC, Ohlin G, Tudor GE, Michelson EL, Califf RM, Pfeffer MA. Women with heart failure are less likely to receive ACE-inhibitors: findings from the SPICE Registry. *Congestive Heart Failure* 1999;Sept/Oct 1999:68
353. Tung CY, Granger CB, Mahaffey KW, Knight JD, Califf RM, Mark DB. Does stroke in the setting of thrombolytics for myocardial infarction alter subsequent management of coronary disease? *J Am Coll Cardiol* 1999;33:296A
354. Velazquez EJ, Krucoff MW, Jones RH, Crater SW, Green CL, Hasselblad V, Bastos E, McCants CB, Califf RM, O'Connor CM. Long-term survival of patients with severe left ventricular dysfunction and multivessel coronary artery disease: 5-year results of the high risk myocardial ischemia trial. *J Am Coll Cardiol* 1999;33:176A

355. Vorchheimer DA, Guzman IC, Greenberg CS, Kitt MM, Harrington RA, Mahaffey KW, Topol EJ, Califf RM. Safety and efficacy of eptifibatid therapy in patients with previous stroke or transient ischemic attack. *J Am Coll Cardiol* 1999;33:330A
356. Yuling F, Wei-Ching C, Mark DB, Granger CB, Topol EJ, Califf RM, Armstrong PW. Impact of on-site interventional facilities on hospital procedures and outcomes: Canada versus the US in GUSTO IIb. *J Am Coll Cardiol* 1999;33:348A
357. Califf RM, Cohen EA, Buller CE, Lincoff AM, Popma JJ, Teirstein PS, Palda VA, Pacchiana CM, O'Shea JC, Lorenz TJ, Tchong JE. High-dose eptifibatid (integrilin) in elective coronary stent implantation: results of the ESPIRIT trial. *Eur Heart J* 2000;21, abstract supplement:146-146.
358. Lincoff AM, Achenbach R, Melsheimer R, Kurz M, Califf RM, Anderson K, Topol E. Long term abciximab survival advantage is not explained by reduction in early major cardiac events. *Am J Cardiol* 2000;The 12th Annual Symposium:13i-13i.
359. O'Shea JC, Wilcox RG, Granger CB, Skene AH, Stebbins AL, Aylward PE, Armstrong PA, Topol EJ, Califf RM, Ohman EM. Educational level and 30 day mortality after acute myocardial infarction: results from the GUSTO III trial. *Eur Heart J* 2000;21, abstract supplement:223-223.
360. O'Shea JC, Wilcox RD, Granger CB, Skene AH, Stebbins AL, Bode C, Sadowski Z, Topol EJ, Califf RM, Ohman EM. Social isolation and 30-day mortality after acute myocardial infarction: results from the GUSTO III trial. *Eur Heart J* 2000;21, abstract supplement:146-146.
361. Al-Khatib SM, Allen-LaPointe NM, Curtis LH, Kramer JM, Califf RM. Outpatient use of antiarrhythmic medications from 1995-2000: Does evidence influence medical practice? *Pace* 2002;24:717
362. Peteren JL, Roe MT, Mulgund J, Blazing MA, Foody JM, Smith SC, Califf RM, Pollack CV, Harrington RA, Ohman EM, Gibler WB, Brindis RG, Peterson ED. Impact of the National Cholesterol Education Program Third Adult Treatment Panel Lipid-Lowering Recommendations on the Management of Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. *Circulation* 2006; 114: II\_899
363. De Lemons JA, Morrow DA, Wiviott SD, Jarolim P, Blazing MA, Shiu A, Sabatine MS, Califf RM, Braunwald E. Evaluation of Monocyte Chemoattractant Protein 1 as a Prognostic Marker in the A to Z Trial. *Circulation* 2006; 114: II\_648 - II\_649
364. Costa R, Stone GW, Clare R, Mahaffey KW, Califf RM, White HD, Ferguson JJ, Gulba DC, Col JJ, Lansky A. Impact of Enoxaparin on Thrombus Formation, Coronary Blood Flow, and Myocardial Perfusion After Early Invasive Treatment During Acute Coronary Syndrome: Results from the SYNERGY Library. *Circulation* 2006; 114: II\_600
365. Goyal A, Alexander JH, Hafley GE, Graham SH, Mehta RH, Mack MJ, Wolf RK, Cohn LH, Kouchoukos NT, Harrington RA, Gennevois D, Gibson CM, Califf RM, Ferguson TB, Peterson ED. Greater Use of Secondary Prevention Medications Following Coronary Artery Bypass Graft Surgery is Associated with Improved Two-Year Outcomes. *Circulation* 2006; 114: II\_796
366. Thune JJ, Signorovitch JE, Kober L, Howlett J, McMurray JJ, Califf RM, Maggioni AP, Rouleau JL, Pfeffer MA, Solomon SD. Post Myocardial Infarction Hypertension and Cardiovascular Outcomes in Patients with Left Ventricular Dysfunction, Heart Failure, or Both Following Acute Myocardial Infarction. *Circulation* 2006; 114: II\_537
367. Thomas KL, Al-Khatib SM, Lokhnygina Y, Solomon SD, Kober L, Zelenkofske S, McMurray JJ, Califf RM, Velazquez EJ. Amiodarone Use After Acute Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Is Associated with Excess Mortality. *Circulation* 2006; 114: II\_768
368. Thomas KL, Prisant LM, Lewis EF, Huang Z, Francis GS, Weaver WD, Pfeffer MA, McMurray JJ, Califf RM, Velazquez EJ. Racial Analysis of Patients with Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated with Valsartan, Captopril, or Both. *Circulation* 2006; 114: II\_671
369. Tricoci P, Lokhnygina Y, Berdan LG, Steinhubl SR, Gulba DC, White HD, Kleiman NS, Langer A, Califf RM, Ferguson JJ, Antman EM, Newby LK, Harrington RA, Mahaffey KW. Shortening Time to Cardiac Catheterization Is Associated with

Improved Outcomes Among Patients with Non-ST-segment Elevation Acute Coronary Syndromes: Results from the Randomized SYNERGY Trial. *Circulation* 2006; 114: II\_421

370. Linefsky JP, Mahaffey KW, Pieper KS, Lin A, Reist CJ, Antman E, Goodman SG, French JK, Roe MT, Harrington RA, Ferguson JJ, Califf RM. Differences between Site-Reported and Core Laboratory Creatine Kinase-MB Values in an International Clinical Trial: Results from the SYNERGY Trial. *Circulation* 2006; 114: II\_417
371. Al-Khatib S, Shaw LK, O'Connor CM, Califf RM. Sudden Cardiac Death in Patients with Diastolic Heart Failure. *Circulation* 2006; 114: II\_405
372. Meadows JL, McMurray JJ, Kober L, Califf RM, Varshavsky S, Velazquez EJ, Maggioni AP, Pfeffer MA, Solomon SD. Renal Dysfunction Influences the Relationship Between Left Ventricular Systolic Dysfunction and Survival in the Post-Myocardial Infarction Patient. *Circulation* 2007; 116: II\_707
373. Brilakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, Banerjee S, Blazing MA, Califf RM, Braunwald E. Outcomes of Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Grafting. Results From the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT-TIMI 22) and the Aggrastat to Zocor (A to Z) trials. *Circulation* 2007; 116: II\_314
374. Li JS, Smith PB, Murphy MD, Califf RM, Benjamin, Jr., DK. Racial Differences in Blood Pressure Response to Angiotensin Converting Enzyme Inhibitors in Children: An Analysis of 6 Pediatric Hypertension Trials. *Circulation* 2007; 116: II\_614
375. Verma A, Signorovitch JE, Pfeffer MA, McMurray JJ, Califf RM, Pieper K, Velazquez EJ, Solomon SD. Incremental Value of Echocardiographic Assessment Beyond Clinical Evaluation for Prediction of Death and Development of Heart Failure After Myocardial Infarction in Patients with Left Ventricular Dysfunction, Heart Failure, or Both. *Circulation*, 2007; 116: II\_402
376. Meadows TA, Bhatt DL, Hirsch AT, Creager MA, Califf RM, Ohman EM, Cannon CP, Eagle KA, Alberts M, Goto S, Wilson PW, Ph. G Steg on behalf of the REACH Registry Investigators. Ethnic Differences in the Prevalence and Treatment of Cardiovascular Risk Factors in Outpatients with Peripheral Arterial Disease: Insights from the REACH Registry. *Circulation* 2007; 116: II\_775
377. Chan MY, Mahaffey KW, Sun JL, Pieper KS, White HD, Aylward PE, Ferguson JJ, Califf RM, Roe MT. Catheterization without In-hospital Revascularization is Associated with Increased Long-term Mortality in Patients with Non-ST Elevation Myocardial Infarction and Significant Coronary Artery Disease. *Circulation* 2007; 116: II\_384.
378. Wang TY, Ou FS, Blazing MA, De Lemos JA, Califf RM, Peterson ED. Lack of association between bleeding and inflammation among patients with acute coronary syndrome: Insights from the Aggrastat to Zocor Trial [abstract]. Presented at: American College of Cardiology Scientific Sessions, March 2008: Chicago, IL.
379. Ezekowitz JA, Hernandez AF, Starling RC, Yancy CW, Massie B, Hill JA, Krum H, Diaz R, Ponikowski P, Metra M, Howlett JG, Gennevois D, O'Connor CM, Califf RM, Fonarow GC. Standardizing care for acute decompensated heart failure in a large megatrial: The approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). *Am Heart J* 2009;157(2):219-28.
380. Wang, T, White JA, Giugliano RP, Tricoci P, Harrington RA, Montalescot G, Zeymer U, Van de Werf F, Armstrong PW, Braunwald E, Califf RM, Newby LK. Upfront clopidogrel use and the efficacy and safety of early eptifibatide use in patients with acute coronary syndrome: An analysis from the early versus delayed provisional eptifibatide in acute coronary syndromes (EARLY ACS) Trial. *JACC* 2010; 55: A47.
381. Shah SH, Sun JL, Pieper K, Haynes C, Muehlbauer M, Bain JR, Hauser ER, Kraus WE, Newgard CB, Granger CB, Califf RM, Newby LK. Insulin-like growth factor binding protein (IGFBP) 2: A novel metabolic biomarker strongly predictive of future cardiovascular events. *JACC* 2010; 55: A97.
382. Lopes R, Alexander JH, Mehta RH, Hafley GE, Mack MJ, Allen KB, Peterdon ED, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB. Vein graft failure following coronary artery bypass surgery: Does it matter? *JACC* 2010; 55: A99.

383. Melloni C, James SK, White JA, Giugliano RP, Harrington RA, Huber K, Armstrong PW, Califf RM, Van de Werf F, Montalescot G, Newby LK. Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. *JACC* 2010; 55: A102.
384. Tanguay JF, Newby LK, Hochman J, Westerhout CM, Califf RM, Gibson CM, Giugliano RP, Harrington RA, Van de Werf F, Armstrong PW. Sex differences in high-risk acute coronary syndromes: Insights from EARLY-ACS. *JACC* 2010; 55:A120.
385. Mudrick DW, Reed SD, Li Y, McMurray JJ, Kober L, Califf RM, Lewis EF, Solomon SD, Velazques EJ. Mitral regurgitation after myocardial infarction predicts increased medical costs and decreased quality of life: Analysis of the VALIANT (VALsartan in Acute myocardial iNfarcTion) Trial. *JACC* 2010; 55:A125.
386. Chan MY, Sun JL, Newby LK, White HD, Moliterno DJ, Theroux P, Ohman EM, Pieper KS, Giugliano RP, Armstrong PW, Califf RM, Van de Werf F, Harrington RA. Temporal trends over 15 years of clinical trials of non-ST elevation acute coronary syndromes: more aggressive treatment yields similar mortality despite higher-risk profiles. *JACC* 2010; 55:A136.

#### **Editorial**

1. Harrell FE, Jr., Lee KL, McKinnis RA, Hlatky MA, Mark D, Califf RM, Pryor DB. Analysis of risk factors for sudden death after acute myocardial infarction. *Am J Cardiol* 1985;55:621-622.
2. Hlatky MA, Mark DB, Harrell FE, Jr., Lee KL, Califf RM, Pryor DB. Rethinking sensitivity and specificity. *Am J Cardiol* 1987;59:1195-1198.
3. Topol EJ, Califf RM, George BS, Kereiakes DJ, Candela RJ, Abbottsmith CW, Pitt B, Stack RS. Letter to the editor. *N Engl J Med* 1988;319:578-579.
4. Califf RM. Myocardial reperfusion: is it ever too late? *J Am Coll Cardiol* 1989;13:1130-1132.
5. Topol EJ, Califf RM. Tissue plasminogen activator: why the backlash? *J Am Coll Cardiol* 1989;13:1477-1480.
6. Califf RM, Harrelson-Woodleif SL. At home thrombolysis. *J Am Coll Cardiol* 1990;15(5):937-939.

7. Ohman EM, Sigmon KN, Califf RM. Is diagnostic certainty essential for the use of thrombolytic therapy during myocardial infarction in the 1990s? *Circulation* 1990;82:1073-1075.
8. Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. *Circulation* 1991;84:1426-1436.
9. Sane DC, Stump DC, Topol EJ, Sigmon KN, Clair WK, Kereiakes DJ, George BS, Stoddard MF, Bates ER, Stack RS, Califf RM. Response. *Circulation* 1991;84:2206
10. Califf RM, Topol EJ, for the GUSTO Investigators. Thrombolytic therapy for myocardial infarction: a perspective of clinical trialists. *Clin Cardiol* 1992;15:143-144.
11. Califf RM, Granger C. TIMI IIB follow-up. Lessons for clinicians and investigators. *Circulation* 1992;85:839-841.
12. Califf RM. Problems that limit the applicability of clinical trials. *J Invas Cardiol* 1992;4(1):
13. Califf RM, Popma JJ, Topol EJ. Small trials and new therapies. *Circulation* 1992;85:1636-1637.
14. Topol EJ, Califf RM. Thrombolytic therapy for elderly patients. *N Engl J Med* 1992;327:45-47.
15. Topol EJ, Califf RM, Lee KL, for the GUSTO Investigators. The irony of biased editors who write editorials. *Br J Clin Pract* 1993;47:283-284.
16. Califf RM. Withdrawal of digoxin after treatment of chronic heart failure. *ACP Journal Club* 1994;120:1
17. Lee KL, Califf RM, Topol EJ. The last word on GUSTO, for now. *Ann Intern Med* 1994;120:970
18. Lee KL, Topol EJ, Califf RM. More on the GUSTO Trial (response). *Ann Intern Med* 1994;121:819-820.
19. Ross AM, Califf RM, Topol EJ. GUSTO: the principal investigators respond to the criticism. *Journal of Myocardial Ischemia* 1994;6:11-16.
20. Topol EJ, Califf RM, Lee KL. More on the GUSTO trial. *N Engl J Med* 1994;331:277-278.
21. Zabel KM, Califf RM. The value of exercise thallium imaging. *Ann Intern Med* 1994;121:891-893.
22. Califf RM. Identifying electrocardiographic left ventricular hypertrophy was problematic among patients with suspected acute cardiac ischemia. *ACP Journal Club* 1995;75:
23. Fortin DF, Califf RM, Pryor DB, Mark DB. The way of the future redux. *Am J Cardiol* 1995;76:1177-1182.
24. Peterson ED, Califf RM. The complexity of studying coronary heart disease in women. *Ann Epidemiol* 1995;5:79-81.
25. Sheldon WS, Califf RM, Topol EJ. Reconfiguring health maintenance organizations to support clinical investigation. *Ann Intern Med* 1995;
26. Barbash GI, Reiner JS, Ross AM, Califf RM. Effect of smoking status in response to thrombolytic therapy (reply). *J Am Coll Cardiol* 1996;28(1):283
27. Califf RM, Jollis JG, Peterson ED. Operator-specific outcomes. A call to professional responsibility. *Circulation* 1996;93:403-406.
28. Eisenstein EL, Mark DB, Califf RM. Importance of cost and quality of life in decisions about routine angiography after acute myocardial infarction. The role of cost-effectiveness models. *Circulation* 1996;94:869-871.
29. Jollis JG, Califf RM. Left main stenosis (reply). *Ann Thorac Surg* 1996;62(4):1240-1241.
30. Jollis JG, Califf RM. A randomized study would answer the question. *Ann Thorac Surg* 1996;61:513-514.

31. Califf RM. How will we manage acute coronary syndromes in the new millenium? *Am Heart J* 1997;134:S53-S54
32. Califf RM, Silver MJ, Topol EJ, Bartsness, Sketch MH, Jr., Harrington RA, Granger CB, Ohman EM, Brener SJ, Ellis SG. New Standards of Care, Part IV: Treatment Issues. *Am J Cardiol* 1997;2:
33. Califf RM, Mark DB. Our vision for the American Heart Journal. *Am Heart J* 1997;133:137-138.
34. Califf RM. Forward. *Eur Heart J* 1997;18:
35. Califf RM. Lessons for the editors. *Am Heart J* 1997;134(1):1-2.
36. Ellis SG, Topol EJ, Betriu A, Califf RM. Primary coronary angioplasty versus thrombolysis (reply). *N Engl J Med* 1997;337:1170
37. Lincoff AM, Topol EJ, Califf RM. Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty (reply). *N Engl J Med* 1997;337(17):1244
38. Ohman EM, Califf RM, Topol EJ. Trials in myocardial infarction. *Circulation* 1997;96:3814-3816.
39. Ohman EM, Califf RM, Topol EJ. Cardiac troponins in acute coronary syndromes. *N Engl J Med* 1997;337(17):1257-1259.
40. Pilote L, Califf RM, Topol EJ. Use of coronary angiography and revascularization after acute myocardial infarction (reply). *N Engl J Med* 1997;336(14):1025
41. Simes RJ, Kleiman NS, Califf RM, Topol EJ. Does the Early Hazard Phenomenon Exist? Do the GUSTO Findings Prove or Disprove?: Response. *Circulation* 1997;96(10):3780-3781.
42. Topol EJ, Califf RM, Van de Werf F. Heparin versus hirudin for acute coronary syndromes (reply). *N Engl J Med* 1997;336(10):730-731.
43. Califf RM, Granger CB. Hypertension and diabetes and the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). More ammunition against surrogate end points. *Diabetes Care* 1998;21:655-657.
44. Califf RM, Kramer JM. What have we learned from the calcium channel blocker controversy? *Circulation* 1998;97:1529-1531.
45. Califf RM, Harrington RA. Improved outlook for patients with acute myocardial infarction: an interim progress report. *Eur Heart J* 1998;19:1416-1418.
46. Califf RM, Simoons ML. Use of GP IIb/IIIa inhibitors in coronary syndromes: state of the art. *Eur Heart J* 1998;19:D1
47. Califf RM, Simoons ML. Introduction (Davos Supplement). *Am Heart J* 1998;135(4):S33-S34
48. Califf RM, Gheorghiade M. Managing the patient with advanced heart failure - introduction. *Am Heart J* 1998;135(6 Part 2 Suppl):S201-S202
49. Califf RM, Harrington RA. Improved long-term prognosis after myocardial infarction 1984-1991. *Eur Heart J* 1998;
50. Califf RM. Ten years of benefit from a one-hour intervention. *Circulation* 1998;98:2649-2651.
51. Kong DF, Califf RM. Post-procedure heparin: boon or burden? *Am Heart J* 1998;136:183-185.
52. Reimer KA, Califf RM. Good news for experimental concept but bad news for clinically effective therapy. *Circulation* 1998;99:198-200.
53. Topol EJ, Califf RM, Wilcox RD. Response to letters to the editor on October 16th article in the NEJM. *N Engl J Med* 1998;338(8):546-547.

54. Califf RM. Lifeline. *Lancet* 1999;354(9172):84:
55. Califf RM, Mark DB. Dealing with success at the American Heart Journal. *Am Heart J* 1999;137:769
56. Califf RM. When I have acute coronary syndrome treat me gingerly. *Eur Heart J* 1999;Supplement N:N20-N25
57. Califf RM. Integrated plan of care. *Cardiology Review* 1999;16(10):24
58. Califf RM. What to do with acute atrial fibrillation? *Am Heart J* 1999;137(4 Pt 1):601-602.
59. Califf RM. The role of glycoprotein IIb/IIIa inhibition in acute coronary syndromes. *Presentations in Focus* 1999;
60. Kong DF, Califf RM. Coronary interventions "to go": is faster better? *J Invasive Cardiol* 1999;11(6):401-402.
61. Califf RM. Dual randomization in cardiovascular trials. *Am Heart J* 2000;
62. Califf RM. Cigarette smoking. How much worse can it get? *Circulation* 2000;102, No.12:1340-1341.
63. Califf RM, Shah MR. Proceedings of a symposium - How should phase II trials in cardiovascular medicine be conducted? *Am Heart J* 2000;139(4):S131-S132
64. Califf RM. Genetics,genomics,proteomics: what is a cardiologist to do? *Am Heart J* 2000;140 No. 4:S48-S52
65. Califf RM, O'Connor CM. The evidence is in: now the work begins. *JAMA* 2000;283 (10):1335-1337.
66. Califf RM, Shah MR. How should phase II trials in cardiovascular medicine be conducted? *Am Heart J* 2000;139:S131-S132
67. Califf RM. State of the art: ACS treatment at the turn of the century. *Eur Heart J* 2000;vol 2 (Supple F):F2-F6
68. Dyke CK, Califf RM. National and regional registries: what good are they? *Eur Heart J* 2000;1401-1403.
69. O'Shea JC, Califf RM. Inter-regional differences in acute coronary syndrome trials. *Eur Heart J* 2000;2000.2121:1397-1398.
70. Velasquez EJ, Califf RM. All that glitters is not gold. *Lancet* 2000;355(9215):1568-1569.
71. Califf RM. Clopidogrel: A viewpoint by Robert M. Califf. *American Journal of Cardiovascular Drugs* 2001;1:476
72. Califf RM. The Coxib story: Some lessons and more questions. *Am J Cardiol* 2002;15:971-972.
73. Califf RM. Publication policy, informed consent, and the randomized clinical trial. *Am Heart J* 2002;143:187-188.
74. Moya MP, Gow AJ, Califf RM, Goldberg RN, Stamler JS. Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn. *Lancet* 2002;360:141-143.
75. Belch JF, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clements FM, Creager MA, Easton D, Gavin JR, Greenland P, Hankey G, Hanrath P, Hirsch AT, Meyer J, Smith SC, Sullivan F, Weber M, for the prevention of atherothrombotic disease network. Critical issues in peripheral arterial disease detection and management. *Arch Intern Med* 2003;163:884-892.
76. Califf RM, Faxon DP. Need for centers to care for patients with acute coronary syndromes. *Circulation* 2003;107:1467-1470.
77. Califf RM. Cardiac markers in acute coronary syndromes-refining our knowledge. *Eur Heart J* 2003;24:136-137.
78. Yancy WS, Westman EC, French PA, Califf RM. Diets and clinical coronary events. The truth is out there. *Circulation* 2003;107:10-16.
79. Califf RM. Watching the WATCH trial: the role of sponsors and data monitoring committees. *J Card Failure* 2004;10:113-114.

80. Califf RM. Can we make payment for medical care rational? Commentary on using clinical trials as a basis for coverage by Carino, Sheingold, and Tunis. *Clinical Trials* 2004;1:115
81. Mark DB, Califf RM. Introduction of a new section: Cardiology Fellows: Quick Evidence-Based Consult. *Am.Heart J.* 2004;147:1
82. Califf RM. Simple principles of clinical trials remain powerful. *JAMA* 2005; 293 (4):489-491.
83. Califf RM. Stenting or surgery: an opportunity to do it right. *J Am Coll Cardiol* 2005; 46 (4):575-581
84. Califf RM and Mark DB. Plagiarism notice. *Am Heart J* 2005; 149 (4):743
85. Califf RM. Simple principles of clinical trials remain powerful. *JAMA* 2005;293:489-491.
86. Califf RM. Fondaparinux in ST-segment elevation myocardial infarction: the drug, the strategy, the environment, or all of the above? *JAMA* 2006;295:1579-1580.
87. Harrington RA, Califf RM. Late ischemic events after clopidogrel cessation following drug-eluting stenting: should we be worried? *J Am Coll Cardiol* 2006;48:2592-259.
88. Harrington RA, Hasselblad V, Califf RM. Defining and utilizing surrogates in the evaluation of coronary stents: what do we really want and need to know? *J Am Coll Cardiol.* 2008;51(1):33-6.
89. Califf RM, Kramer JM. The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment. *Pharmacoepidemiol Drug Saf.* 2008;17(8):782-6.
90. Califf RM. The benefits of moving quality to a national level. *Am Heart J* 2008; 156 (6):1019-22.
91. Califf RM, Ginsberg GS. "Organizational Improvements to Enhance Modern Clinical Epidemiology. *JAMA* 2008 Nov 19;300(19):2300-2
92. Harrington RA, Hasselblad V, Califf RM. Defining and utilizing surrogates in the evaluation of coronary stents: what do we really want and need to know? *J Am Coll Cardiol* 2008;51:33-6.
93. Califf RM, Peterson ED. Public reporting of quality measures what are we trying to accomplish? *J Am Coll Cardiol* 2009;53:831-3.
94. Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). *Am J Cardiol* 2009;104:151-7.
95. Califf RM. Rational use of medications: if Canada can't do it .. *CMAJ* 2009;181:15-6. PMID:19581612
96. Califf RM, Shah SH, Newby LK. Biomarker bonanza? *J Am Coll Cardiol* 2010; 55:1197-9.
97. Ohman EM, Califf RM. When can noninferior be superior? The multidimensional nature of clinical decision-making calls for innovative approaches to clinical trials. *J Am Coll Cardiol* 2010; 55:555-7.
98. Rao SV, Califf RM. Is old blood bad blood? *Am Heart J* 2010; 159:710-2.
99. Califf RM, Lokhnygina Y, Cannon CP, Stepanavage ME, McCabe CH, Musliner TA, Pasternak RC, Blazing MA, Giugliano RP, Harrington RA, Braunwald E. An update on the IMProved reduction of outcomes: Vytorin efficacy international trial (IMPROVE-IT) design. *Am Heart J* 2010; 159:705-9.
100. Demets DL, Califf, RM. A Historical Perspective on Clinical Trials Innovation and Leadership; Where Have the Academics Gone? *JAMA* 2011; Vol 305, No. 7.



101. Vamadevan AS, Shah BR, Califf RM, Prabhakaran D. Cardiovascular research in India: a perspective. *Am Heart J* 2011 Mar; 161(3): 431-8.
102. Selker HP, Califf RM. The need for academic leadership in full-spectrum translational research. *Clin Transl Sci* 2011 Apr; 4(2): 78-9.
103. Califf RM, Harrington RA. American industry and the U.S. Cardiovascular clinical research enterprise an appropriate analogy? *J Am Coll Cardiol* 2011 Aug 9;58(7): 677-80.

#### **Interview**

1. Califf, RM. a conversation with the editor. *Am J Card* 82, 639-658. 1998.
2. Califf RM, Kong DF. Drug-coated Stents: Frequently Asked Questions. *DukeMed News* 2006;15:4

## Whole Book

1. Califf RM, Wagner GS, eds. Acute Coronary Care, Principles, and Practice, 1985; 1986; 1987 ed. Boston: Martinus Nijhoff Publishing; 1985.
2. Califf RM, Mark DB, Wagner GS, eds. Acute Coronary Care in the Thrombolytic Era. Chicago: Year Book Medical Publishers; 1988.
3. Roubin GS, Califf RM, O'Neill WW, Phillips HR, III, Stack RS, eds. Interventional Cardiovascular Medicine: Principles and Practice. New York: Churchill Livingstone; 1994.
4. Califf RM, Mark DB, Wagner GS, eds. Acute Coronary Care, 2nd ed. Chicago: Mosby Year Book, Inc.; 1995.
5. Califf RM, Braunwald E, eds. Atlas of Heart Disease: Acute Myocardial Infarction and Other Acute Ischemic Syndromes, Vol. VIII ed. Philadelphia: Current Medicine, Inc.; 1996.
6. Califf RM, ed. Thrombolytic therapy: new standards of care, I, II, III, IV ed. American Journal of Cardiology; 1996.
7. Califf RM, ed. Supplement to the American Heart Journal. American Heart Journal; 1996.
8. Califf RM, Maseri A, eds. Update on Thrombolytic Agents: Emerging Options for AMI Management. The European Society of Cardiology; 1997.
9. Califf RM, Shah M, eds. Phase II Clinical Trials. Supplement ed. American Heart Journal; 1997.
10. Califf RM, ed. Coagulation Markers Supplement. American Heart Journal; 1997.
11. Califf RM, ed. Hypertension Therapy (RPR), Supplement to American Heart Journal ed. Mosby-Year Book, Inc.; 1997.
12. Califf RM, Simoons ML, Joint Supplement to the American Heart Journal and the European Heart Journal, 135 & 19(Sup. D) ed. American Heart Journal & European Heart Journal; 1998.
13. Califf RM, ed. Managing acute coronary syndromes: what is the new standard of care. Medical Education Network; 1998.
14. Califf RM, Granger CB, eds. Diabetes Supplement. American Heart Journal; 1998.
15. Califf RM, ed. Good news for the treatment of thrombotic disorders. New York: Medical Education Networks; 1998.
16. Califf RM, Wallentin L, Fox K, Wilcox RG, Van de Werf F, eds. Using Clinical Data to Improve the Treatment of ACS-What the Acronyms Tell Us About Management Options and Outcomes, Monograph ed. Interactive Sciences, Inc.; 1998.
17. Califf RM, Gheorghiade M, eds. Congestive Heart Failure Supplement. American Heart Journal; 1998.
18. Califf RM, ed. Acute Coronary Syndromes: Current Perspectives and Directives. New York: Medical Education Networks; 1998.
19. Califf RM, Hochman J, White H, Moliterno D, eds. Thrombolytic therapy: new standards of care, Part V: special populations. American Journal of Cardiology; 1998.
20. Freed M, Califf RM, eds. The new essentials of cardiovascular medicine., 2nd ed. Birmingham: Physicians' Press; 1998.
21. Topol EJ, Califf RM, eds. The Textbook of Cardiovascular Medicine. Philadelphia: Lippincott-Raven Publisher; 1998.
22. Califf RM, ed. Presentations in Focus: 48th Annual Scientific Session of the ACC. New York: Medical Education Network; 1999. p. 1-14.
23. Califf RM. Using clinical trial data to improve the treatment of acute coronary syndromes: what the acronyms tell us about management options and outcomes. Egham, UK: Medical Action Communications; 2000.

24. Califf RM. Acute Myocardial Infarction, 2nd ed. Philadelphia, PA: Current Medicine; 2000.
25. Califf RM, Falk E, Fitchett E, Goodman S, Granger CB, Harrington RA *et al.* Acute myocardial infarction and other acute ischemic syndromes, Second Edition ed. Current Medicine; 2001.
26. Information Technology Enabling Clinical Research. Findings and recommendations from a conference sponsored by the Association of American Medical Colleges with Funding from the National Science Foundation; AAMC 2002
27. Califf RM. Coronary Syndromes, ACS Essentials. 2003
28. Califf RM, Acute Coronary Syndromes: ACS Essentials. Royal Oak MI; Physicians Press; 2005
29. Califf RM, Roe MT, ACS Essentials. 3<sup>rd</sup> ed. Boston: Physicians' press ( Jones and Barlett Publishers); 2010

## Book Chapter

1. Blumenthal JA, Califf RM. Secondary prevention of coronary heart disease., In: Surwit R, Williams RB, Steptoe A, Biersner R, editors. *NATO Symposium on Behavioral Medicine: Behavioral Treatment of Disease*. New York: Academic Press; 1982. p. 43-69.
2. Lee KL, Harrell FE, Jr., Califf RM, Pryor DB, Hlatky MA, Rosati RA. Secondary prevention trials in post-myocardial infarction patients: methodological issues., In: Kuffertus HE, Wellens HJ, editors. *The First Year After Myocardial Infarction*. Futura Publishing Company; 1983. p. 407-19.
3. Califf RM, Palmeri ST, Wagner GS. Strategies for assessing the risk status of patients following acute myocardial infarction or unstable angina., In: Califf RM, Wagner GS, editors. *Acute Coronary Care: Principles and Practice*.. Boston: Martinus Nijhoff Publishers; 1985. p. 517-27.
4. Califf RM. The changing prognosis of patients with unstable angina and acute myocardial infarction., In: Califf RM, Wagner GS, editors. *Acute Coronary Care: Principles and Practice*. Boston: Martinus Nijhoff Publishers; 1985. p. 107-11.
5. English M, Califf RM. Organization and administration of the Cardiac Care Unit., *Acute Coronary Care: Principles and Practice*.. Boston: Martinus Nijhoff Publishing; 1985. p. 359-68.
6. Grierson DS, Califf RM, Wagner GS. The clinical use of thrombolytic agents., In: Califf RM, Wagner GS, editors. *Acute Coronary Care: Principles and Practice*.. Boston: Martinus Nijhoff Publishers; 1985. p. 321-34.
7. Hindman NB, Corsa AT, Califf RM, McKinnis RA, Wagner GS. The ability of initial quantitative epicardial injury to predict infarct size estimated by QRS score., *Proceedings of the 1984 Engineering Foundation Conference on Computerized Interpretation of the Electrocardiogram*.. New York: Engineering Foundation Press; 1985. p. 199-204.
8. Kottke T, Hlatky MA, Hindman MC, Califf RM. Rehabilitation after myocardial infarction., In: Dornbrand L, Hoole AJ, Fletcher RH, Pickard CG, Jr., editors. *Manual of Clinical Problems in Adult Ambulatory Care*.. Boston: Little, Brown and Co.; 1985. p. 132-35.
9. Mark DB, Califf RM, Stack RS, Phillips HR3. Cardiac catheterization., *The Davis-Christopher Textbook of Surgery*., 13th ed. Philadelphia: W.B. Saunders; 1986. p. 2135-65.
10. Bellinger RL, Weber RA, Califf RM. Helicopter transport of patients with acute ischemic syndromes., In: Califf RM, Wagner GS, editors. *Acute Coronary Care 1987*.. Boston: Martinus Nijhoff Publishers; 1987. p. 19-35.
11. Topol EJ, Califf RM. The role of tissue plasminogen activator in myocardial infarction., In: Califf RM, Wagner GS, editors. *Acute Coronary Care 1987*.. Boston: Martinus Nijhoff Publishers; 1987. p. 73-88.
12. Tyson GS, Rankin JS, Califf RM. Use of the intra-aortic balloon pump in unstable angina., In: Califf RM, Wagner GS, editors. *Acute Coronary Care 1987*.. Boston: Martinus Nijhoff Publishers; 1987. p. 203-13.
13. Bellinger RL, Califf RM. Emergency transportation of the patient with acute myocardial infarction: methods, risks, and benefits., In: Califf RM, Mark DB, Wagner GS, editors. *Acute Coronary Care in the Thrombolytic Era*.. Chicago: Year Book Publishers; 1988. p. 158-69.
14. Califf RM, Mantell SJ. Administration and monitoring of thrombolytic therapy., In: Califf RM, Mark DB, Wagner GS, editors. *Acute Coronary Care in the Thrombolytic Era*.. Chicago: Year Book Publishers; 1988. p. 217-38.
15. Califf RM, Massey EW. Myocardial infarction and stroke in the thrombolytic era., In: Califf RM, Mark DB, Wagner GS, editors. *Acute Coronary Care in the Thrombolytic Era*.. Chicago: Year Book Publishers; 1988. p. 539-47.
16. Califf RM, Bellinger RL. A regionalized approach to acute coronary intervention., In: Topol EJ, editor. *Acute Coronary Intervention*.. New York: Alan R. Liss, Inc.; 1988. p. 231-53.
17. Califf RM, Mark DB, Topol EJ. Current and future randomized trials of acute coronary intervention., In: Califf RM, Mark DB, Wagner GS, editors. *Acute Coronary Care in the Thrombolytic Era*.. Chicago: Year Book Publishers; 1988. p. 347-63.

18. Mark DB, Dunham G, Califf RM. Therapeutic drug monitoring in the acutely ill cardiac patient., In: Califf RM, Mark DB, Wagner GS, editors. *Acute Coronary Care in the Thrombolytic Era.* Chicago: Year Book Publishers; 1988. p. 492-507.
19. Martin JC, Califf RM. Approach to the identification and management of the high risk, unstable angina patient., In: Califf RM, Mark DB, Wagner GS, editors. *Acute Coronary Care in the Thrombolytic Era.* Chicago: Year Book Publishers; 1988. p. 407-28.
20. O'Connor CM, Mark DB, Califf RM. Combined thrombolysis and angioplasty in acute myocardial infarction: clinical results., In: Califf RM, Mark DB, Wagner GS, editors. *Acute Coronary Care in the Thrombolytic Era.* Chicago: Year Book Publishers; 1988. p. 331-46.
21. Pryor DB, Harrell FE, Jr., Rankin JS, Lee KL, Muhlbaier LH, Hlatky MA *et al.* Trends in the presentation, management and survival of patients with coronary artery disease: the Duke Data Base for cardiovascular disease., In: Higgins MW, Luepker RV, editors. *Trends in Coronary Heart Disease Mortality: The Influence of Medical Care.* New York: Oxford University Press; 1988. p. 76-87.
22. Massey EW, Coffey CE, Califf RM. Myocardial infarction and stroke., In: Weintraub MI, Fass A, editors. *Heart and Brain Interactions of Cardiac and Neurologic Disease.* New York: PMA Publishing Company; 1989. p. 171-89.
23. Califf RM. Fibrinolytic therapy in the management of acute myocardial infarction., *Surgery of the Chest*, 5th ed. Philadelphia: W.B. Saunders; 1990. p. 1046-57.
24. Califf RM, Ohman EM, Frid DJ, Fortin DF, Mark DB, Hlatky MA *et al.* Restenosis: the clinical issues., In: Topol EJ, editor. *Interventional Cardiology.* Philadelphia: W.B. Saunders; 1990. p. 363-94.
25. Wagner GS, Munster MB, Bride WM, Califf RM. Administration of the referral comprehensive coronary care unit., In: Francis GS, Alpert JS, editors. *Modern Coronary Care.* Boston: Little, Brown, and Company; 1990. p. 743-45.
26. Hlatky MA, Califf RM, Harrell FE, Jr., Mark DB, Lee KL, Muhlbaier LH *et al.* Clinical judgment and therapeutic decision making., In: Knoebel SB, Dack S, editors. *An Era in Cardiovascular Medicine.* New York: Elsevier; 1991. p. 303-15.
27. Ohman EM, Califf RM. Thrombolytic therapy: overview of clinical trials., In: Gersh BJ, Rahimtoola SH, editors. *Acute Myocardial Infarction.* New York: Elsevier; 1991. p. 308-32.
28. Wall TC, Ohman EM, Califf RM. Reperfusion therapy: significance of recent trials to the practicing cardiologist., In: Anderson JL, editor. *Modern Management of Acute Myocardial Infarction in the Community Hospital.* New York: Marcel Dekker, Inc.; 1991. p. 103-18.
29. Califf RM, Willerson JT. PTCA: prevention of occlusion and restenosis., In: Fuster V, Verstraete M, editors. *Thrombosis in Cardiovascular Disorder.* Philadelphia: W.B. Saunders; 1992. p. 389-408.
30. Selker HP, Griffith JL, Beshansky JR, Califf RM, D'Agostino RB, Laks MM *et al.* The thrombolytic predictive instrument project: combining clinical study data bases to take medical effectiveness research to the streets.. Rockville: Agency for Health Care Policy and Research Data Methods; 1992. p. 9-37.
31. Califf RM. Why are large-scale trials needed?, In: Sobel BE, Christomanou K, editors. *Coronary Artery Disease - Reviews in Depth Monograph.* London: Current Science; 1993. p. 156-60.
32. Hillegass WB, Ohman EM, Califf RM. Restenosis: the clinical issues., In: Topol EJ, editor. *Textbook of Interventional Cardiology.*, 2nd ed. Philadelphia: W.B. Saunders; 1993. p. 415-35.
33. Sane DC, Califf RM. Complications of thrombolytic therapy., In: Bates ER, editor. *Thrombolysis and Adjunctive Therapy for Acute Myocardial Infarction.* New York: Marcel Dekker, Inc.; 1993. p. 91-115.
34. Califf RM, Nelson CL, Mark DB. Using a clinical database for quality assurance and clinical research., In: Phillips HR, III, O'Neill WW, Califf RM, Stack RS, editors. *Interventional Cardiovascular Medicine: Principles and Practice.* New York: Churchill Livingstone, Inc.; 1994. p. 951-57.

35. Califf RM, Fortin DF, Tcheng JE, Pryor DB. Goals of clinical databases in interventional cardiology., In: Phillips HR, III, O'Neill WW, Califf RM, Stack RS, editors. *Interventional Cardiovascular Medicine: Principles and Practice.* New York: Churchill Livingstone, Inc.; 1994. p. 937-43.
36. Fortin DF, Blunden PB, Pryor DB, Tcheng JE, Califf RM. The Duke Data Bank for cardiovascular diseases., In: Phillips HR, III, O'Neill WW, Califf RM, Stack RS, editors. *Interventional Cardiovascular Medicine: Principles and Practice.* New York: Churchill Livingstone, Inc.; 1994. p. 959-66.
37. Harrington RA, Califf RM. The TAMI Trials, In: Becker RC, editor. *The Modern Era of Thrombolysis.* 1994. p. 91-106.
38. Harrington RA, Califf RM. The thrombolysis and angioplasty in myocardial infarction (TAMI) Trials., In: Becker RC, editor. *The Modern Era of Coronary Thrombolysis.* Kluwer Academic Publishers; 1994. p. 91-106.
39. Krucoff MW, Crater SW, O'Connor CM, Califf RM. Patient management following percutaneous transluminal revascularization., In: Phillips HR, III, O'Neill WW, Califf RM, Stack RS, editors. *Interventional Cardiovascular Medicine: Principles and Practice.* New York: Churchill Livingstone, Inc.; 1994. p. 217-37.
40. Ohman EM, Phillips HR3, Califf RM. An approach to percutaneous revascularization in patients with stable coronary ischemia., In: O'Neill B, Califf RM, Stack RS, editors. *Interventional Cardiovascular Medicine: Principles and Practice.* New York: Churchill Livingstone, Inc.; 1994. p. 217-37.
41. Tcheng JE, Fortin DF, Pryor DB, Califf RM. A guide to the technology of information management., In: Phillips HR, III, O'Neill WW, Califf RM, Stack RS, editors. *Interventional Cardiovascular Medicine: Principles and Practice.* New York: Churchill Livingstone, Inc.; 1994. p. 945-678.
42. Anderson JL, Califf RM. Anisoylated plasminogen streptokinase activator complex (APSAC)., *Cardiovascular Drug Therapy.* Louisiana: Alton Ochsner Medical Foundation; 1995.
43. Califf RM, Phillips HR. Percutaneous coronary revascularization in patients with unstable angina., In: Califf RM, Mark DB, editors. *Acute Coronary Care*, 2nd ed. Chicago: Mosby-Year Book Medical Publishers; 1995. p. 551-59.
44. Califf RM. Special diagnostic and therapeutic procedures in cardiac surgery: fibrinolytic therapy in the management of acute myocardial infarction., In: Sabiston DC, Jr., Spencer FC, editors. *Surgery of the Chest.*, 6th ed. Philadelphia: W.B. Saunders; 1995. p. 1182-94.
45. Califf RM, Topol EJ. The paradigm of acute reperfusion and the GUSTO Trial., In: Califf RM, Mark DB, Wagner GS, editors. *Acute Coronary Care*, 2nd ed. Chicago: Mosby Year Book Medical Publishers; 1995. p. 69-83.
46. Califf RM, Rogers M, Curtis J, Roth D, Bride WM, Fitzpatrick K *et al.* Developing a rational system to contain costs on the cardiac care unit., In: Califf RM, Mark DB, Wagner GS, editors. *Acute Coronary Care*, 2nd ed. Chicago: Mosby-Year Book Medical Publishers; 1995. p. 895-912.
47. Califf RM, Woodlief LH. Endpoints for trials of reperfusion in acute myocardial infarction., In: Califf RM, Mark DB, Wagner GS, editors. *Acute Coronary Care*, 2nd ed. Chicago: Mosby-Year Book Medical Publishers; 1995. p. 149-65.
48. Califf RM. The role of randomized trials, registries and experience-based common sense: the Duke perspective., In: Ellis SG, Holmes DR, Jr., editors. *Strategic Approaches in Coronary Intervention.* Baltimore: Williams & Wilkins; 1995. p. 173-82.
49. Granger CB, Califf RM. Stabilizing the unstable artery., In: Califf RM, Mark DB, Wagner GS, editors. *Acute Coronary Care*, 2nd ed. Chicago: Mosby-Year Book Medical; 1995. p. 525-41.
50. Harrington RA, Califf RM, Phillips HR3, Mark DB. Primary angioplasty for acute myocardial infarction., In: Califf RM, Mark DB, Wagner GS, editors. *Acute Coronary Care.* Chicago: Mosby-Year Book Medical Publishers; 1995. p. 305-13.
51. Herzog W, Califf RM. Efforts to prevent reperfusion injury., In: Califf RM, Mark DB, Wagner GS, editors. *Acute Coronary Care*, 2nd ed. Chicago: Mosby-Year Book Medical Publishers; 1995. p. 377-89.

52. Krucoff MW, Ohman EM, Trollinger KM, Christensen RH, Sawchak ST, Shah A *et al.* Non-invasive definition of failed reperfusion at the bedside: looking beyond the tip of the catheter., In: Califf RM, Mark DB, Wagner GS, editors. *Acute Coronary Care*. Chicago: Mosby-Year Book Medical Publishers; 1995. p. 443-68.
53. Sketch MH, Labinaz M, Nathan PE, Puma JA, Califf RM. Acute care of the patient with previous coronary bypass surgery., In: Califf RM, Mark DB, editors. *Acute Coronary Care*. Chicago: Mosby-Year Book Medical Publishers; 1995. p. 663-73.
54. Wagner GS, Bartrug BL, Bride WM, Califf RM. Administration of the extended comprehensive coronary care unit., In: Alpert JS, editor. *Coronary Care*, 2nd ed. Boston: Little, Brown and Company; 1995. p. 759-62.
55. Zabel KM, Califf RM. The open artery hypothesis., In: Francis GS, Alpert JS, editors. *Coronary Care*, 2nd ed. Boston: Little, Brown and Company; 1995. p. 451-72.
56. Antman EM, Califf RM. Clinical trials and meta-analysis., In: Smith TW, editor. *Cardiovascular Therapeutics*. Philadelphia: W.B. Saunders; 1996.
57. Califf RM, Harrington RA, Granger CB. Anticoagulation and antiplatelet regimens during and following coronary intervention., In: Pepine CJ, editor. *Diagnostic and Therapeutic Cardiac Catheterization*. Baltimore: Williams and Wilkins; 1996.
58. Califf RM, Mark DB. Unstable angina: clinical presentation and diagnostic techniques., In: Fuster V, Ross A, Topol EJ, editors. *Atherosclerosis and Coronary Artery Disease*. New York: Raven Press; 1996. p. 1299-314.
59. Califf RM. Spectrum of acute ischemic heart disease: unstable angina to acute myocardial infarction., In: Braunwald E, editor. *Atlas of Heart Disease*. Philadelphia: Current Medicine; 1996.
60. Califf RM. Acute myocardial infarction., In: Smith TW, editor. *Cardiovascular Therapeutics*. Philadelphia: W.B. Saunders; 1996.
61. Califf RM, Tardiff BE. Coronary bypass grafting in acute ischemic heart disease., In: Braunwald E, editor. *Atlas of Heart Disease*, vol. Mar/Apr. Philadelphia: ACC Current Journal Review; 1996. p. 73-76.
62. Califf RM, Harrington RA, Stack RS, Phillips HR3. The use of direct angioplasty in the treatment of acute myocardial infarction., In: Vetrovec GW, Carabello BA, editors. *Invasive Cardiology: Current Diagnostic and Therapeutic Issues*. New York: Futura Publishing Company; 1996. p. 537-58.
63. Jollis J, Califf RM, Topol EJ. Quality of acute MI care: scorecards., In: Topol EJ, editor. *Acute Coronary Syndromes*. New York: Marcel Dekker, Inc.; 1996.
64. Kruse KR, Califf RM, Ohman EM. Thrombolytic therapy: a critical review of clinical trials., In: Gersh BJ, Rahimtoola SH, editors. *Acute Myocardial Infarction*, 2nd ed. New York: Chapman Hall; 1996. p. 434-71.
65. Miller J, Califf RM. Synthetic peptide inhibitors against the platelet glycoprotein IIb/IIIa receptor: integrelin., In: Sashara AA, Loscalzo J, editors. *New Therapeutic Agents in Thrombosis and Thrombolysis*. New York: Marcel Dekker, Inc.; 1996.
66. Califf RM. Acute ischemic syndromes., In: Talley JD, Mauldin P, Becker E, editors. *Cost Effective Diagnosis and Treatment of Coronary Artery Disease*. Baltimore: Williams and Wilkins; 1997.
67. Califf RM. Thrombolytics., In: Kuppersmith J, Deedwania P, editors. *The Pharmacologic Management of Heart Disease*. Baltimore: Williams and Wilkins; 1997. p. 223-77.
68. Califf RM. Considerations in the design, conduct, and interpretation of quantitative clinical evidence., In: Topol EJ, Bristow M, Califf RM, Isner J, Prystowsky EN, Serruys P *et al.*, editors. *Textbook of Cardiovascular Medicine*. Philadelphia: Lippincott-Raven Publishers; 1998.
69. Califf RM. Insights from GUSTO., In: Nash IS, editor. *Myocardial Infarction Therapy: Efficacy Review*. 1998.

70. Califf RM. Introduction to "The heart and other organ systems.", In: Califf RM, Isner J, Prsyrowsky EN, Serruys P, Swain J, Thomas J *et al.*, editors. Textbook of Cardiovascular Medicine. Philadelphia: Lippincott-Raven; 1998.
71. Peterson ED, Phillips HR3, Jollis JG, Califf RM, Ohman EM. Surgical therapy versus interventional therapy in patients with stable coronary ischemia., In: Roubin GS, O'Neill WW, Stack RS, editors. *Interventional Cardiovascular Principles and Practice*, 2nd ed. New York: Churchill Livingstone; 1998.
72. Tardiff BE, Miller JM, Harrington RA, Tcheng JE, Califf RM. Integrilin synthetic peptides against the platelet glycoprotein IIb/IIIa receptor., In: Sasahara AA, Loscalzo J, editors. *New Therapeutic Agents in Thrombosis and Thrombolysis*.. New York: Marcel Dekker, Inc.; 1998.
73. Tardiff BE, Mahaffey KW, Ohman EM, Califf RM. Microinfarction associated with percutaneous coronary intervention., In: Pepine CJ, Hill JA, Lambert CR, editors. *Diagnostic and Therapeutic Cardiac Catheterization*, 3rd ed. Baltimore: Williams and Wilkins; 1998. p. 872-91.
74. Topol EJ, Califf RM. Quality of care in cardiovascular medicine., In: Topol EJ, Bristow M, Califf RM, Isner J, Prsyrowsky EN, Serruys P *et al.*, editors. Textbook of Cardiovascular Medicine. Philadelphia: Lippincott-Raven Publishers; 1998.
75. Califf RM, Kong DF. The future of glycoprotein IIb/IIIa inhibitors., In: Lincoff AM, editor. *Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease*..Humana Press; 1999.
76. Granger CB, Califf RM. The GUSTO Trials., In: Timmis G, editor. *Thrombolytic Therapy*. Armonk: Futura Publishing; 1999. p. 249-75.
77. Antman EM, Armstrong PW, Bovill EG, Falk E, Granger CB, Hochman JS *et al.* Acute myocardial infarction and other acute ischemic syndromes, In: Califf RM, editor. *Essential atlas of heart disease*, Second Edition ed.McGraw-Hill Medical Publishing Division; 2001. p. 41-74.
78. Califf RM, Tardiff BE. Coronary artery bypass grafting in acute ischemic heart disease, In: Braunwald E, Califf RM, editors. *Acute myocardial infarction and other ischemic syndromes*, Second Edition ed.Current Medicine; 2001. p. 179-98.
79. Califf RM. Spectrum of acute ischemic heart disease: unstable angina to acute myocardial infarction, In: Braunwald E, Califf RM, editors. *Acute myocardial infarctions and other ischemic syndromes*, Second Edition ed.Current Medicine; 2001. p. 1-20.
80. Califf RM. Guidelines for treatment of acute coronary syndromes, In: Braunwald E, Califf RM, editors. *Acute myocardial infarction and other ischemic syndromes*, Second edition ed.Current Medicine; 2001. p. 217-32.
81. Antman EM, Califf RM, Kuppersmith J. Tools for assessment of cardiovascular test and therapies., In: Colucci W, Gotto AM, Josephson ME, Oparil S, Popma JJ, editors. *Cardiovascular Therapeutics. A companion to Braunwald's Heart Disease*, 2nd ed.W.B. Saunders Company; 2002. p. 1-33.
82. Califf RM. Large clinical trials: Clinical Research Institutes., In: Gallin JI, editor. *Principles and Practices of Clinical Research*.Academic Press; 2002. p. 225-57.
83. Hochman J, Califf RM. Acute myocardial infarction, In: Colucci W, Gotto AM, Josephson ME, Oparil S, Popma JJ, editors. *Cardiovascular Therapeutics. A companion to Braunwald's Heart Disease*, 2nd ed.W.B. Saunders; 2002. p. 233-91.
84. O'Shea JC, Tchen JE, Harrington RA, Califf RM. Eptifibatide: A potent inhibitor of the platelet receptor integrin, glycoprotein IIb/IIIa, In: Sasahara A, Loscalzo J, editors. *New Therapeutic Agents in Thrombosis and Thrombolysis*, Second Edition Revised and Expanded, 2nd ed. New York; Basel: Marcel Dekker, Inc; 2002. p. 371-87.
85. Califf RM. Considerations in the design, conduct, and interpretation of quantitative clinical evidence (Chapter 43). In: Eric Topol. Ed. *The Textbook of Cardiovascular Medicine*. 3<sup>rd</sup> ed. New York: Lippincott, Wilkins and Williams, 2006.
86. Peterson ED, Califf RM. Quality of care and medical errors in cardiovascular disease (Chapter 45). In: Eric Topol, ed. *The Textbook of Cardiovascular Medicine*. 3<sup>rd</sup> ed. New York: Lippincott, Wilkins and Williams, 2006.



87. Califf RM. Large clinical trials and registries—clinical research institutes. In: Principles and Practice of Clinical Research. 2<sup>nd</sup> edition. Gallin JI, Ognibene F, eds. Burlington, MA: Academic Press (Elsevier); 2007. p. 237-261.
88. Califf RM. Patient-oriented research, In Robertson D, Williams GH. Principles of Clinical and Translational Science. Burlington MA: Elsevier 2009. p.13-40.
89. Califf RM. Medical management of acute coronary syndromes. In: Sellke WE, de Nido PJ, Swanson SJ, eds. Sabiston and Spencer Surgery of the Chest. 8<sup>th</sup> ed. Burlington, MA: Elsevier;(In Press).
90. Califf RM. Large Clinical Trials and Registries – Clinical Research Institutes. In: Principles and Practices of Clinical Research. 3<sup>rd</sup> Edition. Gallin JI, Ognibene F, eds. Burlington, MA: Academic Press (Elsevier); 2012. P. 331-359.